+ All Categories
Home > Documents > Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The...

Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The...

Date post: 25-Mar-2018
Category:
Upload: tranliem
View: 224 times
Download: 4 times
Share this document with a friend
355
Saskatchewan Ministry of Health Formulary Sixty-Second Edition July 1, 2012 - March 31, 2013 Drug Plan
Transcript
Page 1: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

Saskatchewan Ministry of Health Formulary

Sixty-Second Edition

July 1, 2012 - March 31, 2013

Drug Plan

Page 2: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

Inquiries should be directed to:

Pharmaceutical Services Drug Plan & Extended Benefits Branch

Saskatchewan Health 2nd Floor, 3475 Albert Street

Regina, Saskatchewan S4S 6X6

Website Address: http://formulary.drugplan.health.gov.sk.ca/

Telephone inquiries should be directed as follows: Consumer Inquiries………………..……………Toll Free…….. …………………………………………….……...Regina….…...

1-800-667-7581 (306) 787-3317

Pharmacy Inquiries……………………………...Toll Free……. ………………………………………………..……Regina………

1-800-667-7578 (306) 787-3315

Special Support Program Inquiries……………Toll Free…….. …………………………………………….……....Regina….…...

1-800-667-7581 (306) 787-3317

EDS, Palliative Care, "No Substitution" Inquiries…….………. (306) 787-8744 EDS Requests (24-hour message system)…..Toll Free…….. 1-800-667-2549 Profile Release Program………………….……Toll Free…….. …………………………………………….……....Regina….…...

1-888-798-8083 (306) 798-8083

Pricing, Contract Inquiries………………………………………. (306) 787-3420 Product Submission Inquiries………………………….……….. (306) 933-5599 Research and Utilization Inquiries……………………………... (306) 787-3307 Hospital Benefit List Inquiries………………………….……….. (306) 787-3420 Facsimile numbers: EDS Unit Fax (EDS requests, Palliative Care forms and "No Substitution" requests only)……………………. General Fax ………………………………………..…..………...

(306) 798-1089 (306) 787-8679

Saskatchewan Drug Information Service: Healthcare Professionals……………….……..Toll Free.…...... ……………………………………………………Saskatoon…… Consumers………………………………………Toll Free……... ……………………………………………………Saskatoon…… Website Address: www.usask.ca/druginfo

1-800-667-3425 (306) 966-6340 1-800-665-3784 (306) 966-6378

Copyright - 2012 Her Majesty the Queen in right of the Dominion of Canada, as represented by the Minister of Health of the Province of Saskatchewan

Ministry of Health Government of Saskatchewan The Honourable Dustin Duncan Minister of Health

ISSN 1929-5022 (Online) Produced in Canada

Page 3: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

TABLE OF CONTENTS

MEMBERSHIP OF DRUG ADVISORY COMMITTEE OF SASKATCHEWAN...................... . iiPREFACE.............................................................................................................................. . iiiPRODUCT SUBMISSION PROCESS................................................................................... . ivREQUEST FOR PRODUCT ASSESSMENT......................................................................... . vNOTES CONCERNING THE FORMULARY......................................................................... . viiiLEGEND................................................................................................................................ . xvi

PHARMACOLOGICAL - THERAPEUTIC CLASSIFICATION OF DRUGS 08:00 ANTI-INFECTIVE AGENTS..................................................................................... . 210:00 ANTINEOPLASTIC AGENTS.................................................................................. . 2612:00 AUTONOMIC DRUGS............................................................................................. . 2820:00 BLOOD FORMATION AND COAGULATION.......................................................... . 4024:00 CARDIOVASCULAR DRUGS................................................................................. . 4828:00 CENTRAL NERVOUS SYSTEM AGENTS............................................................. . 9236:00 DIAGNOSTIC AGENTS.......................................................................................... . 14240:00 ELECTROLYTIC, CALORIC AND WATER BALANCE........................................... . 14648:00 ANTITUSSIVES, EXPECTORANTS AND MUCOLYTIC AGENTS......................... . 15052:00 EYE, EAR, NOSE AND THROAT PREPARATIONS.............................................. . 15256:00 GASTROINTESTINAL DRUGS............................................................................... . 16260:00 GOLD COMPOUNDS.............................................................................................. . 17264:00 HEAVY METAL ANTAGONISTS............................................................................. . 17468:00 HORMONES AND SYNTHETIC SUBSTITUTES.................................................... . 17684:00 SKIN AND MUCOUS MEMBRANE AGENTS......................................................... . 19886:00 SMOOTH MUSCLE RELAXANTS.......................................................................... . 21288:00 VITAMINS................................................................................................................ . 21692:00 UNCLASSIFIED THERAPEUTIC AGENTS............................................................ . 22094:00 DIABETIC SUPPLIES...............................................................................………… . 234

APPENDICESAPPENDIX A - EXCEPTION DRUG STATUS PROGRAM................................................ . 242APPENDIX B - ONLINE CRITERIA ADJUDICATION........................................................ . 295APPENDIX C - SPECIAL COVERAGES............................................................................ . 298APPENDIX D - SASKATCHEWAN MS DRUGS PROGRAM..……................................... . 299

INDICESINDEX A - THERAPEUTIC CLASSIFICATION LIST......................................................... . 304INDEX B - ALPHABETICAL LIST OF PHARMACEUTICAL PRODUCT NAMES.............. . 306

Page 4: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...
Page 5: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

62nd EDITION

INTRODUCTION

The Saskatchewan Formulary isupdated Annually

Updates will be providedPeriodically

Page 6: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

COMMITTEE DRUG ADVISORY COMMITTEE OF SASKATCHEWAN (DACS) Dr. Dennis Gorecki Chair Pharmacist, Professor of Pharmacy Dr. Shahid Ahmed Physician - Medical Oncologist Clinical Associate Professor of Medicine Dr. Rob Basi Physician - Internal Medicine Clinical Assistant Professor of Medicine Dr. Marilyn Caughlin Family Physician and Pharmacist Dr. Adam Gruszczynski Family Physician Assistant Professor of Medicine Dr. Derek Jorgenson Pharmacist Associate Professor of Pharmacy Ms. Namarta Kochar Public Representative Director, Major Projects Refresh Inc. STAFF ASSISTANCE Ms. Donna Herbert/ Ms. Arlene Kuntz Pharmacist, Pharmaceutical Services Drug Plan & Extended Benefits Branch Dr. Lorne Davis Pharmacologist, Pharmaceutical Services Drug Plan & Extended Benefits Branch

Mr. Allen Lefebvre Public Representative Project Coordinator Dr. Anne PausJenssen Physician - Internal Medicine Professor of Medicine Dr. Nazmi Sari Health Economist Associate Professor of Economics Dr. William Semchuk Clinical Pharmacist Assistant Clinical Professor of Pharmacy and Medicine Dr. Yvonne Shevchuk Clinical Pharmacist Professor of Pharmacy Associate Dean, College of Pharmacy and Nutrition Dr. Lilian Thorpe Physician - Psychiatry and Geriatric Psychiatry Professor of Medicine and Community Health and Epidemiology Dr. Thomas W. Wilson Internal Medicine/Clinical Pharmacology Professor, Department of Medicine University of Saskatchewan Ms. Kathy Gesy Pharmacy Leader, Oncology Pharmacist Saskatchewan Cancer Agency Ms. Tracey Smith Director, Pharmaceutical Services Drug Plan & Extended Benefits Branch Mr. Kevin Wilson Executive Director, Drug Plan & Extended Benefits Branch

ii

Page 7: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PREFACE

OBJECTIVES The Drug Plan has been established to: • provide coverage to Saskatchewan residents for quality pharmaceutical products of

proven therapeutic effectiveness; • reduce the direct cost of prescription drugs to Saskatchewan residents; • reduce the cost of drug materials; • encourage the rational use of prescription drugs. THE FORMULARY The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven high quality that have been approved for coverage under the Drug Plan. It is compiled by the Minister of Health with the advice of the Drug Advisory Committee of Saskatchewan (DACS) and is published annually, with regular updates. The members of the DACS are appointed by the Minister of Health and provide independent, specialized advice on drug-related matters. The membership on the DACS is composed of two public representatives as well as clinical specialists in the areas of medicine, pharmacology, pharmacy, and economics. The ongoing work of the DACS includes the evaluation of new products, as well as the re-evaluation of products as required. The goal is to list a range and variety of drugs that will enable prescribers to select an effective course of therapy for most patients. THE DRUG REVIEW PROCESS Saskatchewan is participating in the Common Drug Review (CDR).

The CDR helps support and inform drug plan decisions about drugs by providing:

• systematic reviews of the clinical evidence • reviews of the pharmacoeconomic information • detailed recommendations by the Canadian Drug Expert Committee (CDEC).

The Drug Plan continues to make final benefit-listing and coverage decisions, based on CDEC recommendations, and jurisdictional factors, such as plan mandates, priorities, and resources. For more information about the CDR and CDEC, visit: http://www.cadth.ca. Upon receipt of the CDEC recommendation, the DACS will begin Saskatchewan’s review. Using this information, along with additional details of anticipated cost and impact on patterns of practice, the DACS makes a recommendation to the Minister of Health. These recommendations reflect the "Policy for Inclusion of Products in the Saskatchewan Formulary" (see pages ix - xi).

iii

Page 8: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

1 The DACS provides independent, specialized advice on drug-related matters to the Minister of Health.2 All products listed in the Saskatchewan Formulary are benefits when used in the hospital setting.

* The majority of submissions for interchangeable generic drugs do not require committee review as the Executive Director of the Drug Plan has the authority to approve these products for coverage. More complex interchangeable drug submissions are reviewed by the drug review committee.

PRODUCT SUBMISSION PROCESS *

MANUFACTURERSUBMISSION

DRUG ADVISORY COMMITTEE of

SASKATCHEWAN (DACS) 1

SASKATCHEWAN FORMULARY

SASKATCHEWAN CANCER AGENCY

DRUG FORMULARY

HOSPITAL BENEFIT DRUG LIST 2

RECOMMENDATION TO THE MINISTRY OF HEALTH

ONCOLOGY INDICATION

via the Pan Canadian Oncology Drug Review

(for pCODR eligible products)

Common Drug Review (CDR) Process

(for CDR eligible products)

All other medications

iv

Page 9: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

REQUEST FOR PRODUCT ASSESSMENT Submission Process Any supplier wishing to have products listed in the Saskatchewan Formulary, the Hospital Benefit Drug List or the Saskatchewan Cancer Agency Benefit List may submit requests for product assessment. The route a submission follows is determined by the indication of the products. There is no deadline date for submissions for listing in the Formulary. In general, submissions are reviewed in order of receipt. Clinical Documentation Single-Supplier Product Submissions New Chemical Entities, New Combination Products and New Indications for Listed Products. Saskatchewan is participating in the Common Drug Review (CDR) process. As a consequence, submissions for new chemical entities, new combination products and new indications for listed products should be made directly to CDR Directorate in accordance to the CDR Submission Guidelines as posted on the Canadian Agency for Drugs and Technologies in Health website http://www.cadth.ca. Single Source Products That Do Not Contain New Chemical Entities Saskatchewan Health will accept submissions of single source products that do not contain new chemical entities or new combinations and that will not fall under the jurisdiction of the CDR process; however, the same submission requirements as per CDR guidelines will apply to this category of products. Line Extension Products The following submission requirements pertain to new strengths and formulations or reformulations of drug products that are currently listed in the Saskatchewan Formulary.

1. Copy of NOC 2. Copy of completed Drug Identification Number (DIN) notification form 3. Copy of approved Product Monograph 4. Justification of the need for the Line Extension 5. Copy of Comprehensive Summary (“Clinical Studies” section only) or other

document accepted by Health Canada and copies of critical studies that address key clinical issues relevant to the new strength, formulation or reformulation or evidence of formulation proportionality or bioequivalence data; and evidence of a similar dissolution profile.

Clinical documentation in support of products to be reviewed may be submitted at any time. The committee meets on a regular basis and will review submission as quickly as possible upon receipt. Details of the criteria for product listings are published in each edition of the Formulary and in regular updates to the Formulary. Notification is required whenever there is a change in formulation or in the clinical information published in the product monograph, for any listed product as well as for any product under review.

v

Page 10: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

Interchangeable Product Submissions The following submission requirements pertain to multi-source products submitted for listing in an interchangeable grouping in the Saskatchewan Formulary.

A. Drug products in solid oral dosage forms reviewed by the TPD according to the guidelines, “Conduct and Analysis of Bioavailability and Bioequivalence Studies - Part A and B” and have a Canadian Reference Product on the Notice of Compliance. 1. Copy of NOC 2. Copy of completed Drug Identification Number (DIN) notification form 3. Copy of approved Product Monograph Note: Comparative (Bio) studies may be requested on a case-by-case basis.

B. Drug products in solid oral dosage forms reviewed by the TPD according to the

guidelines “Conduct and Analysis of Bioavailability and Bioequivalence Studies - Report C.

1. Copy of NOC 2. Copy of completed Drug Identification Number (DIN) notification form 3. Copy of approved Product Monograph Note: Comparative (Bio) studies may be requested on a case-by-case basis.

C. Drug Products that are cross-referenced

1. Copy of NOC 2. Copy of completed Drug Identification Number (DIN) notification form 3. Copy of approved Product Monograph 4. Letters from both the manufacturer of the submitted product and the

manufacturer of the cross-licensed product, confirming that the two products are identical in all aspects, except for embossing and labelling.

5. Price information including current pricing should be provided at the time of the generic product submission.

D. Drug products in Aqueous Solutions (e.g. oral, ophthalmics, inhalation,

injections) that have a Canadian Reference Product on the Notice of Compliance.

1. Copy of NOC 2. Copy of completed Drug Identification Number (DIN) notification form 3. Copy of approved Product Monograph Note: Comparative (Bio) studies may be requested on a case-by-case basis.

E. Drug products in semi-solid formulations (e.g. creams, ointments)

1. Copy of NOC 2. Copy of completed Drug Identification Number (DIN) notification form 3. Copy of approved Product Monograph Note: Comparative (Bio) studies may be requested on a case-by-case basis.

vi

Page 11: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

Drug Products Without a Canadian Reference Product The following submission requirements pertain to products submitted for listing in an interchangeable grouping where the active ingredient is designated as an “old drug” by the TPD and the drug product is approved on the basis of DIN application (i.e. an NOC is not issued) or is issued a Notice of Compliance without a Canadian Reference Product.

A. Drug products in solid dosage forms

1. Copy of completed Drug Identification Number (DIN) notification form 2. Copy of approved Product Monograph or Prescribing Information 3. Executive summary of comparative bioavailablity study or

pharmacodynamic study or studies conducted in accordance with the TPD guidelines, “Conduct and Analysis of Bioavailablity and Bioequivalence studies - Part A and B and Report C.

B. Drug Products Not in Solid Oral Dosage Form

1. Copy of completed Drug Identification Number (DIN) notification form 2. Copy of approved Product Monograph or Prescribing Information 3. Executive summary of comparative Bioavailablity study or

pharmacodynamic study or studies conducted in accordance with the TPD guidelines or surrogate comparisons with the reference drug product (i.e. in vivo or vitro test methods or a pharmacodynamic or therapeutic equivalence study).

C. Drug Products That Are Cross-Referenced

1. Copy of completed Drug Identification Number (DIN) notification form 2. Copy of approved Product Monograph or Prescribing Information 3. Letters from both the manufacturer of the submitted product and the

manufacturer of the cross-licensed product, confirming that the two products are identical in all aspects, except for embossing and labelling.

Manufacturing Documentation A copy of completed and approved Certified Product Information Document (C.P.I.D.) should be submitted with the clinical documentation if possible, but will be accepted at a later date. Economic Evaluation Price information including current price list and/or catalogue should be provided at the time of product submission. Submission of pharmacoeconomic analyses are encouraged. The National Pharmacoeconomic Guidelines serve as a guide. The Drug Advisory Committee of Saskatchewan will routinely consider direct “medical” costs such as: • impact on laboratory tests for monitoring, evaluation or diagnosis • impact on physician office visits • impact on hospitalization or institutionalization • impact on surgical procedures • increased or decreased incidence and severity of side effects • impact on surgical procedures

vii

Page 12: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

• expected market share information is requested to allow for an accurate projection of the impact of a new product.

• product patent expiration date is requested to allow for consideration of the potential long-term economic impact of the product.

• copies of the initial product launch material, and any subsequent promotional material sent to physicians and pharmacists.

The availability of quality-of-life analyses is encouraged. Submission of a budget impact analyses for Saskatchewan Health is required. Additional Documentation Required for Generic and Single Source Products: • A letter authorizing unrestricted communication regarding the drug product between

the Saskatchewan Prescription Drug Plan and: 1. Participating federal/provincial/territorial (F/P/T) drug plans 2. F/P/T governments, including their agencies and departments 3. F/P/T health authorities (including regional authorities and related facilities) 4. Health Canada 5. Patented Medicine Prices Review Board (PMPRB) 6. Canadian Agency for Drugs and Technology in Health (CADTH)

• A letter confirming the ability to supply product. Submission Procedure Requests for product assessment, together with complete documentation as noted above should be sent to: Dr. Lorne Davis, Pharmacologist Room 226.10, Thorvaldson Building College of Pharmacy & Nutrition, 110 Science Place University of Saskatchewan Saskatoon, Saskatchewan S7N 5C9 With a complete copy sent to: Director, Pharmaceutical Services, Ministry of Health Drug Plan and Extended Benefits Branch 2nd Floor, 3475 Albert Street Regina, Saskatchewan S4S 6X6

NOTES CONCERNING THE FORMULARY Benefits The Saskatchewan Formulary lists the drugs, which are covered by the Drug Plan. A prescription is required for all drugs dispensed under the Drug Plan with the exception of insulin, blood-testing agents, urine-testing agents, syringes, needles, lancets and swabs used by diabetic patients. Certain drugs are covered under the Exception Drug Status Program (EDS) and require that specific medical criteria are met before coverage is granted. See Exception Drug Status criteria (Appendix A) for more information regarding EDS.

viii

Page 13: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

Eligibility With a few exceptions, all Saskatchewan residents with a valid Saskatchewan Health Services card are eligible for coverage under the Drug Plan. The exceptions include those who have prescription costs paid by another agency. For example: Health Canada; First Nations and Inuit Health Branch Workers' Compensation Board Veterans Affairs Canada members of the Royal Canadian Mounted Police members of the Canadian Forces inmates of Federal Penitentiaries

Policy for Inclusion of Products in the Saskatchewan Formulary

1. Only products produced by manufacturers approved by Health Canada will be considered.

2. Only drug products formulated and produced in accordance with sound

manufacturing principles and found to comply with official standards will be considered.

3. Only drug products which are valid therapeutic agents, with proven clinical

effectiveness, for the diagnosis, prevention or treatment of mental or physical disorders will be listed. The availability of suitable alternative agents, and potential for undesirable effects will be considered.

The medical literature and clinical studies are reviewed and evaluated to determine if

the drug product is therapeutically effective for the treatment of the conditions for which the drug is indicated.

The clinical literature is also reviewed to determine the therapeutic advantages or

disadvantages in relation to alternative agents, which may or may not be listed in the Saskatchewan Formulary.

The rate and severity of potential undesirable effects are reviewed and compared

with those for alternative products. In reviewing products for which suitable alternatives are listed in the Formulary,

consideration will be given to the following additional criteria:

• clinical documentation must clearly demonstrate therapeutic advantages such as:

• more effective for treatment of the condition(s) for which the drug is intended; • increased safety as shown by reduced toxicity and reduced incidence of

adverse reactions and/or side effects; • improved dosing schedule; • reduced potential for abuse or inappropriate use;

OR • anticipated cost of a product of equivalent therapeutic effectiveness must offer a

potential economic advantage over listed alternatives.

4. The cost of therapy relative to the clinical efficacy is reviewed and compared to the cost of therapy relative to the clinical efficacy of alternative agents.

ix

Page 14: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

An increased cost may be justified if the drug product produces better clinical results in a significant portion of the patient population, demonstrates fewer or less severe undesirable effects, or has a dosage regime which improves patient compliance.

The cost of oral combination products relative to the combined costs of the single entities, the cost of the various dosage strengths relative to therapeutic advantages, and the cost of additional dosage forms relative to the therapeutic advantages will be considered when reviewing such products.

5. Some drug products will not be listed as regular benefits, but may be made

available on Exception Drug Status for treatment of approved clinical indications. (See Appendix A) for Exception Drug Status criteria.

6. Combination products are required to meet the following additional criteria:

• each component must make a contribution to the claimed effect; • the dosage of each component (amount, frequency, duration of therapeutic effect) must be such that the combination is safe and effective for a significant patient population, requiring such concurrent therapy as defined in the labelling; A component may be added to: • enhance safety or effectiveness of the principal active ingredient; • minimize the potential for abuse of the principal active ingredient. • combination fixed ratio must be "right" for: • significant portion of patients; • significant amount of natural history of disease.

7. Sustained, prolonged or delayed release dosage forms are required to meet the

following additional criteria:

• clinical studies have demonstrated the sustained, prolonged or delayed action of the active ingredient;

• the dosage form possesses therapeutic advantages in the treatment of the

disease entity for which the product is indicated;

8. The various strengths of one dosage form will be considered if they possess therapeutic advantages and meet the required standards for quality and cost.

9. The various dosage forms of a drug product will be evaluated individually.

10. Drug products not listed in the Schedules of the Food and Drugs Act, Narcotic

Control Act or the Saskatchewan Pharmacy Act, but usually sold on prescription, will be considered for inclusion.

11. Products which contain the same amount of the same active ingredient in an

equivalent dosage form and are of acceptable equivalent therapeutic effectiveness will be listed as interchangeable.

12. The following will not be listed:

• fertility agents; • drugs used in erectile dysfunction; • certain over-the-counter preparations;

x

Page 15: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

• drugs used primarily in hospitals; • antineoplastic agents (these are provided to patients through the Saskatchewan

Cancer Agency); • anti-tuberculosis drugs; • blood derivatives - immune serum globulin for prophylaxis against infectious

hepatitis or measles or for treatment of immune deficiency disease is available from the Health Offices.

• vaccines and sera - most immunological agents are available from the Health Offices.

• safety engineered syringes

13. Drug products identified by trade names deemed to be inappropriate, confusing and/or misleading may not be listed. Some examples include:

• products with similar or identical trade names but containing different active

ingredients; • products with a different strength of ingredient, manufactured by the same

supplier, but with a different trade name. Policy for Formulary Deletion The Minister of Health may delete any product from the Saskatchewan Formulary under the following circumstances: 1. Upon the recommendation of the DACS: • where the standards of quality and/or production have altered and are not

considered to meet accepted standards; • where new information demonstrates that the product does not have adequate

therapeutic benefit; • where undesirable effects of the product make the continued listing of the product

inappropriate; • where new products possessing clearly demonstrated therapeutic advantages

have been listed, thereby making the continued listing of the product unnecessary. 2. Upon the recommendation of the Drug Plan where there are undesirable financial,

supply or administrative implications to continued listing of a product, the Drug Plan will consult with the DACS prior to making a recommendation. The comments of the Committee will be brought to the attention of the Minister.

3. Where the Minister of Health believes a product should be deleted, the Minister will

consult with the DACS before making a final decision. 4. Upon notification from the manufacturer that the product has been discontinued. Exception Drug Status Certain drug products may be considered for Exception Drug Status coverage under one or more of the following circumstances: • the drug is ordinarily administered only to hospital inpatients and is being

administered outside of a hospital because of unusual circumstances; • the drug is not ordinarily prescribed or administered in Saskatchewan but is being

prescribed because it is required in the diagnosis or treatment of a patient having an illness, disability or condition rarely found in this province;

xi

Page 16: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

• the drug is infrequently used since therapeutic alternatives listed in the Formulary are usually effective but are contraindicated or found to be ineffective because of the clinical condition of the patient;

• the drug has been deleted from the Formulary, but is required by patients who were previously stabilized on the drug;

• the drug has potential for use in other than approved indications; • the drug has potential for the development of widespread inappropriate use; • the drug is more expensive than listed alternatives and offers an advantage in only

a limited number of indications.

The following information is required to process Exception Drug Status requests: * patient name * patient Health Services Number (9 digits) * name of drug * diagnosis relevant to use of drug * prescriber name * prescriber phone number

Saskatchewan Prescription Drug Plan policy does not allow a fee to be charged to clients for Exception Drug Status applications made to the Drug Plan on the client's behalf. See Appendix A for further details regarding Exception Drug Status. "No Substitution" Prescriptions Drug Plan benefits will be based only on the lowest priced interchangeable brand as listed in the Formulary or sticker updates. Credit towards established deductibles or thresholds (for income based drug coverage under Special Support) will also be based on the lowest priced interchangeable brand. Although the Formulary will continue to list all approved brands, patients will, in addition to their normal share of cost, be responsible for any incremental cost associated with the selection of a higher cost brand. It is important to note that both generic and brand name products are manufactured under the same standards of good manufacturing practice, and that only those brands, which meet the standards for bioequivalence, are accepted as interchangeable in Saskatchewan. In cases where a patient experiences problems with a specific brand of a medication, a prescriber may make application for exemption from the cost of the "no sub" brand. (See Special Coverages for details) http://formulary.drugplan.health.gov.sk.ca/PDFs/SpecialCoverages.pdf Adverse Drug Reactions Health Canada encourages the reporting of suspected adverse reactions. Saskatchewan prescribers, pharmacists, and other health professionals are encouraged to participate in the Canada Vigilance Program; see Supplementary Information at the back of the book. Index Drug products are listed alphabetically by generic name and brand name at the back of the Formulary.

xii

Page 17: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

Pharmacologic-Therapeutic Classification of Drugs The drugs are classified according to the pharmacologic-therapeutic classification developed by the American Society of Health System Pharmacists for the purpose of the American Hospital Formulary Service. Permission to use this system has been granted by the American Society of Health System Pharmacists. The Society is not responsible for the accuracy of transpositions or excerpts from the original content. Within each therapeutic classification the drugs are listed alphabetically according to their generic names. Under each drug, acceptable products are listed. Drugs with multiple uses may be listed in one or more classes. Prescription Quantities The Drug Plan places no limitation on the quantities of drugs that may be prescribed. Prescribers shall exercise their professional judgment in determining the course and duration of treatment for their patients. However, in most cases, the Drug Plan will not pay benefits or credit deductibles for more than a 3-month supply of a drug at one time. The quantity dispensed for one dispensing fee shall be determined by the terms of the contract in force when the prescription was dispensed. For drugs listed on the Two Month and 100 Day maintenance drug lists, refer to the Maintenance Drug Schedule. Because of possible waste and the potential danger of storing large quantities of potent drugs in the home, the Drug Plan does not encourage the dispensing of unreasonably large quantities of prescription drugs.

xiii

Page 18: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...
Page 19: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

LEGEND

Page 20: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

LEGEND

1 Pharmacological-Therapeutic classification.

2 Pharmacological-Therapeutic sub-classification.

3 Non-proprietary or generic name of the drug.

4 An asterisk (*) to the left of a drug strength and dosage form indicates that the products listed below are interchangeable.

5 An asterisk (*) to the right of a price indicates that the Drug Plan has negotiated a contract price (Standing Offer Contract - SOC) for that product. Pharmacists will dispense these products except where a prescriber indicates "no substitution" for a product in an interchangeable category (see page xvii). In cases where contracts have been negotiated with two suppliers of an interchangeable product, either brand may be used.

7 The following symbol: ⌧, to the left of a drug strength and dosage form indicates that the products listed below are NOT interchangeable.

10 This product requires Exception Drug Status (EDS) approval (see Appendix A for EDS criteria).

The price published in the formulary is the manufacturer's confirmed price, excluding mark-up (at time of publication) expressed as decimal dollars. Pharmacies are required by contract to submit their actual acquisition cost of the drug. For the most up to date information on formulary drug prices refer to the online formulary at http://formulary.drugplan.health.gov.sk.ca.

The Drug Identification Number (DIN), which has been assigned by Health Canada, uniquely identifies the drug product and its manufacturer, name and strength of active ingredients, route of administration, and pharmaceutical dosage form. In some cases, as noted in the formulary, identification numbers are generated by the Drug Plan for billing purposes only.

Drug strength and dosage form.

The Natural Product Number (NPN), which has been assigned by Health Canada, uniquely identifies the natural product and its manufacturer, name and strength of active ingredients, route of administration, and pharmaceutical dosage form.

All active ingredients of combination products are listed.

12 Strengths of active ingredients are listed in the same order as the ingredients. This example indicates that the tablet contains 100mg of levodopa and 25mg of carbidopa.

13 Brand name of drug.

14 Three letter identification code assigned to each manufacturer. The list of manufacturer codes can be located at: http://formulary.drugplan.health.gov.sk.ca/; under Formulary Appendices, Indices & Other.

15 The size of vials or ampoules of injectables is listed in brackets.

The size of a tube of ophthalmic ointment is listed in brackets.

This product is affected by the Maximum Allowable Cost (MAC) Policy (see Appendix C for MAC policy information).

16

14

13

6

9

11

12

8

2

3

4

5

1

15

17

18

10

7

xvi

Page 21: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:04.00 CARDIAC DRUGS

AMLODIPINE BESYLATE* 5MG TABLET

02280132 GD-AMLODIPINE GDI $ 0.3195 *00123456 Generic-Amlodipine PHY 0.4473

SOMATROPIN⌧ 10MG INJECTION (VIAL)

02325071 OMNITROPE (EDS) SDZ 311.600002229722 NUTROPIN AQ (EDS) HLR 389.4400 02216191 NUTROPIN (EDS) HLR 389.4400

PYRIDOXINE HCL* 25MG TABLET

80002890 JAMP-VITAMIN B6 JPC $ 0.018301943200 VITAMIN B6 ODN 0.0293

LEVODOPA/CARBIDOPA* 100MG/25MG TABLET

02182823 NU-LEVOCARB NXP 0.2803 02195941 APO-LEVOCARB APX 0.2803 02244495 NOVO-LEVOCARBIDOPA NOP 0.2803 00513997 SINEMET BMY 0.7126

FLUPENTHIXOL DECANOATE 20MG/ML INJECTION SOLUTION (ML)

02156032 FLUANXOL DEPOT LUD $ 7.1900

GENTAMICIN SO4* 5MG/G OPHTHALMIC OINTMENT (3.5G)

02230888 SANDOZ GENTAMICIN SDZ 5.2500

ESOMEPRAZOLE MAGNESIUM TRIHYDRATE (MAC)SEE APPENDIX A FOR EDS CRITERIASEE APPENDIX C FOR MAC POLICY 20MG DELAYED RELEASE TABLET

02244521 NEXIUM (EDS) AST $ 2.1780 40MG DELAYED RELEASE TABLET

02244522 NEXIUM (EDS) AST $ 2.1780

9

11

13

6

2

3

45

1

7 8

16

15

14

12

17

18

10

xvii

Page 22: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...
Page 23: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

ANTI-INFECTIVE AGENTS8:00

Page 24: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

08:00 ANTI-INFECTIVE AGENTS

08:04.00 AMEBICIDES

DIIODOHYDROXYQUIN 650MG TABLET

01997750 DIODOQUIN GLW $ 0.7855

08:08.00 ANTHELMINTICS

MEBENDAZOLE 100MG TABLET

00556734 VERMOX JAN $ 4.1800

PRAZIQUANTEL 600MG TABLET

02230897 BILTRICIDE BAY $ 6.0450

PYRANTEL PAMOATE 125MG TABLET

01944363 COMBANTRIN MCL $ 1.0459 50MG/ML ORAL SUSPENSION

01944355 COMBANTRIN MCL $ 0.2789

08:12.02 ANTIBIOTICS (AMINOGLYCOSIDES)

GENTAMICIN SO4 40MG/ML INJECTION SOLUTION (2ML)

02242652 GENTAMICIN SDZ $ 5.9300

TOBRAMYCIN SEE APPENDIX A FOR EDS CRITERIA 60MG/ML INHALATION SOLUTION (5ML)

02239630 TOBI (EDS) NVR $ 51.4400 28MG INHALATION CAPSULE

02365154 TOBI PODHALER (EDS) NVR $ 12.8588

62nd Edition 2 July 1, 2012

Page 25: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

08:00 ANTI-INFECTIVE AGENTS

08:12.04 ANTIBIOTICS (ANTIFUNGALS)

FLUCONAZOLE SEE APPENDIX A FOR EDS CRITERIA

* 150MG CAPSULE02241895 APO-FLUCONAZOLE APX $ 5.0948 02282348 PMS-FLUCONAZOLE PMS 5.0948 02311690 CANESORAL BCD 15.4200

* 50MG TABLET02236978 NOVO-FLUCONAZOLE (EDS) NOP $ 1.8065 02237370 APO-FLUCONAZOLE (EDS) APX 1.8065 02245292 MYLAN-FLUCONAZOLE (EDS) MYL 1.8065 02245643 PMS-FLUCONAZOLE (EDS) PMS 1.8065 02246108 DOM-FLUCONAZOLE (EDS) DOM 1.8065 02281260 CO FLUCONAZOLE (EDS) COB 1.8065

* 100MG TABLET02236979 NOVO-FLUCONAZOLE (EDS) NOP $ 3.2047 02237371 APO-FLUCONAZOLE (EDS) APX 3.2047 02245293 MYLAN-FLUCONAZOLE (EDS) MYL 3.2047 02245644 PMS-FLUCONAZOLE (EDS) PMS 3.2047 02246109 DOM-FLUCONAZOLE (EDS) DOM 3.2047 02281279 CO FLUCONAZOLE (EDS) COB 3.2047

10MG/ML POWDER FOR ORAL SUSPENSION02024152 DIFLUCAN P.O.S. (EDS) PFI $ 0.9909

FLUCONAZOLE/CLOTRIMAZOLE 150MG CAPSULE/1% CREAM

02311739 CANESORAL COMBI-PAK BCD $ 17.6300

ITRACONAZOLE SEE APPENDIX A FOR EDS CRITERIA 100MG CAPSULE

02047454 SPORANOX (EDS) JAN $ 4.1200 10MG/ML ORAL SOLUTION

02231347 SPORANOX (EDS) JAN $ 0.7830

KETOCONAZOLE SEE APPENDIX A FOR EDS CRITERIA

* 200MG TABLET02122197 NU-KETOCON (EDS) NXP $ 0.9393 02231061 NOVO-KETOCONAZOLE (EDS) NOP 0.9393 02237235 APO-KETOCONAZOLE (EDS) APX 0.9393

62nd Edition 3 July 1, 2012

Page 26: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

08:00 ANTI-INFECTIVE AGENTS

08:12.04 ANTIBIOTICS (ANTIFUNGALS)

NYSTATIN 500,000U TABLET

02194198 RATIO-NYSTATIN RPH $ 0.2472 * 100,000U/ML ORAL SUSPENSION

00792667 PMS-NYSTATIN PMS $ 0.0521 02125145 DOM-NYSTATIN DOM 0.0521 02194201 RATIO-NYSTATIN RPH 0.0521

TERBINAFINE HCL* 250MG TABLET

02239893 APO-TERBINAFINE APX $ 1.8527 02240346 NOVO-TERBINAFINE NOP 1.8527 02242503 MYLAN-TERBINAFINE MYL 1.8527 02248845 NU-TERBINAFINE NXP 1.8527 02254727 CO TERBINAFINE COB 1.8527 02262177 SANDOZ TERBINAFINE SDZ 1.8527 02320134 AURO-TERBINAFINE API 1.8527 02353121 TERBINAFINE SAN 1.8527 02031116 LAMISIL NVR 4.1300

VORICONAZOLE SEE APPENDIX A FOR EDS CRITERIA 50MG TABLET

02256460 VFEND (EDS) PFI $ 12.4817 200MG TABLET

02256479 VFEND (EDS) PFI $ 49.9064

08:12.06 ANTIBIOTICS (CEPHALOSPORINS)

CEFIXIME SEE APPENDIX A FOR EDS CRITERIA 400MG TABLET

00868981 SUPRAX (EDS) AVT $ 3.5400 20MG/ML ORAL SUSPENSION

00868965 SUPRAX (EDS) AVT $ 0.4166

62nd Edition 4 July 1, 2012

Page 27: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

08:00 ANTI-INFECTIVE AGENTS

08:12.06 ANTIBIOTICS (CEPHALOSPORINS)

CEFPROZIL SEE APPENDIX A FOR EDS CRITERIA

* 250MG TABLET02292998 APO-CEFPROZIL (EDS) APX $ 0.6065 02293528 RAN-CEFPROZIL (EDS) RAN 0.6065 02302179 SANDOZ CEFPROZIL (EDS) SDZ 0.6065 02347245 AURO-CEFPROZIL (EDS) API 0.6065 02163659 CEFZIL (EDS) BMY 1.8159

* 500MG TABLET02293005 APO-CEFPROZIL (EDS) APX $ 1.1891 02293536 RAN-CEFPROZIL (EDS) RAN 1.1891 02302187 SANDOZ CEFPROZIL (EDS) SDZ 1.1891 02347253 AURO-CEFPROZIL (EDS) API 1.1891 02163667 CEFZIL (EDS) BMY 3.5604

* 25MG/ML ORAL SUSPENSION02293943 APO-CEFPROZIL (EDS) APX $ 0.0593 02303426 SANDOZ CEFPROZIL (EDS) SDZ 0.0593 02329204 RAN-CEFPROZIL (EDS) RAN 0.0593 02347261 AURO-CEFPROZIL (EDS) API 0.0593 02163675 CEFZIL (EDS) BMY 0.1775

* 50MG/ML ORAL SUSPENSION02293579 RAN-CEFPROZIL (EDS) RAN $ 0.1186 02293951 APO-CEFPROZIL (EDS) APX 0.1186 02303434 SANDOZ CEFPROZIL (EDS) SDZ 0.1186 02347288 AURO-CEFPROZIL (EDS) API 0.1186 02163683 CEFZIL (EDS) BMY 0.3547

CEFUROXIME AXETIL SEE APPENDIX A FOR EDS CRITERIA

* 250MG TABLET02242656 RATIO-CEFUROXIME (EDS) RPH $ 0.7237 02244393 APO-CEFUROXIME (EDS) APX 0.7237 02344823 AURO-CEFUROXIME (EDS) API 0.7237 02212277 CEFTIN (EDS) GSK 1.6527

* 500MG TABLET02242657 RATIO-CEFUROXIME (EDS) RPH $ 1.4337 02244394 APO-CEFUROXIME (EDS) APX 1.4337 02344831 AURO-CEFUROXIME (EDS) API 1.4337 02212285 CEFTIN (EDS) GSK 3.2740

25MG/ML ORAL SUSPENSION02212307 CEFTIN (EDS) GSK $ 0.1748

62nd Edition 5 July 1, 2012

Page 28: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

08:00 ANTI-INFECTIVE AGENTS

08:12.06 ANTIBIOTICS (CEPHALOSPORINS)

CEPHALEXIN MONOHYDRATE 250MG CAPSULE

00342084 NOVO-LEXIN NOP $ 0.3515 500MG CAPSULE

00342114 NOVO-LEXIN NOP $ 0.6646 * 250MG TABLET

00583413 NOVO-LEXIN NOP $ 0.2250 00768723 APO-CEPHALEX APX 0.2250 00865877 NU-CEPHALEX NXP 0.2250

* 500MG TABLET00583421 NOVO-LEXIN NOP $ 0.4500 00768715 APO-CEPHALEX APX 0.4500 00865885 NU-CEPHALEX NXP 0.4500

25MG/ML ORAL SUSPENSION00342106 NOVO-LEXIN NOP $ 0.0860

50MG/ML ORAL SUSPENSION00342092 NOVO-LEXIN NOP $ 0.1351

08:12.12 ANTIBIOTICS (MACROLIDES)

AZITHROMYCIN SEE APPENDIX A FOR EDS CRITERIA

* 250MG TABLET02247423 APO-AZITHROMYCIN (EDS) APX $ 1.7239 02255340 CO AZITHROMYCIN (EDS) COB 1.7239 02261634 PMS-AZITHROMYCIN (EDS) PMS 1.7239 02265826 SANDOZ AZITHROMYCIN (EDS) SDZ 1.7239 02267845 NOVO-AZITHROMYCIN (EDS) NOP 1.7239 02274531 GD-AZITHROMYCIN (EDS) GDI 1.7239 02275287 RATIO-AZITHROMYCIN (EDS) RPH 1.7239 02278359 MYLAN-AZITHROMYCIN (EDS) MYL 1.7239 02278499 DOM-AZITHROMYCIN (EDS) DOM 1.7239 02330881 AZITHROMYCIN (EDS) SAN 1.7239 02363364 AVA-AZITHROMYCIN (EDS) AVA 1.7239 02212021 ZITHROMAX (EDS) PFI 5.0290

62nd Edition 6 July 1, 2012

Page 29: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

08:00 ANTI-INFECTIVE AGENTS

08:12.12 ANTIBIOTICS (MACROLIDES)

* 600MG TABLET02256088 CO AZITHROMYCIN (EDS) COB $ 6.0000 02261642 PMS-AZITHROMYCIN (EDS) PMS 6.0000 02278502 DOM-AZITHROMYCIN (EDS) DOM 6.0000 02330911 AZITHROMYCIN (EDS) SAN 6.0000 02231143 ZITHROMAX (EDS) PFI 12.0694

* 20MG/ML ORAL SUSPENSION02274388 PMS-AZITHROMYCIN (EDS) PMS $ 0.3960 02315157 NOVO-AZITHROMYCIN (EDS) NOP 0.3960 02332388 SANDOZ AZITHROMYCIN (EDS) SDZ 0.3960 02363372 AVA-AZITHROMYCIN (EDS) AVA 0.3960 02223716 ZITHROMAX (EDS) PFI 1.0874

* 40MG/ML ORAL SUSPENSION02274396 PMS-AZITHROMYCIN (EDS) PMS $ 0.5607 02315165 NOVO-AZITHROMYCIN (EDS) NOP 0.5607 02332396 SANDOZ AZITHROMYCIN (EDS) SDZ 0.5607 02363380 AVA-AZITHROMYCIN (EDS) AVA 0.5607 02223724 ZITHROMAX (EDS) PFI 1.5407

CLARITHROMYCIN SEE APPENDIX A FOR EDS CRITERIA

* 250MG TABLET02247573 PMS-CLARITHROMYCIN (EDS) PMS $ 0.5770 02247818 RATIO-CLARITHROMYCIN (EDS) RPH 0.5770 02248856 MYLAN-CLARITHROMYCIN (EDS) MYL 0.5770 02266539 SANDOZ CLARITHROMYCIN (EDS) SDZ 0.5770 02274744 APO-CLARITHROMYCIN (EDS) APX 0.5770 02361426 RAN-CLARITHROMYCIN (EDS) RAN 0.5770 02366371 AVA-CLARITHROMYCIN (EDS) AVA 0.5770 01984853 BIAXIN BID (EDS) ABB 1.6833

* 500MG TABLET02247574 PMS-CLARITHROMCYIN (EDS) PMS $ 1.6293 02247819 RATIO-CLARITHROMYCIN (EDS) RPH 1.6293 02248857 MYLAN-CLARITHROMYCIN (EDS) MYL 1.6293 02266547 SANDOZ CLARITHROMYCIN (EDS) SDZ 1.6293 02274752 APO-CLARITHROMYCIN (EDS) APX 1.6293 02361434 RAN-CLARITHROMYCIN (EDS) RAN 1.6293 02366398 AVA-CLARITHROMYCIN (EDS) AVA 1.6293 02126710 BIAXIN BID (EDS) ABB 3.3271

500MG EXTENDED-RELEASE TABLET02244756 BIAXIN XL (EDS) ABB $ 2.5144

25MG/ML ORAL SUSPENSION02146908 BIAXIN (EDS) ABB $ 0.2924

50MG/ML ORAL SUSPENSION02244641 BIAXIN (EDS) ABB $ 0.5713

62nd Edition 7 July 1, 2012

Page 30: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

08:00 ANTI-INFECTIVE AGENTS

08:12.12 ANTIBIOTICS (MACROLIDES)

ERYTHROMYCIN BASE 250MG TABLET

00682020 ERYTHRO-BASE AAP $ 0.1828 250MG CAPSULE (ENTERIC COATED PELLETS)

00607142 ERYC PFI $ 0.4916 333MG CAPSULE (ENTERIC COATED PELLETS)

00873454 ERYC PFI $ 0.5462

ERYTHROMYCIN ESTOLATE 50MG/ML ORAL SUSPENSION

00262595 NOVO-RYTHRO ESTOLATE NOP $ 0.1234

ERYTHROMYCIN ETHYLSUCCINATE 40MG/ML ORAL SUSPENSION

00605859 NOVO-RYTHRO ETHYLSUCC NOP $ 0.0923 80MG/ML ORAL SUSPENSION

00652318 NOVO-RYTHRO ETHYLSUCC NOP $ 0.1398

ERYTHROMYCIN STEARATE 250MG TABLET

00545678 ERYTHRO-S AAP $ 0.2118

08:12.16 ANTIBIOTICS (PENICILLINS)

AMOXICILLIN (AMOXYCILLIN)* 250MG CAPSULE

00406724 NOVAMOXIN NOP $ 0.1750 00628115 APO-AMOXI APX 0.1750 00865567 NU-AMOXI NXP 0.1750 02230243 PMS-AMOXICILLIN PMS 0.1750 02238171 MYLAN-AMOXICILLIN MYL 0.1750 02352710 AMOXICILLIN SAN 0.1750

* 500MG CAPSULE00406716 NOVAMOXIN NOP $ 0.3417 00628123 APO-AMOXI APX 0.3417 00865575 NU-AMOXI NXP 0.3417 02230244 PMS-AMOXICILLIN PMS 0.3417 02238172 MYLAN-AMOXICILLIN MYL 0.3417 02352729 AMOXICILLIN SAN 0.3417

125MG CHEWABLE TABLET02036347 NOVAMOXIN NOP $ 0.4167

250MG CHEWABLE TABLET02036355 NOVAMOXIN NOP $ 0.6138

62nd Edition 8 July 1, 2012

Page 31: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

08:00 ANTI-INFECTIVE AGENTS

08:12.16 ANTIBIOTICS (PENICILLINS)

* 25MG/ML ORAL SUSPENSION00452149 NOVAMOXIN NOP $ 0.0353 00628131 APO-AMOXI APX 0.0353 00865540 NU-AMOXI NXP 0.0353 01934171 NOVAMOXIN (SUGAR REDUCED) NOP 0.0353 02230245 PMS-AMOXICILLIN PMS 0.0353 02352745 AMOXICILLIN SAN 0.0353 02352761 AMOXICILLIN LS SAN 0.0353

* 50MG/ML ORAL SUSPENSION00452130 NOVAMOXIN NOP $ 0.0540 00628158 APO-AMOXI APX 0.0540 00865559 NU-AMOXI NXP 0.0540 01934163 NOVAMOXIN (SUGAR REDUCED) NOP 0.0540 02230246 PMS-AMOXICILLIN PMS 0.0540 02352753 AMOXICILLIN SAN 0.0540 02352788 AMOXICILLIN LS SAN 0.0540

AMOXICILLIN TRIHYDRATE/POTASSIUM CLAVULANATE SEE APPENDIX A FOR EDS CRITERIA 250MG/125MG TABLET

02243350 APO-AMOXI CLAV (EDS) APX $ 0.9375 * 500MG/125MG TABLET

02243351 APO-AMOXI CLAV (EDS) APX $ 0.6673 02243771 RATIO-ACLAVULANATE (EDS) RPH 0.6673 01916858 CLAVULIN-500 (EDS) GSK 1.4800

* 875MG/125MG TABLET02245623 APO-AMOXI CLAV (EDS) APX $ 0.7771 02247021 RATIO-ACLAVULANATE (EDS) RPH 0.7771 02248138 NOVO-CLAVAMOXIN (EDS) NOP 0.7771 02238829 CLAVULIN-875 (EDS) GSK 2.2205

* 25MG/6.25MG/ML ORAL SUSPENSION02243986 APO-AMOXI CLAV (EDS) APX $ 0.0517 02244646 RATIO-ACLAVULANATE (EDS) RPH 0.0517 01916882 CLAVULIN-125F (EDS) GSK 0.1170

40MG/5.3MG/ML ORAL SUSPENSION02238831 CLAVULIN-200 (EDS) GSK $ 0.1440

* 50MG/12.5MG/ML ORAL SUSPENSION02243987 APO-AMOXI CLAV (EDS) APX $ 0.0869 02244647 RATIO-ACLAVULANATE (EDS) RPH 0.0869 01916874 CLAVULIN-250F (EDS) GSK 0.2011

* 80MG/11.4MG/ML ORAL SUSPENSION02288559 APO-AMOX CLAV (EDS) APX $ 0.1969 02238830 CLAVULIN-400 (EDS) GSK 0.2753

62nd Edition 9 July 1, 2012

Page 32: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

08:00 ANTI-INFECTIVE AGENTS

08:12.16 ANTIBIOTICS (PENICILLINS)

AMPICILLIN 250MG CAPSULE

00020877 NOVO-AMPICILLIN NOP $ 0.3532 500MG CAPSULE

00020885 NOVO-AMPICILLIN NOP $ 0.6848

CLOXACILLIN 250MG CAPSULE

00337765 NOVO-CLOXIN NOP $ 0.3515 500MG CAPSULE

00337773 NOVO-CLOXIN NOP $ 0.6646 25MG/ML ORAL LIQUID

00337757 NOVO-CLOXIN NOP $ 0.0855

PENICILLIN V (POTASSIUM)* 300MG TABLET

00021202 NOVO-PEN-VK NOP $ 0.0710 00642215 APO-PEN-VK APX 0.0710 00717568 NU-PEN-VK NXP 0.0710

25MG/ML ORAL SOLUTION00642223 APO-PEN-VK APX $ 0.0535

08:12.24 ANTIBIOTICS (TETRACYCLINES)

DOXYCYCLINE* 100MG CAPSULE

00725250 NOVO-DOXYLIN TEV $ 0.5860 00740713 APO-DOXY APX 0.5860 02044668 NU-DOXYCYCLINE NXP 0.5860 02351234 DOXYCYCLINE SAN 0.5860 00024368 VIBRAMYCIN PFI 1.7304

* 100MG TABLET00874256 APO-DOXY APX $ 0.5860 02044676 NU-DOXYCYCLINE NXP 0.5860 02158574 NOVO-DOXYLIN NOP 0.5860 02351242 DOXYCYLINE SAN 0.5860

MINOCYCLINE HCL SEE APPENDIX A FOR EDS CRITERIA

* 50MG CAPSULE02084090 APO-MINOCYCLINE (EDS) APX $ 0.3064 02108143 NOVO-MINOCYCLINE (EDS) NOP 0.3064 02230735 MYLAN-MINOCYCLINE (EDS) MYL 0.3064 02237313 SANDOZ MINOCYCLINE (EDS) SDZ 0.3064 02287226 MINOCYCLINE (EDS) SAN 0.3064 02294419 PMS-MINOCYCLINE (EDS) PMS 0.3064

62nd Edition 10 July 1, 2012

Page 33: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

08:00 ANTI-INFECTIVE AGENTS08:12.24 ANTIBIOTICS (TETRACYCLINES)

* 100MG CAPSULE02084104 APO-MINOCYCLINE (EDS) APX $ 0.5912 02108151 NOVO-MINOCYCLINE (EDS) NOP 0.5912 02230736 MYLAN-MINOCYCLINE (EDS) MYL 0.5912 02237314 SANDOZ MINOCYCLINE (EDS) SDZ 0.5912 02287234 MINOCYCLINE (EDS) SAN 0.5912 02294427 PMS-MINOCYCLINE (EDS) PMS 0.5912

TETRACYCLINE 250MG CAPSULE

00580929 TETRACYCLINE AAP $ 0.0657

08:12.28 ANTIBIOTICS (MISCELLANEOUS ANTIBIOTICS)

AZTREONAM SEE APPENDIX A FOR EDS CRITERIA 75MG VIAL INHALATION POWDER FOR SOLUTION

02329840 CAYSTON (EDS) GSI $ 48.1600

CLINDAMYCIN HCL* 150MG CAPSULE

02241709 TEVA-CLINDAMYCIN NOP $ 0.3284 02245232 APO-CLINDAMYCIN APX 0.3284 02258331 MYLAN-CLINDAMYCIN MYL 0.3284 00030570 DALACIN C PFI 0.9412

* 300MG CAPSULE02241710 NOVO-CLINDAMYCIN NOP $ 0.6568 02245233 APO-CLINDAMYCIN APX 0.6568 02258358 MYLAN-CLINDAMYCIN MYL 0.6568 02182866 DALACIN C PFI 1.8823

CLINDAMYCIN PALMITATE HCL 15MG/ML ORAL SOLUTION

00225851 DALACIN C PFI $ 0.1243

LINEZOLID SEE APPENDIX A FOR EDS CRITERIA 600MG TABLET

02243684 ZYVOXAM (EDS) PFI $ 74.2180 100MG/5ML ORAL SUSPENSION

02243686 ZYVOXAM (EDS) PFI $ 2.4546

VANCOMYCIN HCL SEE APPENDIX A FOR EDS CRITERIA 125MG CAPSULE

00800430 VANCOCIN (EDS) MRL $ 8.1340 250MG CAPSULE

00788716 VANCOCIN (EDS) MRL $ 16.2680

62nd Edition 11 July 1, 2012

Page 34: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

08:00 ANTI-INFECTIVE AGENTS

08:12.28 ANTIBIOTICS (MISCELLANEOUS ANTIBIOTICS)

* 500MG INJECTION02241820 PMS-VANCOMYCIN (EDS) PMS $ 31.0500 02342855 VAL-VANCO (EDS) VAL 31.0500

* 1GM INJECTION02241821 PMS-VANCOMYCIN (EDS) PMS $ 58.9900 02342863 VAL-VANCO (EDS) VAL 58.9900

08:18.04 ADAMANTANES

AMANTADINE* 100MG CAPSULE

01990403 PMS-AMANTADINE PMS $ 0.5179 02130963 DOM-AMANTADINE DOM 0.5179 02139200 MYLAN-AMANTADINE MYL 0.5179

10MG/ML SYRUP02022826 PMS-AMANTADINE PMS $ 0.1005

08:18.08 ANTIRETROVIRAL AGENTS (HIV FUSION INHIBITORS)

ENFUVIRTIDE SEE APPENDIX A FOR EDS CRITERIA 108MG/VIAL POWDER FOR SOLUTION

02247725 FUZEON (EDS) HLR $ 39.7600

08:18.08 ANTIRETROVIRAL AGENTS (NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS)

DELAVIRDINE MESYLATE SEE APPENDIX A FOR EDS CRITERIA 100MG TABLET

02238348 RESCRIPTOR (EDS) VII $ 0.7329

EFAVIRENZ SEE APPENDIX A FOR EDS CRITERIA 50MG CAPSULE

02239886 SUSTIVA (EDS) BMY $ 1.2310 200MG CAPSULE

02239888 SUSTIVA (EDS) BMY $ 4.9232 600MG TABLET

02246045 SUSTIVA (EDS) BMY $ 14.7694

62nd Edition 12 July 1, 2012

Page 35: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

08:00 ANTI-INFECTIVE AGENTS

08:18.08 ANTIRETROVIRAL AGENTS (NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS)

ETRAVIRINE SEE APPENDIX A FOR EDS CRITERIA 100MG TABLET

02306778 INTELENCE (EDS) JAN $ 5.7310 200MG TABLET

02375931 INTELENCE (EDS) JAN $ 10.9000

NEVIRAPINE SEE APPENDIX A FOR EDS CRITERIA

* 200MG TABLET02318601 AURO-NEVIRAPINE (EDS) API $ 1.7285 02352893 TEVA-NEVIRAPINE (EDS) TEV 1.7285 02238748 VIRAMUNE (EDS) BOE 4.9384

08:18.08 ANTIRETROVIRAL AGENTS (NUCLEOSIDE/ NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS)

ABACAVIR SO4 SEE APPENDIX A FOR EDS CRITERIA 300MG TABLET

02240357 ZIAGEN (EDS) VII $ 6.8694 20MG/ML ORAL SOLUTION

02240358 ZIAGEN (EDS) VII $ 0.4568

ABACAVIR SO4/LAMIVUDINE SEE APPENDIX A FOR EDS CRITERIA 600MG/300MG TABLET

02269341 KIVEXA (EDS) VII $ 23.2700

ABACAVIR SO4/LAMIVUDINE/ZIDOVUDINE SEE APPENDIX A FOR EDS CRITERIA 300MG/150MG/300MG TABLET

02244757 TRIZIVIR (EDS) VII $ 17.6737

DIDANOSINE SEE APPENDIX A FOR EDS CRITERIA 125MG CAPSULE (ENTERIC COATED BEADLET)

02244596 VIDEX EC (EDS) BMY $ 3.6344 200MG CAPSULE (ENTERIC COATED BEADLET)

02244597 VIDEX EC (EDS) BMY $ 5.8154 250MG CAPSULE (ENTERIC COATED BEADLET)

02244598 VIDEX EC (EDS) BMY $ 7.2034 400MG CAPSULE (ENTERIC COATED BEADLET)

02244599 VIDEX EC (EDS) BMY $ 11.6530

EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXILFUMARATE SEE APPENDIX A FOR EDS CRITERIA 600MG/200MG/300MG TABLET

02300699 ATRIPLA (EDS) BMY $ 41.0864

62nd Edition 13 July 1, 2012

Page 36: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

08:00 ANTI-INFECTIVE AGENTS

08:18.08 ANTIRETROVIRAL AGENTS (NUCLEOSIDE/ NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS)

EMTRICITABINE/TENOFOVIR DISOPROXIL FUMARATE SEE APPENDIX A FOR EDS CRITERIA 200MG/300MG TABLET

02274906 TRUVADA (EDS) GSI $ 26.3170

LAMIVUDINE SEE APPENDIX A FOR EDS CRITERIA 100MG TABLET

02239193 HEPTOVIR (EDS) GSK $ 4.7089 150MG TABLET

02192683 3TC (EDS) VII $ 4.8959 300MG TABLET

02247825 3TC (EDS) VII $ 9.6717 10MG/ML ORAL SOLUTION

02192691 3TC (EDS) VII $ 0.3140

LAMIVUDINE/ZIDOVUDINE SEE APPENDIX A FOR EDS CRITERIA 150MG/300MG TABLET

02239213 COMBIVIR (EDS) VII $ 10.4412

STAVUDINE SEE APPENDIX A FOR EDS CRITERIA 15MG CAPSULE

02216086 ZERIT (EDS) BMY $ 4.4307 20MG CAPSULE

02216094 ZERIT (EDS) BMY $ 4.6072 30MG CAPSULE

02216108 ZERIT (EDS) BMY $ 4.8057 40MG CAPSULE

02216116 ZERIT (EDS) BMY $ 4.9820

TENOFOVIR DISOPROXIL FUMARATE SEE APPENDIX A FOR EDS CRITERIA 300MG TABLET

02247128 VIREAD (EDS) GSI $ 17.8290

ZIDOVUDINE SEE APPENDIX A FOR EDS CRITERIA

* 100MG CAPSULE01946323 APO-ZIDOVUDINE (EDS) APX $ 1.2750 01902660 RETROVIR (EDS) VII 1.8636

10MG/ML SOLUTION01902652 RETROVIR (EDS) VII $ 0.1975

10MG/ML INJECTION SOLUTION01902644 RETROVIR (EDS) VII $ 17.3500

62nd Edition 14 July 1, 2012

Page 37: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

08:00 ANTI-INFECTIVE AGENTS

08:18.08 INTEGRASE INHIBITORS

RALTEGRAVIR SEE APPENDIX A FOR EDS CRITERIA 400MG TABLET

02301881 ISENTRESS (EDS) MRK $ 13.5000

08:18.08 ANTIRETROVIRAL AGENTS (PROTEASE INHIBITORS)

ATAZANAVIR SO4 SEE APPENDIX A FOR EDS CRITERIA 150MG CAPSULE

02248610 REYATAZ (EDS) BMY $ 11.1077 200MG CAPSULE

02248611 REYATAZ (EDS) BMY $ 11.1454 300MG CAPSULE

02294176 REYATAZ (EDS) BMY $ 21.7797

DARUNAVIR SEE APPENDIX A FOR EDS CRITERIA 75MG TABLET

02338432 PREZISTA (EDS) JAN $ 1.8380 400MG TABLET

02324016 PREZISTA (EDS) JAN $ 10.5410 600MG TABLET

02324024 PREZISTA (EDS) JAN $ 14.9890

FOSAMPRENAVIR CALCIUM SEE APPENDIX A FOR EDS CRITERIA 700MG TABLET

02261545 TELZIR (EDS) VII $ 8.0864 50MG/ML ORAL SUSPENSION

02261553 TELZIR (EDS) VII $ 0.5912

INDINAVIR SO4 SEE APPENDIX A FOR EDS CRITERIA 200MG CAPSULE

02229161 CRIXIVAN (EDS) MRK $ 1.3467 400MG CAPSULE

02229196 CRIXIVAN (EDS) MRK $ 2.6934

LOPINAVIR/RITONAVIR SEE APPENDIX A FOR EDS CRITERIA 100MG/25MG TABLET

02312301 KALETRA (EDS) ABB $ 2.7002 200MG/50MG TABLET

02285533 KALETRA (EDS) ABB $ 5.4490 80MG/20MG (ML) ORAL SOLUTION

02243644 KALETRA (EDS) ABB $ 2.1649

62nd Edition 15 July 1, 2012

Page 38: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

08:00 ANTI-INFECTIVE AGENTS08:18.08 ANTIRETROVIRAL AGENTS (PROTEASE INHIBITORS)

NELFINAVIR MESYLATE SEE APPENDIX A FOR EDS CRITERIA 250MG TABLET

02238617 VIRACEPT (EDS) VII $ 1.8583 625MG TABLET

02248761 VIRACEPT (EDS) VII $ 4.6456

RITONAVIR SEE APPENDIX A FOR EDS CRITERIA 100MG SOFT ELASTIC CAPSULE

02241480 NORVIR SEC (EDS) ABB $ 1.4671 100MG TABLET

02357593 NORVIR (EDS) ABB $ 1.4670 80MG/ML ORAL SOLUTION

02229145 NORVIR (EDS) ABB $ 1.1840

SAQUINAVIR SEE APPENDIX A FOR EDS CRITERIA 200MG CAPSULE

02216965 INVIRASE (EDS) HLR $ 1.8564 500MG TABLET

02279320 INVIRASE (EDS) HLR $ 4.2840

TIPRANAVIR SEE APPENDIX A FOR EDS CRITERIA 250MG CAPSULE

02273322 APTIVUS (EDS) BOE $ 8.2500

08:18.20 INTERFERONS

INTERFERON ALFA-2B SEE APPENDIX A FOR EDS CRITERIA 6 MILLION IU/ML INJECTION SOLUTION ALBUMIN (HUMAN) FREE (0.5ML)

02238674 INTRON-A (EDS) SCH $ 71.4900 10 MILLION IU POWDER FOR INJECTION

02223406 INTRON-A (EDS) SCH $ 123.3500 10 MILLION IU/ML INJECTION SOLUTION ALBUMIN (HUMAN) FREE (0.5ML, 1ML)

02238675 INTRON-A (EDS) MRK $ 148.9350 18 MILLION IU/PEN MULTI-DOSE PEN (KIT) ALBUMIN (HUMAN) FREE

02240693 INTRON-A (EDS) SCH $ 214.4700 30 MILLION IU/PEN MULTI-DOSE PEN (KIT) ALBUMIN (HUMAN) FREE

02240694 INTRON-A (EDS) SCH $ 357.4200 60 MILLION IU/PEN MULTI-DOSE PEN (KIT) ALBUMIN (HUMAN) FREE

02240695 INTRON-A (EDS) SCH $ 714.8900

62nd Edition 16 July 1, 2012

Page 39: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

08:00 ANTI-INFECTIVE AGENTS08:18.20 INTERFERONS

PEGINTERFERON ALFA-2A SEE APPENDIX A FOR EDS CRITERIA 180UG/0.5ML PRE-FILLED SYRINGE

02248077 PEGASYS (EDS) HLR $ 395.8400

PEGINTERFERON ALFA-2A/RIBAVIRIN SEE APPENDIX A FOR EDS CRITERIA 180UG/0.5ML PRE-FILLED SYRINGE/200MG TABLET

02253429 PEGASYS RBV (EDS) HLR $ 395.8400

PEGINTERFERON ALFA-2B/RIBAVIRIN SEE APPENDIX A FOR EDS CRITERIA 50UG/0.5ML POWDER FOR SOLUTION/200MG CAPSULE

02246026 PEGETRON (EDS) SCH $ 752.2000 80UG/0.5ML SINGLE DOSE REDIPEN/200MG CAPSULE

02254581 PEGETRON REDIPEN (EDS) SCH $ 752.2000 100UG/0.5ML SINGLE DOSE REDIPEN/200MG CAPSULE

02254603 PEGETRON REDIPEN (EDS) SCH $ 752.2000 120UG/0.5ML SINGLE DOSE REDIPEN/200MG CAPSULE

02254638 PEGETRON REDIPEN (EDS) SCH $ 831.1800 150UG/0.5ML POWDER FOR SOLUTION/200MG CAPSUL E

02246030 PEGETRON (EDS) SCH $ 831.1800 150UG/0.5ML SINGLE DOSE REDIPEN/200MG CAPSULE

02254646 PEGETRON REDIPEN (EDS) SCH $ 831.1800

08:18.32 NUCLEOSIDES AND NUCLEOTIDES

ACYCLOVIR* 200MG TABLET

02078627 RATIO-ACYCLOVIR RPH $ 0.6397 02197405 NU-ACYCLOVIR NXP 0.6397 02207621 APO-ACYCLOVIR APX 0.6397 02242784 MYLAN-ACYCLOVIR MYL 0.6397 02285959 NOVO-ACYCLOVIR NOP 0.6397 02286556 ACYCLOVIR SAN 0.6397 00634506 ZOVIRAX GSK 1.3063

* 400MG TABLET02078635 RATIO-ACYCLOVIR RPH $ 1.2700 02197413 NU-ACYCLOVIR NXP 1.2700 02207648 APO-ACYCLOVIR APX 1.2700 02242463 MYLAN-ACYCLOVIR MYL 1.2700 02285967 NOVO-ACYCLOVIR NOP 1.2700 02286564 ACYCLOVIR SAN 1.2700 01911627 ZOVIRAX WELLSTAT PAC GSK 4.7000

62nd Edition 17 July 1, 2012

Page 40: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

08:00 ANTI-INFECTIVE AGENTS

08:18.32 NUCLEOSIDES AND NUCLEOTIDES

* 800MG TABLET02078651 RATIO-ACYCLOVIR RPH $ 1.7742 02197421 NU-ACYCLOVIR NXP 1.7742 02207656 APO-ACYCLOVIR APX 1.7742 02242464 MYLAN-ACYCLOVIR MYL 1.7742 02285975 NOVO-ACYCLOVIR NOP 1.7742 02286572 ACYCLOVIR SAN 1.7742

ADEFOVIR DIPIVOXIL SEE APPENDIX A FOR EDS CRITERIA 10MG TABLET

02247823 HEPSERA (EDS) GSI $ 23.3467

ENTECAVIR SEE APPENDIX A FOR EDS CRITERIA 0.5MG TABLET

02282224 BARACLUDE (EDS) BMY $ 22.0000

FAMCICLOVIR* 125MG TABLET

02278081 PMS-FAMCICLOVIR PMS $ 1.3940 02278634 SANDOZ FAMCICLOVIR SDZ 1.3940 02292025 APO-FAMCICLOVIR APX 1.3940 02305682 CO FAMCICLOVIR COB 1.3940 02366827 AVA-FAMCICLOVIR AVA 1.3940 02229110 FAMVIR NVR 2.8520

* 250MG TABLET02278103 PMS-FAMCICLOVIR PMS $ 1.8733 02278642 SANDOZ FAMCICLOVIR SDZ 1.8733 02292041 APO-FAMCICLOVIR APX 1.8733 02305690 CO FAMCICLOVIR COB 1.8733 02366835 AVA-FAMCICLOVIR AVA 1.8733 02229129 FAMVIR NVR 3.8684

* 500MG TABLET02278111 PMS-FAMCICLOVIR PMS $ 2.3668 02278650 SANDOZ FAMCICLOVIR SDZ 2.3668 02292068 APO-FAMCICLOVIR APX 2.3668 02305704 CO FAMCICLOVIR COB 2.3668 02366843 AVA-FAMCICLOVIR AVA 2.3668 02177102 FAMVIR NVR 6.9048

VALACYCLOVIR* 500MG TABLET

02295822 APO-VALACYCLOVIR APX $ 1.1873 02298457 PMS-VALACYCLOVIR PMS 1.1873 02331748 CO VALACYCLOVIR COB 1.1873 02351579 MYLAN-VALACYCLOVIR MYL 1.1873 02219492 VALTREX GSK 3.3927

62nd Edition 18 July 1, 2012

Page 41: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

08:00 ANTI-INFECTIVE AGENTS

08:18.32 NUCLEOSIDES AND NUCLEOTIDES

VALGANCICLOVIR HCL SEE APPENDIX A FOR EDS CRITERIA 450MG TABLET

02245777 VALCYTE (EDS) HLR $ 22.8582 50MG/ML POWDER FOR ORAL SOLUTION (ML)

02306085 VALCYTE (EDS) HLR $ 2.5398

08:20.00 ANTIMALARIAL AGENTS

CHLOROQUINE PHOSPHATE 250MG TABLET

00021261 NOVO-CHLOROQUINE NOP $ 0.4010

HYDROXYCHLOROQUINE SO4* 200MG TABLET

02246691 APO-HYDROXYQUINE APX $ 0.2620 02252600 MYLAN-HYDROXYCHLOROQUINE MYL 0.2620 02017709 PLAQUENIL AVT 0.6154

PYRIMETHAMINE 25MG TABLET

00004774 DARAPRIM TRI $ 1.3770

QUININE SO4* 200MG CAPSULE

00021008 NOVO-QUININE NOP $ 0.2390 00695440 QUININE-ODAN ODN 0.2390 02254514 APO-QUININE APX 0.2390

* 300MG CAPSULE00021016 NOVO-QUININE NOP $ 0.3750 00695459 QUININE-ODAN ODN 0.3750 02254522 APO-QUININE APX 0.3750

300MG TABLET00695432 QUININE-ODAN ODN $ 0.3750

62nd Edition 19 July 1, 2012

Page 42: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

08:00 ANTI-INFECTIVE AGENTS

08:22.00 QUINOLONES

CIPROFLOXACIN SEE APPENDIX A FOR EDS CRITERIA

* 250MG TABLET02161737 NOVO-CIPROFLOXACIN (EDS) NOP $ 0.8660 02229521 APO-CIPROFLOX (EDS) APX 0.8660 02245647 MYLAN-CIPROFLOXACIN (EDS) MYL 0.8660 02246825 RATIO-CIPROFLOXACIN (EDS) RPH 0.8660 02247339 CO CIPROFLOXACIN (EDS) COB 0.8660 02248437 PMS-CIPROFLOXACIN (EDS) PMS 0.8660 02248756 SANDOZ CIPROFLOXACIN (EDS) SDZ 0.8660 02249634 NU-CIPROFLOXACIN (EDS) NXP 0.8660 02251272 DOM-CIPROFLOXACIN (EDS) DOM 0.8660 02303728 RAN-CIPROFLOX (EDS) RAN 0.8660 02317427 MINT-CIPROFLOXACIN (EDS) MNT 0.8660 02353318 CIPROFLOXACIN (EDS) SAN 0.8660 02379627 SEPTA-CIPROFLOXACIN (EDS) SPT 0.8660 02379686 MAR-CIPROFLOXACIN (EDS) MPI 0.8660 02155958 CIPRO (EDS) BAY 2.4742

* 500MG TABLET02161745 NOVO-CIPROFLOXACIN (EDS) NOP $ 0.9770 02229522 APO-CIPROFLOX (EDS) APX 0.9770 02245648 MYLAN-CIPROFLOXACIN (EDS) MYL 0.9770 02246826 RATIO-CIPROFLOXACIN (EDS) RPH 0.9770 02247340 CO CIPROFLOXACIN (EDS) COB 0.9770 02248438 PMS-CIPROFLOXACIN (EDS) PMS 0.9770 02248757 SANDOZ CIPROFLOXACIN (EDS) SDZ 0.9770 02249642 NU-CIPROFLOXACIN (EDS) NXP 0.9770 02251280 DOM-CIPROFLOXACIN (EDS) DOM 0.9770 02303736 RAN-CIPROFLOX (EDS) RAN 0.9770 02317435 MINT-CIPROFLOXACIN (EDS) MNT 0.9770 02353326 CIPROFLOXACIN (EDS) SAN 0.9770 02379635 SEPTA-CIPROFLOXACIN (EDS) SPT 0.9770 02379694 MAR-CIPROFLOXACIN (EDS) MPI 0.9770 02155966 CIPRO (EDS) BAY 2.7915

* 750MG TABLET02161753 NOVO-CIPROFLOXACIN (EDS) NOP $ 1.7891 02229523 APO-CIPROFLOX (EDS) APX 1.7891 02245649 MYLAN-CIPROFLOXACIN (EDS) MYL 1.7891 02246827 RATIO-CIPROFLOXACIN (EDS) RPH 1.7891 02247341 CO CIPROFLOXACIN (EDS) COB 1.7891 02248439 PMS-CIPROFLOXACIN (EDS) PMS 1.7891 02248758 SANDOZ CIPROFLOXACIN (EDS) SDZ 1.7891 02249650 NU-CIPROFLOXACIN (EDS) NXP 1.7891 02251299 DOM-CIPROFLOXACIN (EDS) DOM 1.7891 02303744 RAN-CIPROFLOX (EDS) RAN 1.7891 02317443 MINT-CIPROFLOXACIN (EDS) MNT 1.7891 02353334 CIPROFLOXACIN (EDS) SAN 1.7891 02379643 SEPTA-CIPROFLOXACIN (EDS) SPT 1.7891 02379708 MAR-CIPROFLOXACIN (EDS) MAR 1.7891 02155974 CIPRO (EDS) BAY 5.1118

62nd Edition 20 July 1, 2012

Page 43: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

08:00 ANTI-INFECTIVE AGENTS

08:22.00 QUINOLONES

500MG EXTENDED RELEASE TABLET02247916 CIPRO XL (EDS) BAY $ 3.0813

1000MG EXTENDED RELEASE TABLET02251787 CIPRO XL (EDS) BAY $ 3.0813

100MG/ML ORAL SUSPENSION02237514 CIPRO (EDS) BAY $ 0.5699

LEVOFLOXACIN SEE APPENDIX A FOR EDS CRITERIA

* 250MG TABLET02248262 NOVO-LEVOFLOXACIN (EDS) NOP $ 1.6567 02284677 PMS-LEVOFLOXACIN (EDS) PMS 1.6567 02284707 APO-LEVOFLOXACIN (EDS) APX 1.6567 02298635 SANDOZ LEVOFLOXACIN (EDS) SDZ 1.6567 02313979 MYLAN-LEVOFLOXACIN (EDS) MYL 1.6567 02315424 CO LEVOFLOXACIN (EDS) COB 1.6567 02361027 AVA-LEVOFLOXACIN (EDS) AVA 1.6567 02236841 LEVAQUIN (EDS) JAN 5.4660

* 500MG TABLET02248263 NOVO-LEVOFLOXACIN (EDS) NOP $ 1.8694 02284685 PMS-LEVOFLOXACIN (EDS) PMS 1.8694 02284715 APO-LEVOFLOXACIN (EDS) APX 1.8694 02298643 SANDOZ LEVOFLOXACIN (EDS) SDZ 1.8694 02313987 MYLAN-LEVOFLOXACIN (EDS) MYL 1.8694 02315432 CO LEVOFLOXACIN (EDS) COB 1.8694 02361035 AVA-LEVOFLOXACIN (EDS) AVA 1.8694 02236842 LEVAQUIN (EDS) JAN 6.2288

* 750MG TABLET02285649 NOVO-LEVOFLOXACIN (EDS) NOP $ 4.8480 02298651 SANDOZ LEVOFLOXACIN (EDS) SDZ 4.8480 02305585 PMS-LEVOFLOXACIN (EDS) PMS 4.8480 02315440 CO LEVOFLOXACIN (EDS) COB 4.8480 02325942 APO-LEVOFLOXACIN (EDS) APX 4.8480 02246804 LEVAQUIN (EDS) JAN 10.7276

MOXIFLOXACIN HCL SEE APPENDIX A FOR EDS CRITERIA 400MG TABLET

02242965 AVELOX (EDS) BAY $ 5.9428

NORFLOXACIN SEE APPENDIX A FOR EDS CRITERIA

* 400MG TABLET02229524 APO-NORFLOX (EDS) APX $ 0.7933 02237682 NOVO-NORFLOXACIN (EDS) NOP 0.7933 02246596 PMS-NORFLOXACIN (EDS) PMS 0.7933 02269627 CO NORFLOXACIN (EDS) COB 0.7933

62nd Edition 21 July 1, 2012

Page 44: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

08:00 ANTI-INFECTIVE AGENTS

08:26.00 SULFONES

DAPSONE 100MG TABLET

02041510 DAPSONE JAC $ 1.3391

08:36.00 URINARY ANTI-INFECTIVES

FOSFOMYCIN TROMETHAMINE SEE APPENDIX A FOR EDS CRITERIA 3G ORAL POWDER (SACHET)

02240335 MONUROL (EDS) TPI $ 22.5900

METHENAMINE MANDELATE 500MG ENTERIC TABLET

00499013 MANDELAMINE ERF $ 0.3448

NITROFURANTOIN 50MG CAPSULE (MACROCRYSTALS)

02231015 NOVO-FURANTOIN NOP $ 0.3984 50MG TABLET

00319511 NITROFURANTOIN AAP $ 0.1670 100MG TABLET

00312738 NITROFURANTOIN AAP $ 0.2227

NITROFURANTOIN MONOHYDRATE 100MG CAPSULE (MACROCRYSTALS)

02063662 MACROBID WCI $ 0.7040

TRIMETHOPRIM 100MG TABLET

02243116 TRIMETHOPRIM AAP $ 0.2566 200MG TABLET

02243117 TRIMETHOPRIM AAP $ 0.5273

08:40.00 MISCELLANEOUS ANTI-INFECTIVES

ATOVAQUONE SEE APPENDIX A FOR EDS CRITERIA 150MG/ML SUSPENSION

02217422 MEPRON (EDS) GSK $ 2.6162

62nd Edition 22 July 1, 2012

Page 45: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

08:00 ANTI-INFECTIVE AGENTS

08:40.00 MISCELLANEOUS ANTI-INFECTIVES

METRONIDAZOLE 250MG TABLET

00545066 METRONIDAZOLE AAP $ 0.0595 500MG CAPSULE

02248562 METRONIDAZOLE AAP $ 0.7028

SULFAMETHOXAZOLE/TRIMETHOPRIM(CO-TRIMOXAZOLE)* 400MG/80MG TABLET

00445274 APO-SULFATRIM APX $ 0.0482 00510637 NOVO-TRIMEL NOP 0.0482 00865710 NU-COTRIMOX NXP 0.0482

* 800MG/160MG TABLET00445282 APO-SULFATRIM DS APX $ 0.1221 00510645 NOVO-TRIMEL DS NOP 0.1221

100MG/20MG PEDIATRIC TABLET00445266 APO-SULFATRIM APX $ 0.0911

40MG/8MG PER ML ORAL SUSPENSION00726540 NOVO-TRIMEL NOP $ 0.0929

62nd Edition 23 July 1, 2012

Page 46: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...
Page 47: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

ANTINEOPLASTIC AGENTS10:00

Page 48: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

10:00 ANTINEOPLASTIC AGENTS

10:00.00 ANTINEOPLASTIC AGENTS

CYPROTERONE ACETATE SEE APPENDIX A FOR EDS CRITERIA

* 50MG TABLET00704431 ANDROCUR (EDS) PMS $ 1.4085 02245898 CYPROTERONE (EDS) AAP 1.4085

100MG/ML INJECTION00704423 ANDROCUR (EDS) PMS $ 81.5900

MEGESTROL SEE APPENDIX A FOR EDS CRITERIA 40MG TABLET

02195917 APO-MEGESTROL (EDS) AAP $ 1.0073 160MG TABLET

02195925 APO-MEGESTROL (EDS) AAP $ 4.2630 40MG/ML ORAL SUSPENSION

02168979 MEGACE OS (EDS) BMY $ 1.6978

MERCAPTOPURINE SEE APPENDIX A FOR EDS CRITERIA 50MG TABLET

00004723 PURINETHOL (EDS) NOP $ 4.7684

62nd Edition 26 July 1, 2012

Page 49: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

AUTONOMIC DRUGS12:00

Page 50: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

12:00 AUTONOMIC DRUGS

12:04.00 PARASYMPATHOMIMETIC (CHOLINERGIC) AGENTS

BETHANECHOL CHLORIDE 10MG TABLET

01947958 DUVOID PAL $ 0.2858 25MG TABLET

01947931 DUVOID PAL $ 0.4631 50MG TABLET

01947923 DUVOID PAL $ 0.6100

DONEPEZIL HCL SEE APPENDIX A FOR EDS CRITERIA 5MG TABLET

02232043 ARICEPT (EDS) PFI $ 4.8187 10MG TABLET

02232044 ARICEPT (EDS) PFI $ 4.8187

GALANTAMINE HYDROBROMIDE SEE APPENDIX A FOR EDS CRITERIA

* 8MG EXTENDED-RELEASE CAPSULE02316943 PAT-GALANTAMINE ER (EDS) PAT $ 1.7451 02339439 MYLAN-GALANTAMINE ER (EDS) MYL 1.7451 02377950 TEVA-GALANTAMINE ER (EDS) TEV 1.7451 02266717 REMINYL ER (EDS) JAN 5.1460

* 16MG EXTENDED-RELEASE CAPSULE02316951 PAT-GALANTAMINE ER (EDS) PAT $ 1.7451 02339447 MYLAN-GALANTAMINE ER (EDS) MYL 1.7451 02377969 TEVA-GALANTAMINE ER (EDS) TEV 1.7451 02266725 REMINYL ER (EDS) JAN 5.1460

* 24MG EXTENDED-RELEASE CAPSULE02316978 PAT-GALANTAMINE ER (EDS) PAT $ 1.7451 02339455 MYLAN-GALANTAMINE ER (EDS) MYL 1.7451 02377977 TEVA-GALANTAMINE ER (EDS) TEV 1.7451 02266733 REMINYL ER (EDS) JAN 5.1460

NEOSTIGMINE BROMIDE 15MG TABLET

00869945 PROSTIGMIN VAE $ 0.4562

PYRIDOSTIGMINE BROMIDE 60MG TABLET

00869961 MESTINON VAE $ 0.4484 180MG LONG ACTING TABLET

00869953 MESTINON VAE $ 0.9807

62nd Edition 28 July 1, 2012

Page 51: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

12:00 AUTONOMIC DRUGS

12:04.00 PARASYMPATHOMIMETIC (CHOLINERGIC) AGENTS

RIVASTIGMINE SEE APPENDIX A FOR EDS CRITERIA

* 1.5MG CAPSULE02306034 PMS-RIVASTIGMINE (EDS) PMS $ 0.9121 02311283 RATIO-RIVASTIGMINE (EDS) RPH 0.9121 02324563 SANDOZ RIVASTIGMINE (EDS) SDZ 0.9121 02336715 APO-RIVASTIGMINE (EDS) APX 0.9121 02242115 EXELON (EDS) NVR 2.6059

* 3MG CAPSULE02306042 PMS-RIVASTIGMINE (EDS) PMS $ 0.9121 02311291 RATIO-RIVASTIGMINE (EDS) RPH 0.9121 02324571 SANDOZ RIVASTIGMINE (EDS) SDZ 0.9121 02336723 APO-RIVASTIGMINE (EDS) APX 0.9121 02242116 EXELON (EDS) NVR 2.6059

* 4.5MG CAPSULE02306050 PMS-RIVASTIGMINE (EDS) PMS $ 0.9121 02311305 RATIO-RIVASTIGMINE (EDS) RPH 0.9121 02324598 SANDOZ RIVISTIGMINE (EDS) SDZ 0.9121 02336731 APO-RIVASTIGMINE (EDS) APX 0.9121 02242117 EXELON (EDS) NVR 2.6059

* 6MG CAPSULE02306069 PMS-RIVASTIGMINE (EDS) PMS $ 0.9121 02311313 RATIO-RIVASTIGMINE (EDS) RPH 0.9121 02324601 SANDOZ RIVASTIGMINE (EDS) SDZ 0.9121 02336758 APO-RIVASTIGMINE (EDS) APX 0.9121 02242118 EXELON (EDS) NVR 2.6059

2MG/ML ORAL SOLUTION02245240 EXELON (EDS) NVR $ 1.3700

12:08.04 ANTIPARKINSONIAN AGENTS

BENZTROPINE MESYLATE* 2MG TABLET

00426857 BENZTROPINE APX $ 0.0540 00587265 PMS-BENZTROPINE PMS 0.0540

1MG/ML INJECTION SOLUTION (2ML)02238903 BENZTROPINE OMEGA OMG $ 15.0000

ETHOPROPAZINE 50MG TABLET

01927744 PARSITAN ERF $ 0.2277

62nd Edition 29 July 1, 2012

Page 52: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

12:00 AUTONOMIC DRUGS12:08.04 ANTIPARKINSONIAN AGENTS

PROCYCLIDINE HCL 5MG TABLET

00587354 PMS-PROCYCLIDINE PMS $ 0.1287 0.5MG/ML ELIXIR

00587362 PMS-PROCYCLIDINE PMS $ 0.2516

TRIHEXYPHENIDYL HCL 2MG TABLET

00545058 TRIHEXYPHENIDYL AAP $ 0.0369 5MG TABLET

00545074 TRIHEXYPHENIDYL AAP $ 0.0668

12:08.08 ANTIMUSCARINICS/ANTISPASMODICS

DICYCLOMINE HCL 20MG TABLET

02103095 BENTYLOL AXC $ 0.2207 2MG/ML SYRUP

02102978 BENTYLOL AXC $ 0.0626

HYOSCINE BUTYLBROMIDE 10MG TABLET

00363812 BUSCOPAN BOE $ 0.3222

IPRATROPIUM BROMIDE 20UG INHALER AEROSOL (PACKAGE)

02247686 ATROVENT HFA BOE $ 18.9200 * 0.0125% INHALATION SOLUTION (2ML)

02097176 RATIO-IPRATROPIUM UDV RPH $ 0.3295 02231135 PMS-IPRATROPIUM PMS 0.3295

* 0.025% INHALATION SOLUTION02126222 APO-IPRAVENT APX $ 0.3157 02210479 NOVO-IPRAMIDE NOP 0.3157 02231136 PMS-IPRATROPIUM PMS 0.3157 02239131 MYLAN-IPRATROPIUM MYL 0.3157

* 0.025% INHALATION SOLUTION (2ML)02097168 RATIO-IPRATROPIUM UDV RPH $ 1.3180 02216221 MYLAN-IPRATROPIUM MYL 1.3180 02231245 PMS-IPRATROPIUM PMS 1.3180

62nd Edition 30 July 1, 2012

Page 53: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

12:00 AUTONOMIC DRUGS12:08.08 ANTIMUSCARINICS/ANTISPASMODICS

IPRATROPIUM BROMIDE/SALBUTAMOL SO4 NOTE: SALBUTAMOL STRENGTHS ARE EXPRESSED IN TERMS OF SALBUTAMOL BASE EQUIVALENT.* 0.5MG/2.5MG INHALATION SOLUTION (2.5ML)

02243789 RATIO-IPRA SAL UDV RPH $ 0.7340 02272695 MYLAN-COMBO STERINEBS MYL 0.7340 02231675 COMBIVENT BOE 1.5075

TIOTROPIUM BROMIDE MONOHYDRATE SEE APPENDIX A FOR EDS CRITERIA 18UG/DOSE INHALATION POWDER CAPSULE

02246793 SPIRIVA (EDS) BOE $ 2.1667

12:12.00 SYMPATHOMIMETIC (ADRENERGIC) AGENTS

EPINEPHRINE 0.15MG/DOSE INJECTION SOLUTION (PACKAGE)

02268205 TWINJECT PAL $ 82.4600 00578657 EPIPEN JR. KNG 82.6200

0.3MG/DOSE INJECTION SOLUTION (PACKAGE)02247310 TWINJECT PAL $ 82.4600 00509558 EPIPEN KNG 82.6200

EPINEPHRINE HCL 1MG/ML INJECTION SOLUTION (1ML)

00721891 EPINEPHRINE HOS $ 3.3500

FORMOTEROL FUMARATE SEE APPENDIX A FOR EDS CRITERIA 12UG/INHALATION POWDER CAPSULE

02230898 FORADIL (EDS) NVR $ 0.8180 6UG/DOSE POWDER FOR INHALATION (PACKAGE)

02237225 OXEZE TURBUHALER (EDS) AST $ 33.6500 12UG/DOSE POWDER FOR INHALATION (PACKAGE)

02237224 OXEZE TURBUHALER (EDS) AST $ 44.8000

FORMOTEROL FUMARATE DIHYDRATE/BUDESONIDE SEE APPENDIX A FOR EDS CRITERIA 6UG/100UG POWDER FOR INHALATION (PACKAGE)

02245385 SYMBICORT TURBUHALER (EDS) AST $ 63.2400 6UG/200UG POWDER FOR INHALATION (PACKAGE)

02245386 SYMBICORT TURBUHALER (EDS) AST $ 82.2000

62nd Edition 31 July 1, 2012

Page 54: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

12:00 AUTONOMIC DRUGS12:12.00 SYMPATHOMIMETIC (ADRENERGIC) AGENTS

MIDODRINE HCL SEE APPENDIX A FOR EDS CRITERIA 2.5MG TABLET

02278677 APO-MIDODRINE (EDS) AAP $ 0.3378 5MG TABLET

02278685 APO-MIDODRINE (EDS) AAP $ 0.5630

ORCIPRENALINE SO4 2MG/ML SYRUP

02236783 APO-ORCIPRENALINE APX $ 0.0574

SALBUTAMOL SO4 NOTE: PRODUCT STRENGTHS ARE EXPRESSED IN TERMS OF SALBUTAMOL BASE EQUIVALENT. 2MG TABLET

02146843 APO-SALVENT APX $ 0.1274 4MG TABLET

02146851 APO-SALVENT APX $ 0.2134 * 100MCG/DOSE METERED DOSE INHALER (PACKAGE) (CFC-FREE)

02232570 AIROMIR MDC $ 6.0000 02241497 VENTOLIN HFA GSK 6.0000 02245669 APO-SALVENT CFC FREE APX 6.0000 02326450 NOVO-SALBUTAMOL HFA NOP 6.0000

* 0.5MG/ML INHALATION SOLUTION PRESERVATIVE FREE (2.5ML)

02208245 PMS-SALBUTAMOL PMS $ 0.2685 02239365 RATIO-SALBUTAMOL P.F. RPH 0.2685

* 1MG/ML INHALATION SOLUTION PRESERVATIVE FREE (2.5ML)

01926934 MYLAN-SALBUTAMOL STERINEB MYL $ 0.3618 01986864 RATIO-SALBUTAMOL RPH 0.3618 02208229 PMS-SALBUTAMOL PMS 0.3618 02216949 DOM-SALBUTAMOL DOM 0.3618 02213419 VENTOLIN NEBULES P.F. GSK 1.0335

* 2MG/ML INHALATION SOLUTION PRESERVATIVE FREE (2.5ML)

02173360 MYLAN-SALBUTAMOL STERINEB MYL $ 0.6870 02208237 PMS-SALBUTAMOL PMS 0.6870 02239366 RATIO-SALBUTAMOL P.F. RPH 0.6870 02213427 VENTOLIN NEBULES P.F. GSK 1.9630

* 5MG/ML INHALATION SOLUTION00860808 RATIO-SALBUTAMOL RPH $ 0.3511 02069571 PMS-SALBUTAMOL RESP. SOL. PMS 0.3511 02139324 DOM-SALBUTAMOL RESPIR.SOL DOM 0.3511 02154412 SANDOZ SALBUTAMOL RES.SOL SDZ 0.3511 02213486 VENTOLIN RESPIRATOR SOL. GSK 1.0030

62nd Edition 32 July 1, 2012

Page 55: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

12:00 AUTONOMIC DRUGS

12:12.00 SYMPATHOMIMETIC (ADRENERGIC) AGENTS

SALMETEROL XINAFOATE SEE APPENDIX A FOR EDS CRITERIA 50UG/DOSE AEROSOL POWDER DISK (4)

02214261 SEREVENT (EDS) GSK $ 3.7400 50UG/DOSE POWDER FOR INHALATION (PACKAGE)

02231129 SEREVENT DISKUS (EDS) GSK $ 56.1000

SALMETEROL XINAFOATE/FLUTICASONE PROPIONATE SEE APPENDIX A FOR EDS CRITERIA 25UG/125UG INHALER AEROSOL (PACKAGE)

02245126 ADVAIR (EDS) GSK $ 96.0000 25UG/250UG INHALER AEROSOL (PACKAGE)

02245127 ADVAIR (EDS) GSK $ 136.2700 50UG/100UG POWDER FOR INHALATION (PACKAGE)

02240835 ADVAIR DISKUS (EDS) GSK $ 80.1900 50UG/250UG POWDER FOR INHALATION (PACKAGE)

02240836 ADVAIR DISKUS (EDS) GSK $ 95.9900 50UG/500UG POWDER FOR INHALATION (PACKAGE)

02240837 ADVAIR DISKUS (EDS) GSK $ 136.2700

TERBUTALINE SO4 0.5MG/DOSE POWDER FOR INHALATION (PACKAGE)

00786616 BRICANYL TURBUHALER AST $ 15.2800

12:16.00 SYMPATHOLYTIC AGENTS (ANTIMIGRAINE DRUGS)

ALMOTRIPTAN MALATE THE MAXIMUM QUANTITY THAT CAN BE CLAIMED THROUGH THE DRUG PLAN IS LIMITED TO 6 DOSES PER 30 DAYS WITHIN A 60 DAY PERIOD. SEE APPENDIX A FOR EDS CRITERIA 6.25MG TABLET

02248128 AXERT (EDS) MCL $ 13.0434 12.5MG TABLET

02248129 AXERT (EDS) MCL $ 13.0434

DIHYDROERGOTAMINE MESYLATE* 1MG/ML INJECTION SOLUTION (1ML)

00027243 DIHYDROERGOTAMINE STE $ 3.4820 02241163 DIHYDROERGOTAMINE MESYL. SDZ 3.7933

4MG/ML NASAL SPRAY02228947 MIGRANAL STE $ 10.2134

FLUNARIZINE HCL SEE APPENDIX A FOR EDS CRITERIA 5MG CAPSULE

02246082 FLUNARIZINE (EDS) AAP $ 0.7204

62nd Edition 33 July 1, 2012

Page 56: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

12:00 AUTONOMIC DRUGS

12:16.00 SYMPATHOLYTIC AGENTS (ANTIMIGRAINE DRUGS)

NARATRIPTAN HCL THE MAXIMUM QUANTITY THAT CAN BE CLAIMED THROUGH THE DRUG PLAN IS LIMITED TO 6 DOSES PER 30 DAYS WITHIN A 60 DAY PERIOD. SEE APPENDIX A FOR EDS CRITERIA

* 1MG TABLET02314290 NOVO-NARATRIPTAN (EDS) NOP $ 7.7950 02237820 AMERGE (EDS) GSK 14.1700

* 2.5MG TABLET02314304 NOVO-NARATRIPTAN (EDS) NOP $ 6.1436 02322323 SANDOZ NARATRIPTAN (EDS) SDZ 6.1436 02237821 AMERGE (EDS) GSK 14.9350

PIZOTYLINE HYDROGEN MALATE 0.5MG TABLET

00329320 SANDOMIGRAN PAL $ 0.3875 1MG TABLET

00511552 SANDOMIGRAN DS PAL $ 0.6434

PROPRANOLOL SEE SECTION 24:04.00 (CARDIAC DRUGS)

RIZATRIPTAN BENZOATE THE MAXIMUM QUANTITY THAT CAN BE CLAIMED THROUGH THE DRUG PLAN IS LIMITED TO 6 DOSES PER 30 DAYS WITHIN A 60 DAY PERIOD. SEE APPENDIX A FOR EDS CRITERIA 5MG TABLET

02379651 MAR-RIZATRIPTAN (EDS) MPI $ 5.1870 * 10MG TABLET

02379678 MAR-RIZATRIPTAN (EDS) MPI $ 5.3270 02240521 MAXALT (EDS) MRK 15.2200

* 5MG ORALLY DISINTEGRATING TABLET02351870 SANDOZ RIZATRIPTAN ODT (EDS) SDZ $ 5.1870 02374730 CO RIZATRIPTAN ODT (EDS) COB 5.1870 02379198 MYLAN-RIZATRIPTAN ODT (EDS) MYL 5.1870 02240518 MAXALT RPD (EDS) MRK 15.2200

* 10MG ORALLY DISINTEGRATING TABLET02351889 SANDOZ RIZATRIPTAN ODT (EDS) SDZ $ 5.1870 02374749 CO RIZATRIPTAN ODT (EDS) COB 5.1870 02379201 MYLAN-RIZATRIPTAN ODT (EDS) MYL 5.1870 02240519 MAXALT RPD (EDS) MRK 15.2200

62nd Edition 34 July 1, 2012

Page 57: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

12:00 AUTONOMIC DRUGS

12:16.00 SYMPATHOLYTIC AGENTS (ANTIMIGRAINE DRUGS)

SUMATRIPTAN THE MAXIMUM QUANTITY THAT CAN BE CLAIMED THROUGH THE DRUG PLAN IS LIMITED TO 6 DOSES PER 30 DAYS WITHIN A 60 DAY PERIOD. SEE APPENDIX A FOR EDS CRITERIA

* 25MG TABLET02256428 PMS-SUMATRIPTAN (EDS) PMS $ 6.8817 02257882 CO SUMATRIPTAN (EDS) COB 6.8817 02268906 MYLAN-SUMATRIPTAN (EDS) MYL 6.8817 02270749 DOM-SUMATRIPTAN (EDS) DOM 6.8817 02286513 SUMATRIPTAN (EDS) SAN 6.8817 02286815 NOVO-SUMATRIPTAN DF (EDS) NOP 6.8817

* 50MG TABLET02256436 PMS-SUMATRIPTAN (EDS) PMS $ 7.1350 02257890 CO SUMATRIPTAN (EDS) COB 7.1350 02263025 SANDOZ SUMATRIPTAN (EDS) SDZ 7.1350 02268388 APO-SUMATRIPTAN (EDS) APX 7.1350 02268914 MYLAN-SUMATRIPTAN (EDS) MYL 7.1350 02270757 DOM-SUMATRIPTAN (EDS) DOM 7.1350 02286521 SUMATRIPTAN (EDS) SAN 7.1350 02286823 NOVO-SUMATRIPTAN DF (EDS) NOP 7.1350 02366258 AVA-SUMATRIPTAN (EDS) AVA 7.1350 02212153 IMITREX DF (EDS) GSK 15.1567

* 100MG TABLET02239367 NOVO-SUMATRIPTAN (EDS) NOP $ 7.8600 02256444 PMS-SUMATRIPTAN (EDS) PMS 7.8600 02257904 CO SUMATRIPTAN (EDS) COB 7.8600 02263033 SANDOZ SUMATRIPTAN (EDS) SDZ 7.8600 02268396 APO-SUMATRIPTAN (EDS) APX 7.8600 02268922 MYLAN-SUMATRIPTAN (EDS) MYL 7.8600 02270765 DOM-SUMATRIPTAN (EDS) DOM 7.8600 02286548 SUMATRIPTAN (EDS) SAN 7.8600 02286831 NOVO-SUMATRIPTAN DF (EDS) NOP 7.8600 02366266 AVA-SUMATRIPTAN (EDS) AVA 7.8600 02212161 IMITREX DF (EDS) GSK 16.6967

6MG/0.5ML INJECTION SOLUTION02212188 IMITREX (EDS) GSK $ 44.0900

5MG NASAL SPRAY02230418 IMITREX (EDS) GSK $ 14.3850

20MG NASAL SPRAY02230420 IMITREX (EDS) GSK $ 14.8050

62nd Edition 35 July 1, 2012

Page 58: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

12:00 AUTONOMIC DRUGS

12:16.00 SYMPATHOLYTIC AGENTS (ANTIMIGRAINE DRUGS)

ZOLMITRIPTAN THE MAXIMUM QUANTITY THAT CAN BE CLAIMED THROUGH THE DRUG PLAN IS LIMITED TO 6 DOSES PER 30 DAYS WITHIN A 60 DAY PERIOD. SEE APPENDIX A FOR EDS CRITERIA.

* 2.5MG TABLET02313960 TEVA-ZOLMITRIPTAN (EDS) TEV $ 4.6667 02324229 PMS-ZOLMITRIPTAN (EDS) PMS 4.6667 02362988 SANDOZ ZOLMITRIPTAN (EDS) SDZ 4.6667 02369036 MYLAN-ZOLMITRIPTAN (EDS) MYL 4.6667 02380951 APO-ZOLMITRIPTAN (EDS) APX 4.6667 02238660 ZOMIG (EDS) AST 14.0100

* 2.5MG ORALLY DISPERSIBLE TABLET02324768 PMS-ZOLMITRIPTAN ODT (EDS) PMS $ 4.6690 02342545 TEVA-ZOLMITRIPTAN OD (EDS) TEV 4.6690 02362996 SDZ ZOLMITRIPTAN ODT (EDS) SDZ 4.6690 02243045 ZOMIG RAPIMELT (EDS) AST 14.0100

5MG NASAL SPRAY02248993 ZOMIG (EDS) AST $ 28.0200

12:20.00 SKELETAL MUSCLE RELAXANTS

BACLOFEN* 10MG TABLET

02063735 PMS-BACLOFEN PMS $ 0.2233 02088398 MYLAN-BACLOFEN MYL 0.2233 02136090 NU-BACLO NXP 0.2233 02139332 APO-BACLOFEN APX 0.2233 02236507 RATIO-BACLOFEN RPH 0.2233 02287021 BACLOFEN SAN 0.2233 00455881 LIORESAL NVR 0.6689

* 20MG TABLET02063743 PMS-BACLOFEN PMS $ 0.4346 02088401 MYLAN-BACLOFEN MYL 0.4346 02136104 NU-BACLO NXP 0.4346 02139391 APO-BACLOFEN APX 0.4346 02236508 RATIO-BACLOFEN RPH 0.4346 02287048 BACLOFEN SAN 0.4346 00636576 LIORESAL-DS NVR 1.3018

0.05MG/ML INJECTION (1ML)02131048 LIORESAL INTRATHECAL (EDS) NVR $ 13.8280

0.5MG/ML INJECTION (20ML)02131056 LIORESAL INTRATHECAL (EDS) NVR $ 207.2200

2MG/ML INJECTION (5ML)02131064 LIORESAL INTRATHECAL (EDS) NVR $ 207.2200

62nd Edition 36 July 1, 2012

Page 59: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

12:00 AUTONOMIC DRUGS

12:20.00 SKELETAL MUSCLE RELAXANTS

CYCLOBENZAPRINE HCL SEE APPENDIX A FOR EDS CRITERIA

* 10MG TABLET02080052 NOVO-CYCLOPRINE (EDS) NOP $ 0.3727 02171848 NU-CYCLOBENZAPRINE (EDS) NXP 0.3727 02177145 APO-CYCLOBENZAPRINE (EDS) APX 0.3727 02212048 PMS-CYCLOBENZAPRINE (EDS) PMS 0.3727 02231353 MYLAN-CYCLOBENZAPRINE (EDS) MYL 0.3727 02238633 DOM-CYCLOBENZAPRINE (EDS) DOM 0.3727 02287064 CYCLOBENZAPRINE (EDS) SAN 0.3727 02348853 AURO-CYCLOBENZAPRINE (EDS) API 0.3727

DANTROLENE SODIUM 25MG CAPSULE

01997602 DANTRIUM MET $ 0.3780 100MG CAPSULE

01997653 DANTRIUM MET $ 0.7684

TIZANIDINE HCL SEE APPENDIX A FOR EDS CRITERIA

* 4MG TABLET02259893 APO-TIZANIDINE (EDS) APX $ 0.3686 02272059 MYLAN-TIZANIDINE (EDS) MYL 0.3686 02239170 ZANAFLEX (EDS) PAL 0.7746

12:92.00 MISC. AUTONOMIC DRUGS

VARENICLINE TARTRATE THE MAXIMUM QUANTITY THAT CAN BE CLAIMED THROUGH THE DRUG PLAN IS LIMITED TO 12 WEEKS/PATIENT/365 DAYS. 0.5/1.0MG TABLET

02298309 CHAMPIX (STARTER PACK) PFI $ 1.7208 0.5MG TABLET

02291177 CHAMPIX PFI $ 1.7206 1.0MG TABLET

02291185 CHAMPIX PFI $ 1.7204

62nd Edition 37 July 1, 2012

Page 60: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...
Page 61: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

BLOOD FORMATION AND COAGULATION20:00

Page 62: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

20:00 BLOOD FORMATION AND COAGULATION

20:04.04 IRON PREPARATIONS

IRON DEXTRAN SEE APPENDIX A FOR EDS CRITERIA

* 50MG/ML INJECTION SOLUTION (ML)02205963 DEXIRON (EDS) MYL $ 13.7500 02221780 INFUFER (EDS) SDZ 13.7500

IRON SODIUM FERRIC GLUCONATE SEE APPENDIX A FOR EDS CRITERIA 12.5MG/ML INJECTION SOLUTION

02243333 FERRLECIT (EDS) JAN $ 25.8400

IRON SUCROSE SEE APPENDIX A FOR EDS CRITERIA 20MG/ML INJECTION

02243716 VENOFER (EDS) MYL $ 37.5000

20:12.04 ANTICOAGULANTS

ACENOCOUMAROL 1MG TABLET

00010383 SINTROM PAL $ 0.5119 4MG TABLET

00010391 SINTROM PAL $ 1.5997

DABIGATRAN SEE APPENDIX A FOR EDS CRITERIA 110MG TABLET

02312441 PRADAX (EDS) BOE $ 1.6000 150MG TABLET

02358808 PRADAX (EDS) BOE $ 1.6000

62nd Edition 40 July 1, 2012

Page 63: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

20:00 BLOOD FORMATION AND COAGULATION

20:12.04 ANTICOAGULANTS

DALTEPARIN SODIUM SEE APPENDIX A FOR EDS CRITERIA 2,500IU SYRINGE (0.2ML)

02132621 FRAGMIN (EDS) PFI $ 5.0500 5,000IU/ML INJECTION SOLUTION (0.2ML)

02132648 FRAGMIN (EDS) PFI $ 10.0900 7,500IU SYRINGE (0.3ML)

02352648 FRAGMIN (EDS) PFI $ 15.1400 10,000IU/ML INJECTION SOLUTION (1ML)

02132664 FRAGMIN (EDS) PFI $ 15.9300 10,000IU/ML PF SYRINGE (0.4ML)

02352656 FRAGMIN (EDS) PFI $ 20.1800 12,500IU/ML PF SYRINGE (0.5ML)

02352664 FRAGMIN (EDS) PFI $ 25.2200 15,000IU/ML PF SYRINGE (0.6ML)

02352672 FRAGMIN (EDS) PFI $ 30.2700 18,000IU/ML PF SYRINGE (0.72ML)

02352680 FRAGMIN (EDS) PFI $ 36.3200 25,000IU/ML INJECTION SOLUTION (3.8ML)

02231171 FRAGMIN (EDS) PFI $ 151.3200

ENOXAPARIN SEE APPENDIX A FOR EDS CRITERIA 30MG/0.3ML SYRINGE (0.3ML)

02012472 LOVENOX (EDS) AVT $ 6.3200 100MG/ML SYRINGE (0.4ML, 0.6ML,0.8ML,1ML)

02236883 LOVENOX (EDS) AVT $ 20.9300 100MG/ML INJECTION SOLUTION (3ML)

02236564 LOVENOX (EDS) AVT $ 62.7900 150MG/ML SYRINGE (0.8ML, 1ML)

02242692 LOVENOX HP (EDS) AVT $ 31.4000

HEPARIN 10,000 USP U/ML INJECTION SOLUTION

00579718 HEPARIN LEO LEO $ 12.8360

NADROPARIN CALCIUM SEE APPENDIX A FOR EDS CRITERIA 9,500IU/ML SYRINGE (0.3ML, 0.4ML, 0.6ML, 1ML)

02236913 FRAXIPARINE (EDS) GSK $ 9.1300 19,000IU/ML SYRINGE (0.6ML, 0.8ML, 1ML)

02240114 FRAXIPARINE FORTE (EDS) GSK $ 18.2600

62nd Edition 41 July 1, 2012

Page 64: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

20:00 BLOOD FORMATION AND COAGULATION

20:12.04 ANTICOAGULANTS

RIVAROXABAN SEE APPENDIX A FOR EDS CRITERIA 10MG TABLET

02316986 XARELTO (EDS) BAY $ 8.8598

TINZAPARIN SODIUM SEE APPENDIX A FOR EDS CRITERIA 10,000IU/ML INJECTION SOLUTION (2ML)

02167840 INNOHEP (EDS) LEO $ 33.6600 10,000IU/ML SYRINGE (0.25ML)

02229755 INNOHEP (EDS) LEO $ 4.2500 10,000IU/ML SYRINGE (0.35ML)

02358158 INNOHEP (EDS) LEO $ 5.9400 10,000IU/ML SYRINGE (0.45ML)

02358166 INNOHEP (EDS) LEO $ 7.6400 20,000IU/ML INJECTION SOLUTION (2ML)

02229515 INNOHEP (EDS) LEO $ 68.3600 20,000IU/ML SYRINGE (0.5ML)

02231478 INNOHEP (EDS) LEO $ 17.3400 20,000IU/ML SYRINGE (0.7ML)

02358174 INNOHEP (EDS) LEO $ 24.2700 20,000IU/ML SYRINGE (0.9ML)

02358182 INNOHEP (EDS) LEO $ 31.2000

WARFARIN* 1MG TABLET

02242680 TARO-WARFARIN TAR $ 0.1092 02242924 APO-WARFARIN APX 0.1092 02244462 MYLAN-WARFARIN MYL 0.1092 02265273 NOVO-WARFARIN NOP 0.1092 02344025 WARFARIN SAN 0.1092 01918311 COUMADIN BMY 0.3395

* 2MG TABLET02242681 TARO-WARFARIN TAR $ 0.1155 02242925 APO-WARFARIN APX 0.1155 02244463 MYLAN-WARFARIN MYL 0.1155 02265281 NOVO-WARFARIN NOP 0.1155 02344033 WARFARIN SAN 0.1155 01918338 COUMADIN BMY 0.3591

62nd Edition 42 July 1, 2012

Page 65: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

20:00 BLOOD FORMATION AND COAGULATION

20:12.04 ANTICOAGULANTS

* 2.5MG TABLET02242682 TARO-WARFARIN TAR $ 0.0924 02242926 APO-WARFARIN APX 0.0924 02244464 MYLAN-WARFARIN MYL 0.0924 02265303 NOVO-WARFARIN NOP 0.0924 02344041 WARFARIN SAN 0.0924 01918346 COUMADIN BMY 0.2872

* 3MG TABLET02242683 TARO-WARFARIN TAR $ 0.1432 02245618 APO-WARFARIN APX 0.1432 02265311 NOVO-WARFARIN NOP 0.1432 02287498 MYLAN-WARFARIN MYL 0.1432 02344068 WARFARIN SAN 0.1432 02240205 COUMADIN BMY 0.4451

* 4MG TABLET02242684 TARO-WARFARIN TAR $ 0.1432 02242927 APO-WARFARIN APX 0.1432 02244465 MYLAN-WARFARIN MYL 0.1432 02265338 NOVO-WARFARIN NOP 0.1432 02344076 WARFARIN SAN 0.1432 02007959 COUMADIN BMY 0.4452

* 5MG TABLET02242685 TARO-WARFARIN TAR $ 0.0926 02242928 APO-WARFARIN APX 0.0926 02244466 MYLAN-WARFARIN MYL 0.0926 02265346 NOVO-WARFARIN NOP 0.0926 02344084 WARFARIN SAN 0.0926 01918354 COUMADIN BMY 0.2877

* 10MG TABLET02242687 TARO-WARFARIN TAR $ 0.1662 02242929 APO-WARFARIN APX 0.1662 02244467 MYLAN-WARFARIN MYL 0.1662 02344114 WARFARIN SAN 0.1662 01918362 COUMADIN BMY 0.5165

62nd Edition 43 July 1, 2012

Page 66: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

20:00 BLOOD FORMATION AND COAGULATION

20:12.20 ANTIPLATELET DRUGS

SULFINPYRAZONE SEE SECTION 40:40:00 (URICOSURIC DRUGS)

20:16.00 HEMATOPOIETIC AGENTS

DARBEPOETIN ALFA SEE APPENDIX A FOR EDS CRITERIA 25UG/ML PRE-FILLED SYRINGE (0.4ML)

02246354 ARANESP (EDS) AMG $ 27.6600 40UG/ML PRE-FILLED SYRINGE (0.5ML)

02246355 ARANESP (EDS) AMG $ 55.3200 100UG/ML PRE-FILLED SYRINGE (0.3ML, 0.4ML, 0.5ML)

02246357 ARANESP (EDS) AMG $ 138.2900 200UG/ML PRE-FILLED SYRINGE (0.3ML, 0.4ML, 0.5ML, 0.65ML)

02246358 ARANESP (EDS) AMG $ 359.5500 500UG/ML PRE-FILLED SYRINGE (0.3ML, 0.4ML)

02246360 ARANESP (EDS) AMG $ 530.9300

EPOETIN ALFA SEE APPENDIX A FOR EDS CRITERIA 1000IU/0.5ML PRE-FILLED SYRINGE

02231583 EPREX (EDS) JAN $ 14.2500 2000IU/0.5ML PRE-FILLED SYRINGE

02231584 EPREX (EDS) JAN $ 28.5000 3000IU/0.3ML PRE-FILLED SYRINGE

02231585 EPREX (EDS) JAN $ 42.7500 4000IU/0.4ML PRE-FILLED SYRINGE

02231586 EPREX (EDS) JAN $ 57.0000 5000IU/0.5ML PRE-FILLED SYRINGE

02243400 EPREX (EDS) JAN $ 71.2500 6000IU/0.6ML PRE-FILLED SYRINGE

02243401 EPREX (EDS) JAN $ 85.5000 8000IU/0.8ML PRE-FILLED SYRINGE

02243403 EPREX (EDS) JAN $ 114.0000 10000IU/ML PRE-FILLED SYRINGE

02231587 EPREX (EDS) JAN $ 142.5000 20000IU/0.5ML PRE-FILLED SYRINGE

02243239 EPREX (EDS) JAN $ 285.6000

FILGRASTIM SEE APPENDIX A FOR EDS CRITERIA 300UG/ML INJECTION SOLUTION

01968017 NEUPOGEN (EDS) AMG $ 293.2200

62nd Edition 44 July 1, 2012

Page 67: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

20:00 BLOOD FORMATION AND COAGULATION

20:24.00 HEMORRHEOLOGIC AGENTS

CLOPIDOGREL BISULFATE SEE APPENDIX A FOR EDS CRITERIA

* 75MG TABLET02252767 APO-CLOPIDOGREL (EDS) APX $ 0.9207 02293161 TEVA-CLOPIDOGREL (EDS) TEV 0.9207 02303027 CO CLOPIDOGREL (EDS) COB 0.9207 02348004 PMS-CLOPIDOGREL (EDS) PMS 0.9207 02351536 MYLAN-CLOPIDOGREL (EDS) MYL 0.9207 02359316 SANDOZ CLOPIDOGREL (EDS) SDZ 0.9207 02379813 RAN-CLOPIDOGREL (EDS) RAN 0.9207 02238682 PLAVIX (EDS) BMY 2.6512

PENTOXIFYLLINE* 400MG SUSTAINED RELEASE TABLET

02230090 APO-PENTOXIFYLLINE SR APX $ 0.5846 02221977 TRENTAL AVT 0.8099

PRASUGREL SEE APPENDIX A FOR EDS CRITERIA 10 MG TABLET

02349124 EFFIENT (EDS) LIL $ 2.6600

TICAGRELOR SEE APPENDIX A FOR EDS CRITERIA 90MG TABLET

02368544 BRILINTA (EDS) AST $ 1.4800

TICLOPIDINE HCL SEE APPENDIX A FOR EDS CRITERIA

* 250MG TABLET02236848 NOVO-TICLOPIDINE (EDS) NOP $ 0.4397 02237560 NU-TICLOPIDINE (EDS) NXP 0.4397 02237701 APO-TICLOPIDINE (EDS) APX 0.4397 02239744 MYLAN-TICLOPIDINE (EDS) MYL 0.4397 02343045 TICLOPIDINE (EDS) SAN 0.4397

62nd Edition 45 July 1, 2012

Page 68: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...
Page 69: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

CARDIOVASCULAR DRUGS24:00

Page 70: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:04.00 CARDIAC DRUGS

ACEBUTOLOL HCL* 100MG TABLET

02147602 APO-ACEBUTOLOL APX $ 0.1156 02165546 NU-ACEBUTOLOL NXP 0.1156 02204517 NOVO-ACEBUTOLOL NOP 0.1156 02237721 MYLAN-ACEBUTOLOL MYL 0.1156 02237885 MYLAN-ACEBUTOLOL (TYPE S) MYL 0.1156 02286246 ACEBUTOLOL SAN 0.1156 01926543 SECTRAL AVT 0.3450

* 200MG TABLET02147610 APO-ACEBUTOLOL APX $ 0.1735 02165554 NU-ACEBUTOLOL NXP 0.1735 02204525 NOVO-ACEBUTOLOL NOP 0.1735 02237722 MYLAN-ACEBUTOLOL MYL 0.1735 02237886 MYLAN-ACEBUTOLOL (TYPE S) MYL 0.1735 02286254 ACEBUTOLOL SAN 0.1735 01926551 SECTRAL AVT 0.5176

* 400MG TABLET02147629 APO-ACEBUTOLOL APX $ 0.3452 02165562 NU-ACEBUTOLOL NXP 0.3452 02204533 NOVO-ACEBUTOLOL NOP 0.3452 02237723 MYLAN-ACEBUTOLOL MYL 0.3452 02237887 MYLAN-ACEBUTOLOL (TYPE S) MYL 0.3452 02286262 ACEBUTOLOL SAN 0.3452 01926578 SECTRAL AVT 1.0300

AMIODARONE 100MG TABLET

02292173 PMS-AMIODARONE PMS $ 0.7269 * 200MG TABLET

02239835 TEVA-AMIODARONE NOP $ 0.7206 02240071 RATIO-AMIODARONE RPH 0.7206 02240604 MYLAN-AMIODARONE MYL 0.7206 02242472 PMS-AMIODARONE PMS 0.7206 02243836 SANDOZ AMIODARONE SDZ 0.7206 02246194 APO-AMIODARONE APX 0.7206 02364263 AVA-AMIODARONE AVA 0.7206 02364336 AMIODARONE SAN 0.7206 02036282 CORDARONE PFI 2.0589

62nd Edition 48 July 1, 2012

Page 71: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:04.00 CARDIAC DRUGS

AMLODIPINE BESYLATE* 5MG TABLET

02280132 GD-AMLODIPINE GDI $ 0.3195 *02250497 TEVA-AMLODIPINE NOP 0.4473 02259605 RATIO-AMLODIPINE RPH 0.4473 02272113 MYLAN-AMLODIPINE MYL 0.4473 02273373 APO-AMLODIPINE APX 0.4473 02284065 PMS-AMLODIPINE PMS 0.4473 02284383 SANDOZ AMLODIPINE SDZ 0.4473 02297485 CO AMLODIPINE COB 0.4473 02321858 RAN-AMLODIPINE RAN 0.4473 02331071 JAMP-AMLODIPINE JPC 0.4473 02331284 AMLODIPINE SAN 0.4473 02342790 ZYM-AMLODIPINE ZYP 0.4473 02357194 JAMP-AMLODIPINE JPC 0.4473 02357712 SEPTA-AMLODIPINE SPT 0.4473 02362651 MINT-AMLODIPINE MNT 0.4473 02371715 MAR-AMLODIPINE MPI 0.4473 02378760 AMLODIPINE-ODAN ODN 0.4473 00878928 NORVASC PFI 1.3426

* 10MG TABLET02280140 GD-AMLODIPINE GDI $ 0.4743 *02250500 TEVA-AMLODIPINE NOP 0.6639 02259613 RATIO-AMLODIPINE RPH 0.6639 02272121 MYLAN-AMLODIPINE MYL 0.6639 02273381 APO-AMLODIPINE APX 0.6639 02284073 PMS-AMLODIPINE PMS 0.6639 02284391 SANDOZ AMLODIPINE SDZ 0.6639 02297493 CO AMLODIPINE COB 0.6639 02321866 RAN-AMLODIPINE RAN 0.6639 02331098 JAMP-AMLODIPINE JPC 0.6639 02331292 AMLODIPINE SAN 0.6639 02342804 ZYM-AMLODIPINE ZYP 0.6639 02357208 JAMP-AMLODIPINE JPC 0.6639 02357720 SEPTA-AMLODIPINE SPT 0.6639 02362678 MINT-AMLODIPINE MNT 0.6639 02371723 MAR-AMLODIPINE MPI 0.6639 02378779 AMLODIPINE-ODAN ODN 0.6639 00878936 NORVASC PFI 1.9930

62nd Edition 49 July 1, 2012

Page 72: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:04.00 CARDIAC DRUGS

AMLODIPINE BESYLATE/ATORVASTATIN CALCIUM 5MG/10MG TABLET

02273233 CADUET PFI $ 2.3206 5MG/20MG TABLET

02273241 CADUET PFI $ 2.7366 5MG/40MG TABLET

02273268 CADUET PFI $ 2.8926 5MG/80MG TABLET

02273276 CADUET PFI $ 2.8926 10MG/10MG TABLET

02273284 CADUET PFI $ 2.4500 10MG/20MG TABLET

02273292 CADUET PFI $ 3.0545 10MG/40MG TABLET

02273306 CADUET PFI $ 3.2000 10MG/80MG TABLET

02273314 CADUET PFI $ 3.2000

ATENOLOL* 25MG TABLET

02303647 MYLAN-ATENOLOL MYL $ 0.0946 02368633 SEPTA-ATENOLOL SPT 0.0946 02373963 RAN-ATENOLOL RAN 0.0946

* 50MG TABLET00773689 APO-ATENOL APX $ 0.2011 00886114 NU-ATENOL NXP 0.2011 01912062 TEVA-ATENOL NOP 0.2011 02146894 MYLAN-ATENOLOL MYL 0.2011 02171791 RATIO-ATENOLOL RPH 0.2011 02229467 DOM-ATENOLOL DOM 0.2011 02231731 SANDOZ ATENOLOL SDZ 0.2011 02237600 PMS-ATENOLOL PMS 0.2011 02255545 CO ATENOLOL COB 0.2011 02267985 RAN-ATENOLOL RAN 0.2011 02367564 JAMP-ATENOLOL JPC 0.2011 02368021 MINT-ATENOL MNT 0.2011 02368641 SEPTA-ATENOLOL SPT 0.2011 02371987 MAR-ATENOLOL MPI 0.2011 02039532 TENORMIN AST 0.6034

62nd Edition 50 July 1, 2012

Page 73: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:04.00 CARDIAC DRUGS

* 100MG TABLET00773697 APO-ATENOL APX $ 0.3306 00886122 NU-ATENOL NXP 0.3306 01912054 TEVA-ATENOL NOP 0.3306 02147432 MYLAN-ATENOLOL MYL 0.3306 02171805 RATIO-ATENOLOL RPH 0.3306 02229468 DOM-ATENOLOL DOM 0.3306 02231733 SANDOZ ATENOLOL SDZ 0.3306 02237601 PMS-ATENOLOL PMS 0.3306 02255553 CO ATENOLOL COB 0.3306 02267993 RAN-ATENOLOL RAN 0.3306 02367572 JAMP-ATENOLOL JPC 0.3306 02368048 MINT-ATENOL MNT 0.3306 02368668 SEPTA-ATENOLOL SPT 0.3306 02371995 MAR-ATENOLOL MPI 0.3306 02039540 TENORMIN AST 0.9920

BISOPROLOL FUMARATE* 5MG TABLET

02247439 SANDOZ BISOPROLOL SDZ $ 0.1391 02256134 APO-BISOPROLOL APX 0.1391 02267470 NOVO-BISOPROLOL NOP 0.1391 02302632 PMS-BISOPROLOL PMS 0.1391

* 10MG TABLET02247440 SANDOZ BISOPROLOL SDZ $ 0.2030 02256177 APO-BISOPROLOL APX 0.2030 02267489 NOVO-BISOPROLOL NOP 0.2030 02302640 PMS-BISOPROLOL PMS 0.2030

CAPTOPRIL SEE SECTION 24:08.00 (HYPOTENSIVE DRUGS)

CARVEDILOL SEE APPENDIX A FOR EDS CRITERIA

* 3.125MG TABLET02245914 PMS-CARVEDILOL (EDS) PMS $ 0.4728 02247933 APO-CARVEDILOL (EDS) APX 0.4728 02248715 NU-CARVEDILOL (EDS) NXP 0.4728 02252309 RATIO-CARVEDILOL (EDS) RPH 0.4728 02268027 RAN-CARVEDILOL (EDS) RAN 0.4728 02347512 MYLAN-CARVEDILOL (EDS) MYL 0.4728 02364913 CARVEDILOL (EDS) SAN 0.4728

62nd Edition 51 July 1, 2012

Page 74: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:04.00 CARDIAC DRUGS

* 6.25MG TABLET02245915 PMS-CARVEDILOL (EDS) PMS $ 0.4728 02247934 APO-CARVEDILOL (EDS) APX 0.4728 02248716 NU-CARVEDILOL (EDS) NXP 0.4728 02252317 RATIO-CARVEDILOL (EDS) RPH 0.4728 02268035 RAN-CARVEDILOL (EDS) RAN 0.4728 02347520 MYLAN-CARVEDILOL (EDS) MYL 0.4728 02364921 CARVEDILOL (EDS) SAN 0.4728

* 12.5MG TABLET02245916 PMS-CARVEDILOL (EDS) PMS $ 0.4728 02247935 APO-CARVEDILOL (EDS) APX 0.4728 02248717 NU-CARVEDILOL (EDS) NXP 0.4728 02252325 RATIO-CARVEDILOL (EDS) RPH 0.4728 02268043 RAN-CARVEDILOL (EDS) RAN 0.4728 02347555 MYLAN-CARVEDILOL (EDS) MYL 0.4728 02364948 CARVEDILOL (EDS) SAN 0.4728

* 25MG TABLET02245917 PMS-CARVEDILOL (EDS) PMS $ 0.4728 02247936 APO-CARVEDILOL (EDS) APX 0.4728 02248718 NU-CARVEDILOL (EDS) NXP 0.4728 02252333 RATIO-CARVEDILOL (EDS) RPH 0.4728 02268051 RAN-CARVEDILOL (EDS) RAN 0.4728 02347571 MYLAN-CARVEDILOL (EDS) MYL 0.4728 02364956 CARVEDILOL (EDS) SAN 0.4728

DIGOXIN 0.0625MG TABLET

02335700 TOLOXIN MMT $ 0.2445 0.125MG TABLET

02335719 TOLOXIN MMT $ 0.2445 0.25MG TABLET

02335727 TOLOXIN MMT $ 0.2445 0.05MG/ML ELIXIR

02242320 TOLOXIN MMT $ 1.0411

DILTIAZEM HCL* 30MG TABLET

00771376 APO-DILTIAZ APX $ 0.1866 00862924 NOVO-DILTAZEM NOP 0.1866 00886068 NU-DILTIAZ NXP 0.1866

* 60MG TABLET00771384 APO-DILTIAZ APX $ 0.3273 00862932 NOVO-DILTAZEM NOP 0.3273 00886076 NU-DILTIAZ NXP 0.3273

62nd Edition 52 July 1, 2012

Page 75: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:04.00 CARDIAC DRUGS

* 120MG CONTROLLED DELIVERY CAPSULE02229781 RATIO-DILTIAZEM CD RPH $ 0.4940 02230997 APO-DILTIAZ CD APX 0.4940 02231052 NU-DILTIAZ-CD NXP 0.4940 02242538 NOVO-DILTAZEM CD NOP 0.4940 02243338 SANDOZ DILTIAZEM CD SDZ 0.4940 02355752 PMS-DILTIAZEM CD PMS 0.4940 02370611 CO DILTIAZEM CD COB 0.4940 02097249 CARDIZEM CD VAE 1.5177

* 120MG EXTENDED RELEASE CAPSULE02245918 SANDOZ DILTIAZEM T SDZ $ 0.2987 02271605 NOVO-DILTIAZEM HCL NOP 0.2987 02291037 APO-DILTIAZEM TZ APX 0.2987 02370441 CO DILTIAZEM T COB 0.2987 02231150 TIAZAC VAE 0.8533

120MG EXTENDED RELEASE TABLET02256738 TIAZAC XC VAE $ 0.8195

* 180MG CONTROLLED DELIVERY CAPSULE02229782 RATIO-DILTIAZEM CD RPH $ 0.6557 02230998 APO-DILTIAZ CD APX 0.6557 02231053 NU-DILTIAZ-CD NXP 0.6557 02242539 NOVO-DILTAZEM CD NOP 0.6557 02243339 SANDOZ DILTIAZEM CD SDZ 0.6557 02355760 PMS-DILTIAZEM CD PMS 0.6557 02370638 CO DILTIAZEM CD COB 0.6557 02097257 CARDIZEM CD VAE 2.0147

* 180MG EXTENDED RELEASE CAPSULE02245919 SANDOZ DILTIAZEM T SDZ $ 0.4045 02271613 NOVO-DILTIAZEM HCL NOP 0.4045 02291045 APO-DILTIAZEM TZ APX 0.4045 02370492 CO DILTIAZEM T COB 0.4045 02231151 TIAZAC VAE 1.1556

180MG EXTENDED RELEASE TABLET02256746 TIAZAC XC VAE $ 1.0887

62nd Edition 53 July 1, 2012

Page 76: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:04.00 CARDIAC DRUGS

* 240MG CONTROLLED DELIVERY CAPSULE02229783 RATIO-DILTIAZEM CD RPH $ 0.8698 02230999 APO-DILTIAZ CD APX 0.8698 02231054 NU-DILTIAZ-CD NXP 0.8698 02242540 NOVO-DILTAZEM CD NOP 0.8698 02243340 SANDOZ DILTIAZEM CD SDZ 0.8698 02355779 PMS-DILTIAZEM CD PMS 0.8698 02370646 CO DILTIAZEM CD COB 0.8698 02097265 CARDIZEM CD VAE 2.6723

* 240MG EXTENDED RELEASE CAPSULE02245920 SANDOZ DILTIAZEM T SDZ $ 0.5365 02271621 NOVO-DILTIAZEM HCL NOP 0.5365 02291053 APO-DILTIAZEM TZ APX 0.5365 02370506 CO DILTIAZEM T COB 0.5365 02231152 TIAZAC VAE 1.5328

240MG EXTENDED RELEASE TABLET02256754 TIAZAC XC VAE $ 1.4470

* 300MG CONTROLLED DELIVERY CAPSULE02229526 APO-DILTIAZ CD APX $ 1.0872 02229784 RATIO-DILTIAZEM CD RPH 1.0872 02242541 NOVO-DILTAZEM CD NOP 1.0872 02243341 SANDOZ DILTIAZEM CD SDZ 1.0872 02355787 PMS-DILTIAZEM CD PMS 1.0872 02370654 CO DILTIAZEM CD COB 1.0872 02097273 CARDIZEM CD VAE 3.3403

* 300MG EXTENDED RELEASE CAPSULE02245921 SANDOZ DILTIAZEM T SDZ $ 0.6607 02271648 NOVO-DILTIAZEM HCL NOP 0.6607 02291061 APO-DILTIAZEM TZ APX 0.6607 02370514 CO DILTIAZEM T COB 0.6607 02231154 TIAZAC VAE 1.8878

300MG EXTENDED RELEASE TABLET02256762 TIAZAC XC VAE $ 1.4442

* 360MG EXTENDED RELEASE CAPSULE02245922 SANDOZ DILTIAZEM T SDZ $ 0.8089 02271656 NOVO-DILTIAZEM HCL NOP 0.8089 02291088 APO-DILTIAZEM TZ APX 0.8089 02370522 CO DILTIAZEM T COB 0.8089 02231155 TIAZAC VAE 2.3112

360MG EXTENDED RELEASE TABLET02256770 TIAZAC XC VAE $ 1.4631

62nd Edition 54 July 1, 2012

Page 77: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS24:04.00 CARDIAC DRUGS

DISOPYRAMIDE 150MG CAPSULE

02224828 RYTHMODAN AVT $ 0.3924

FLECAINIDE ACETATE* 50MG TABLET

02275538 FLECAINIDE AAP $ 0.3956 01966197 TAMBOCOR MDC 0.5556

* 100MG TABLET02275546 FLECAINIDE AAP $ 0.7912 01966200 TAMBOCOR MDC 1.1115

METOPROLOL TARTRATE* 25MG TABLET

02246010 APO-METOPROLOL APX $ 0.0643 02248855 PMS-METOPROLOL-L PMS 0.0643 02252252 DOM-METOPROLOL-L DOM 0.0643 02302055 MYLAN-METOPROLOL MYL 0.0643 02356813 JAMP-METOPROLOL-L JPC 0.0643

* 50MG TABLET00618632 APO-METOPROLOL APX $ 0.0874 00648035 TEVA-METOPROLOL NOP 0.0874 00749354 APO-METOPROLOL-TYPE L APX 0.0874 00842648 TEVA-METOPROLOL NOP 0.0874 00865605 NU-METOP NXP 0.0874 02174545 MYLAN-METOPROLOL (TYPE L) MYL 0.0874 02230803 PMS-METOPROLOL-L PMS 0.0874 02231121 DOM-METOPROLOL-L DOM 0.0874 02247875 SANDOZ METOPROLOL L SDZ 0.0874 02350394 METOPROLOL SAN 0.0874 02354187 SANDOZ-METOPROLOL(TYPE L) SDZ 0.0874 02356821 JAMP-METOPROLOL-L JPC 0.0874 00397423 LOPRESOR NVR 0.2781

62nd Edition 55 July 1, 2012

Page 78: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:04.00 CARDIAC DRUGS

* 100MG TABLET00618640 APO-METOPROLOL APX $ 0.1941 00648043 TEVA-METOPROLOL NOP 0.1941 00751170 APO-METOPROLOL-TYPE L APX 0.1941 00842656 NOVO-METOPROL (UNCOATED) NOP 0.1941 00865613 NU-METOP NXP 0.1941 02174553 MYLAN-METOPROLOL (TYPE L) MYL 0.1941 02230804 PMS-METOPROLOL-L PMS 0.1941 02231122 DOM-METOPROLOL-L DOM 0.1941 02247876 SANDOZ METOPROLOL L SDZ 0.1941 02350408 METOPROLOL SAN 0.1941 02354195 SANDOZ-METOPROLOL(TYPE L) SDZ 0.1941 02356848 JAMP-METOPROLOL-L JPC 0.1941 00397431 LOPRESOR NVR 0.5706

* 100MG SUSTAINED RELEASE TABLET02285169 APO-METOPROLOL SR APX $ 0.1312 02303396 SANDOZ METOPROLOL SR SDZ 0.1312 00658855 LOPRESOR-SR NVR 0.3116

* 200MG SUSTAINED RELEASE TABLET02285177 APO-METOPROLOL SR APX $ 0.2499 02303418 SANDOZ METOPROLOL SR SDZ 0.2499 00534560 LOPRESOR-SR NVR 0.5655

MEXILETINE HCL 100MG CAPSULE

02230359 NOVO-MEXILETINE NOP $ 1.0203 200MG CAPSULE

02230360 NOVO-MEXILETINE NOP $ 1.3663

NADOLOL* 40MG TABLET

00782505 APO-NADOL APX $ 0.2465 02126753 NOVO-NADOLOL NOP 0.2465

* 80MG TABLET00782467 APO-NADOL APX $ 0.3515 02126761 NOVO-NADOLOL NOP 0.3515

160MG TABLET00782475 APO-NADOL APX $ 1.2046

62nd Edition 56 July 1, 2012

Page 79: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:04.00 CARDIAC DRUGS

NIFEDIPINE 5MG CAPSULE

00725110 NIFEDIPINE AAP $ 0.3679 10MG CAPSULE

00755907 APO-NIFED AAP $ 0.4877 20MG EXTENDED-RELEASE TABLET

02237618 ADALAT XL TEV $ 1.2600 * 30MG EXTENDED-RELEASE TABLET

02155907 ADALAT XL TEV $ 0.6171 02349167 MYLAN-NIFEDIPINE MYL 0.6171

* 60MG EXTENDED-RELEASE TABLET02155990 ADALAT XL TEV $ 0.9374 02321149 MYLAN-NIFEDIPINE XL MYL 0.9374

PINDOLOL* 5MG TABLET

00755877 APO-PINDOL APX $ 0.1905 00869007 NOVO-PINDOL NOP 0.1905 00886149 NU-PINDOL NXP 0.1905 02231536 PMS-PINDOLOL PMS 0.1905 02231650 DOM-PINDOLOL DOM 0.1905 02261782 SANDOZ PINDOLOL SDZ 0.1905 00417270 VISKEN NVR 0.5706

* 10MG TABLET00755885 APO-PINDOL APX $ 0.3253 00869015 NOVO-PINDOL NOP 0.3253 00886009 NU-PINDOL NXP 0.3253 02231537 PMS-PINDOLOL PMS 0.3253 02238046 DOM-PINDOLOL DOM 0.3253 02261790 SANDOZ PINDOLOL SDZ 0.3253 00443174 VISKEN NVR 0.9744

* 15MG TABLET00755893 APO-PINDOL APX $ 0.4718 00869023 NOVO-PINDOL NOP 0.4718 00886130 NU-PINDOL NXP 0.4718 02231539 PMS-PINDOLOL PMS 0.4718 02238047 DOM-PINDOLOL DOM 0.4718 02261804 SANDOZ PINDOLOL SDZ 0.4718 00417289 VISKEN NVR 1.4135

62nd Edition 57 July 1, 2012

Page 80: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:04.00 CARDIAC DRUGS

PROCAINAMIDE HCL 250MG SUSTAINED RELEASE TABLET

00638692 PROCAN-SR ERF $ 0.4659 500MG SUSTAINED RELEASE TABLET

00638676 PROCAN-SR ERF $ 0.6601 750MG SUSTAINED RELEASE TABLET

00638684 PROCAN-SR ERF $ 1.0611

PROPAFENONE HCL* 150MG TABLET

02243324 APO-PROPAFENONE APX $ 0.3954 02245372 MYLAN-PROPAFENONE MYL 0.3954 02249480 NU-PROPAFENONE NXP 0.3954 02294559 PMS-PROPAFENONE PMS 0.3954 02343053 PROPAFENONE SAN 0.3954 00603708 RYTHMOL ABB 1.2426

* 300MG TABLET02243325 APO-PROPAFENONE APX $ 0.6970 02245373 MYLAN-PROPAFENONE MYL 0.6970 02294575 PMS-PROPAFENONE PMS 0.6970 02343061 PROPAFENONE SAN 0.6970 00603716 RYTHMOL ABB 2.1902

PROPRANOLOL* 10MG TABLET

00402788 APO-PROPRANOLOL APX $ 0.0192 00496480 NOVO-PRANOL NOP 0.0192

* 20MG TABLET00663719 APO-PROPRANOLOL APX $ 0.0346 00740675 NOVO-PRANOL NOP 0.0346 02044692 NU-PROPRANOLOL NXP 0.0346

* 40MG TABLET00402753 APO-PROPRANOLOL APX $ 0.0348 00496499 NOVO-PRANOL NOP 0.0348 02044706 NU-PROPRANOLOL NXP 0.0348

* 80MG TABLET00402761 APO-PROPRANOLOL APX $ 0.0585 00496502 NOVO-PRANOL NOP 0.0585

120MG TABLET00504335 APO-PROPRANOLOL APX $ 0.3091

62nd Edition 58 July 1, 2012

Page 81: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:04.00 CARDIAC DRUGS

60MG LONG ACTING CAPSULE02042231 INDERAL-LA PFI $ 0.5562

80MG LONG ACTING CAPSULE02042258 INDERAL-LA PFI $ 0.6272

120MG LONG ACTING CAPSULE02042266 INDERAL-LA PFI $ 0.9656

160MG LONG ACTING CAPSULE02042274 INDERAL-LA PFI $ 1.1420

SOTALOL HCL* 80MG TABLET

02084228 RATIO-SOTALOL RPH $ 0.2966 02200996 NU-SOTALOL NXP 0.2966 02210428 APO-SOTALOL APX 0.2966 02229778 MYLAN-SOTALOL MYL 0.2966 02231181 NOVO-SOTALOL NOP 0.2966 02238326 PMS-SOTALOL PMS 0.2966 02238634 DOM-SOTALOL DOM 0.2966 02270625 CO SOTALOL COB 0.2966 02363674 AVA-SOTALOL AVA 0.2966

* 160MG TABLET02084236 RATIO-SOTALOL RPH $ 0.2272 02163772 NU-SOTALOL NXP 0.2272 02167794 APO-SOTALOL APX 0.2272 02229779 MYLAN-SOTALOL MYL 0.2272 02231182 NOVO-SOTALOL NOP 0.2272 02238327 PMS-SOTALOL PMS 0.2272 02270633 CO SOTALOL COB 0.2272 02363682 AVA-SOTALOL AVA 0.2272

TIMOLOL MALEATE* 5MG TABLET

00755842 APO-TIMOL APX $ 0.1649 01947796 NOVO-TIMOL NOP 0.1649

* 10MG TABLET00755850 APO-TIMOL APX $ 0.2572 01947818 NOVO-TIMOL NOP 0.2572

* 20MG TABLET00755869 APO-TIMOL APX $ 0.5005 01947826 NOVO-TIMOL NOP 0.5005

VERAPAMIL HCL SEE SECTION 24:08.00 (HYPOTENSIVE DRUGS)

62nd Edition 59 July 1, 2012

Page 82: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:06.00 ANTILIPEMIC DRUGS

ATORVASTATIN CALCIUM* 10MG TABLET

02288346 GD-ATORVASTATIN GDI $ 0.5824 02295261 APO-ATORVASTATIN APX 0.5824 02302675 TEVA-ATORVASTATIN TEV 0.5824 02310899 CO ATORVASTATIN COB 0.5824 02313448 PMS-ATORVASTATIN PMS 0.5824 02313707 RAN-ATORVASTATIN RAN 0.5824 02324946 SANDOZ ATORVASTATIN SDZ 0.5824 02348705 ATORVASTATIN SAN 0.5824 02350297 RATIO-ATORVASTATIN RPH 0.5824 02355612 DOM-ATORVASTATIN DOM 0.5824 02373203 MYLAN-ATORVASTATIN MYL 0.5824 02230711 LIPITOR PFI 1.7432

* 20MG TABLET02288354 GD-ATORVASTATIN GDI $ 0.7280 02295288 APO-ATORVASTATIN APX 0.7280 02302683 TEVA-ATORVASTATIN TEV 0.7280 02310902 CO ATORVASTATIN COB 0.7280 02313456 PMS-ATORVASTATIN PMS 0.7280 02313715 RAN-ATORVASTATIN RAN 0.7280 02324954 SANDOZ ATORVASTATIN SDZ 0.7280 02348713 ATORVASTATIN SAN 0.7280 02350319 RATIO-ATORVASTATIN RPH 0.7280 02355620 DOM-ATORVASTATIN DOM 0.7280 02373211 MYLAN-ATORVASTATIN MYL 0.7280 02230713 LIPITOR PFI 2.1789

* 40MG TABLET02288362 GD-ATORVASTATIN GDI $ 0.7825 02295296 APO-ATORVASTATIN APX 0.7825 02302691 TEVA-ATORVASTATIN TEV 0.7825 02310910 CO ATORVASTATIN COB 0.7825 02313464 PMS-ATORVASTATIN PMS 0.7825 02313723 RAN-ATORVASTATIN RAN 0.7825 02324962 SANDOZ ATORVASTATIN SDZ 0.7825 02348721 ATORVASTATIN SAN 0.7825 02350327 RATIO-ATORVASTATIN RPH 0.7825 02355639 DOM-ATORVASTATIN DOM 0.7825 02373238 MYLAN-ATORVASTATIN MYL 0.7825 02230714 LIPITOR PFI 2.3420

62nd Edition 60 July 1, 2012

Page 83: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:06.00 ANTILIPEMIC DRUGS

* 80MG TABLET02288370 GD-ATORVASTATIN GDI $ 0.7825 02295318 APO-ATORVASTATIN APX 0.7825 02302713 TEVA-ATORVASTATIN TEV 0.7825 02310929 CO ATORVASTATIN COB 0.7825 02313472 PMS-ATORVASTATIN PMS 0.7825 02313758 RAN-ATORVASTATIN RAN 0.7825 02324970 SANDOZ ATORVASTATIN SDZ 0.7825 02348748 ATORVASTATIN SAN 0.7825 02350335 RATIO-ATORVASTATIN RPH 0.7825 02355647 DOM-ATORVASTATIN DOM 0.7825 02373246 MYLAN-ATORVASTATIN MYL 0.7825 02243097 LIPITOR PFI 2.3420

BEZAFIBRATE SEE APPENDIX A FOR EDS CRITERIA 400MG SUSTAINED RELEASE TABLET

02083523 BEZALIP SR (EDS) TRI $ 1.9167

CHOLESTYRAMINE RESIN 444MG/G ORAL POWDER

02210320 OLESTYR MMT $ 1.4333 800MG/G ORAL POWDER

00890960 OLESTYR MMT $ 1.4333

COLESTIPOL HCL RESIN 5G GRANULES

00642975 COLESTID PFI $ 0.9210 7.5G GRANULES

02132699 COLESTID PFI $ 0.9210 1G TABLET

02132680 COLESTID PFI $ 0.2576

EZETIMIBE 10MG TABLET

02247521 EZETROL MRK $ 1.7927

62nd Edition 61 July 1, 2012

Page 84: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:06.00 ANTILIPEMIC DRUGS

FENOFIBRATE* 200MG CAPSULE

02239864 APO-FENO-MICRO APX $ 0.3812 02240210 MYLAN-FENOFIBRATE MICRO MYL 0.3812 02243552 NOVO-FENOFIBRATE MICRO NOP 0.3812 02250039 RATIO-FENOFIBRATE MC RPH 0.3812 02273551 PMS-FENOFIBRATE MICRO PMS 0.3812 02286092 FENOFIBRATE MICRO SAN 0.3812 02146959 LIPIDIL-MICRO FFR 1.0890

48MG TABLET02269074 LIPIDIL EZ FFR $ 0.4187

145MG TABLET02269082 LIPIDIL EZ FFR $ 1.0720

FLUVASTATIN SODIUM 20MG CAPSULE

02061562 LESCOL NVR $ 0.8732 40MG CAPSULE

02061570 LESCOL NVR $ 1.2261

GEMFIBROZIL* 300MG CAPSULE

01979574 APO-GEMFIBROZIL APX $ 0.1803 02058456 NU-GEMFIBROZIL NXP 0.1803 02185407 MYLAN-GEMFIBROZIL MYL 0.1803 02239951 PMS-GEMFIBROZIL PMS 0.1803 02241608 DOM-GEMFIBROZIL DOM 0.1803 02241704 NOVO-GEMFIBROZIL NOP 0.1803

* 600MG TABLET01979582 APO-GEMFIBROZIL APX $ 0.5157 02058464 NU-GEMFIBROZIL NXP 0.5157 02142074 NOVO-GEMFIBROZIL NOP 0.5157 02230183 PMS-GEMFIBROZIL PMS 0.5157 02230476 MYLAN-GEMFIBROZIL MYL 0.5157 02230580 DOM-GEMFIBROZIL DOM 0.5157

62nd Edition 62 July 1, 2012

Page 85: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:06.00 ANTILIPEMIC DRUGS

LOVASTATIN* 20MG TABLET

02220172 APO-LOVASTATIN APX $ 0.6886 02231434 NU-LOVASTATIN NXP 0.6886 02243127 MYLAN-LOVASTATIN MYL 0.6886 02245822 RATIO-LOVASTATIN RPH 0.6886 02246013 PMS-LOVASTATIN PMS 0.6886 02246542 NOVO-LOVASTATIN NOP 0.6886 02247056 SANDOZ LOVASTATIN SDZ 0.6886 02248572 CO LOVASTATIN COB 0.6886 02353229 LOVASTATIN SAN 0.6886 00795860 MEVACOR MRK 2.1694

* 40MG TABLET02220180 APO-LOVASTATIN APX $ 1.2579 02231435 NU-LOVASTATIN NXP 1.2579 02243129 MYLAN-LOVASTATIN MYL 1.2579 02245823 RATIO-LOVASTATIN RPH 1.2579 02246014 PMS-LOVASTATIN PMS 1.2579 02246543 NOVO-LOVASTATIN NOP 1.2579 02247057 SANDOZ LOVASTATIN SDZ 1.2579 02247232 DOM-LOVASTATIN DOM 1.2579 02248573 CO LOVASTATIN COB 1.2579 02353237 LOVASTATIN SAN 1.2579 00795852 MEVACOR MRK 3.9624

PRAVASTATIN* 10MG TABLET

02243506 APO-PRAVASTATIN APX $ 0.5670 02244350 NU-PRAVASTATIN NXP 0.5670 02247008 NOVO-PRAVASTATIN NOP 0.5670 02247655 PMS-PRAVASTATIN PMS 0.5670 02247856 SANDOZ PRAVASTATIN SDZ 0.5670 02248182 CO PRAVASTATIN COB 0.5670 02249723 DOM-PRAVASTATIN DOM 0.5670 02257092 MYLAN-PRAVASTATIN MYL 0.5670 02284421 RAN-PRAVASTATIN RAN 0.5670 02317451 MINT-PRAVASTATIN MNT 0.5670 02330954 JAMP-PRAVASTATIN JPC 0.5670 02356546 PRAVASTATIN SAN 0.5670 00893749 PRAVACHOL BMY 0.9530

62nd Edition 63 July 1, 2012

Page 86: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:06.00 ANTILIPEMIC DRUGS

* 20MG TABLET02243507 APO-PRAVASTATIN APX $ 0.6689 02244351 NU-PRAVASTATIN NXP 0.6689 02247009 NOVO-PRAVASTATIN NOP 0.6689 02247656 PMS-PRAVASTATIN PMS 0.6689 02247857 SANDOZ PRAVASTATIN SDZ 0.6689 02248183 CO PRAVASTATIN COB 0.6689 02257106 MYLAN-PRAVASTATIN MYL 0.6689 02284448 RAN-PRAVASTATIN RAN 0.6689 02317478 MINT-PRAVASTATIN MNT 0.6689 02330962 JAMP-PRAVASTATIN JPC 0.6689 02356554 PRAVASTATIN SAN 0.6689 00893757 PRAVACHOL BMY 1.1244

* 40MG TABLET02243508 APO-PRAVASTATIN APX $ 0.8057 02244352 NU-PRAVASTATIN NXP 0.8057 02247010 NOVO-PRAVASTATIN NOP 0.8057 02247657 PMS-PRAVASTATIN PMS 0.8057 02247858 SANDOZ PRAVASTATIN SDZ 0.8057 02248184 CO PRAVASTATIN COB 0.8057 02249758 DOM-PRAVASTATIN DOM 0.8057 02257114 MYLAN-PRAVASTATIN MYL 0.8057 02284456 RAN-PRAVASTATIN RAN 0.8057 02317486 MINT-PRAVASTATIN MNT 0.8057 02330970 JAMP-PRAVASTATIN JPC 0.8057 02356562 PRAVASTATIN SAN 0.8057 02222051 PRAVACHOL BMY 1.3544

ROSUVASTATIN CALCIUM* 5MG TABLET

02337975 APO-ROSUVASTATIN APX $ 0.4515 02338726 SANDOZ ROSUVASTATIN SDZ 0.4515 02339765 CO ROSUVASTATIN COB 0.4515 02354608 TEVA-ROSUVASTATIN TEV 0.4515 02378523 PMS-ROSUVASTATIN PMS 0.4515 02381265 MYLAN-ROSUVASTATIN MYL 0.4515 02382644 RAN-ROSUVASTATIN RAN 0.4515 02265540 CRESTOR AST 1.2900

62nd Edition 64 July 1, 2012

Page 87: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:06.00 ANTILIPEMIC DRUGS

* 10MG TABLET02337983 APO-ROSUVASTATIN APX $ 0.4760 02338734 SANDOZ ROSUVASTATIN SDZ 0.4760 02339773 CO ROSUVASTATIN COB 0.4760 02354616 TEVA-ROSUVASTATIN TEV 0.4760 02378531 PMS-ROSUVASTATIN PMS 0.4760 02381273 MYLAN-ROSUVASTATIN MYL 0.4760 02382652 RAN-ROSUVASTATIN RAN 0.4760 02247162 CRESTOR AST 1.3600

* 20MG TABLET02337991 APO-ROSUVASTATIN APX $ 0.5950 02338742 SANDOZ ROSUVASTATIN SCZ 0.5950 02339781 CO ROSUVASTATIN COB 0.5950 02354624 TEVA-ROSUVASTATIN TEV 0.5950 02378558 PMS-ROSUVASTATIN PMS 0.5950 02381281 MYLAN-ROSUVASTATIN MYL 0.5950 02382660 RAN-ROSUVASTATIN RAN 0.5950 02247163 CRESTOR AST 1.7000

* 40MG TABLET02338009 APO-ROSUVASTATIN APX $ 0.6965 02338750 SANDOZ ROSUVASTATIN SDZ 0.6965 02339803 CO ROSUVASTATIN COB 0.6965 02354632 TEVA-ROSUVASTATIN TEV 0.6965 02378566 PMS-ROSUVASTATIN PMS 0.6965 02381303 MYLAN-ROSUVASTATIN MYL 0.6965 02382679 RAN-ROSUVASTATIN RAN 0.6965 02247164 CRESTOR AST 1.9900

SIMVASTATIN* 5MG TABLET

02246582 MYLAN-SIMVASTATIN MYL $ 0.3579 02247011 APO-SIMVASTATIN APX 0.3579 02247072 NU-SIMVASTATIN NXP 0.3579 02248103 CO SIMVASTATIN COB 0.3579 02250144 TEVA-SIMVASTATIN NOP 0.3579 02269252 PMS-SIMVASTATIN PMS 0.3579 02281619 DOM-SIMVASTATIN DOM 0.3579 02284723 SIMVASTATIN SAN 0.3579 02329131 RAN-SIMVASTATIN RAN 0.3579 02331020 JAMP-SIMVASTATIN JPC 0.3579 02372932 MINT-SIMVASTATIN MNT 0.3579 02375036 MAR-SIMVASTATIN MPI 0.3579 02378884 SIMVASTATIN-ODAN ODN 0.3579 00884324 ZOCOR MRK 1.0800

62nd Edition 65 July 1, 2012

Page 88: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:06.00 ANTILIPEMIC DRUGS

* 10MG TABLET02246583 MYLAN-SIMVASTATIN MYL $ 0.7081 02247012 APO-SIMVASTATIN APX 0.7081 02247075 NU-SIMVASTATIN NXP 0.7081 02247828 SANDOZ SIMVASTATIN SDZ 0.7081 02248104 CO SIMVASTATIN COB 0.7081 02250152 NOVO-SIMVASTATIN NOP 0.7081 02269260 PMS-SIMVASTATIN PMS 0.7081 02281627 DOM-SIMVASTATIN DOM 0.7081 02284731 SIMVASTATIN SAN 0.7081 02329158 RAN-SIMVASTATIN RAN 0.7081 02331039 JAMP-SIMVASTATIN JPC 0.7081 02372940 MINT-SIMVASTATIN MNT 0.7081 02375044 MAR-SIMVASTATIN MPI 0.7081 02378892 SIMVASTATIN-ODAN ODN 0.7081 00884332 ZOCOR MRK 2.1243

* 20MG TABLET02246737 MYLAN-SIMVASTATIN MYL $ 0.8751 02247013 APO-SIMVASTATIN APX 0.8751 02247076 NU-SIMVASTATIN NXP 0.8751 02247830 SANDOZ SIMVASTATIN SDZ 0.8751 02248105 CO SIMVASTATIN COB 0.8751 02250160 NOVO-SIMVASTATIN NOP 0.8751 02269279 PMS-SIMVASTATIN PMS 0.8751 02281635 DOM-SIMVASTATIN DOM 0.8751 02284758 SIMVASTATIN SAN 0.8751 02329166 RAN-SIMVASTATIN RAN 0.8751 02331047 JAMP-SIMVASTATIN JPC 0.8751 02372959 MINT-SIMVASTATIN MNT 0.8751 02375052 MAR-SIMVASTATIN MPI 0.8751 02378906 SIMVASTATIN-ODAN ODN 0.8751 00884340 ZOCOR MRK 2.6254

62nd Edition 66 July 1, 2012

Page 89: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:06.00 ANTILIPEMIC DRUGS

* 40MG TABLET02246584 MYLAN-SIMVASTATIN MYL $ 0.8751 02247014 APO-SIMVASTATIN APX 0.8751 02247077 NU-SIMVASTATIN NXP 0.8751 02247831 SANDOZ SIMVASTATIN SDZ 0.8751 02248106 CO SIMVASTATIN COB 0.8751 02250179 TEVA-SIMVASTATIN NOP 0.8751 02269287 PMS-SIMVASTATIN PMS 0.8751 02284766 SIMVASTATIN SAN 0.8751 02329174 RAN-SIMVASTATIN RAN 0.8751 02331055 JAMP-SIMVASTATIN JPC 0.8751 02372967 MINT-SIMVASTATIN MNT 0.8751 02375060 MAR-SIMVASTATIN MPI 0.8751 02378914 SIMVASTATIN-ODAN ODN 0.8751 00884359 ZOCOR MRK 2.6254

* 80MG TABLET02246585 MYLAN-SIMVASTATIN MYL $ 0.8751 02247015 APO-SIMVASTATIN APX 0.8751 02247078 NU-SIMVASTATIN NXP 0.8751 02247833 SANDOZ SIMVASTATIN SDZ 0.8751 02248107 CO SIMVASTATIN COB 0.8751 02250187 TEVA-SIMVASTATIN NOP 0.8751 02269295 PMS-SIMVASTATIN PMS 0.8751 02284774 SIMVASTATIN SAN 0.8751 02329182 RAN-SIMVASTATIN RAN 0.8751 02331063 JAMP-SIMVASTATIN JPC 0.8751 02372975 MINT-SIMVASTATIN MNT 0.8751 02375079 MAR-SIMVASTATIN MPI 0.8751 02378922 SIMVASTATIN-ODAN ODN 0.8751 02240332 ZOCOR MRK 2.6254

24:08.00 HYPOTENSIVE DRUGS

ACEBUTOLOL HCL SEE SECTION 24:04.00 (CARDIAC DRUGS)

AMILORIDE HCL/HYDROCHLOROTHIAZIDE* 5MG/50MG TABLET

00784400 APO-AMILZIDE APX $ 0.1293 00886106 NU-AMILZIDE NXP 0.1293 01937219 NOVAMILOR NOP 0.1293

ATENOLOL SEE SECTION 24:04.00 (CARDIAC DRUGS)

62nd Edition 67 July 1, 2012

Page 90: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:08.00 HYPOTENSIVE DRUGS

ATENOLOL/CHLORTHALIDONE* 50MG/25MG TABLET

02248763 APO-ATENIDONE APX $ 0.3195 02302918 TEVA-ATENOL/CHLORTHAL NOP 0.3195 02049961 TENORETIC AST 0.6714

* 100MG/25MG TABLET02248764 APO-ATENIDONE APX $ 0.5236 02302926 TEVA-ATENOL/CHLORTHAL NOP 0.5236 02049988 TENORETIC AST 1.1000

BENAZEPRIL HCL* 5MG TABLET

02290332 BENAZEPRIL AAP $ 0.5577 00885835 LOTENSIN NVR 0.7797

10MG TABLET02290340 BENAZEPRIL AAP $ 0.6595

* 20MG TABLET02273918 APO-BENAZEPRIL AAP $ 0.7567 00885851 LOTENSIN NVR 1.0575

CANDESARTAN CILEXETIL* 4MG TABLET

02326957 SANDOZ-CANDESARTAN SDZ $ 0.2380 02365340 APO-CANDESARTAN APX 0.2380 02376520 CO CANDESARTAN COB 0.2380 02379120 MYLAN-CANDESARTAN MYL 0.2380 02379260 CANDESARTAN CILEXETIL AHI 0.2380 02239090 ATACAND AST 0.7120

* 8MG TABLET02326965 SANDOZ-CANDESARTAN SDZ $ 0.3990 02365359 APO-CANDESARTAN APX 0.3990 02366312 TEVA-CANDESARTAN TEV 0.3990 02376539 CO CANDESARTAN COB 0.3990 02379139 MYLAN-CANDESARTAN MYL 0.3990 02379279 CANDESARTEN CILEXETIL AHI 0.3990 02239091 ATACAND AST 1.1980

62nd Edition 68 July 1, 2012

Page 91: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:08.00 HYPOTENSIVE DRUGS

* 16MG TABLET02326973 SANDOZ-CANDESARTAN SDZ $ 0.3990 02365367 APO-CANDESARTAN APX 0.3990 02366320 TEVA-CANDESARTAN TEV 0.3990 02376547 CO CANDESARTAN COB 0.3990 02379147 MYLAN-CANDESARTAN MYL 0.3990 02379287 CANDESARTAN CILEXETIL AHI 0.3990 02239092 ATACAND AST 1.1980

* 32MG TABLET02366339 TEVA-CANDESARTAN TEV $ 0.4105 02376555 CO CANDESARTAN COB 0.4105 02379155 MYLAN-CANDESARTAN MYL 0.4105 02379295 CANDESARTAN CILEXETIL AHI 0.4105 02311658 ATACAND AST 1.1980

CANDESARTAN CILEXETIL/HYDROCHLOROTHIAZIDE 16MG/12.5MG TABLET

02244021 ATACAND PLUS AST $ 1.1980 32MG/12.5MG TABLET

02332922 ATACAND PLUS AST $ 1.1980 32MG/25MG TABLET

02332957 ATACAND PLUS AST $ 1.1980

CAPTOPRIL 6.25MG TABLET

01999559 APO-CAPTO APX $ 0.1237 * 12.5MG TABLET

00893595 APO-CAPTO APX $ 0.1060 01913824 NU-CAPTO NXP 0.1060 01942964 NOVO-CAPTORIL NOP 0.1060 02163551 MYLAN-CAPTOPRIL MYL 0.1060

* 25MG TABLET00893609 APO-CAPTO APX $ 0.1500 01913832 NU-CAPTO NXP 0.1500 01942972 NOVO-CAPTORIL NOP 0.1500 02163578 MYLAN-CAPTOPRIL MYL 0.1500

* 50MG TABLET00893617 APO-CAPTO APX $ 0.2795 01913840 NU-CAPTO NXP 0.2795 01942980 NOVO-CAPTORIL NOP 0.2795 02163586 MYLAN-CAPTOPRIL MYL 0.2795

* 100MG TABLET00893625 APO-CAPTO APX $ 0.5198 01913859 NU-CAPTO NXP 0.5198 01942999 NOVO-CAPTORIL NOP 0.5198 02163594 MYLAN-CAPTOPRIL MYL 0.5198

62nd Edition 69 July 1, 2012

Page 92: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:08.00 HYPOTENSIVE DRUGS

CILAZAPRIL* 1MG TABLET

02266350 NOVO-CILAZAPRIL NOP $ 0.2804 02280442 PMS-CILAZAPRIL PMS 0.2804 02283778 MYLAN-CILAZAPRIL MYL 0.2804 02291134 APO-CILAZAPRIL APX 0.2804 02350963 CILAZAPRIL SAN 0.2804

* 2.5MG TABLET02266369 NOVO-CILAZAPRIL NOP $ 0.2513 02280450 PMS-CILAZAPRIL PMS 0.2513 02283786 MYLAN-CILAZAPRIL MYL 0.2513 02285215 CO CILAZAPRIL COB 0.2513 02291142 APO-CILAZAPRIL APX 0.2513 02350971 CILAZAPRIL SAN 0.2513 01911473 INHIBACE HLR 0.7323

* 5MG TABLET02266377 NOVO-CILAZAPRIL NOP $ 0.2919 02280469 PMS-CILAZAPRIL PMS 0.2919 02283794 MYLAN-CILAZAPRIL MYL 0.2919 02285223 CO CILAZAPRIL COB 0.2919 02291150 APO-CILAZAPRIL APX 0.2919 02350998 CILAZAPRIL SAN 0.2919 01911481 INHIBACE HLR 0.8508

CILAZAPRIL/HYDROCHLOROTHIAZIDE* 5MG/12.5MG TABLET

02284987 APO-CILAZAPRIL/HCTZ APX $ 0.4170 02313731 NOVO-CILAZAPRIL/HCTZ NOP 0.4170 02181479 INHIBACE PLUS HLR 0.8508

CLONIDINE HCL SEE APPENDIX A FOR EDS CRITERIA

* 0.025MG TABLET02304163 NOVO-CLONIDINE (EDS) NOP $ 0.1523 00519251 DIXARIT (EDS) BOE 0.2720

* 0.1MG TABLET00868949 APO-CLONIDINE APX $ 0.1358 02046121 NOVO-CLONIDINE NOP 0.1358 00259527 CATAPRES BOE 0.1853

* 0.2MG TABLET00868957 APO-CLONIDINE APX $ 0.2424 02046148 NOVO-CLONIDINE NOP 0.2424 00291889 CATAPRES BOE 0.3306

62nd Edition 70 July 1, 2012

Page 93: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:08.00 HYPOTENSIVE DRUGS

DILTIAZEM HCL NOTE: THE SUSTAINED RELEASE DOSAGE FORMS ARE APPROVED AS ANTIHYPERTENSIVE AGENTS (SEE SECTION 24:04.00)

DOXAZOSIN MESYLATE* 1MG TABLET

02240498 MYLAN-DOXAZOSIN MYL $ 0.1983 02240588 APO-DOXAZOSIN APX 0.1983 02242728 NOVO-DOXAZOSIN NOP 0.1983 02244527 PMS-DOXAZOSIN PMS 0.1983 01958100 CARDURA-1 PFI 0.5784

* 2MG TABLET02240499 MYLAN-DOXAZOSIN MYL $ 0.2378 02240589 APO-DOXAZOSIN APX 0.2378 02242729 NOVO-DOXAZOSIN NOP 0.2378 02244528 PMS-DOXAZOSIN PMS 0.2378 01958097 CARDURA-2 PFI 0.6938

* 4MG TABLET02240500 MYLAN-DOXAZOSIN MYL $ 0.3092 02240590 APO-DOXAZOSIN APX 0.3092 02242730 NOVO-DOXAZOSIN NOP 0.3092 02244529 PMS-DOXAZOSIN PMS 0.3092 01958119 CARDURA-4 PFI 0.9022

ENALAPRIL MALEATE* 2.5MG TABLET

02323478 SIG-ENALAPRIL SLI $ 0.1919 *02020025 APO-ENALAPRIL APX 0.2686 02291878 CO ENALAPRIL COB 0.2686 02299933 SANDOZ ENALAPRIL SDZ 0.2686 02300036 MYLAN-ENALAPRIL MYL 0.2686 02300079 PMS-ENALAPRIL PMS 0.2686 02300680 NOVO-ENALAPRIL NOP 0.2686 02352230 RAN-ENALAPRIL RAN 0.2686 00851795 VASOTEC MRK 0.8058

62nd Edition 71 July 1, 2012

Page 94: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:08.00 HYPOTENSIVE DRUGS

* 5MG TABLET02323486 SIG-ENALAPRIL SLI $ 0.2270 *02019884 APO-ENALAPRIL APX 0.3177 02233005 NOVO-ENALAPRIL NOP 0.3177 02291886 CO ENALAPRIL COB 0.3177 02299941 SANDOZ ENALAPRIL SDZ 0.3177 02300044 MYLAN-ENALAPRIL MYL 0.3177 02300087 PMS-ENALAPRIL PMS 0.3177 02352249 RAN-ENALAPRIL RAN 0.3177 00708879 VASOTEC MRK 0.9533

* 10MG TABLET02323494 SIG-ENALAPRIL SLI $ 0.2728 *02019892 APO-ENALAPRIL APX 0.3818 02233006 NOVO-ENALAPRIL NOP 0.3818 02291894 CO ENALAPRIL COB 0.3818 02299968 SANDOZ ENALAPRIL SDZ 0.3818 02300052 MYLAN-ENALAPRIL MYL 0.3818 02300095 PMS-ENALAPRIL PMS 0.3818 02352257 RAN-ENALAPRIL RAN 0.3818 00670901 VASOTEC MRK 1.1454

* 20MG TABLET02323508 SIG-ENALAPRIL SLI $ 0.3291 *02019906 APO-ENALAPRIL APX 0.4607 02233007 NOVO-ENALAPRIL NOP 0.4607 02291908 CO ENALAPRIL COB 0.4607 02299976 SANDOZ ENALAPRIL SDZ 0.4607 02300060 MYLAN-ENALAPRIL MYL 0.4607 02300109 PMS-ENALAPRIL PMS 0.4607 02352265 RAN-ENALAPRIL RAN 0.4607 00670928 VASOTEC MRK 1.3821

ENALAPRIL MALEATE/HYDROCHLOROTHIAZIDE* 5MG/12.5MG TABLET

02300222 NOVO-ENALAPRIL/HCTZ NOP $ 0.6417 02352923 APO-ENALAPRIL/HCTZ APX 0.6417

* 10MG/25MG TABLET02300230 NOVO-ENALAPRIL/HCTZ NOP $ 0.7713 02352931 APO-ENALAPRIL/HCTZ APX 0.7713 00657298 VASERETIC MRK 1.1797

EPROSARTAN MESYLATE 400MG TABLET

02240432 TEVETEN SLV $ 0.7075 600MG TABLET

02243942 TEVETEN SLV $ 1.0836

EPROSARTAN MESYLATE/HYDROCHOLORTHIAZIDE 600MG/12.5MG TABLET

02253631 TEVETEN PLUS SLV $ 1.0836

62nd Edition 72 July 1, 2012

Page 95: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:08.00 HYPOTENSIVE DRUGS

FELODIPINE* 2.5MG SUSTAINED RELEASE TABLET

02221985 RENEDIL AVT $ 0.3170 02057778 PLENDIL AST 0.5230

* 5MG SUSTAINED RELEASE TABLET02280264 SANDOZ FELODIPINE SDZ $ 0.4634 02221993 RENEDIL AVT 0.4634 00851779 PLENDIL AST 0.6990

* 10MG SUSTAINED RELEASE TABLET02280272 SANDOZ FELODIPINE SDZ $ 0.6734 02222000 RENEDIL AVT 0.6734 00851787 PLENDIL AST 1.0487

FOSINOPRIL* 10MG TABLET

02247802 TEVA-FOSINOPRIL NOP $ 0.3049 02262401 MYLAN-FOSINOPRIL MYL 0.3049 02266008 APO-FOSINOPRIL APX 0.3049 02294524 RAN-FOSINOPRIL RAN 0.3049 02331004 JAMP-FOSINOPRIL JPC 0.3049 01907107 MONOPRIL BMY 0.9290

* 20MG TABLET02247803 TEVA-FOSINOPRIL NOP $ 0.3667 02262428 MYLAN-FOSINOPRIL MYL 0.3667 02266016 APO-FOSINOPRIL APX 0.3667 02294532 RAN-FOSINOPRIL RAN 0.3667 02331012 JAMP-FOSINOPRIL JPC 0.3667 01907115 MONOPRIL BMY 1.1178

HYDRALAZINE HCL 10MG TABLET

00441619 APO-HYDRALAZINE APX $ 0.1347 25MG TABLET

00441627 APO-HYDRALAZINE APX $ 0.2314 50MG TABLET

00441635 APO-HYDRALAZINE APX $ 0.3633

62nd Edition 73 July 1, 2012

Page 96: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:08.00 HYPOTENSIVE DRUGS

IRBESARTAN* 75MG TABLET

02315971 TEVA-IRBESARTAN TEV $ 0.4234 02316390 RATIO-IRBESARTAN RPH 0.4234 02317060 PMS-IRBESARTAN PMS 0.4234 02328070 CO IRBESARTAN COB 0.4234 02328461 SANDOZ IRBESARTAN SDZ 0.4234 02347296 MYLAN-IRBESARTAN MYL 0.4234 02372347 IRBESARTAN SAN 0.4234 02237923 AVAPRO BMY 1.2672

* 150MG TABLET02315998 TEVA-IRBESARTAN TEV $ 0.4234 02316404 RATIO-IRBESARTAN TEV 0.4234 02317079 PMS-IRBESARTAN PMS 0.4234 02328089 CO IRBESARTAN COB 0.4234 02328488 SANDOZ IRBESARTAN SDZ 0.4234 02347318 MYLAN-IRBESARTAN MYL 0.4234 02372371 IRBESARTAN SAN 0.4234 02237924 AVAPRO BMY 1.2672

* 300MG TABLET02316005 TEVA-IRBESARTAN TEV $ 0.4234 02316412 RATIO-IRBESARTAN TEV 0.4234 02317087 PMS-IRBESARTAN PMS 0.4234 02328100 CO IRBESARTAN COB 0.4234 02328496 SANDOZ IRBESARTAN SDZ 0.4234 02347326 MYLAN-IRBESARTAN MYL 0.4234 02372398 IRBESARTAN SAN 0.4234 02237925 AVAPRO BMY 1.2672

IRBESARTAN/HYDROCHLOROTHIAZIDE* 150MG/12.5MG TABLET

02316013 TEVA-IRBESARTAN/HCTZ TEV $ 0.4234 02328518 PMS-IRBESARTAN HCTZ PMS 0.4234 02330512 RATIO-IRBESARTAN HCTZ RPH 0.4234 02337428 SANDOZ IRBESARTAN HCT SDZ 0.4234 02357399 CO IRBESARTAN/HCT COB 0.4234 02363208 RAN-IRBESARTAN HCTZ RAN 0.4234 02372886 IRBESARTAN/HCTZ SAN 0.4234 02241818 AVALIDE BMY 1.2672

62nd Edition 74 July 1, 2012

Page 97: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:08.00 HYPOTENSIVE DRUGS

* 300MG/12.5MG TABLET02316021 TEVA-IRBESARTAN/HCTZ TEV $ 0.4234 02328526 PMS-IRBESARTAN HCTZ PMS 0.4234 02330520 RATIO-IRBESARTAN HCTZ RPH 0.4234 02337436 SANDOZ IRBESARTAN HCT SDZ 0.4234 02357402 CO IRBESARTAN/HCT COB 0.4234 02363216 RAN-IRBESARTAN HCTZ RAN 0.4234 02372894 IRBESARTAN/HCTZ SAN 0.4234 02241819 AVALIDE BMY 1.2672

* 300MG/25MG TABLET02316048 TEVA-IRBESARTAN/HCTZ TEV $ 0.4206 02328534 PMS-IRBESARTAN HCTZ PMS 0.4206 02330539 RATIO-IRBESARTAN HCTZ RPH 0.4206 02337444 SANDOZ IRBESARTAN HCT SDZ 0.4206 02357410 CO IRBESARTAN/HCT COB 0.4206 02363224 RAN-IRBESARTAN HCTZ RAN 0.4206 02372908 IRBESARTAN/HCTZ SAN 0.4206

LABETALOL HCL 100MG TABLET

02106272 TRANDATE PAL $ 0.2814 200MG TABLET

02106280 TRANDATE PAL $ 0.4976

LISINOPRIL* 5MG TABLET

02217481 APO-LISINOPRIL APX $ 0.2001 02256797 RATIO-LISINOPRIL P RPH 0.2001 02271443 CO LISINOPRIL COB 0.2001 02274833 MYLAN-LISINOPRIL MYL 0.2001 02285061 NOVO-LISINOPRIL (TYPE P) NOP 0.2001 02285118 NOVO-LISINOPRIL (TYPE Z) NOP 0.2001 02289199 SANDOZ LISINOPRIL SDZ 0.2001 02292203 PMS-LISINOPRIL PMS 0.2001 02294230 RAN-LISINOPRIL RAN 0.2001 02299879 RATIO-LISINOPRIL Z RPH 0.2001 02361531 JAMP-LISINOPRIL JPC 0.2001 02049333 ZESTRIL AST 0.5660 00839388 PRINIVIL MRK 0.6180

62nd Edition 75 July 1, 2012

Page 98: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:08.00 HYPOTENSIVE DRUGS

* 10MG TABLET02217503 APO-LISINOPRIL APX $ 0.2402 02256800 RATIO-LISINOPRIL P RPH 0.2402 02271451 CO LISINOPRIL COB 0.2402 02274841 MYLAN-LISINOPRIL MYL 0.2402 02285088 TEVA-LISINOPRIL (TYPE P) NOP 0.2402 02285126 NOVO-LISINOPRIL (TYPE Z) NOP 0.2402 02289202 SANDOZ LISINOPRIL SDZ 0.2402 02292211 PMS-LISINOPRIL PMS 0.2402 02294249 RAN-LISINOPRIL RAN 0.2402 02299887 RATIO-LISINOPRIL Z RPH 0.2402 02361558 JAMP-LISINOPRIL JPC 0.2402 02049376 ZESTRIL AST 0.6800 00839396 PRINIVIL MRK 0.7425

* 20MG TABLET02217511 APO-LISINOPRIL APX $ 0.2889 02256819 RATIO-LISINOPRIL P RPH 0.2889 02271478 CO LISINOPRIL COB 0.2889 02274868 MYLAN-LISINOPRIL MYL 0.2889 02285096 TEVA-LISINOPRIL (TYPE P) NOP 0.2889 02285134 NOVO-LISINOPRIL (TYPE Z) NOP 0.2889 02289229 SANDOZ LISINOPRIL SDZ 0.2889 02292238 PMS-LISINOPRIL PMS 0.2889 02294257 RAN-LISINOPRIL RAN 0.2889 02299895 RATIO-LISINOPRIL Z RPH 0.2889 02361566 JAMP-LISINOPRIL JPC 0.2889 02049384 ZESTRIL AST 0.8168 00839418 PRINIVIL MRK 0.8926

LISINOPRIL/HYDROCHLOROTHIAZIDE* 10MG/12.5MG TABLET

02261979 APO-LISINOPRIL/HCTZ APX $ 0.2917 02297736 MYLAN-LISINOPRIL HCTZ MYL 0.2917 02301768 NOVO-LISINOPRIL/HCTZ (Z) NOP 0.2917 02302136 NOVO-LISINOPRIL/HCTZ (P) NOP 0.2917 02302365 SANDOZ LISINOPRIL HCT SDZ 0.2917 02362945 LISINOPRIL/HCTZ (Z) SAN 0.2917 02103729 ZESTORETIC AST 0.8753

* 20MG/12.5MG TABLET02261987 APO-LISINOPRIL/HCTZ APX $ 0.3506 02297744 MYLAN-LISINOPRIL HCTZ MYL 0.3506 02301776 TEVA-LISINOPRIL/HCTZ (Z) NOP 0.3506 02302144 NOVO-LISINOPRIL/HCTZ (P) NOP 0.3506 02302373 SANDOZ LISINOPRIL HCT SDZ 0.3506 02362953 LISINOPRIL/HCTZ (Z) SAN 0.3506 00884413 PRINZIDE MRK 0.9193 02045737 ZESTORETIC AST 1.0517

* 20MG/25MG TABLET02297752 MYLAN-LISINOPRIL HCTZ MYL $ 0.3506 02045729 ZESTORETIC AST 1.0517

62nd Edition 76 July 1, 2012

Page 99: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:08.00 HYPOTENSIVE DRUGS

LOSARTAN POTASSIUM* 25MG TABLET

02309750 PMS-LOSARTAN PMS $ 0.4407 02313332 SANDOZ LOSARTAN SDZ 0.4407 02354829 CO LOSARTAN COB 0.4407 02368277 MYLAN-LOSARTAN MYL 0.4407 02379058 APO-LOSARTAN APX 0.4407 02380838 TEVA-LOSARTAN TEV 0.4407 02182815 COZAAR MRK 1.2590

* 50MG TABLET02309769 PMS-LOSARTAN PMS $ 0.4407 02313340 SANDOZ LOSARTAN SDZ 0.4407 02353504 APO-LOSARTAN APX 0.4407 02354837 CO LOSARTAN COB 0.4407 02357968 TEVA-LOSARTAN TEV 0.4407 02368285 MYLAN-LOSARTAN MYL 0.4407 02182874 COZAAR MRK 1.2590

* 100MG TABLET02309777 PMS-LOSARTAN PMS $ 0.4407 02313359 SANDOZ LOSARTAN SDZ 0.4407 02353512 APO-LOSARTAN APX 0.4407 02354845 CO LOSARTAN COB 0.4407 02357976 TEVA-LOSARTAN TEV 0.4407 02368293 MYLAN-LOSARTAN MYL 0.4407 02182882 COZAAR MRK 1.2590

LOSARTAN POTASSIUM/HYDROCHLOROTHIAZIDE* 50MG/12.5MG TABLET

02313375 SANDOZ LOSARTAN HCT SDZ $ 0.4407 02358263 TEVA-LOSARTAN/HCTZ TEV 0.4407 02371235 APO-LOSARTAN/HCTZ APX 0.4407 02378078 MYLAN-LOSARTAN HCTZ MYL 0.4407 02230047 HYZAAR MRK 1.2590

* 100MG/12.5MG TABLET02362449 SANDOZ LOSARTAN HCT SDZ $ 0.4315 02371243 APO-LOSARTAN/HCTZ APX 0.4315 02377144 TEVA-LOSARTAN/HCTZ TEV 0.4315 02378086 MYLAN-LOSARTAN HCTZ MYL 0.4315 02297841 HYZAAR MRK 1.2327

* 100MG/25MG TABLET02313383 SANDOZ LOSARTAN HCT DS SDZ $ 0.4407 02371251 APO-LOSARTAN/HCTZ APX 0.4407 02377152 TEVA-LOSARTAN/HCTZ TEV 0.4407 02378094 MYLAN-LOSARTAN HCTZ MYL 0.4407 02241007 HYZAAR DS MRK 1.2590

62nd Edition 77 July 1, 2012

Page 100: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:08.00 HYPOTENSIVE DRUGS

METHYLDOPA 125MG TABLET

00360252 METHYLDOPA AAP $ 0.0989 250MG TABLET

00360260 METHYLDOPA AAP $ 0.1433 500MG TABLET

00426830 METHYLDOPA AAP $ 0.2537

METOPROLOL TARTRATE SEE SECTION 24:04.00 (CARDIAC DRUGS)

MINOXIDIL SEE APPENDIX A FOR EDS CRITERIA 2.5MG TABLET

00514497 LONITEN (EDS) PFI $ 0.3432 10MG TABLET

00514500 LONITEN (EDS) PFI $ 0.7565

NADOLOL SEE SECTION 24:04.00 (CARDIAC DRUGS)

NIFEDIPINE SEE SECTION 24:04.00 (CARDIAC DRUGS)

OLMESARTAN MEDOXOMIL 20MG TABLET

02318660 OLMETEC MRK $ 1.0218 40MG TABLET

02318679 OLMETEC MRK $ 1.0218

OLMESARTAN MEDOXOMIL/HCTZ 20MG/12.5MG TABLET

02319616 OLMETEC PLUS MRK $ 1.0218 40MG/12.5MG TABLET

02319624 OLMETEC PLUS MRK $ 1.0218 40MG/25MG TABLET

02319632 OLMETEC PLUS MRK $ 1.0218

PERINDOPRIL ERBUMINE 2MG TABLET

02123274 COVERSYL SEV $ 0.6527 4MG TABLET

02123282 COVERSYL SEV $ 0.8170 8MG TABLET

02246624 COVERSYL SEV $ 1.1437

62nd Edition 78 July 1, 2012

Page 101: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:08.00 HYPOTENSIVE DRUGS

PERINDOPRIL ERBUMINE/INDAPAMIDE 4MG/1.25MG TABLET

02246569 COVERSYL PLUS SEV $ 0.9844 8MG/2.5MG TABLET

02321653 COVERSYL PLUS HD SEV $ 1.0920

PINDOLOL SEE SECTION 24:04.00 (CARDIAC DRUGS)

PINDOLOL/HYDROCHLOROTHIAZIDE 10MG/25MG TABLET

00568627 VISKAZIDE NVR $ 0.8747 10MG/50MG TABLET

00568635 VISKAZIDE NVR $ 0.8747

PRAZOSIN* 1MG TABLET

00882801 APO-PRAZO APX $ 0.1371 01934198 NOVO-PRAZIN NOP 0.1371

* 2MG TABLET00882828 APO-PRAZO APX $ 0.1862 01934201 NOVO-PRAZIN NOP 0.1862

* 5MG TABLET00882836 APO-PRAZO APX $ 0.2560 01934228 NOVO-PRAZIN NOP 0.2560

PROPRANOLOL SEE SECTION 24:04.00 (CARDIAC DRUGS)

QUINAPRIL HCL 5MG TABLET

01947664 ACCUPRIL PFI $ 0.8977 10MG TABLET

01947672 ACCUPRIL PFI $ 0.8977 20MG TABLET

01947680 ACCUPRIL PFI $ 0.8977 40MG TABLET

01947699 ACCUPRIL PFI $ 0.8977

62nd Edition 79 July 1, 2012

Page 102: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:08.00 HYPOTENSIVE DRUGS

QUINAPRIL HCL/HYDROCHLOROTHIAZIDE 10MG/12.5MG TABLET

02237367 ACCURETIC PFI $ 0.8975 20MG/12.5MG TABLET

02237368 ACCURETIC PFI $ 0.8975 20MG/25MG TABLET

02237369 ACCURETIC PFI $ 0.8683

RAMIPRIL* 1.25MG CAPSULE/TABLET

02251515 APO-RAMIPRIL APX $ 0.2427 02287692 RATIO-RAMIPRIL RPH 0.2427 02291398 SANDOZ RAMIPRIL SDZ 0.2427 02295369 PMS-RAMIPRIL PMS 0.2427 02295482 CO RAMIPRIL COB 0.2427 02299372 RAMIPRIL PMS 0.2427 02301148 MYLAN-RAMIPRIL MYL 0.2427 02310503 RAN-RAMIPRIL RAN 0.2427 02331101 JAMP-RAMIPRIL JPC 0.2427 02363267 AVA-RAMIPRIL AVA 0.2427 02221829 ALTACE AVT 0.7077

* 2.5MG CAPSULE/TABLET02247917 PMS-RAMIPRIL PMS $ 0.2800 02247945 TEVA-RAMIPRIL NOP 0.2800 02251531 APO-RAMIPRIL APX 0.2800 02255316 RAMIPRIL PMS 0.2800 02287706 RATIO-RAMIPRIL RPH 0.2800 02291401 SANDOZ RAMIPRIL SDZ 0.2800 02295490 CO RAMIPRIL COB 0.2800 02301156 MYLAN-RAMIPRIL MYL 0.2800 02310511 RAN-RAMIPRIL RAN 0.2800 02331128 JAMP-RAMIPRIL JPC 0.2800 02363275 AVA-RAMIPRIL AVA 0.2800 02374846 RAMIPRIL SAN 0.2800 02221837 ALTACE AVT 0.8167

62nd Edition 80 July 1, 2012

Page 103: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:08.00 HYPOTENSIVE DRUGS

* 5MG CAPSULE/TABLET02247918 PMS-RAMIPRIL PMS $ 0.2800 02247946 TEVA-RAMIPRIL NOP 0.2800 02251574 APO-RAMIPRIL APX 0.2800 02255324 RAMIPRIL PMS 0.2800 02287714 RATIO-RAMIPRIL RPH 0.2800 02291428 SANDOZ RAMIPRIL SDZ 0.2800 02295504 CO RAMIPRIL COB 0.2800 02301164 MYLAN-RAMIPRIL MYL 0.2800 02310538 RAN-RAMIPRIL RAN 0.2800 02331136 JAMP-RAMIPRIL JPC 0.2800 02363283 AVA-RAMIPRIL AVA 0.2800 02374854 RAMIPRIL SAN 0.2800 02221845 ALTACE AVT 0.8167

* 10MG CAPSULE/TABLET02247919 PMS-RAMIPRIL PMS $ 0.3547 02247947 TEVA-RAMIPRIL NOP 0.3547 02251582 APO-RAMIPRIL APX 0.3547 02255332 RAMIPRIL PMS 0.3547 02287722 RATIO-RAMIPRIL RPH 0.3547 02291436 SANDOZ RAMIPRIL SDZ 0.3547 02295512 CO RAMIPRIL COB 0.3547 02301172 MYLAN-RAMIPRIL MYL 0.3547 02310546 RAN-RAMIPRIL RAN 0.3547 02331144 JAMP-RAMIPRIL JPC 0.3547 02363291 AVA-RAMIPRIL AVA 0.3547 02374862 RAMIPRIL SAN 0.3547 02221853 ALTACE AVT 1.0344

RAMIPRIL/HYDROCHLOROTHIAZIDE* 2.5MG/12.5MG TABLET

02342138 PMS-RAMIPRIL/HCTZ PMS $ 0.2250 02283131 ALTACE HCT AVT 0.2990

* 5MG/12.5MG TABLET02342146 PMS-RAMIPRIL/HCTZ PMS $ 0.2263 02283158 ALTACE HCT AVT 0.3829

* 10MG/12.5MG TABLET02342154 PMS-RAMIPRIL/HCTZ PMS $ 0.2865 02283166 ALTACE HCT AVT 0.4875

* 5MG/25MG TABLET02342162 PMS-RAMIPRIL/HCTZ PMS $ 0.2263 02283174 ALTACE HCT AVT 0.3829

* 10MG/25MG TABLET02342170 PMS-RAMIPRIL/HCTZ PMS $ 0.2865 02283182 ALTACE HCT AVT 0.4875

62nd Edition 81 July 1, 2012

Page 104: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS24:08.00 HYPOTENSIVE DRUGS

SPIRONOLACTONE/HYDROCHLOROTHIAZIDE* 25MG/25MG TABLET

00613231 NOVO-SPIROZINE NOP $ 0.1078 00180408 ALDACTAZIDE-25 PFI 0.1307

* 50MG/50MG TABLET00657182 NOVO-SPIROZINE NOP $ 0.2281 00594377 ALDACTAZIDE-50 PFI 0.2771

TELMISARTAN* 40MG TABLET

02320177 TEVA-TELMISARTAN TEV $ 0.3954 02375958 SANDOZ TELMISARTAN SDZ 0.3954 02376717 MYLAN-TELMISARTAN MYL 0.3954 02240769 MICARDIS BOE 1.1658

* 80MG TABLET02320185 TEVA-TELMISARTAN TEV $ 0.3954 02375966 SANDOZ TELMISARTAN SDZ 0.3954 02376725 MYLAN-TELMISARTAN MYL 0.3954 02240770 MICARDIS BOE 1.1658

TELMISARTAN/AMLODIPINE 40MG/5MG TABLET

02371022 TWYNSTA BOE $ 0.6819 40MG/10MG TABLET

02371030 TWYNSTA BOE $ 0.6819 80MG/5MG TABLET

02371049 TWYNSTA BOE $ 0.6819 80MG/10MG TABLET

02371057 TWYNSTA BOE $ 0.6819

TELMISARTAN/HYDROCHLOROTHIAZIDE* 80MG/12.5MG TABLET

02330288 TEVA-TELMISARTAN HCTZ TEV $ 0.3954 02373564 MYLAN-TELMISARTAN HCTZ MYL 0.3954 02244344 MICARDIS PLUS BOE 1.1658

* 80MG/25MG TABLET02373572 MYLAN-TELMISARTAN HCTZ MYL $ 0.3954 02379252 TEVA-TELMISARTAN HCTZ TEV 0.3954 02318709 MICARDIS PLUS BOE 1.1658

62nd Edition 82 July 1, 2012

Page 105: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:08.00 HYPOTENSIVE DRUGS

TERAZOSIN HCL* 1MG TABLET

02218941 RATIO-TERAZOSIN RPH $ 0.2447 02230805 TEVA-TERAZOSIN TEV 0.2447 02233047 NU-TERAZOSIN NXP 0.2447 02234502 APO-TERAZOSIN APX 0.2447 02243518 PMS-TERAZOSIN PMS 0.2447 02350475 TERAZOSIN SAN 0.2447 00818658 HYTRIN ABB 0.7690

* 2MG TABLET02218968 RATIO-TERAZOSIN RPH $ 0.3111 02230806 TEVA-TERAZOSIN TEV 0.3111 02233048 NU-TERAZOSIN NXP 0.3111 02234503 APO-TERAZOSIN APX 0.3111 02243519 PMS-TERAZOSIN PMS 0.3111 02350483 TERAZOSIN SAN 0.3111 00818682 HYTRIN ABB 0.9774

* 5MG TABLET02218976 RATIO-TERAZOSIN RPH $ 0.4225 02230807 TEVA-TERAZOSIN TEV 0.4225 02233049 NU-TERAZOSIN NXP 0.4225 02234504 APO-TERAZOSIN APX 0.4225 02243520 PMS-TERAZOSIN PMS 0.4225 02350491 TERAZOSIN SAN 0.4225 00818666 HYTRIN ABB 1.3274

* 10MG TABLET02218984 RATIO-TERAZOSIN RPH $ 0.6183 02230808 TEVA-TERAZOSIN NOP 0.6183 02233050 NU-TERAZOSIN NXP 0.6183 02234505 APO-TERAZOSIN APX 0.6183 02243521 PMS-TERAZOSIN PMS 0.6183 02243749 DOM-TERAZOSIN DOM 0.6183 02350505 TERAZOSIN SAN 0.6183 00818674 HYTRIN ABB 1.9431

TIMOLOL MALEATE SEE SECTION 24:04.00 (CARDIAC DRUGS)

62nd Edition 83 July 1, 2012

Page 106: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:08.00 HYPOTENSIVE DRUGS

TRANDOLAPRIL 0.5MG CAPSULE

02231457 MAVIK ABB $ 0.4030 1MG CAPSULE

02231459 MAVIK ABB $ 0.6901 2MG CAPSULE

02231460 MAVIK ABB $ 0.7931 4MG CAPSULE

02239267 MAVIK ABB $ 0.9785

TRIAMTERENE/HYDROCHLOROTHIAZIDE* 50MG/25MG TABLET

00441775 APO-TRIAZIDE APX $ 0.0608 00532657 NOVO-TRIAMZIDE NOP 0.0608 00865532 NU-TRIAZIDE NXP 0.0608

VALSARTAN* 40MG TABLET

02312999 PMS-VALSARTAN PMS $ 0.4075 02337487 CO VALSARTAN COB 0.4075 02356643 TEVA-VALSARTAN TEV 0.4075 02356740 SANDOZ VALSARTAN SDZ 0.4075 02363062 RAN-VALSARTAN RAN 0.4075 02367114 AVA-VALSARTAN AVA 0.4075 02371510 APO-VALSARTAN APX 0.4075 02383527 MYLAN-VALSARTAN MYL 0.4075 02270528 DIOVAN NVR 1.1672

* 80MG TABLET02313006 PMS-VALSARTAN PMS $ 0.4141 02337495 CO VALSARTAN COB 0.4141 02356651 TEVA-VALSARTAN TEV 0.4141 02356759 SANDOZ VALSARTAN SDZ 0.4141 02363100 RAN-VALSARTAN RAN 0.4141 02367122 AVA-VALSARTAN AVA 0.4141 02371529 APO-VALSARTAN APX 0.4141 02383535 MYLAN-VALSARTAN MYL 0.4141 02244781 DIOVAN NVR 1.1997

62nd Edition 84 July 1, 2012

Page 107: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:08.00 HYPOTENSIVE DRUGS

* 160MG TABLET02313014 PMS-VALSARTAN PMS $ 0.4141 02337509 CO VALSARTAN COB 0.4141 02356678 TEVA-VALSARTAN TEV 0.4141 02356767 SANDOZ VALSARTAN SDZ 0.4141 02363119 RAN-VALSARTAN RAN 0.4141 02367130 AVA-VALSARTAN AVA 0.4141 02371537 APO-VALSARTAN APX 0.4141 02383543 MYLAN-VALSARTAN MYL 0.4141 02244782 DIOVAN NVR 1.1993

* 320MG TABLET02337517 CO VALSARTAN COB $ 0.3980 02344564 PMS-VALSARTAN PMS 0.3980 02356686 TEVA-VALSARTAN TEV 0.3980 02356775 SANDOZ VALSARTAN SDZ 0.3980 02367149 AVA-VALSARTAN AVA 0.3980 02371545 APO-VALSARTAN APX 0.3980 02383551 MYLAN-VALSARTAN MYL 0.3980 02289504 DIOVAN NVR 1.1554

VALSARTAN/HYDROCHLOROTHIAZIDE* 80MG/12.5MG TABLET

02356694 SANDOZ VALSARTAN HCT SDZ $ 0.4141 02356996 TEVA-VALSARTAN/HCTZ TEV 0.4141 02367068 AVA-VALSARTAN HCT AVA 0.4141 02373734 MYLAN-VALSARTAN-HCTZ MYL 0.4141 02382547 APO-VALSARTAN/HCTZ APX 0.4141 02241900 DIOVAN-HCT NVR 1.1940

* 160MG/12.5MG TABLET02356708 SANDOZ VALSARTAN HCT SDZ $ 0.4141 02357003 TEVA-VALSARTAN/HCTZ TEV 0.4141 02367076 AVA-VALSARTAN HCT AVA 0.4141 02373742 MYLAN-VALSARTAN-HCTZ MYL 0.4141 02382555 APO-VALSARTAN/HCTZ APX 0.4141 02241901 DIOVAN-HCT NVR 1.1972

* 160MG/25MG TABLET02356716 SANDOZ VALSARTAN HCT SDZ $ 0.4141 02357011 TEVA-VALSARTAN/HCTZ TEV 0.4141 02367084 AVA-VALSARTAN HCT AVA 0.4141 02373750 MYLAN-VALSARTAN-HCTZ MYL 0.4141 02382563 APO-VALSARTAN/HCTZ PAX 0.4141 02246955 DIOVAN-HCT NVR 1.2011

62nd Edition 85 July 1, 2012

Page 108: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS

24:08.00 HYPOTENSIVE DRUGS

* 320MG/12.5MG TABLET02356724 SANDOZ VALSARTAN HCT SDZ $ 0.3980 02357038 TEVA-VALSARTAN/HCTZ TEV 0.3980 02367092 AVA-VALSARTAN HCT AVA 0.3980 02373769 MYLAN-VALSARTAN-HCTZ MYL 0.3980 02382571 APO-VALSARTAN/HCTZ APX 0.3980 02308908 DIOVAN-HCT NVR 1.1833

* 320MG/25MG TABLET02356732 SANDOZ VALSARTAN HCT SDZ $ 0.3980 02357046 TEVA-VALSARTAN/HCTZ TEV 0.3980 02367106 AVA-VALSARTAN HCT AVA 0.3980 02373777 MYLAN-VALSARTAN-HCTZ MYL 0.3980 02382598 APO-VASARTAN/HCTZ APX 0.3980 02308916 DIOVAN-HCT NVR 1.1833

VERAPAMIL HCL* 80MG TABLET

00782483 APO-VERAP APX $ 0.2735 00886033 NU-VERAP NXP 0.2735 02237921 MYLAN-VERAPAMIL MYL 0.2735

* 120MG TABLET00782491 APO-VERAP APX $ 0.4250 00886041 NU-VERAP NXP 0.4250 02237922 MYLAN-VERAPAMIL MYL 0.4250

* 120MG SUSTAINED RELEASE TABLET02210347 MYLAN-VERAPAMIL SR MYL $ 0.5078 02246893 APO-VERAP SR APX 0.5078 01907123 ISOPTIN SR ABB 1.4121

* 180MG SUSTAINED RELEASE TABLET02210355 MYLAN-VERAPAMIL SR MYL $ 0.5204 02246894 APO-VERAP SR APX 0.5204 01934317 ISOPTIN SR ABB 1.5945

* 240MG SUSTAINED RELEASE TABLET02210363 MYLAN-VERAPMIL SR MYL $ 0.6767 02211920 NOVO-VERAMIL SR NOP 0.6767 02237791 PMS-VERAPAMIL SR PMS 0.6767 02240321 DOM-VERAPAMIL SR DOM 0.6767 02246895 APO-VERAP SR APX 0.6767 02249812 NU-VERAP SR NXP 0.6767 00742554 ISOPTIN SR ABB 2.1264

62nd Edition 86 July 1, 2012

Page 109: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS24:12.00 VASODILATING DRUGS

AMBRISENTAN SEE APPENDIX A FOR EDS CRITERIA 5MG TABLET

02307065 VOLIBRIS (EDS) GSK $ 122.5200 10MG TABLET

02307073 VOLIBRIS (EDS) GSK $ 122.5200

BETAHISTINE DIHYDROCHLORIDE* 16MG TABLET

02280191 NOVO-BETAHISTINE NOP $ 0.1770 02374757 CO BETAHISTINE COB 0.1770 02243878 SERC SLV 0.4599

* 24MG TABLET02280205 NOVO-BETAHISTINE NOP $ 0.3040 02374765 CO BETAHISTINE COB 0.3040 02247998 SERC SLV 0.6897

BOSENTAN SEE APPENDIX A FOR EDS CRITERIA 62.5MG TABLET

02244981 TRACLEER (EDS) ACT $ 64.1786 125MG TABLET

02244982 TRACLEER (EDS) ACT $ 64.1786

DIPYRIDAMOLE/ACETYLSALICYLIC ACID SEE APPENDIX A FOR EDS CRITERIA 200MG/25MG CAPSULE

02242119 AGGRENOX (EDS) BOE $ 0.8492

EPOPROSTENOL PLEASE CONTACT THE DRUG PLAN FOR DETAILS. SEE APPENDIX A FOR EDS CRITERIA 0.5MG/VIAL INJECTION

02230845 FLOLAN (EDS) GSK $ 18.3600 1.5MG/VIAL INJECTION

02230848 FLOLAN (EDS) GSK $ 36.7300 FLOLAN DILUENT

02230857 FLOLAN DILUENT (EDS) GSK $ 10.4900 PER DIEM SUPPLIES

00950964 FLOLAN SUPP/PER DIEM (EDS) GSK $ 46.0000

62nd Edition 87 July 1, 2012

Page 110: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS24:12.00 VASODILATING DRUGS

ISOSORBIDE DINITRATE 10MG TABLET

00441686 ISDN AAP $ 0.0365 30MG TABLET

00441694 ISDN AAP $ 0.0857 5MG SUBLINGUAL TABLET

00670944 ISDN AAP $ 0.0621

ISOSORBIDE-5 MONONITRATE* 60MG EXTENDED-RELEASE TABLET

02272830 APO-ISMN APX $ 0.3523 02301288 PMS-ISMN PMS 0.3523 02126559 IMDUR AST 0.6934

NIMODIPINE SEE APPENDIX A FOR EDS CRITERIA 30MG TABLET

02325926 NIMOTOP (EDS) BAY $ 9.8800

NITROGLYCERIN 0.2MG/HR. TRANSDERMAL THERAPEUTIC SYSTEM

01911910 NITRO-DUR 0.2 MRK $ 0.5667 02230732 TRINIPATCH 0.2 PAL 0.5780 02162806 MINITRAN 0.2 MDC 0.6027 00584223 TRANSDERM-NITRO 0.2 NVR 0.6617

0.4MG/HR. TRANSDERMAL THERAPEUTIC SYSTEM01911902 NITRO-DUR 0.4 MRK $ 0.6400 02230733 TRINIPATCH 0.4 PAL 0.6527 02163527 MINITRAN 0.4 MDC 0.6810 00852384 TRANSDERM-NITRO 0.4 NVR 0.7474

0.6MG/HR. TRANSDERMAL THERAPEUTIC SYSTEM01911929 NITRO-DUR 0.6 MRK $ 0.6400 02230734 TRINIPATCH 0.6 PAL 0.6527 02163535 MINITRAN 0.6 MDC 0.6814 02046156 TRANSDERM-NITRO 0.6 NVR 0.7474

0.8MG/HR. TRANSDERMAL THERAPEUTIC SYSTEM02011271 NITRO-DUR 0.8 MRK $ 1.1100

0.3MG SUBLINGUAL TABLET00037613 NITROSTAT PFI $ 0.1169

0.6MG SUBLINGUAL TABLET00037621 NITROSTAT PFI $ 0.1169

2% OINTMENT01926454 NITROL PAL $ 0.6390

* 0.4MG/DOSE LINGUAL SPRAY (PACKAGE)02238998 RHO-NITRO PUMPSPRAY SDZ $ 8.4600 02243588 MYLAN-NITROL SL SPRAY MYL 8.4600 02231441 NITROLINGUAL PUMPSPRAY AVT 14.6000

62nd Edition 88 July 1, 2012

Page 111: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

24:00 CARDIOVASCULAR DRUGS24:12.00 VASODILATING DRUGS

SILDENAFIL CITRATE SEE APPENDIX A FOR EDS CRITERIA 20MG TABLET

02279401 REVATIO (EDS) PFI $ 10.9587

TADALAFIL SEE APPENDIX A FOR EDS CRITERIA 20MG TABLET

02338327 ADCIRCA (EDS) LIL $ 13.0725

TREPROSTINIL PLEASE CONTACT THE DRUG PLAN FOR DETAILS. SEE APPENDIX A FOR EDS CRITERIA 1MG INJECTION SOLUTION

02246552 REMODULIN (EDS) UTI $ 46.7500 2.5MG INJECTION SOLUTION

02246553 REMODULIN (EDS) UTI $ 114.2500 5MG INJECTION SOLUTION

02246554 REMODULIN (EDS) UTI $ 226.7500 10MG INJECTION SOLUTION

02246555 REMODULIN (EDS) UTI $ 451.7500 PER DIEM SUPPLIES

00950963 REMODULIN SUPP/DIEM (EDS) UTI $ 46.0000

62nd Edition 89 July 1, 2012

Page 112: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...
Page 113: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

CENTRAL NERVOUS SYSTEM AGENTS28:00

Page 114: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:08.04 NON-STEROIDAL ANTI-INFLAMMATORY AGENTS

ACETYLSALICYLIC ACID* 325MG ENTERIC TABLET

02284529 PMS-ASA EC PMS $ 0.0304 00010332 ENTROPHEN PED 0.0484

650MG ENTERIC TABLET00010340 ENTROPHEN PED $ 0.0797

CELECOXIB SEE APPENDIX A FOR EDS CRITERIA 100MG CAPSULE

02239941 CELEBREX (EDS) PFI $ 0.6828 200MG CAPSULE

02239942 CELEBREX (EDS) PFI $ 1.3659

DICLOFENAC SODIUM* 25MG ENTERIC TABLET

00808539 NOVO-DIFENAC NOP $ 0.1094 00839175 APO-DICLO APX 0.1094 00886017 NU-DICLO NXP 0.1094 02231662 DOM-DICLOFENAC DOM 0.1094 02261952 SANDOZ DICLOFENAC SDZ 0.1094 02302616 PMS-DICLOFENAC PMS 0.1094

* 50MG ENTERIC TABLET00808547 NOVO-DIFENAC NOP $ 0.2890 00839183 APO-DICLO APX 0.2890 00886025 NU-DICLO NXP 0.2890 02231663 DOM-DICLOFENAC DOM 0.2890 02261960 SANDOZ DICLOFENAC SDZ 0.2890 02302624 PMS-DICLOFENAC PMS 0.2890 02352397 DICLOFENAC EC SAN 0.2890 00514012 VOLTAREN NVR 0.8656

* 75MG SUSTAINED RELEASE TABLET02158582 NOVO-DIFENAC SR NOP $ 0.4060 02162814 APO-DICLO SR APX 0.4060 02231504 PMS-DICLOFENAC-SR PMS 0.4060 02231664 DOM-DICLOFENAC SR DOM 0.4060 02261901 SANDOZ DICLOFENAC SR SDZ 0.4060 02352400 DICLOFENAC SR SAN 0.4060 00782459 VOLTAREN-SR NVR 1.1937

62nd Edition 92 July 1, 2012

Page 115: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:08.04 NON-STEROIDAL ANTI-INFLAMMATORY AGENTS

* 100MG SUSTAINED RELEASE TABLET02048698 NOVO-DIFENAC SR NOP $ 0.5788 02091194 APO-DICLO SR APX 0.5788 02231505 PMS-DICLOFENAC-SR PMS 0.5788 02231665 DOM-DICLOFENAC SR DOM 0.5788 02261944 SANDOZ DICLOFENAC SR SDZ 0.5788 00590827 VOLTAREN-SR NVR 1.7016

* 50MG SUPPOSITORY02231506 PMS-DICLOFENAC PMS $ 0.4339 02241224 SANDOZ DICLOFENAC SDZ 0.4339 02261928 SANDOZ DICLOFENAC SDZ 0.4339 00632724 VOLTAREN NVR 1.3000

* 100MG SUPPOSITORY02231508 PMS-DICLOFENAC PMS $ 0.5840 02241225 SANDOZ DICLOFENAC SDZ 0.5840 02261936 SANDOZ DICLOFENAC SDZ 0.5840 00632732 VOLTAREN NVR 1.7497

DICLOFENAC SODIUM/MISOPROSTOL 50MG/200UG ENTERIC TABLET

01917056 ARTHROTEC PFI $ 0.6054 75MG/200UG ENTERIC TABLET

02229837 ARTHROTEC 75 PFI $ 0.8239

DIFLUNISAL 250MG TABLET

02039486 APO-DIFLUNISAL APX $ 0.5366 500MG TABLET

02039494 APO-DIFLUNISAL APX $ 0.7150

ETODOLAC SEE APPENDIX A FOR EDS CRITERIA 200MG CAPSULE

02232317 ETODOLAC (EDS) AAP $ 0.7600 300MG CAPSULE

02232318 ETODOLAC (EDS) AAP $ 0.7600

FLURBIPROFEN* 50MG TABLET

01912046 APO-FLURBIPROFEN APX $ 0.2221 02020661 NU-FLURBIPROFEN NXP 0.2221 02100509 NOVO-FLURPROFEN NOP 0.2221

* 100MG TABLET01912038 APO-FLURBIPROFEN APX $ 0.3039 02020688 NU-FLURBIPROFEN NXP 0.3039 02100517 NOVO-FLURPROFEN NOP 0.3039

62nd Edition 93 July 1, 2012

Page 116: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:08.04 NON-STEROIDAL ANTI-INFLAMMATORY AGENTS

IBUPROFEN* 300MG TABLET

00441651 APO-IBUPROFEN APX $ 0.1087 02242632 MOTRIN EXTRA STRENGTH IB MCL 0.1222

* 400MG TABLET00506052 APO-IBUPROFEN APX $ 0.0450 00629340 NOVO-PROFEN NOP 0.0450 02317338 IBUPROFEN JPC 0.0450 02242658 MOTRIN SUPER STRENGTH IB MCL 0.1588

* 600MG TABLET00585114 APO-IBUPROFEN APX $ 0.1313 00629359 NOVO-PROFEN NOP 0.1313 02020726 NU-IBUPROFEN NXP 0.1313

INDOMETHACIN* 25MG CAPSULE

00337420 NOVO-METHACIN NOP $ 0.0871 00865850 NU-INDO NXP 0.0871

* 50MG CAPSULE00337439 NOVO-METHACIN NOP $ 0.1511 00865869 NU-INDO NXP 0.1511

50MG SUPPOSITORY02231799 SANDOZ INDOMETHACIN SDZ $ 0.8840

100MG SUPPOSITORY02231800 SANDOZ INDOMETHACIN SDZ $ 0.8910

KETOPROFEN 50MG CAPSULE

00790427 KETOPROFEN AAP $ 0.3373 50MG ENTERIC COATED TABLET

00790435 KETOPROFEN-E AAP $ 0.3373 100MG ENTERIC COATED TABLET

00842664 KETOPROFEN-E AAP $ 0.6823 200MG SUSTAINED RELEASE TABLET

02172577 KETOPROFEN SR AAP $ 1.3890 100MG SUPPOSITORY

02015951 PMS-KETOPROFEN PMS $ 1.1454

MEFENAMIC ACID 250MG CAPSULE

02229452 MEFENAMIC AAP $ 0.4988

62nd Edition 94 July 1, 2012

Page 117: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS28:08.04 NON-STEROIDAL ANTI-INFLAMMATORY AGENTS

MELOXICAM SEE APPENDIX A FOR EDS CRITERIA* 7.5MG TABLET

02248267 PMS-MELOXICAM (EDS) PMS $ 0.2804 02248605 DOM-MELOXICAM (EDS) DOM 0.2804 02248973 APO-MELOXICAM (EDS) APX 0.2804 02250012 CO MELOXICAM (EDS) COB 0.2804 02255987 MYLAN-MELOXICAM (EDS) MYL 0.2804 02258315 NOVO-MELOXICAM (EDS) NOP 0.2804 02353148 MELOXICAM (EDS) SAN 0.2804 02365545 AVA-MELOXICAM (EDS) AVA 0.2804 02242785 MOBICOX (EDS) BOE 0.8011

* 15MG TABLET02248268 PMS-MELOXICAM (EDS) PMS $ 0.3235 02248606 DOM-MELOXICAM (EDS) DOM 0.3235 02248974 APO-MELOXICAM (EDS) APX 0.3235 02250020 CO MELOXICAM (EDS) COB 0.3235 02255995 MYLAN-MELOXICAM (EDS) MYL 0.3235 02258323 TEVA-MELOXICAM (EDS) NOP 0.3235 02353156 MELOXICAM (EDS) SAN 0.3235 02365553 AVA-MELOXICAM (EDS) AVA 0.3235 02242786 MOBICOX (EDS) BOE 0.8011

NABUMETONE SEE APPENDIX A FOR EDS CRITERIA* 500MG TABLET

02238639 APO-NABUMETONE (EDS) APX $ 0.3625 02240867 NOVO-NABUMETONE (EDS) NOP 0.3625 02244563 MYLAN-NABUMETONE (EDS) MYL 0.3625

750MG TABLET02240868 NOVO-NABUMETONE (EDS) NOP $ 0.7071

NAPROXEN 125MG TABLET

00522678 APO-NAPROXEN APX $ 0.0781 * 250MG TABLET

00522651 APO-NAPROXEN APX $ 0.1068 00565350 TEVA-NAPROXEN NOP 0.1068 00865648 NU-NAPROX NXP 0.1068 02350750 NAPROXEN SAN 0.1068

62nd Edition 95 July 1, 2012

Page 118: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:08.04 NON-STEROIDAL ANTI-INFLAMMATORY AGENTS

* 375MG TABLET00600806 APO-NAPROXEN APX $ 0.1458 00627097 TEVA-NAPROXEN NOP 0.1458 00865656 NU-NAPROX NXP 0.1458 02350769 NAPROXEN SAN 0.1458

* 500MG TABLET00589861 TEVA-NAPROXEN NOP $ 0.2110 00592277 APO-NAPROXEN APX 0.2110 00865664 NU-NAPROX NXP 0.2110 02350777 NAPROXEN SAN 0.2110

750MG SUSTAINED RELEASE TABLET02162466 NAPROSYN-S.R. HLR $ 1.3211

500MG SUPPOSITORY02017237 PMS-NAPROXEN PMS $ 0.8883

25MG/ML SUSPENSION02162431 NAPROSYN HLR $ 0.0626

PIROXICAM* 10MG CAPSULE

00642886 APO-PIROXICAM APX $ 0.3210 00695718 NOVO-PIROCAM NOP 0.3210 00865761 NU-PIROX NXP 0.3210

* 20MG CAPSULE00642894 APO-PIROXICAM APX $ 0.5195 00695696 NOVO-PIROCAM NOP 0.5195 00865788 NU-PIROX NXP 0.5195

20MG SUPPOSITORY02154463 PMS-PIROXICAM PMS $ 2.0580

SULINDAC* 150MG TABLET

00745588 NOVO-SUNDAC NOP $ 0.3824 00778354 APO-SULIN APX 0.3824 02042576 NU-SULINDAC NXP 0.3824

* 200MG TABLET00745596 NOVO-SUNDAC NOP $ 0.3920 00778362 APO-SULIN APX 0.3920

TIAPROFENIC ACID* 200MG TABLET

02136112 APO-TIAPROFENIC APX $ 0.3437 02179679 NOVO-TIAPROFENIC NOP 0.3437

* 300MG TABLET02136120 APO-TIAPROFENIC APX $ 0.3257 02146886 NU-TIAPROFENIC NXP 0.3257 02179687 NOVO-TIAPROFENIC NOP 0.3257

62nd Edition 96 July 1, 2012

Page 119: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:08.08 OPIATE AGONISTS (NARCOTIC ANALGESICS)

ACETAMINOPHEN/CAFFEINE/CODEINE* 300MG ACETAMINOPHEN & 15MG CODEINE/TABLET

00653241 RATIO-LENOLTEC NO.2 RPH $ 0.0690 02163934 TYLENOL WITH CODEINE NO.2 JAN 0.0807

325MG ACETAMINOPHEN & 15MG CODEINE/TABLET00293504 ATASOL-15 CDC $ 0.0910

* 300MG ACETAMINOPHEN & 30MG CODEINE/TABLET00653276 RATIO-LENOLTEC NO.3 RPH $ 0.0760 02163926 TYLENOL WITH CODEINE NO.3 JAN 0.0888

325MG ACETAMINOPHEN & 30MG CODEINE/TABLET00293512 ATASOL-30 CDC $ 0.1325

ACETAMINOPHEN/CODEINE 300MG/30MG TABLET

00608882 RATIO-EMTEC RPH $ 0.1300 * 300MG/60MG TABLET

00621463 RATIO-LENOLTEC NO.4 RPH $ 0.1384 02163918 TYLENOL WITH CODEINE NO.4 JAN 0.1877

32MG/1.6MG/ML ELIXIR02163942 TYLENOL WITH CODEINE ELX JAN $ 0.1043

ACETYLSALICYLIC ACID/CAFFEINE/CODEINE 375MG/30MG/30MG TABLET

02238645 292 PED $ 0.1762

CODEINE SEE APPENDIX A FOR EDS CRITERIA 50MG CONTROLLED RELEASE TABLET

02230302 CODEINE CONTIN (EDS) PFR $ 0.3175 100MG CONTROLLED RELEASE TABLET

02163748 CODEINE CONTIN (EDS) PFR $ 0.6360 150MG CONTROLLED RELEASE TABLET

02163780 CODEINE CONTIN (EDS) PFR $ 0.9615 200MG CONTROLLED RELEASE TABLET

02163799 CODEINE CONTIN (EDS) PFR $ 1.2720

CODEINE PHOSPHATE 15MG TABLET

00593435 RATIO-CODEINE RPH $ 0.0691 30MG TABLET

00593451 RATIO-CODEINE RPH $ 0.0966

62nd Edition 97 July 1, 2012

Page 120: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:08.08 OPIATE AGONISTS (NARCOTIC ANALGESICS)

FENTANYL SEE APPENDIX B FOR ONLINE ADJUDICATION

* 12MCG/HR TRANSDERMAL SYSTEM02311925 RATIO-FENTANYL (EDS) RPH $ 2.2310 02327112 SANDOZ FENTANYL PATCH (EDS) SDZ 2.2310 02330105 RAN-FENTANYL MATRIX (EDS) RAN 2.2310 02341379 PMS-FENTANYL MTX (EDS) PMS 2.2310 02334186 DURAGESTIC MAT (EDS) JAN 4.6000

* 25MCG/HR TRANSDERMAL SYSTEM02282941 RATIO-FENTANYL (EDS) RPH $ 3.6582 02314630 NOVO-FENTANYL (EDS) NOP 3.6582 02327120 SANDOZ FENTANYL PATCH (EDS) SDZ 3.6582 02330113 RAN-FENTANYL MATRIX (EDS) RAN 3.6582 02341387 PMS-FENTANYL MTX (EDS) PMS 3.6582 02275813 DURAGESIC MAT (EDS) JAN 11.8600

* 50MCG/HR TRANSDERMAL SYSTEM02282968 RATIO-FENTANYL (EDS) RPH $ 6.8838 02314649 NOVO-FENTANYL (EDS) NOP 6.8838 02327147 SANDOZ FENTANYL PATCH (EDS) SDZ 6.8838 02330121 RAN-FENTANYL MATRIX (EDS) RAN 6.8838 02341395 PMS-FENTANYL MTX (EDS) PMS 6.8838 02275821 DURAGESIC MAT (EDS) JAN 22.3300

* 75MCG/HR TRANSDERMAL SYSTEM02282976 RATIO-FENTANYL (EDS) RPH $ 9.6817 02314657 NOVO-FENTANYL (EDS) NOP 9.6817 02327155 SANDOZ FENTANYL PATCH (EDS) SDZ 9.6817 02330148 RAN-FENTANYL MATRIX (EDS) RAN 9.6817 02341409 PMS-FENTANYL (EDS) PMS 9.6817 02275848 DURAGESIC MAT (EDS) JAN 31.4000

* 100MCG/HR TRANSDERMAL SYSTEM02282984 RATIO-FENTANYL (EDS) RPH $ 12.0512 02314665 NOVO-FENTANYL (EDS) NOP 12.0512 02327163 SANDOZ FENTANYL PATCH (EDS) SDZ 12.0512 02330156 RAN-FENTANYL MATRIX (EDS) RAN 12.0512 02341417 PMS-FENTANYL MTX (EDS) PMS 12.0512 02275856 DURAGESIC MAT (EDS) JAN 39.0800

HYDROMORPHONE HCL* 1MG TABLET

00705438 DILAUDID PFR $ 0.0959 00885444 PMS-HYDROMORPHONE PMS 0.0959 02319403 TEVA-HYDROMORPHONE TEV 0.0959 02364115 APO-HYDROMORPHONE APX 0.0959

* 2MG TABLET00125083 DILAUDID PFR $ 0.1417 00885436 PMS-HYDROMORPHONE PMS 0.1417 02319411 TEVA-HYDROMORPHONE TEV 0.1417 02364123 APO-HYDROMORPHONE APX 0.1417

62nd Edition 98 July 1, 2012

Page 121: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:08.08 OPIATE AGONISTS (NARCOTIC ANALGESICS)

* 4MG TABLET00125121 DILAUDID PFR $ 0.2240 00885401 PMS-HYDROMORPHONE PMS 0.2240 02319438 TEVA-HYDROMORPHONE TEV 0.2240 02364131 APO-HYDROMORPHONE APX 0.2240

* 8MG TABLET00786543 DILAUDID PFR $ 0.3528 00885428 PMS-HYDROMORPHONE PMS 0.3528 02319446 TEVA-HYDROMORPHONE TEV 0.3528 02364158 APO-HYDROMORPHONE APX 0.3528

3MG CONTROLLED-RELEASE CAPSULE02125323 HYDROMORPH CONTIN PFR $ 0.6745

4.5MG CONTROLLED-RELEASE CAPSULE02359502 HYDROMORPH CONTIN PFR $ 0.8140

6MG CONTROLLED RELEASE CAPSULE02125331 HYDROMORPH CONTIN PFR $ 1.0115

9MG CONTROLLED-RELEASE CAPSULE02359510 HYDROMORPH CONTIN PFR $ 1.3340

12MG CONTROLLED-RELEASE CAPSULE02125366 HYDROMORPH CONTIN PFR $ 1.7530

18MG CONTROLLED-RELEASE CAPSULE02243562 HYDROMORPH CONTIN PFR $ 2.5290

24MG CONTROLLED-RELEASE CAPSULE02125382 HYDROMORPH CONTIN PFR $ 3.2365

30MG CONTROLLED-RELEASE CAPSULE02125390 HYDROMORPH CONTIN PFR $ 3.8775

* 1MG/ML ORAL LIQUID01916386 PMS-HYDROMORPHONE PMS $ 0.0666 00786535 DILAUDID PFR 0.0791

* 2MG/ML INJECTION SOLUTION (1ML)02145901 HYDROMORPHONE HCL SDZ $ 0.9450 00627100 DILAUDID PFR 1.1400

10MG/ML INJECTION SOLUTION (1ML)02145928 HYDROMORPHONE HP 10 SDZ $ 3.0230

20MG/ML INJECTION SOLUTION (1ML)02145936 HYDROMORPHONE HP 20 SDZ $ 4.8200

50MG/ML INJECTION SOLUTION (1ML)02146126 HYDROMORPHONE HP 50 SDZ $ 13.1500

250MG/VIAL POWDER FOR SOLUTION02085895 DILAUDID PFR $ 70.1400

3MG SUPPOSITORY01916394 PMS-HYDROMORPHONE PMS $ 2.9641

62nd Edition 99 July 1, 2012

Page 122: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:08.08 OPIATE AGONISTS (NARCOTIC ANALGESICS)

MEPERIDINE HCL 50MG TABLET

02138018 DEMEROL AVT $ 0.1503 50MG/ML INJECTION SOLUTION (1ML)

00725765 MEPERIDINE HYDROCHLORIDE SDZ $ 0.9600 100MG/ML INJECTION SOLUTION (1ML)

00725749 MEPERIDINE HYDROCHLORIDE SDZ $ 1.0700

METHADONE HCL COVERAGE RESTRICTED TO DRUG PLAN REGISTERED PALLIATIVE CARE PATIENTS ONLY. EDS IS NOT REQUIRED FOR THESE PATIENTS. 1MG TABLET

02247698 METADOL (PALL CARE) PAL $ 0.1689 5MG TABLET

02247699 METADOL (PALL CARE) PAL $ 0.5627 10MG TABLET

02247700 METADOL (PALL CARE) PAL $ 0.9003 25MG TABLET

02247701 METADOL (PALL CARE) PAL $ 1.6879 1MG/ML ORAL SUSPENSION

02247694 METADOL (PALL CARE) PAL $ 0.1018 10MG/ML ORAL SUSPENSION

02241377 METADOL (PALL CARE) PAL $ 0.3676

MORPHINE ORAL FORMS CONTAIN MORPHINE HYDROCHLORIDE OR SULFATE, INJECTABLE FORMS CONTAIN MORPHINE SULFATE.

* 5MG TABLET00594652 STATEX PAL $ 0.1100 02009773 MOS-SULFATE VAE 0.1100 02014203 MSIR PFR 0.1240

* 10MG TABLET00594644 STATEX PAL $ 0.1700 02009765 MOS-SULFATE VAE 0.1700 02014211 MSIR PFR 0.1930

20MG TABLET02014238 MSIR PFR $ 0.3440

* 25MG TABLET00594636 STATEX PAL $ 0.2250 02009749 MOS-SULFATE VAE 0.2250

30MG TABLET02014254 MSIR PFR $ 0.4410

* 50MG TABLET00675962 STATEX PAL $ 0.3450 02009706 MOS-SULFATE VAE 0.3450

10MG EXTENDED-RELEASE CAPSULE02019930 M-ESLON ETH $ 0.2985

62nd Edition 100 July 1, 2012

Page 123: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:08.08 OPIATE AGONISTS (NARCOTIC ANALGESICS)

10MG SUSTAINED RELEASE CAPSULE02242163 KADIAN ABB $ 0.3680

15MG EXTENDED-RELEASE CAPSULE02177749 M-ESLON ETH $ 0.3448

* 15MG SUSTAINED RELEASE TABLET02244790 SANDOZ MORPHINE SR SDZ $ 0.2318 02302764 NOVO-MORPHINE SR NOP 0.2318 02350815 MORPHINE SR SAN 0.2318 02015439 MS CONTIN PFR 0.6800

20MG SUSTAINED-RELEASE CAPSULE02184435 KADIAN ABB $ 0.7921

30MG EXTENDED-RELEASE CAPSULE02019949 M-ESLON ETH $ 0.5146

* 30MG SUSTAINED RELEASE TABLET02244791 SANDOZ MORPHINE SR SDZ $ 0.3500 02302772 NOVO-MORPHINE SR NOP 0.3500 02350890 MORPHINE SR SAN 0.3500 02014297 MS CONTIN PFR 1.0290

30MG SUSTAINED-RELEASE TABLET00776181 M.O.S.-S.R. VAE $ 0.4614

50MG SUSTAINED-RELEASE CAPSULE02184443 KADIAN ABB $ 1.4480

60MG EXTENDED-RELEASE CAPSULE02019957 M-ESLON ETH $ 0.9132

* 60MG SUSTAINED RELEASE TABLET02244792 SANDOZ MORPHINE SR SDZ $ 0.6168 02302780 NOVO-MORPHINE SR NOP 0.6168 02350912 MORPHINE SR SAN 0.6168 02014300 MS CONTIN PFR 1.8130

60MG SUSTAINED-RELEASE TABLET00776203 M.O.S.-S.R. VAE $ 0.8134

100MG SUSTAINED-RELEASE CAPSULE02184451 KADIAN ABB $ 2.5410

100MG EXTENDED-RELEASE CAPSULE02019965 M-ESLON ETH $ 1.9655

* 100MG SUSTAINED RELEASE TABLET02302799 NOVO-MORPHINE SR NOP $ 0.9402 02350920 MORPHINE SR SAN 0.9402 02014319 MS CONTIN PFR 2.7640

200MG EXTENDED-RELEASE CAPSULE02177757 M-ESLON ETH $ 3.9306

* 200MG SUSTAINED RELEASE TABLET02302802 NOVO-MORPHINE SR NOP $ 1.7480 02350947 MORPHINE SR SAN 1.7480 02014327 MS CONTIN PFR 5.1390

62nd Edition 101 July 1, 2012

Page 124: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:08.08 OPIATE AGONISTS (NARCOTIC ANALGESICS)

* 1MG/ML ORAL SOLUTION00591467 STATEX PAL $ 0.0200 00607762 RATIO-MORPHINE RPH 0.0200

* 5MG/ML ORAL SOLUTION00607770 RATIO-MORPHINE RPH $ 0.0791 00591475 STATEX PAL 0.0804

10MG/ML ORAL SOLUTION00690783 RATIO-MORPHINE RPH $ 0.1875

* 20MG/ML ORAL SOLUTION00690791 RATIO-MORPHINE RPH $ 0.4840 00621935 STATEX PAL 0.4980

10MG/ML INJECTION SOLUTION (1ML)00392588 MORPHINE SO4 SDZ $ 0.9900

15MG/ML INJECTION SOLUTION (1ML)00392561 MORPHINE SO4 SDZ $ 1.0050

50MG/ML INJECTION SOLUTION (1ML)00617288 MORPHINE HP50 SDZ $ 3.9900

5MG SUPPOSITORY00632228 STATEX PAL $ 1.6690

10MG SUPPOSITORY00632201 STATEX PAL $ 1.8640

20MG SUPPOSITORY00596965 STATEX PAL $ 2.2190

30MG SUPPOSITORY00639389 STATEX PAL $ 2.4340

62nd Edition 102 July 1, 2012

Page 125: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:08.08 OPIATE AGONISTS (NARCOTIC ANALGESICS)

OXYCODONE HCL SEE APPENDIX A FOR EDS CRITERIA

* 5MG IMMEDIATE RELEASE TABLET00789739 SUPEUDOL SDZ $ 0.1287 02319977 PMS-OXYCODONE PMS 0.1287 02231934 OXY-IR PFR 0.2620

* 10MG IMMEDIATE RELEASE TABLET00443948 SUPEUDOL SDZ $ 0.1896 02319985 PMS-OXYCODONE PMS 0.1896 02240131 OXY-IR PFR 0.3860

* 20MG IMMEDIATE RELEASE TABLET02319993 PMS-OXYCODONE PMS $ 0.2964 02262983 SUPEUDOL SDZ 0.3293 02240132 OXY-IR PFR 0.6710

10MG CONTROLLED-RELEASE TABLET02372525 OXYNEO (EDS) PFR $ 0.8780

15MG CONTROLLED-RELEASE TABLET02372533 OXYNEO (EDS) PFR $ 1.0600

20MG CONTROLLED-RELEASE TABLET02372797 OXYNEO (EDS) PFR $ 1.3170

30MG CONTROLLED-RELEASE TABLET02372541 OXYNEO (EDS) PFR $ 1.7400

40MG CONTROLLED-RELEASE TABLET02372568 OXYNEO (EDS) PFR $ 2.2825

60MG CONTROLLED-RELEASE TABLET02372576 OXYNEO (EDS) PFR $ 3.1500

80MG CONTROLLED-RELEASE TABLET02372584 OXYNEO (EDS) PFR $ 4.2160

62nd Edition 103 July 1, 2012

Page 126: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:08.12 OPIATE PARTIAL AGONISTS

BUPRENORPHINE/NALOXONE SEE APPENDIX A FOR EDS CRITERIA 2MG/0.5MG SUBLINGUAL TABLET

02295695 SUBOXONE (EDS) RBI $ 2.6700 8MG/2MG SUBLINGUAL TABLET

02295709 SUBOXONE (EDS) RBI $ 4.7300

PENTAZOCINE 50MG TABLET

02137984 TALWIN AVT $ 0.4337

28:08.92 MISCELLANEOUS ANALGESICS AND ANTIPYRETICS

FLOCTAFENINE 200MG TABLET

02244680 FLOCTAFENINE AAP $ 0.4175 400MG TABLET

02244681 FLOCTAFENINE AAP $ 0.8123

28:12.04 ANTICONVULSANTS (BARBITURATES)

PHENOBARBITAL 15MG TABLET

00178799 PHENOBARB PMS $ 0.0874 30MG TABLET

00178802 PHENOBARB PMS $ 0.1040 60MG TABLET

00178810 PHENOBARB PMS $ 0.1410 100MG TABLET

00178829 PHENOBARB PMS $ 0.1930 5MG/ML ELIXIR

00645575 PHENOBARB ELIXIR PMS $ 0.1167

PRIMIDONE 125MG TABLET

00399310 PRIMIDONE AAP $ 0.0553 250MG TABLET

00396761 PRIMIDONE AAP $ 0.0870

62nd Edition 104 July 1, 2012

Page 127: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:12.08 ANTICONVULSANTS (BENZODIAZEPINES)

CLONAZEPAM* 0.5MG TABLET

02048701 PMS-CLONAZEPAM PMS $ 0.0694 02103656 RATIO-CLONAZEPAM RPH 0.0694 02130998 DOM-CLONAZEPAM DOM 0.0694 02177889 APO-CLONAZEPAM APX 0.0694 02207818 PMS-CLONAZEPAM-R PMS 0.0694 02224100 DOM-CLONAZEPAM-R DOM 0.0694 02230950 MYLAN-CLONAZEPAM MYL 0.0694 02233960 SANDOZ CLONAZEPAM SDZ 0.0694 02239024 NOVO-CLONAZEPAM NOP 0.0694 02270641 CO CLONAZEPAM COB 0.0694 00382825 RIVOTRIL HLR 0.1982

* 1MG TABLET02048728 PMS-CLONAZEPAM PMS $ 0.1487 02233982 SANDOZ CLONAZEPAM SDZ 0.1487 02270668 CO CLONAZEPAM COB 0.1487

* 2MG TABLET02048736 PMS-CLONAZEPAM PMS $ 0.1196 02103737 RATIO-CLONAZEPAM RPH 0.1196 02131013 DOM-CLONAZEPAM DOM 0.1196 02177897 APO-CLONAZEPAM APX 0.1196 02230951 MYLAN-CLONAZEPAM MYL 0.1196 02233985 SANDOZ CLONAZEPAM SDZ 0.1196 02239025 NOVO-CLONAZEPAM NOP 0.1196 02270676 CO CLONAZEPAM COB 0.1196 00382841 RIVOTRIL HLR 0.3417

NITRAZEPAM* 5MG TABLET

02234003 SANDOZ NITRAZEPAM SDZ $ 0.0500 02245230 APO-NITRAZEPAM APX 0.0500 00511528 MOGADON VAE 0.1490

* 10MG TABLET02234007 SANDOZ NITRAZEPAM SDZ $ 0.0748 02245231 APO-NITRAZEPAM APX 0.0748 00511536 MOGADON VAE 0.2230

62nd Edition 105 July 1, 2012

Page 128: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:12.12 ANTICONVULSANTS (HYDANTOINS)

PHENYTOIN 30MG CAPSULE

00022772 DILANTIN PFI $ 0.0528 100MG CAPSULE

00022780 DILANTIN PFI $ 0.0734 50MG TABLET

00023698 DILANTIN PFI $ 0.0724 6MG/ML ORAL SUSPENSION

00023442 DILANTIN PFI $ 0.0399 * 25MG/ML ORAL SUSPENSION

02250896 TARO-PHENYTOIN TAR $ 0.0311 00023450 DILANTIN PFI 0.0472

28:12.20 ANTICONVULSANTS (SUCCINIMIDES)

ETHOSUXIMIDE 250MG CAPSULE

00022799 ZARONTIN ERF $ 0.3416 50MG/ML ORAL SYRUP

00023485 ZARONTIN ERF $ 0.0683

METHSUXIMIDE 300MG CAPSULE

00022802 CELONTIN ERF $ 1.0870

62nd Edition 106 July 1, 2012

Page 129: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:12.92 MISCELLANEOUS ANTICONVULSANTS

CARBAMAZEPINE* 100MG CHEWABLE TABLET

02231542 PMS-CARBAMAZEPINE CHEWTAB PMS $ 0.0531 02244403 TARO-CARBAMAZEPINE TAR 0.0531 02261855 SANDOZ CARBAMAZEPINE CHEW SDZ 0.0531 00369810 TEGRETOL CHEWTABS NVR 0.1591

* 200MG CHEWABLE TABLET02231540 PMS-CARBAMAZEPINE CHEWS PMS $ 0.1048 02244404 TARO-CARBAMAZEPINE CHEWS TAR 0.1048 02261863 SANDOZ CARBAMAZEPINE CHEW SDZ 0.1048 00665088 TEGRETOL CHEWTABS NVR 0.3139

* 200MG TABLET00402699 APO-CARBAMAZEPINE APX $ 0.0795 00782718 TEVA-CARBAMAZEPINE NOP 0.0795 02042568 NU-CARBAMAZEPINE NXP 0.0795 00010405 TEGRETOL NVR 0.3867

* 200MG CONTROLLED RELEASE TABLET02231543 PMS-CARBAMAZEPINE CR PMS $ 0.1301 02238222 DOM-CARBAMAZEPINE CR DOM 0.1301 02241882 MYLAN-CARBAMAZEPINE CR MYL 0.1301 02261839 SANDOZ CARBAM. CR SDZ 0.1301 00773611 TEGRETOL CR NVR 0.3899

* 400MG CONTROLLED RELEASE TABLET02231544 PMS-CARBAMAZEPINE CR PMS $ 0.2602 02238223 DOM-CARBAMAZEPINE CR DOM 0.2602 02241883 MYLAN-CARBAMAZEPINE CR MYL 0.2602 02261847 SANDOZ CARBAM. CR SDZ 0.2602 00755583 TEGRETOL CR NVR 0.7796

20MG/ML ORAL SUSPENSION02194333 TEGRETOL NVR $ 0.0752

CLOBAZAM* 10MG TABLET

02238334 NOVO-CLOBAZAM NOP $ 0.1538 02244474 PMS-CLOBAZAM PMS 0.1538 02244638 APO-CLOBAZAM APX 0.1538 02247230 DOM-CLOBAZAM DOM 0.1538 02221799 FRISIUM OVA 0.4394

62nd Edition 107 July 1, 2012

Page 130: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:12.92 MISCELLANEOUS ANTICONVULSANTS

DIVALPROEX SODIUM* 125MG ENTERIC COATED TABLET

02239517 NU-DIVALPROEX NXP $ 0.0966 02239698 APO-DIVALPROEX APX 0.0966 02239701 NOVO-DIVALPROEX NOP 0.0966 00596418 EPIVAL ABB 0.3033

* 250MG ENTERIC COATED TABLET02239518 NU-DIVALPROEX NXP $ 0.1735 02239699 APO-DIVALPROEX APX 0.1735 02239702 NOVO-DIVALPROEX NOP 0.1735 00596426 EPIVAL ABB 0.5453

* 500MG ENTERIC COATED TABLET02239519 NU-DIVALPROEX NXP $ 0.3472 02239700 APO-DIVALPROEX APX 0.3472 02239703 NOVO-DIVALPROEX NOP 0.3472 00596434 EPIVAL ABB 1.0911

GABAPENTIN* 100MG CAPSULE

02243446 PMS-GABAPENTIN PMS $ 0.1456 02243743 DOM-GABAPENTIN DOM 0.1456 02244304 APO-GABAPENTIN APX 0.1456 02244513 TEVA-GABAPENTIN NOP 0.1456 02246742 NU-GABAPENTIN NXP 0.1456 02248259 MYLAN-GABAPENTIN MYL 0.1456 02256142 CO GABAPENTIN COB 0.1456 02260883 RATIO-GABAPENTIN RPH 0.1456 02285819 GD-GABAPENTIN GDI 0.1456 02319055 RAN-GABAPENTIN RAN 0.1456 02321203 AURO-GABAPENTIN API 0.1456 02353245 GABAPENTIN SAN 0.1456 02361469 JAMP-GABAPENTIN JPC 0.1456 02084260 NEURONTIN PFI 0.4247

62nd Edition 108 July 1, 2012

Page 131: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:12.92 MISCELLANEOUS ANTICONVULSANTS

* 300MG CAPSULE02243447 PMS-GABAPENTIN PMS $ 0.3542 02243744 DOM-GABAPENTIN DOM 0.3542 02244305 APO-GABAPENTIN APX 0.3542 02244514 TEVA-GABAPENTIN TEV 0.3542 02246743 NU-GABAPENTIN NXP 0.3542 02248260 MYLAN-GABAPENTIN MYL 0.3542 02256150 CO GABAPENTIN COB 0.3542 02285827 GD-GABAPENTIN GDI 0.3542 02319063 RAN-GABAPENTIN RAN 0.3542 02321211 AURO-GABAPENTIN API 0.3542 02353253 GABAPENTIN SAN 0.3542 02361485 JAMP-GABAPENTIN JPC 0.3542 02084279 NEURONTIN PFI 1.0332

* 400MG CAPSULE02243448 PMS-GABAPENTIN PMS $ 0.4221 02243745 DOM-GABAPENTIN DOM 0.4221 02244306 APO-GABAPENTIN APX 0.4221 02244515 TEVA-GABAPENTIN NOP 0.4221 02246744 NU-GABAPENTIN NXP 0.4221 02248261 MYLAN-GABAPENTIN MYL 0.4221 02256169 CO GABAPENTIN COB 0.4221 02260905 RATIO-GABAPENTIN RPH 0.4221 02285835 GD-GABAPENTIN GDI 0.4221 02319071 RAN-GABAPENTIN RAN 0.4221 02321238 AURO-GABAPENTIN API 0.4221 02353261 GABAPENTIN SAN 0.4221 02361493 JAMP-GABAPENTIN JPC 0.4221 02084287 NEURONTIN PFI 1.2313

LACOSAMIDE SEE APPENDIX A FOR EDS CRITERIA 50MG TABLET

02357615 VIMPAT (EDS) UCB $ 2.3200 100MG TABLET

02357623 VIMPAT (EDS) UCB $ 3.3200 150MG TABLET

02357631 VIMPAT (EDS) UCB $ 4.3200 200MG TABLET

02357658 VIMPAT (EDS) UCB $ 5.3200

62nd Edition 109 July 1, 2012

Page 132: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:12.92 MISCELLANEOUS ANTICONVULSANTS

LAMOTRIGINE 5MG CHEWABLE TABLET

02240115 LAMICTAL GSK $ 0.1629 * 25MG TABLET

02243352 RATIO-LAMOTRIGINE RPH $ 0.1310 02245208 APO-LAMOTRIGINE APX 0.1310 02246897 PMS-LAMOTRIGINE PMS 0.1310 02248232 NOVO-LAMOTRIGINE NOP 0.1310 02265494 MYLAN-LAMOTRIGINE MYL 0.1310 02343010 LAMOTRIGINE SAN 0.1310 02142082 LAMICTAL GSK 0.3821

* 100MG TABLET02243353 RATIO-LAMOTRIGINE RPH $ 0.5229 02245209 APO-LAMOTRIGINE APX 0.5229 02246898 PMS-LAMOTRIGINE PMS 0.5229 02248233 NOVO-LAMOTRIGINE NOP 0.5229 02265508 MYLAN-LAMOTRIGINE MYL 0.5229 02343029 LAMOTRIGINE SAN 0.5229 02142104 LAMICTAL GSK 1.5254

* 150MG TABLET02245210 APO-LAMOTRIGINE APX $ 0.7707 02246899 PMS-LAMOTRIGINE PMS 0.7707 02246963 RATIO-LAMOTRIGINE RPH 0.7707 02248234 NOVO-LAMOTRIGINE NOP 0.7707 02265516 MYLAN-LAMOTRIGINE MYL 0.7707 02343037 LAMOTRIGINE SAN 0.7707 02142112 LAMICTAL GSK 2.2480

LEVETIRACETAM* 250MG TABLET

02274183 CO LEVETIRACETAM COB $ 0.8000 02285924 APO-LEVETIRACETAM APX 0.8000 02296101 PMS-LEVETIRACETAM PMS 0.8000 02297396 DOM-LEVETIRACETAM DOM 0.8000 02353342 LEVETIRACETAM SAN 0.8000 02375249 AURO-LEVETIRACETAM API 0.8000 02247027 KEPPRA UCB 1.7060

62nd Edition 110 July 1, 2012

Page 133: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS28:12.92 MISCELLANEOUS ANTICONVULSANTS

* 500MG TABLET02274191 CO LEVETIRACETAM COB $ 0.9750 02285932 APO-LEVETIRACETAM APX 0.9750 02296128 PMS-LEVETIRACETAM PMS 0.9750 02297418 DOM-LEVETIRACETAM DOM 0.9750 02353350 LEVETIRACETAM SAN 0.9750 02375257 AURO-LEVETRICETAM API 0.9750 02247028 KEPPRA UCB 2.0780

* 750MG TABLET02274205 CO LEVETIRACETAM COB $ 1.3500 02285940 APO-LEVETIRACETAM APX 1.3500 02296136 PMS-LEVETIRACETAM PMS 1.3500 02297426 DOM-LEVETIRACETAM DOM 1.3500 02353369 LEVETIRACETAM SAN 1.3500 02375265 AURO-LEVETIRACETAM API 1.3500 02247029 KEPPRA UCB 2.8780

OXCARBAZEPINE SEE APPENDIX A FOR EDS CRITERIA* 150MG TABLET

02284294 APO-OXCARBAZEPINE (EDS) APX $ 0.6209 02242067 TRILEPTAL (EDS) NVR 0.8278

* 300MG TABLET02242068 TRILEPTAL (EDS) NVR 0.9102 02284308 APO-OXCARBAZEPINE (EDS) APX $ 1.2414

* 600MG TABLET02242069 TRILEPTAL (EDS) NVR 1.8204 02284316 APO-OXCARBAZEPINE (EDS) APX $ 2.4826

60MG/ML ORAL SUSPENSION02244673 TRILEPTAL (EDS) NVR $ 0.3310

62nd Edition 111 July 1, 2012

Page 134: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS28:12.92 MISCELLANEOUS ANTICONVULSANTS

TOPIRAMATE* 25MG TABLET

02248860 NOVO-TOPIRAMATE NOP $ 0.4379 02260050 SANDOZ TOPIRAMATE SDZ 0.4379 02262991 PMS-TOPIRAMATE PMS 0.4379 02263351 MYLAN-TOPIRAMATE MYL 0.4379 02279614 APO-TOPIRAMATE APX 0.4379 02287765 CO TOPIRAMATE COB 0.4379 02315645 MINT-TOPIRAMATE MNT 0.4379 02345803 AURO-TOPIRAMATE API 0.4379 02351307 ACCEL TOPIRAMATE ACC 0.4379 02356856 TOPIRAMATE SAN 0.4379 02230893 TOPAMAX JAN 1.2787

50MG TABLET02312085 PMS-TOPIRAMATE PMS $ 1.0674

* 100MG TABLET02248861 NOVO-TOPIRAMATE NOP $ 0.8300 02260069 SANDOZ TOPIRAMATE SDZ 0.8300 02263009 PMS-TOPIRAMATE PMS 0.8300 02263378 MYLAN-TOPIRAMATE MYL 0.8300 02279630 APO-TOPIRAMATE APX 0.8300 02287773 CO TOPIRAMATE COB 0.8300 02315653 MINT-TOPIRAMATE MNT 0.8300 02345838 AURO-TOPIRAMATE API 0.8300 02351315 ACCEL TOPIRAMATE ACC 0.8300 02356864 TOPIRAMATE SAN 0.8300 02230894 TOPAMAX JAN 2.4235

* 200MG TABLET02248862 NOVO-TOPIRAMATE NOP $ 1.2395 02263017 PMS-TOPIRAMATE PMS 1.2395 02263386 MYLAN-TOPIRAMATE MYL 1.2395 02267837 SANDOZ TOPIRAMATE SDZ 1.2395 02279649 APO-TOPIRAMATE APX 1.2395 02287781 CO TOPIRAMATE COB 1.2395 02315661 MINT-TOPIRAMATE MNT 1.2395 02345846 AURO-TOPIRAMATE API 1.2395 02351323 ACCEL TOPIRAMATE ACC 1.2395 02356872 TOPIRAMATE SAN 1.2395 02230896 TOPAMAX JAN 3.6190

15MG SPRINKLE CAPSULE02239907 TOPAMAX JAN $ 1.1675

25MG SPRINKLE CAPSULE02239908 TOPAMAX JAN $ 1.2255

VALPROATE SODIUM* 50MG/ML ORAL SYRUP

02140063 RATIO-VALPROIC RPH $ 0.0398 02236807 PMS-VALPROIC ACID PMS 0.0398 02238370 APO-VALPROIC APX 0.0398 02238817 DOM-VALPROIC ACID DOM 0.0398 00443832 DEPAKENE ABB 0.1193

62nd Edition 112 July 1, 2012

Page 135: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:12.92 MISCELLANEOUS ANTICONVULSANTS

VALPROIC ACID* 250MG CAPSULE

02100630 NOVO-VALPROIC NOP $ 0.1821 02184648 MYLAN-VALPROIC MYL 0.1821 02230768 PMS-VALPROIC PMS 0.1821 02231030 DOM-VALPROIC ACID DOM 0.1821 02237830 NU-VALPROIC NXP 0.1821 02238048 APO-VALPROIC APX 0.1821 02239714 SANDOZ VALPROIC SDZ 0.1821 00443840 DEPAKENE ABB 0.5723

* 500MG ENTERIC COATED CAPSULE02218321 NOVO-VALPROIC NOP $ 0.5197 02229628 PMS-VALPROIC ACID E.C. PMS 0.5197

VIGABATRIN 500MG TABLET

02065819 SABRIL OVA $ 0.9110 500MG SACHET

02068036 SABRIL OVA $ 0.9110

28:16.04 PSYCHOTHERAPEUTIC AGENTS (ANTIDEPRESSANTS)

AMITRIPTYLINE 10MG TABLET

00335053 ELAVIL AAP $ 0.0664 25MG TABLET

00335061 ELAVIL AAP $ 0.1211 50MG TABLET

00335088 ELAVIL AAP $ 0.2347

BUPROPION HCL* 100MG SUSTAINED RELEASE TABLET

02275074 SANDOZ BUPROPION SR SDZ $ 0.2166 02285657 RATIO-BUPROPION SR RPH 0.2166 02325373 PMS-BUPROPION SR PMS 0.2166 02363399 AVA-BUPROPION SR AVA 0.2166

* 150MG SUSTAINED RELEASE TABLET02275082 SANDOZ BUPROPION SR SDZ $ 0.3217 02285665 RATIO-BUPROPION SR RPH 0.3217 02313421 PMS-BUPROPION SR PMS 0.3217 02363402 AVA-BUPROPION SR AVA 0.3217 02237825 WELLBUTRIN SR VAE 0.9357

150MG SUSTAINED RELEASE TABLET (SMOKING CESS )02238441 ZYBAN VAE $ 0.9467

150MG EXTENDED-RELEASE TABLET02275090 WELLBUTRIN XL VAE $ 0.5574

300MG EXTENDED-RELEASE TABLET02275104 WELLBUTRIN XL VAE $ 1.1150

62nd Edition 113 July 1, 2012

Page 136: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:16.04 PSYCHOTHERAPEUTIC AGENTS (ANTIDEPRESSANTS)

CITALOPRAM HYDROBROMIDE* 20MG TABLET

02246056 APO-CITALOPRAM APX $ 0.4661 02246594 MYLAN-CITALOPRAM MYL 0.4661 02248010 PMS-CITALOPRAM PMS 0.4661 02248050 CO CITALOPRAM COB 0.4661 02248170 SANDOZ CITALOPRAM SDZ 0.4661 02248942 DOM-CITALOPRAM DOM 0.4661 02248996 NU-CITALOPRAM NXP 0.4661 02252112 RATIO-CITALOPRAM RPH 0.4661 02275562 AURO-CITALOPRAM API 0.4661 02285622 RAN-CITALO RAN 0.4661 02293218 TEVA-CITALOPRAM NOP 0.4661 02304686 MINT-CITALOPRAM MNT 0.4661 02306239 CITALOPRAM-ODAN ODN 0.4661 02313405 JAMP-CITALOPRAM JPC 0.4661 02353660 CITALOPRAM SAN 0.4661 02355256 ACCEL-CITALOPRAM ACC 0.4661 02355272 SEPTA-CITALOPRAM SPT 0.4661 02371898 MAR-CITALOPRAM MPI 0.4661 02239607 CELEXA LUD 1.3317

* 40MG TABLET02246057 APO-CITALOPRAM APX $ 0.4661 02246595 MYLAN-CITALOPRAM MYL 0.4661 02248011 PMS-CITALOPRAM PMS 0.4661 02248051 CO CITALOPRAM COB 0.4661 02248171 SANDOZ CITALOPRAM SDZ 0.4661 02248943 DOM-CITALOPRAM DOM 0.4661 02248997 NU-CITALOPRAM NXP 0.4661 02252120 RATIO-CITALOPRAM RPH 0.4661 02275570 AURO-CITALOPRAM API 0.4661 02285630 RAN-CITALO RAN 0.4661 02293226 TEVA-CITALOPRAM NOP 0.4661 02304694 MINT-CITALOPRAM MNT 0.4661 02306247 CITALOPRAM-ODAN ODN 0.4661 02313413 JAMP-CITALOPRAM JPC 0.4661 02353679 CITALOPRAM SAN 0.4661 02355264 ACCEL-CITALOPRAM ACC 0.4661 02355280 SEPTA-CITALOPRAM SPT 0.4661 02371901 MAR-CITALOPRAM MPI 0.4661 02239608 CELEXA LUD 1.3317

62nd Edition 114 July 1, 2012

Page 137: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:16.04 PSYCHOTHERAPEUTIC AGENTS (ANTIDEPRESSANTS)

CLOMIPRAMINE HCL* 10MG TABLET

02040786 APO-CLOMIPRAMINE APX $ 0.1290 02244816 CO CLOMIPRAMINE COB 0.1290 00330566 ANAFRANIL SNV 0.2831

* 25MG TABLET02040778 APO-CLOMIPRAMINE APX $ 0.1758 02244817 CO CLOMIPRAMINE COB 0.1758 00324019 ANAFRANIL SNV 0.3859

* 50MG TABLET02040751 APO-CLOMIPRAMINE APX $ 0.3237 02244818 CO CLOMIPRAMINE COB 0.3237 00402591 ANAFRANIL SNV 0.7107

DESIPRAMINE HCL 10MG TABLET

02216248 APO-DESIPRAMINE APX $ 0.3804 25MG TABLET

02216256 APO-DESIPRAMINE APX $ 0.3804 50MG TABLET

02216264 APO-DESIPRAMINE APX $ 0.6704 75MG TABLET

02216272 APO-DESIPRAMINE APX $ 0.8915 100MG TABLET

02216280 APO-DESIPRAMINE APX $ 0.8915

DOXEPIN HCL* 10MG CAPSULE

02049996 APO-DOXEPIN APX $ 0.1889 00024325 SINEQUAN ERF 0.3324

* 25MG CAPSULE01913425 NOVO-DOXEPIN NOP $ 0.1576 02050005 APO-DOXEPIN APX 0.1576 00024333 SINEQUAN ERF 0.4079

* 50MG CAPSULE01913433 NOVO-DOXEPIN NOP $ 0.2923 02050013 APO-DOXEPIN APX 0.2923 00024341 SINEQUAN ERF 0.7566

* 75MG CAPSULE01913441 NOVO-DOXEPIN NOP $ 0.3916 02050021 APO-DOXEPIN APX 0.3916 00400750 SINEQUAN ERF 1.0862

* 100MG CAPSULE01913468 NOVO-DOXEPIN NOP $ 0.5160 02050048 APO-DOXEPIN APX 0.5160 00326925 SINEQUAN ERF 1.4286

150MG CAPSULE01913476 NOVO-DOXEPIN NOP $ 1.1507

62nd Edition 115 July 1, 2012

Page 138: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:16.04 PSYCHOTHERAPEUTIC AGENTS (ANTIDEPRESSANTS)

DULOXETINE HYDROCHLORIDE SEE APPENDIX A FOR EDS CRITERIA 30MG DELAYED RELEASE CAPSULE

02301482 CYMBALTA (EDS) LIL $ 1.8768 60MG DELAYED RELEASE CAPSULE

02301490 CYMBALTA (EDS) LIL $ 3.7536

FLUOXETINE* 10MG CAPSULE

02177579 PMS-FLUOXETINE PMS $ 0.8650 02177617 DOM-FLUOXETINE DOM 0.8650 02192756 NU-FLUOXETINE NXP 0.8650 02216353 APO-FLUOXETINE APX 0.8650 02216582 TEVA-FLUOXETINE NOP 0.8650 02237813 MYLAN-FLUOXETINE MYL 0.8650 02241371 RATIO-FLUOXETINE RPH 0.8650 02242177 CO FLUOXETINE COB 0.8650 02243486 SANDOZ FLUOXETINE SDZ 0.8650 02286068 FLUOXETINE SAN 0.8650 02018985 PROZAC LIL 1.8379

* 20MG CAPSULE02177587 PMS-FLUOXETINE PMS $ 0.6438 02177625 DOM-FLUOXETINE DOM 0.6438 02192764 NU-FLUOXETINE NXP 0.6438 02216361 APO-FLUOXETINE APX 0.6438 02216590 TEVA-FLUOXETINE NOP 0.6438 02237814 MYLAN-FLUOXETINE MYL 0.6438 02241374 RATIO-FLUOXETINE RPH 0.6438 02242178 CO FLUOXETINE COB 0.6438 02243487 SANDOZ FLUOXETINE SDZ 0.6438 02286076 FLUOXETINE SAN 0.6438 02383241 FLUOXETINE CAPSULES BP AHI 0.6438 00636622 PROZAC LIL 1.8393

4MG/ML ORAL SOLUTION02231328 APO-FLUOXETINE APX $ 0.5859

FLUVOXAMINE MALEATE* 50MG TABLET

02218453 RATIO-FLUVOXAMINE RPH $ 0.2947 02231192 NU-FLUVOXAMINE NXP 0.2947 02231329 APO-FLUVOXAMINE APX 0.2947 02239953 NOVO-FLUVOXAMINE NOP 0.2947 02240682 PMS-FLUVOXAMINE PMS 0.2947 02241347 DOM-FLUVOXAMINE DOM 0.2947 02247054 SANDOZ FLUVOXAMINE SDZ 0.2947 02255529 CO FLUVOXAMINE COB 0.2947 01919342 LUVOX SLV 0.8750

62nd Edition 116 July 1, 2012

Page 139: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:16.04 PSYCHOTHERAPEUTIC AGENTS (ANTIDEPRESSANTS)

* 100MG TABLET02218461 RATIO-FLUVOXAMINE RPH $ 0.5297 02231193 NU-FLUVOXAMINE NXP 0.5297 02231330 APO-FLUVOXAMINE APX 0.5297 02239954 NOVO-FLUVOXAMINE NOP 0.5297 02240683 PMS-FLUVOXAMINE PMS 0.5297 02241348 DOM-FLUVOXAMINE DOM 0.5297 02247055 SANDOZ FLUVOXAMINE SDZ 0.5297 02255537 CO FLUVOXAMINE COB 0.5297 01919369 LUVOX SLV 1.5730

IMIPRAMINE 10MG TABLET

00360201 IMIPRAMINE AAP $ 0.1370 25MG TABLET

00312797 IMIPRAMINE AAP $ 0.2471 50MG TABLET

00326852 IMIPRAMINE AAP $ 0.4822

MAPROTILINE 25MG TABLET

02158612 NOVO-MAPROTILINE NOP $ 0.5687 50MG TABLET

02158620 NOVO-MAPROTILINE NOP $ 1.0769 75MG TABLET

02158639 NOVO-MAPROTILINE NOP $ 1.4707

MIRTAZAPINE* 15MG TABLET

02250594 SANDOZ MIRTAZAPINE SDZ $ 0.2018 02256096 MYLAN-MIRTAZAPINE MYL 0.2018 02273942 PMS-MIRTAZAPINE PMS 0.2018 02281716 DOM-MIRTAZAPINE DOM 0.2018 02286610 APO-MIRTAZAPINE APX 0.2018 02362929 AVA-MIRTAZAPINE AVA 0.2018

* 15MG ORALLY DISINTEGRATING TABLET02279894 NOVO-MIRTAZAPINE OD NOP $ 0.1365 02299801 AURO-MIRTAZAPINE OD API 0.1365 02248542 REMERON RD SCH 0.4137

* 30MG TABLET02248762 PMS-MIRTAZAPINE PMS $ 0.4340 02250608 SANDOZ MIRTAZAPINE SDZ 0.4340 02252287 DOM-MIRTAZAPINE DOM 0.4340 02256118 MYLAN-MIRTAZAPINE MYL 0.4340 02259354 NOVO-MIRTAZAPINE NOP 0.4340 02286629 APO-MIRTAZAPINE APX 0.4340 02362937 AVA-MIRTAZAPINE AVA 0.4340 02370689 MIRTAZAPINE SAN 0.4340 02243910 REMERON SCH 1.3670

62nd Edition 117 July 1, 2012

Page 140: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:16.04 PSYCHOTHERAPEUTIC AGENTS (ANTIDEPRESSANTS)

* 30MG ORALLY DISINTEGRATING TABLET02279908 NOVO-MIRTAZAPINE OD NOP $ 0.2730 02248543 REMERON RD SCH 0.8277

* 45MG TABLET02256126 MYLAN-MIRTAZAPINE MYL $ 0.6053 02286637 APO-MIRTAZAPINE APX 0.6053

* 45MG ORALLY DISINTEGRATING TABLET02279916 NOVO-MIRTAZAPINE OD NOP $ 0.4095 02299836 AURO-MIRTAZAPINE OD API 0.4095 02248544 REMERON RD SCH 1.2414

MOCLOBEMIDE* 100MG TABLET

02232148 APO-MOCLOBEMIDE APX $ 0.2520 02237111 NU-MOCLOBEMIDE NXP 0.2520 02239746 NOVO-MOCLOBEMIDE NOP 0.2520

* 150MG TABLET02232150 APO-MOCLOBEMIDE APX $ 0.2120 02237112 NU-MOCLOBEMIDE NXP 0.2120 02239747 NOVO-MOCLOBEMIDE NOP 0.2120 00899356 MANERIX MVC 0.6058

* 300MG TABLET02239748 NOVO-MOCLOBEMIDE NOP $ 0.4164 02240456 APO-MOCLOBEMIDE APX 0.4164 02166747 MANERIX MVC 1.1896

NORTRIPTYLINE* 10MG CAPSULE

02177692 PMS-NORTRIPTYLINE PMS $ 0.0772 02178729 DOM-NORTRIPTYLINE DOM 0.0772 02223139 NU-NORTRIPTYLINE NXP 0.0772 02223511 APO-NORTRIPTYLINE APX 0.0772 02231781 NOVO-NORTRIPTYLINE NOP 0.0772 00015229 AVENTYL MMT 0.2319

* 25MG CAPSULE02177706 PMS-NORTRIPTYLINE PMS $ 0.1560 02178737 DOM-NORTRIPTYLINE DOM 0.1560 02223147 NU-NORTRIPTYLINE NXP 0.1560 02223538 APO-NORTRIPTYLINE APX 0.1560 02231782 NOVO-NORTRIPTYLINE NOP 0.1560 00015237 AVENTYL MMT 0.4664

62nd Edition 118 July 1, 2012

Page 141: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:16.04 PSYCHOTHERAPEUTIC AGENTS (ANTIDEPRESSANTS)

PAROXETINE HCL* 10MG TABLET

02248012 MYLAN-PAROXETINE MYL $ 0.5612 02262746 CO PAROXETINE COB 0.5612

* 20MG TABLET02240908 APO-PAROXETINE APX $ 0.6320 02247751 PMS-PAROXETINE PMS 0.6320 02247811 RATIO-PAROXETINE RPH 0.6320 02248013 MYLAN-PAROXETINE MYL 0.6320 02248448 DOM-PAROXETINE DOM 0.6320 02248557 TEVA-PAROXETINE NOP 0.6320 02248720 NU-PAROXETINE NXP 0.6320 02262754 CO PAROXETINE COB 0.6320 02269430 SANDOZ PAROXETINE SDZ 0.6320 02282852 PAROXETINE SAN 0.6320 01940481 PAXIL GSK 1.8056

* 30MG TABLET02240909 APO-PAROXETINE APX $ 0.6714 02247752 PMS-PAROXETINE PMS 0.6714 02247812 RATIO-PAROXETINE RPH 0.6714 02248014 MYLAN-PAROXETINE MYL 0.6714 02248449 DOM-PAROXETINE DOM 0.6714 02248558 TEVA-PAROXETINE NOP 0.6714 02248721 NU-PAROXETINE NXP 0.6714 02254778 SANDOZ PAROXETINE SDZ 0.6714 02262762 CO PAROXETINE COB 0.6714 02269449 SANDOZ PAROXETINE SDZ 0.6714 02282860 PAROXETINE SAN 0.6714 01940473 PAXIL GSK 1.9184

PHENELZINE SO4 15MG TABLET

00476552 NARDIL ERF $ 0.3796

62nd Edition 119 July 1, 2012

Page 142: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:16.04 PSYCHOTHERAPEUTIC AGENTS (ANTIDEPRESSANTS)

SERTRALINE HYDROCHLORIDE* 25MG CAPSULE

02238280 APO-SERTRALINE APX $ 0.2806 02240485 NOVO-SERTRALINE NOP 0.2806 02242519 MYLAN-SERTRALINE MYL 0.2806 02244838 PMS-SERTRALINE PMS 0.2806 02245159 SANDOZ SERTRALINE SDZ 0.2806 02247047 NU-SERTRALINE NXP 0.2806 02273683 GD-SERTRALINE GDI 0.2806 02287390 CO SERTRALINE COB 0.2806 02353520 SERTRALINE SAN 0.2806 02374552 RAN-SERTRALINE RAN 0.2806 02132702 ZOLOFT PFI 0.8422

* 50MG CAPSULE02238281 APO-SERTRALINE APX $ 0.5611 02240484 NOVO-SERTRALINE NOP 0.5611 02242520 MYLAN-SERTRALINE MYL 0.5611 02244839 PMS-SERTRALINE PMS 0.5611 02245160 SANDOZ SERTRALINE SDZ 0.5611 02247048 NU-SERTRALINE NXP 0.5611 02273691 GD-SERTRALINE GDI 0.5611 02287404 CO SERTRALINE COB 0.5611 02353539 SERTRALINE SAN 0.5611 02374560 RAN-SERTRALINE RAN 0.5611 01962817 ZOLOFT PFI 1.6844

* 100MG CAPSULE02238282 APO-SERTRALINE APX $ 0.5880 02240481 TEVA-SERTRALINE NOP 0.5880 02242521 MYLAN-SERTRALINE MYL 0.5880 02244840 PMS-SERTRALINE PMS 0.5880 02245161 SANDOZ SERTRALINE SDZ 0.5880 02247050 NU-SERTRALINE NXP 0.5880 02273705 GD-SERTRALINE GDI 0.5880 02287412 CO SERTRALINE COB 0.5880 02353547 SERTRALINE SAN 0.5880 02374579 RAN-SERTRALINE RAN 0.5880 01962779 ZOLOFT PFI 1.7650

TRANYLCYPROMINE SO4 10MG TABLET

01919598 PARNATE GSK $ 0.3759

62nd Edition 120 July 1, 2012

Page 143: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:16.04 PSYCHOTHERAPEUTIC AGENTS (ANTIDEPRESSANTS)

TRAZODONE* 50MG TABLET

01937227 PMS-TRAZODONE PMS $ 0.0775 02144263 TEVA-TRAZODONE NOP 0.0775 02147637 APO-TRAZODONE APX 0.0775 02165384 NU-TRAZODONE NXP 0.0775 02230284 TRAZOREL VAE 0.0775 02348772 TRAZODONE SAN 0.0775

* 100MG TABLET01937235 PMS-TRAZODONE PMS $ 0.1385 02144271 TEVA-TRAZODONE NOP 0.1385 02147645 APO-TRAZODONE APX 0.1385 02165392 NU-TRAZODONE NXP 0.1385 02230285 TRAZOREL VAE 0.1385 02348780 TRAZODONE SAN 0.1385

TRIMIPRAMINE 75MG CAPSULE

02070987 TRIMIPRAMINE AAP $ 0.7314 12.5MG TABLET

00740799 TRIMIPRAMINE AAP $ 0.2156 25MG TABLET

00740802 TRIMIPRAMINE AAP $ 0.2776 50MG TABLET

00740810 TRIMIPRAMINE AAP $ 0.5434 100MG TABLET

00740829 TRIMIPRAMINE AAP $ 0.9273

62nd Edition 121 July 1, 2012

Page 144: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:16.04 PSYCHOTHERAPEUTIC AGENTS (ANTIDEPRESSANTS)

VENLAFAXINE HCL* 37.5MG EXTENDED-RELEASE CAPSULE

02273969 RATIO-VENLAFAXINE XR RPH $ 0.3178 02275023 TEVA-VENLAFAXINE XR NOP 0.3178 02278545 PMS-VENLAFAXINE XR PMS 0.3178 02304317 CO VENLAFAXINE XR COB 0.3178 02310279 MYLAN-VENLAFAXINE XR MYL 0.3178 02310317 SANDOZ VENLAFAXINE XR SDZ 0.3178 02331683 APO-VENLAFAXINE XR APX 0.3178 02354713 VENLAFAXINE XR SAN 0.3178 02360020 GD-VENLAFAXINE XR GDI 0.3178 02380072 RAN-VENLAFAXINE XR RAN 0.3178 02237279 EFFEXOR XR PFI 0.9247

* 75MG EXTENDED-RELEASE CAPSULE02273977 RATIO-VENLAFAXINE XR RPH $ 0.6356 02275031 NOVO-VENLAFAXINE XR NOP 0.6356 02278553 PMS-VENLAFAXINE XR PMS 0.6356 02304325 CO VENLAFAXINE XR COB 0.6356 02310287 MYLAN-VENLAFAXINE XR MYL 0.6356 02310325 SANDOZ VENLAFAXINE XR SDZ 0.6356 02331691 APO-VENLAFAXINE XR APX 0.6356 02354721 VENLAFAXINE XR SAN 0.6356 02360039 GD-VENLAFAXINE XR GDI 0.6356 02380080 RAN-VENLAFAXINE XR RAN 0.6356 02237280 EFFEXOR XR PFI 1.8488

* 150MG EXTENDED-RELEASE CAPSULE02273985 RATIO-VENLAFAXINE XR RPH $ 0.6710 02275058 TEVA-VENLAFAXINE XR NOP 0.6710 02278561 PMS-VENLAFAXINE XR PMS 0.6710 02304333 CO VENLAFAXINE XR COB 0.6710 02310295 MYLAN-VENLAFAXINE XR MYL 0.6710 02310333 SANDOZ VENLAFAXINE XR SDZ 0.6710 02331705 APO-VENLAFAXINE XR APX 0.6710 02354748 VENLAFAXINE XR SAN 0.6710 02360047 GD-VENLAFAXINE XR GDI 0.6710 02380099 RAN-VENLAFAXINE XR RAN 0.6710 02237282 EFFEXOR XR PFI 1.9520

62nd Edition 122 July 1, 2012

Page 145: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS)

ARIPIPRAZOLE SEE APPENDIX A FOR EDS CRITERIA 2MG TABLET

02322374 ABILIFY (EDS) BMY $ 2.9140 5MG TABLET

02322382 ABILIFY (EDS) BMY $ 3.2800 10MG TABLET

02322390 ABILIFY (EDS) BMY $ 3.7800 15MG TABLET

02322404 ABILIFY (EDS) BMY $ 3.7800 20MG TABLET

02322412 ABILIFY (EDS) BMY $ 3.7800 30MG TABLET

02322455 ABILIFY (EDS) BMY $ 3.7800

CHLORPROMAZINE 25MG TABLET

00232823 TEVA-CHLORPROMAZINE NOP $ 0.1765 50MG TABLET

00232807 TEVA-CHLORPROMAZINE NOP $ 0.2019 100MG TABLET

00232831 TEVA-CHLORPROMAZINE NOP $ 0.4000 25MG/ML INJECTION SOLUTION (2ML)

00743518 CHLORPROMAZINE SDZ $ 2.2200

CLOZAPINE SEE APPENDIX A FOR EDS CRITERIA

* 25MG TABLET02247243 GEN-CLOZAPINE (EDS) MYL $ 0.6594 02248034 APO-CLOZAPINE (EDS) APX 0.6594 00894737 CLOZARIL (EDS) NVR 0.9420

50MG TABLET02305003 GEN-CLOZAPINE (EDS) MYL $ 1.3188

* 100MG TABLET02247244 GEN-CLOZAPINE (EDS) MYL $ 2.6446 02248035 APO-CLOZAPINE (EDS) APX 2.6446 00894745 CLOZARIL (EDS) NVR 3.7780

200MG TABLET02305011 GEN-CLOZAPINE (EDS) MYL $ 5.2892

FLUPENTIXOL DECANOATE 20MG/ML INJECTION SOLUTION (ML)

02156032 FLUANXOL DEPOT LUD $ 7.1900 100MG/ML INJECTION SOLUTION (ML)

02156040 FLUANXOL DEPOT LUD $ 35.9300

62nd Edition 123 July 1, 2012

Page 146: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS)

FLUPENTIXOL DIHYDROCHLORIDE 0.5MG TABLET

02156008 FLUANXOL LUD $ 0.2483 3MG TABLET

02156016 FLUANXOL LUD $ 0.5362

FLUPHENAZINE DECANOATE 25MG/ML INJECTION SOLUTION (5ML)

02239636 FLUPHENAZINE OMEGA OMG $ 23.1600 100MG/ML INJECTION SOLUTION (1ML)

00755575 MODECATE CONCENTRATE BMY $ 29.7800

FLUPHENAZINE HCL 1MG TABLET

00405345 APO-FLUPHENAZINE APX $ 0.1739 2MG TABLET

00410632 APO-FLUPHENAZINE APX $ 0.2252 * 5MG TABLET

00405361 APO-FLUPHENAZINE APX $ 0.1720 00726354 PMS-FLUPHENAZINE PMS 0.1720

HALOPERIDOL* 0.5MG TABLET

00363685 NOVO-PERIDOL NOP $ 0.0360 00396796 APO-HALOPERIDOL APX 0.0360

* 1MG TABLET00363677 NOVO-PERIDOL NOP $ 0.0614 00396818 APO-HALOPERIDOL APX 0.0614

* 2MG TABLET00363669 NOVO-PERIDOL NOP $ 0.1050 00396826 APO-HALOPERIDOL APX 0.1050

* 5MG TABLET00363650 NOVO-PERIDOL NOP $ 0.1487 00396834 APO-HALOPERIDOL APX 0.1487

* 10MG TABLET00463698 APO-HALOPERIDOL APX $ 0.1330 00713449 NOVO-PERIDOL NOP 0.1330

5MG/ML INJECTION SOLUTION (1ML)00808652 HALOPERIDOL SDZ $ 4.8300

HALOPERIDOL DECANOATE 50MG/ML INJECTION SOLUTION (5ML)

02130297 HALOPERIDOL LA SDZ $ 29.5200 * 100MG/ML INJECTION SOLUTION (5ML)

02130300 HALOPERIDOL LA SDZ $ 58.3335 02239640 HALOPERIDOL-LA OMEGA OMG 68.3500

62nd Edition 124 July 1, 2012

Page 147: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS)

LOXAPINE SUCCINATE 5MG TABLET

02230837 XYLAC MMT $ 0.1649 10MG TABLET

02230838 XYLAC MMT $ 0.2745 25MG TABLET

02230839 XYLAC MMT $ 0.4255 50MG TABLET

02230840 XYLAC MMT $ 0.5672

OLANZAPINE SEE APPENDIX A FOR EDS CRITERIA

* 2.5MG TABLET02276712 TEVA-OLANZAPINE (EDS) NOP $ 0.6290 02281791 APO-OLANZAPINE (EDS) APX 0.6290 02303116 PMS-OLANZAPINE (EDS) PMS 0.6290 02310341 SANDOZ OLANZAPINE (EDS) SDZ 0.6290 02325659 CO OLANZAPINE (EDS) COB 0.6290 02337878 MYLAN-OLANZAPINE (EDS) MYL 0.6290 02372819 OLANZAPINE (EDS) SAN 0.6290 02229250 ZYPREXA (EDS) LIL 1.7972

* 5MG TABLET02276720 TEVA-OLANZAPINE (EDS) NOP $ 1.2580 02281805 APO-OLANZAPINE (EDS) APX 1.2580 02303159 PMS-OLANZAPINE (EDS) PMS 1.2580 02310368 SANDOZ OLANZAPINE (EDS) SDZ 1.2580 02325667 CO OLANZAPINE (EDS) COB 1.2580 02337886 MYLAN-OLANZAPINE (EDS) MYL 1.2580 02372827 OLANZAPINE (EDS) SAN 1.2580 02229269 ZYPREXA (EDS) LIL 3.5944

* 7.5MG TABLET02276739 TEVA-OLANZAPINE (EDS) NOP $ 1.8871 02281813 APO-OLANZAPINE (EDS) APX 1.8871 02303167 PMS-OLANZAPINE (EDS) PMS 1.8871 02310376 SANDOZ OLANZAPINE (EDS) SDZ 1.8871 02325675 CO OLANZAPINE (EDS) COB 1.8871 02337894 MYLAN-OLANZAPINE (EDS) MYL 1.8871 02372835 OLANZAPINE (EDS) SAN 1.8871 02229277 ZYPREXA (EDS) LIL 5.3916

* 10MG TABLET02276747 TEVA-OLANZAPINE (EDS) NOP $ 2.5161 02281821 APO-OLANZAPINE (EDS) APX 2.5161 02303175 PMS-OLANZAPINE (EDS) PMS 2.5161 02310384 SANDOZ OLANZAPINE (EDS) SDZ 2.5161 02325683 CO OLANZAPINE (EDS) COB 2.5161 02337908 MYLAN-OLANZAPINE (EDS) MYL 2.5161 02372843 OLANZAPINE (EDS) SAN 2.5161 02229285 ZYPREXA (EDS) LIL 7.1888

62nd Edition 125 July 1, 2012

Page 148: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS)

* 15MG TABLET02276755 TEVA-OLANZAPINE (EDS) NOP $ 3.7741 02281848 APO-OLANZAPINE (EDS) APX 3.7741 02303183 PMS-OLANZAPINE (EDS) PMS 3.7741 02310392 SANDOZ OLANZAPINE (EDS) SDZ 3.7741 02325691 CO OLANZAPINE (EDS) COB 3.7741 02337916 MYLAN-OLANZAPINE (EDS) MYL 3.7741 02372851 OLANZAPINE (EDS) SAN 3.7741 02238850 ZYPREXA (EDS) LIL 10.7831

* 5MG ORALLY DISINTEGRATING TABLET02303191 PMS-OLANZAPINE ODT (EDS) PMS $ 1.2511 02321343 NOVO-OLANZAPINE OD (EDS) NOP 1.2511 02327562 CO OLANZAPINE ODT (EDS) COB 1.2511 02327775 SANDOZ OLANZAPINE ODT (EDS) SDZ 1.2511 02352974 OLANZAPINE ODT (EDS) SAN 1.2511 02360616 APO-OLANZAPINE ODT (EDS) APX 1.2511 02382709 MYLAN-OLANZAPINE ODT(EDS) MYL 1.2511 02243086 ZYPREXA ZYDIS (EDS) LIL 3.5747

* 10MG ORALLY DISINTEGRATING TABLET02303205 PMS-OLANZAPINE ODT (EDS) PMS $ 2.5000 02321351 NOVO-OLANZAPINE OD (EDS) NOP 2.5000 02327570 CO OLANZAPINE ODT (EDS) COB 2.5000 02327783 SANDOZ OLANZAPINE ODT (EDS) SDZ 2.5000 02352982 OLANZAPINE ODT (EDS) SAN 2.5000 02360624 APO-OLANZAPINE ODT (EDS) APX 2.5000 02382717 MYLAN-OLANZAPINE ODT (EDS) MYL 2.5000 02243087 ZYPREXA ZYDIS (EDS) LIL 7.1429

* 15MG ORALLY DISINTEGRATING TABLET02303213 PMS-OLANZAPINE ODT (EDS) PMS $ 3.7489 02321378 NOVO-OLANZAPINE OD (EDS) NOP 3.7489 02327589 CO OLANZAPINE ODT (EDS) COB 3.7489 02327791 SANDOZ OLANZAPINE ODT (EDS) SDZ 3.7489 02352990 OLANZAPINE ODT (EDS) SAN 3.7489 02360632 APO-OLANZAPINE ODT (EDS) APX 3.7489 02382725 MYLAN-OLANZAPINE ODT (EDS) MYL 3.7489 02243088 ZYPREXA ZYDIS (EDS) LIL 10.7111

PALIPERIDONE PALMITATE SEE APPENDIX A FOR EDS CRITERIA 50MG PRE-FILLED SYRINGE

02354217 INVEGA SUSTENNA (EDS) JAN $ 304.1000 75MG PRE-FILLED SYRINGE

02354225 INVEGA SUSTENNA (EDS) JAN $ 456.1800 100MG PRE-FILLED SYRINGE

02354233 INVEGA SUSTENNA (EDS) JAN $ 456.1800 150MG PRE-FILLED SYRINGE

02354241 INVEGA SUSTENNA (EDS) JAN $ 608.2200

62nd Edition 126 July 1, 2012

Page 149: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS)

PERICYAZINE 5MG CAPSULE

01926780 NEULEPTIL ERF $ 0.2330 10MG CAPSULE

01926772 NEULEPTIL ERF $ 0.4091 20MG CAPSULE

01926764 NEULEPTIL ERF $ 0.5888 10MG/ML ORAL DROPS

01926756 NEULEPTIL ERF $ 0.4111

PERPHENAZINE 2MG TABLET

00335134 PERPHENAZINE AAP $ 0.0626 4MG TABLET

00335126 PERPHENAZINE AAP $ 0.0758 8MG TABLET

00335118 PERPHENAZINE AAP $ 0.0832 16MG TABLET

00335096 PERPHENAZINE AAP $ 0.1274

PIMOZIDE* 2MG TABLET

00313815 ORAP MMT $ 0.3093 02245432 APO-PIMOZIDE APX 0.3093

* 4MG TABLET00313823 ORAP MMT $ 0.4136 02245433 APO-PIMOZIDE APX 0.4136

PIPOTIAZINE PALMITATE 25MG/ML INJECTION SOLUTION (ML)

01926667 PIPORTIL L4 AVT $ 16.0600 50MG/ML INJECTION SOLUTION (ML)

01926675 PIPORTIL L4 AVT $ 27.2400

PROCHLORPERAZINE 5MG TABLET

00886440 APO-PROCHLORAZINE APX $ 0.1659 10MG TABLET

00886432 APO-PROCHLORAZINE APX $ 0.2025 5MG/ML INJECTION SOLUTION (2ML)

00789747 PROCHLORPERAZINE MESYLATE SDZ $ 2.0900 10MG SUPPOSITORY

00789720 SANDOZ PROCHLORPERAZINE SDZ $ 0.8300

62nd Edition 127 July 1, 2012

Page 150: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS)

QUETIAPINE* 25MG TABLET

02284235 NOVO-QUETIAPINE NOP $ 0.1729 02296551 PMS-QUETIAPINE PMS 0.1729 02307804 MYLAN-QUETIAPINE MYL 0.1729 02313901 APO-QUETIAPINE APX 0.1729 02313995 SANDOZ QUETIAPINE SDZ 0.1729 02316080 CO QUETIAPINE COB 0.1729 02330415 JAMP-QUETIAPINE JPC 0.1729 02353164 QUETIAPINE SAN 0.1729 02236951 SEROQUEL AST 0.5195

50MG TABLET02361892 PMS-QUETIAPINE PMS $ 0.3624

* 100MG TABLET02284243 NOVO-QUETIAPINE NOP $ 0.4613 02296578 PMS-QUETIAPINE PMS 0.4613 02307812 MYLAN-QUETIAPINE MYL 0.4613 02313928 APO-QUETIAPINE APX 0.4613 02314002 SANDOZ QUETIAPINE SDZ 0.4613 02316099 CO QUETIAPINE COB 0.4613 02330423 JAMP-QUETIAPINE JPC 0.4613 02353172 QUETIAPINE SAN 0.4613 02236952 SEROQUEL AST 1.3860

* 200MG TABLET02284278 NOVO-QUETIAPINE NOP $ 0.9265 02296594 PMS-QUETIAPINE PMS 0.9265 02307839 MYLAN-QUETIAPINE MYL 0.9265 02313936 APO-QUETIAPINE APX 0.9265 02314010 SANDOZ QUETIAPINE SDZ 0.9265 02316110 CO QUETIAPINE COB 0.9265 02330458 JAMP-QUETIAPINE JPC 0.9265 02353199 QUETIAPINE SAN 0.9265 02236953 SEROQUEL AST 2.7830

* 300MG TABLET02284286 NOVO-QUETIAPINE NOP $ 1.3519 02296608 PMS-QUETIAPINE PMS 1.3519 02307847 MYLAN-QUETIAPINE MYL 1.3519 02313944 APO-QUETIAPINE APX 1.3519 02314029 SANDOZ QUETIAPINE SDZ 1.3519 02316129 CO QUETIAPINE COB 1.3519 02330466 JAMP-QUETIAPINE JPC 1.3519 02353202 QUETIAPINE SAN 1.3519 02244107 SEROQUEL AST 4.0610

50MG EXTENDED RELEASE TABLET02300184 SEROQUEL XR AST $ 0.9800

150MG EXTENDED RELEASE TABLET02321513 SEROQUEL XR AST $ 1.9300

200MG EXTENDED RELEASE TABLET02300192 SEROQUEL XR AST $ 2.6200

62nd Edition 128 July 1, 2012

Page 151: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS)

300MG EXTENDED RELEASE TABLET02300206 SEROQUEL XR AST $ 3.8600

400MG EXTENDED RELEASE TABLET02300214 SEROQUEL XR AST $ 5.2400

RISPERIDONE* 0.25MG TABLET

02252007 PMS-RISPERIDONE PMS $ 0.1752 02280906 RAN-RISPERIDONE RAN 0.1752 02282119 APO-RISPERIDONE APX 0.1752 02282240 MYLAN-RISPERIDONE MYL 0.1752 02282585 CO RISPERIDONE COB 0.1752 02282690 NOVO-RISPERIDONE NOP 0.1752 02303655 SANDOZ RISPERIDONE SDZ 0.1752 02328305 RBX-RISPERIDONE RAN 0.1752 02356880 RISPERIDONE SAN 0.1752 02359529 JAMP-RISPERIDONE JPC 0.1752 02359790 MINT-RISPERIDON MNT 0.1752 02367173 AVA-RISPERIDONE AVA 0.1752 02371766 MAR-RISPERIDONE MPI 0.1752 02240551 RISPERDAL JAN 0.5425

* 0.5MG TABLET02252015 PMS-RISPERIDONE PMS $ 0.2935 02264188 NOVO-RISPERIDONE NOP 0.2935 02280914 RAN-RISPERIDONE RAN 0.2935 02282127 APO-RISPERIDONE APX 0.2935 02282259 MYLAN-RISPERIDONE MYL 0.2935 02282593 CO RISPERIDONE COB 0.2935 02303663 SANDOZ RISPERIDONE SDZ 0.2935 02328313 RBX-RISPERIDONE RAN 0.2935 02356899 RISPERDONE SAN 0.2935 02359537 JAMP-RISPERIDONE JPC 0.2935 02359804 MINT-RISPERDON MNT 0.2935 02367181 AVA-RISPERIDONE AVA 0.2935 02371774 MAR-RISPERIDONE MPI 0.2935 02240552 RISPERDAL JAN 0.9088

0.5MG ORALLY DISINTEGRATING TABLET02247704 RISPERDAL M-TAB JAN $ 0.7450

62nd Edition 129 July 1, 2012

Page 152: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS)

* 1MG TABLET02252023 PMS-RISPERIDONE PMS $ 0.4055 02264196 NOVO-RISPERIDONE NOP 0.4055 02279800 SANDOZ RISPERIDONE SDZ 0.4055 02280922 RAN-RISPERIDONE RAN 0.4055 02282135 APO-RISPERIDONE APX 0.4055 02282267 MYLAN-RISPERIDONE MYL 0.4055 02282607 CO RISPERIDONE COB 0.4055 02328321 RBX-RISPERIDONE RAN 0.4055 02356902 RISPERIDONE SAN 0.4055 02359545 JAMP-RISPERIDONE JPC 0.4055 02359812 MINT-RISPERIDON MNT 0.4055 02367203 AVA-RISPERIDONE AVA 0.4055 02371782 MAR-RISPERIDONE MPI 0.4055 02025280 RISPERDAL JAN 1.2550

1MG ORALLY DISINTEGRATING TABLET02247705 RISPERDAL M-TAB JAN $ 1.0300

* 2MG TABLET02252031 PMS-RISPERIDONE PMS $ 0.8095 02264218 NOVO-RISPERIDONE NOP 0.8095 02279819 SANDOZ RISPERIDONE SDZ 0.8095 02280930 RAN-RISPERIDONE RAN 0.8095 02282143 APO-RISPERIDONE APX 0.8095 02282275 MYLAN-RISPERIDONE MYL 0.8095 02282615 CO RISPERIDONE COB 0.8095 02328348 RBX-RISPERIDONE RAN 0.8095 02356910 RISPERIDONE SAN 0.8095 02359553 JAMP-RISPERIDONE JPC 0.8095 02359820 MINT-RISPERIDON MNT 0.8095 02367211 AVA-RISPERIDONE AVA 0.8095 02371790 MAR-RISPERIDONE MPI 0.8095 02025299 RISPERDAL JAN 2.5110

2MG ORALLY DISINTEGRATING TABLET02247706 RISPERDAL M-TAB JAN $ 2.0375

62nd Edition 130 July 1, 2012

Page 153: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS)

* 3MG TABLET02252058 PMS-RISPERIDONE PMS $ 1.2143 02264226 NOVO-RISPERIDONE NOP 1.2143 02279827 SANDOZ RISPERIDONE SDZ 1.2143 02280949 RAN-RISPERIDONE RAN 1.2143 02282151 APO-RISPERIDONE APX 1.2143 02282283 MYLAN-RISPERIDONE MYL 1.2143 02282623 CO RISPERIDONE COB 1.2143 02328364 RBX-RISPERIDONE RAN 1.2143 02356929 RISPERIDONE SAN 1.2143 02359561 JAMP-RISPERIDONE JPC 1.2143 02359839 MINT-RISPERIDON MNT 1.2143 02367238 AVA-RISPERIDONE AVA 1.2143 02371804 MAR-RISPERIDONE MPI 1.2143 02025302 RISPERDAL JAN 3.7597

3MG ORALLY DISINTEGRATING TABLET02268086 RISPERDAL M-TAB JAN $ 3.0550

* 4MG TABLET02252066 PMS-RISPERIDONE PMS $ 1.6191 02264234 NOVO-RISPERIDONE NOP 1.6191 02279835 SANDOZ RISPERIDONE SDZ 1.6191 02280957 RAN-RISPERIDONE RAN 1.6191 02282178 APO-RISPERIDONE APX 1.6191 02282291 MYLAN-RISPERIDONE MYL 1.6191 02282631 CO RISPERIDONE COB 1.6191 02328372 RBX-RISPERIDONE RAN 1.6191 02356937 RISPERIDONE SAN 1.6191 02359588 JAMP-RISPERIDONE JPC 1.6191 02359847 MINT-RISPERDON MNT 1.6191 02367246 AVA-RISPERIDONE AVA 1.6191 02371812 MAR-RISPERIDONE MPI 1.6191 02025310 RISPERDAL JAN 5.0130

4MG ORALLY DISINTEGRATING TABLET02268094 RISPERDAL M-TAB JAN $ 4.0850

* 1MG/ML ORAL SOLUTION02279266 PMS-RISPERIDONE PMS $ 0.4662 02280396 APO-RISPERIDONE APX 0.4662 02236950 RISPERDAL JAN 1.4160

12.5MG/VIAL POWDER FOR INJECTION (VIAL)02298465 RISPERDAL CONSTA (EDS) JAN $ 77.8200

25MG/VIAL POWDER FOR INJECTION (VIAL)02255707 RISPERDAL CONSTA (EDS) JAN $ 161.5600

37.5MG/VIAL POWDER FOR INJECTION (VIAL)02255723 RISPERDAL CONSTA (EDS) JAN $ 242.3300

50MG/VIAL POWDER FOR INJECTION (VIAL)02255758 RISPERDAL CONSTA (EDS) JAN $ 323.1100

62nd Edition 131 July 1, 2012

Page 154: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS)

THIOTHIXENE 2MG CAPSULE

00024430 NAVANE ERF $ 0.3209 5MG CAPSULE

00024449 NAVANE ERF $ 0.4555 10MG CAPSULE

00024457 NAVANE ERF $ 0.5694

TRIFLUOPERAZINE 1MG TABLET

00345539 TRIFLUOPERAZINE AAP $ 0.1340 2MG TABLET

00312754 TRIFLUOPERAZINE AAP $ 0.1758 5MG TABLET

00312746 TRIFLUOPERAZINE AAP $ 0.2328 10MG TABLET

00326836 TRIFLUOPERAZINE AAP $ 0.2790

ZIPRASIDONE 20MG CAPSULE

02298597 ZELDOX PFI $ 1.6979 40MG CAPSULE

02298600 ZELDOX PFI $ 1.9449 60MG CAPSULE

02298619 ZELDOX PFI $ 1.9449 80MG CAPSULE

02298627 ZELDOX PFI $ 1.9449

ZUCLOPENTHIXOL ACETATE SEE APPENDIX A FOR EDS CRITERIA 50MG/ML INJECTION (ML)

02230405 CLOPIXOL ACUPHASE (EDS) LUD $ 14.9200

ZUCLOPENTHIXOL DECANOATE SEE APPENDIX A FOR EDS CRITERIA 200MG/ML INJECTION (ML)

02230406 CLOPIXOL DEPOT (EDS) LUD $ 14.9200

ZUCLOPENTHIXOL DIHYDROCHLORIDE SEE APPENDIX A FOR EDS CRITERIA 10MG TABLET

02230402 CLOPIXOL (EDS) LUD $ 0.3835 25MG TABLET

02230403 CLOPIXOL (EDS) LUD $ 0.9588

62nd Edition 132 July 1, 2012

Page 155: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:20.00 RESPIRATORY AND CEREBRAL STIMULANTS

DEXTROAMPHETAMINE SO4 5MG TABLET

01924516 DEXEDRINE PAL $ 0.5748 10MG SPANSULE CAPSULE

01924559 DEXEDRINE PAL $ 0.8246 15MG SPANSULE CAPSULE

01924567 DEXEDRINE PAL $ 1.0081

METHYLPHENIDATE HCL* 5MG TABLET

02234749 PMS-METHYLPHENIDATE PMS $ 0.0947 02273950 APO-METHYLPHENIDATE APX 0.0947

* 10MG TABLET00584991 PMS-METHYLPHENIDATE PMS $ 0.1142 02249324 APO-METHYLPHENIDATE APX 0.1142 00005606 RITALIN NVR 0.3539

* 20MG TABLET00585009 PMS-METHYLPHENIDATE PMS $ 0.2359 02249332 APO-METHYLPHENIDATE APX 0.2359 00005614 RITALIN NVR 0.6183

18MG EXTENDED RELEASE TABLET02247732 CONCERTA JAN $ 2.0985

27MG EXTENDED RELEASE TABLET02250241 CONCERTA JAN $ 2.4218

36MG EXTENDED RELEASE TABLET02247733 CONCERTA JAN $ 2.7451

54MG EXTENDED RELEASE TABLET02247734 CONCERTA JAN $ 3.3915

* 20MG SUSTAINED RELEASE TABLET02266687 APO-METHYLPHENIDATE SR APX $ 0.2820 02320312 SANDOZ METHYLPHENIDATE SR SDZ 0.2820 00632775 RITALIN SR NVR 0.6208

MODAFINIL SEE APPENDIX A FOR EDS CRITERIA

* 100MG TABLET02285398 MODAFINIL (EDS) AAP $ 0.9293 02239665 ALERTEC (EDS) SCI 1.3174

62nd Edition 133 July 1, 2012

Page 156: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:24.04 ANXIOLYTICS, SEDATIVES AND HYPNOTICS (BARBITURATES)

PHENOBARBITAL SEE SECTION 28:12.04 (ANTICONVULSANTS)

28:24.08 ANXIOLYTICS, SEDATIVES AND HYPNOTICS (BENZODIAZEPINES)

ALPRAZOLAM* 0.25MG TABLET

00865397 APO-ALPRAZ APX $ 0.0760 01913484 TEVA-ALPRAZOL NOP 0.0760 02137534 MYLAN-ALPRAZOLAM MYL 0.0760 02349191 ALPRAZOLAM SAN 0.0760 00548359 XANAX PFI 0.2486

* 0.5MG TABLET00865400 APO-ALPRAZ APX $ 0.0920 01913492 TEVA-ALPRAZOL NOP 0.0920 02137542 MYLAN-ALPRAZOLAM MYL 0.0920 02349205 ALPRAZOLAM SAN 0.0920 00548367 XANAX PFI 0.2973

BROMAZEPAM 1.5MG TABLET

02177153 APO-BROMAZEPAM APX $ 0.0515 * 3MG TABLET

02177161 APO-BROMAZEPAM APX $ 0.0525 02230584 NOVO-BROMAZEPAM NOP 0.0525 00518123 LECTOPAM HLR 0.1529

* 6MG TABLET02177188 APO-BROMAZEPAM APX $ 0.0767 02230585 NOVO-BROMAZEPAM NOP 0.0767 00518131 LECTOPAM HLR 0.2234

62nd Edition 134 July 1, 2012

Page 157: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:24.08 ANXIOLYTICS, SEDATIVES AND HYPNOTICS (BENZODIAZEPINES)

CHLORDIAZEPOXIDE 5MG CAPSULE

00522724 APO-CHLORDIAZEPOXIDE APX $ 0.0679 10MG CAPSULE

00522988 APO-CHLORDIAZEPOXIDE APX $ 0.1070 25MG CAPSULE

00522996 APO-CHLORDIAZEPOXIDE APX $ 0.1658

CLORAZEPATE DIPOTASSIUM 3.75MG CAPSULE

00860689 APO-CLORAZEPATE APX $ 0.1476 7.5MG CAPSULE

00860700 APO-CLORAZEPATE APX $ 0.1926 15MG CAPSULE

00860697 APO-CLORAZEPATE APX $ 0.3856

DIAZEPAM* 2MG TABLET

00405329 APO-DIAZEPAM APX $ 0.0508 02247490 PMS-DIAZEPAM PMS 0.0508

* 5MG TABLET00362158 APO-DIAZEPAM APX $ 0.0650 02247491 PMS-DIAZEPAM PMS 0.0650 00013285 VALIUM HLR 0.1563

* 10MG TABLET00405337 APO-DIAZEPAM APX $ 0.0867 02247492 PMS-DIAZEPAM PMS 0.0867

5MG/ML RECTAL GEL (DELIVERY SYSTEM)02238162 DIASTAT VAE $ 73.2300

FLURAZEPAM HCL 15MG CAPSULE

00521698 APO-FLURAZEPAM APX $ 0.1166 30MG CAPSULE

00521701 APO-FLURAZEPAM APX $ 0.1364

62nd Edition 135 July 1, 2012

Page 158: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:24.08 ANXIOLYTICS, SEDATIVES AND HYPNOTICS (BENZODIAZEPINES)

LORAZEPAM* 0.5MG TABLET

00655740 APO-LORAZEPAM APX $ 0.0359 00711101 NOVO-LORAZEM NOP 0.0359 00728187 PMS-LORAZEPAM PMS 0.0359 02041413 ATIVAN PFI 0.0359 02245784 DOM-LORAZEPAM DOM 0.0359 02351072 LORAZEPAM SAN 0.0359

* 1MG TABLET00637742 NOVO-LORAZEM NOP $ 0.0447 00655759 APO-LORAZEPAM APX 0.0447 00728195 PMS-LORAZEPAM PMS 0.0447 02041421 ATIVAN PFI 0.0447 02245785 DOM-LORAZEPAM DOM 0.0447 02351080 LORAZEPAM SAN 0.0447

* 2MG TABLET00637750 NOVO-LORAZEM NOP $ 0.0699 00655767 APO-LORAZEPAM APX 0.0699 00728209 PMS-LORAZEPAM PMS 0.0699 02041448 ATIVAN PFI 0.0699 02245786 DOM-LORAZEPAM DOM 0.0699 02351099 LORAZEPAM SAN 0.0699

OXAZEPAM 10MG TABLET

00402680 APO-OXAZEPAM APX $ 0.0350 15MG TABLET

00402745 APO-OXAZEPAM APX $ 0.0550 30MG TABLET

00402737 APO-OXAZEPAM APX $ 0.0750

TEMAZEPAM* 15MG CAPSULE

02225964 APO-TEMAZEPAM APX $ 0.0665 02230095 NOVO-TEMAZEPAM NOP 0.0665 02244814 CO TEMAZEPAM COB 0.0665 00604453 RESTORIL SNV 0.1998

* 30MG CAPSULE02225972 APO-TEMAZEPAM APX $ 0.0805 02230102 NOVO-TEMAZEPAM NOP 0.0805 02244815 CO TEMAZEPAM COB 0.0805 00604461 RESTORIL SNV 0.2419

TRIAZOLAM 0.125MG TABLET

00808563 APO-TRIAZO APX $ 0.1496 0.25MG TABLET

00808571 APO-TRIAZO APX $ 0.2502

62nd Edition 136 July 1, 2012

Page 159: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:24.92 MISCELLANEOUS ANXIOLYTICS, SEDATIVES AND HYPNOTICS

BUSPIRONE* 10MG TABLET

02207672 NU-BUSPIRONE NXP $ 0.3723 02211076 APO-BUSPIRONE APX 0.3723 02230942 PMS-BUSPIRONE PMS 0.3723 02231492 NOVO-BUSPIRONE NOP 0.3723

CHLORAL HYDRATE* 100MG/ML SYRUP

00792659 PMS-CHLORAL HYDRATE SYRUP PMS $ 0.0434 02247621 CHLORAL HYDRATE SYRUP ODN 0.0434

HYDROXYZINE* 10MG CAPSULE

00646059 APO-HYDROXYZINE APX $ 0.1116 00738824 NOVO-HYDROXYZIN NOP 0.1116

* 25MG CAPSULE00646024 APO-HYDROXYZINE APX $ 0.1425 00738832 NOVO-HYDROXYZIN NOP 0.1425

* 50MG CAPSULE00646016 APO-HYDROXYZINE APX $ 0.2068 00738840 NOVO-HYDROXYZIN NOP 0.2068

* 2MG/ML ORAL SYRUP00741817 PMS-HYDROXYZINE PMS $ 0.0436 00024694 ATARAX ERF 0.0596

METHOTRIMEPRAZINE 2MG TABLET

02238403 APO-METHOPRAZINE APX $ 0.0685 5MG TABLET

02238404 APO-METHOPRAZINE APX $ 0.0991 25MG TABLET

02238405 APO-METHOPRAZINE APX $ 0.2547 50MG TABLET

02238406 APO-METHOPRAZINE APX $ 0.3857

62nd Edition 137 July 1, 2012

Page 160: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS

28:28.00 ANTIMANIC AGENTS

LITHIUM CARBONATE* 150MG CAPSULE

02216132 PMS-LITHIUM CARBONATE PMS $ 0.0449 02242837 APO-LITHIUM CARBONATE APX 0.0449 00461733 CARBOLITH VAE 0.1160

* 300MG CAPSULE02216140 PMS-LITHIUM CARBONATE PMS $ 0.0447 02242838 APO-LITHIUM CARBONATE APX 0.0447 00236683 CARBOLITH VAE 0.0901

* 600MG CAPSULE02216159 PMS-LITHIUM CARBONATE PMS $ 0.1530 02011239 CARBOLITH VAE 0.1773

300MG SUSTAINED RELEASE TABLET02266695 LITHMAX AAP $ 0.2495

28:92.00 MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS

ENTACAPONE* 200MG TABLET

02375559 TEVA-ENTACAPONE TEV $ 0.5670 02380005 SANDOZ ENTACAPONE SDZ 0.5670 02243763 COMTAN NVR 1.6199

LEVODOPA/BENZERAZIDE 50MG/12.5MG CAPSULE

00522597 PROLOPA HLR $ 0.2787 100MG/25MG CAPSULE

00386464 PROLOPA HLR $ 0.4588 200MG/50MG CAPSULE

00386472 PROLOPA HLR $ 0.7702

LEVODOPA/CARBIDOPA* 100MG/10MG TABLET

02182831 NU-LEVOCARB NXP $ 0.1877 02195933 APO-LEVOCARB APX 0.1877 02244494 NOVO-LEVOCARBIDOPA NOP 0.1877 00355658 SINEMET MRK 0.4772

* 100MG/25MG TABLET02182823 NU-LEVOCARB NXP $ 0.2803 02195941 APO-LEVOCARB APX 0.2803 02244495 NOVO-LEVOCARBIDOPA NOP 0.2803 00513997 SINEMET MRK 0.7126

* 250MG/25MG TABLET02182858 NU-LEVOCARB NXP $ 0.3129 02195968 APO-LEVOCARB APX 0.3129 02244496 NOVO-LEVOCARBIDOPA NOP 0.3129 00328219 SINEMET MRK 0.7955

62nd Edition 138 July 1, 2012

Page 161: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS28:92.00 MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS

* 100MG/25MG CONTROLLED RELEASE TABLET02272873 LEVOCARB CR AAP $ 0.5126 02028786 SINEMET CR MRK 0.7326

200MG/50MG CONTROLLED RELEASE TABLET00870935 SINEMET CR MRK $ 1.3552

LEVODOPA/CARBIDOPA/ENTACAPONE 50MG/12.5MG/200MG TABLET

02305933 STALEVO NVR $ 1.6018 75MG/18.75MG/200MG TABLET

02337827 STALEVO NVR $ 1.6018 125MG/31.25MG/200MG TABLET

02337835 STALEVO NVR $ 1.6018 100MG/25MG/200MG TABLET

02305941 STALEVO NVR $ 1.6018 150MG/37.5MG/200MG TABLET

02305968 STALEVO NVR $ 1.6018

PRAMIPEXOLE DIHYDROCHLORIDE* 0.25MG TABLET

02269309 NOVO-PRAMIPEXOLE NOP $ 0.3680 02290111 PMS-PRAMIPEXOLE PMS 0.3680 02292378 APO-PRAMIPEXOLE APX 0.3680 02297302 CO PRAMIPEXOLE COB 0.3680 02315262 SANDOZ PRAMIPEXOLE SDZ 0.3680 02363305 AVA-PRAMIPEXOLE AVA 0.3680 02367602 PRAMIPEXOLE SAN 0.3680 02376350 MYLAN-PRAMIPEXOLE MYL 0.3680 02237145 MIRAPEX BOE 1.0836

* 0.5MG TABLET02269317 NOVO-PRAMIPEXOLE NOP $ 1.0514 02290138 PMS-PRAMIPEXOLE PMS 1.0514 02292386 APO-PRAMIPEXOLE APX 1.0514 02297310 CO PRAMIPEXOLE COB 1.0514 02315270 SANDOZ PRAMIPEXOLE SDZ 1.0514 02363313 AVA-PRAMIPEXOLE AVA 1.0514 02367610 PRAMIPEXOLE SAN 1.0514 02376369 MYLAN-PRAMIPEXOLE MYL 1.0514 02241594 MIRAPEX BOE 2.1673

* 1MG TABLET02269325 NOVO-PRAMIPEXOLE NOP $ 0.7360 02290146 PMS-PRAMIPEXOLE PMS 0.7360 02292394 APO-PRAMIPEXOLE APX 0.7360 02297329 CO PRAMIPEXOLE COB 0.7360 02315289 SANDOZ PRAMIPEXOLE SDZ 0.7360 02363321 AVA-PRAMIPEXOLE AVA 0.7360 02367629 PRAMIPEXOLE SAN 0.7360 02376377 MYLAN-PRAMIPEXOLE MYL 0.7360 02237146 MIRAPEX BOE 2.1673

62nd Edition 139 July 1, 2012

Page 162: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

28:00 CENTRAL NERVOUS SYSTEM AGENTS28:92.00 MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS* 1.5MG TABLET

02269333 NOVO-PRAMIPEXOLE NOP $ 0.7360 02290154 PMS-PRAMIPEXOLE PMS 0.7360 02292408 APO-PRAMIPEXOLE APX 0.7360 02297337 CO PRAMIPEXOLE COB 0.7360 02315297 SANDOZ PRAMIPEXOLE SDZ 0.7360 02363348 AVA-PRAMIPEXOLE AVA 0.7360 02367645 PRAMIPEXOLE SAN 0.7360 02376385 MYLAN-PRAMIPEXOLE MYL 0.7360 02237147 MIRAPEX BOE 2.1673

ROPINIROLE HCL* 0.25MG TABLET

02314037 RAN-ROPINIROLE RAN $ 0.0993 02316846 CO ROPINIROLE COB 0.0993 02326590 PMS-ROPINIROLE PMS 0.0993 02337746 APO-ROPINIROLE APX 0.0993 02352338 JAMP-ROPINIROLE JPC 0.0993 02353040 ROPINIROLE SAN 0.0993 02232565 REQUIP GSK 0.2838

* 1MG TABLET02314053 RAN-ROPINIROLE RAN $ 0.3974 02316854 CO ROPINIROLE COB 0.3974 02326612 PMS-ROPINIROLE PMS 0.3974 02337762 APO-ROPINIROLE APX 0.3974 02352346 JAMP-ROPINIROLE JPC 0.3974 02353059 ROPINIROLE SAN 0.3974 02232567 REQUIP GSK 1.1353

* 2MG TABLET02314061 RAN-ROPINIROLE RAN $ 0.4371 02316862 CO ROPINIROLE COB 0.4371 02326620 PMS-ROPINIROLE PMS 0.4371 02337770 APO-ROPINIROLE APX 0.4371 02352354 JAMP-ROPINIROLE JPC 0.4371 02353067 ROPINIROLE SAN 0.4371 02232568 REQUIP GSK 1.2489

* 5MG TABLET02314088 RAN-ROPINIROLE RAN $ 1.2034 02316870 CO ROPINIROLE COB 1.2034 02326639 PMS-ROPINIROLE PMS 1.2034 02337800 APO-ROPINIROLE APX 1.2034 02352362 JAMP-ROPINIROLE JPC 1.2034 02353075 ROPINIROLE SAN 1.2034 02232569 REQUIP GSK 3.4384

SELEGILINE HCL SEE APPENDIX A FOR EDS CRITERIA* 5MG TABLET

02068087 NOVO-SELEGILINE (EDS) NOP $ 0.7030 02230641 APO-SELEGILINE (EDS) APX 0.7030 02230717 NU-SELEGILINE (EDS) NXP 0.7030 02231036 MYLAN-SELEGILINE (EDS) MYL 0.7030

62nd Edition 140 July 1, 2012

Page 163: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

DIAGNOSTIC AGENTS36:00

Page 164: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

36:00 DIAGNOSTIC AGENTS

36:04.00 ADRENAL INSUFFICIENCY

COSYNTROPIN ZINC HYDROXIDE SEE SECTION 68:28.00 (PITUITARY AGENTS)

36:26.00 DIABETES MELLITUS

NOTE: THE IDENTIFICATION NUMBERS LISTED IN THIS SECTIONHAVE BEEN GENERATED BY THE PRESCRIPTION DRUG PLAN FORBILLING PURPOSES ONLY.

BLOOD GLUCOSE TEST STRIP STRIP

00950957 TRUETRACK SMART SYSTEM NDI $ 0.4180 97799532 TRUETEST NDI 0.5400 97799478 BIONIME RIGHTEST GS100 BNM 0.5730 00950956 ITEST ACM 0.6500 00950432 ACCUTREND ROC 0.6888 97799583 NOVAMAX NBC 0.6990 97799582 ON-CALL PLUS MGM 0.7000 97799564 EZ HEALTH ORACLE THI 0.7290 00950907 FREESTYLE ABC 0.7400 97799597 FREESTYLE LITE ABC 0.7400 97799465 BGSTAR AVT 0.7830 00950893 ONE TOUCH ULTRA LSN 0.7950 00950894 PRECISION XTRA ABC 0.7950 97799476 ONETOUCH VERIO LSN 0.7950 00950960 BREEZE 2 BAY 0.8112 00950900 ACCU-CHEK COMPACT ROC 0.8160 00950926 ACCU-CHEK ADVANTAGE ROC 0.8160 00950949 ACCU-CHEK AVIVA ROC 0.8160 97799497 ACCU-CHEK MOBILE ROC 0.8160 00950924 CONTOUR BAY 0.8162

HYDROXYBUTYRATE DEHYDROGENASE BLOOD KETONE TEST STRIP

00951161 NOVA MAX PLUS NBC $ 1.4990 00950896 PRECISION XTRA KETONE ABC 1.5060

62nd Edition 142 July 1, 2012

Page 165: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

36:00 DIAGNOSTIC AGENTS

36:88.00 URINE CONTENTS

NOTE: THE IDENTIFICATION NUMBERS LISTED IN THIS SECTIONHAVE BEEN GENERATED BY THE PRESCRIPTION DRUG PLAN FORBILLING PURPOSES ONLY.

CUPRIC SO4 REAGENT TABLET

00035122 CLINITEST BAY $ 0.0966

GLUCOSE OXIDASE/PEROXIDASE REAGENT STICK

00035130 DIASTIX BAY $ 0.1094

GLUCOSE OXIDASE/PEROXIDASE/SODIUMNITROFERRICYANIDE/GLYCINE REAGENT STICK

00950238 CHEMSTRIP UG 5000K ROC $ 0.1306

GLUCOSE OXIDASE/PEROXIDASE/SODIUMNITROPRUSSIDE REAGENT STICK

00035149 KETO DIASTIX BAY $ 0.1311

SODIUM NITROPRUSSIDE REAGENT STICK

00035092 KETOSTIX BAY $ 0.1218

62nd Edition 143 July 1, 2012

Page 166: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...
Page 167: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

ELECTROLYTIC, CALORIC AND WATER BALANCE

40:00

Page 168: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

40:00 ELECTROLYTIC, CALORIC AND WATER BALANCE

40:12.00 REPLACEMENT AGENTS

POTASSIUM CHLORIDE 8MMOL LONG ACTING CAPSULE

02042304 MICRO-K EXTENCAPS PAL $ 0.0930 600MG LONG ACTING TABLET

80013005 JAMP K-8 JPC $ 0.0450 00602884 APO-K APX 0.0749 80008214 ODAN K-8 ODN 0.0899 00074225 SLOW-K NVR 0.1475

1500MG LONG ACTING TABLET80004415 ODAN K-20 ODN $ 0.1995 80013007 JAMP K-20 JPC 0.1995 00713376 K-DUR SCH 0.2095

* 1.33MMOL/ML ORAL SOLUTION02238604 PMS-POTASSIUM CHLORIDE PMS $ 0.0146 01918303 K-10 GSK 0.0157

40:18.00 ION REMOVING AGENTS

CALCIUM ACETATE SEE APPENDIX A FOR EDS CRITERIA 667MG TABLET

02229437 PHOSLO (EDS) FMC $ 0.4500

CALCIUM POLYSTYRENE SULFONATE POWDER

02017741 RESONIUM CALCIUM AVT $ 0.3545

SODIUM POLYSTYRENE SULFONATE 250MG/ML ORAL SUSPENSION

00769541 PMS-SOD POLYSTYRENE SULF PMS $ 0.1504 * POWDER

00755338 PMS-SOD POLYSTYRENE SULF PMS $ 0.1696 02026961 KAYEXALATE AVT 0.1835

250MG/ML RETENTION ENEMA00769533 PMS-SOD POLY SULF (120ML) PMS $ 17.6800

40:28.00 DIURETICS

ACETAZOLAMIDE SEE SECTION 52:10.00 (CARBONIC ANHYDRASE INHIBITORS)

BUMETANIDE SEE APPENDIX A FOR EDS CRITERIA 1MG TABLET

00728284 BURINEX (EDS) LEO $ 0.7237 5MG TABLET

00728276 BURINEX (EDS) LEO $ 2.7624

62nd Edition 146 July 1, 2012

Page 169: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

40:00 ELECTROLYTIC, CALORIC AND WATER BALANCE40:28.00 DIURETICS

CHLORTHALIDONE 50MG TABLET

00360279 CHLORTHALIDONE AAP $ 0.1242

ETHACRYNIC ACID SEE APPENDIX A FOR EDS CRITERIA 25MG TABLET

02258528 EDECRIN (EDS) VAL $ 0.8250

FUROSEMIDE* 20MG TABLET

00337730 NOVO-SEMIDE NOP $ 0.0373 00396788 APO-FUROSEMIDE APX 0.0373 02239224 NU-FUROSEMIDE NXP 0.0373 02247493 PMS-FUROSEMIDE PMS 0.0373 02248124 DOM-FUROSEMIDE DOM 0.0373 02351420 FUROSEMIDE SAN 0.0373 02364573 AVA-FUROSEMIDE AVA 0.0373 02224690 LASIX AVT 0.0874

* 40MG TABLET00337749 NOVO-SEMIDE NOP $ 0.0558 00362166 APO-FUROSEMIDE APX 0.0558 02239225 NU-FUROSEMIDE NXP 0.0558 02247494 PMS-FUROSEMIDE PMS 0.0558 02248125 DOM-FUROSEMIDE DOM 0.0558 02351439 FUROSEMIDE SAN 0.0558 02364581 AVA-FUROSEMIDE AVA 0.0558

10MG/ML ORAL SOLUTION02224720 LASIX AVT $ 0.2756

HYDROCHLOROTHIAZIDE* 12.5 TABLET

02274086 PMS-HYDROCHLOROTHIAZIDE PMS $ 0.0322 02282879 DOM-HYDROCHLOROTHIAZIDE DOM 0.0322 02327856 APO-HYDRO APX 0.0322

* 25MG TABLET00021474 TEVA-HYDROCHLOROTHIAZIDE NOP $ 0.0256 00326844 APO-HYDRO APX 0.0256 02247386 PMS-HYDROCHLOROTHIAZIDE PMS 0.0256 02248134 DOM-HYDROCHLOROTHIAZIDE DOM 0.0256 02250659 NU-HYDRO NXP 0.0256 02360594 HYDROCHLOROTHIAZIDE SAN 0.0256

* 50MG TABLET00021482 NOVO-HYDRAZIDE NOP $ 0.0357 00312800 APO-HYDRO APX 0.0357 02247387 PMS-HYDROCHLOROTHIAZIDE PMS 0.0357 02248135 DOM-HYDROCHLOROTHIAZIDE DOM 0.0357 02250667 NU-HYDRO NXP 0.0357 02360608 HYDROCHLOROTHIAZIDE SAN 0.0357

62nd Edition 147 July 1, 2012

Page 170: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

40:00 ELECTROLYTIC, CALORIC AND WATER BALANCE

40:28.00 DIURETICS

INDAPAMIDE HEMIHYDRATE* 1.25MG TABLET

02239619 PMS-INDAPAMIDE PMS $ 0.1043 02239913 DOM-INDAPAMIDE DOM 0.1043 02240067 MYLAN-INDAPAMIDE MYL 0.1043 02245246 APO-INDAPAMIDE APX 0.1043 02373904 JAMP-INDAPAMIDE JPC 0.1043 02179709 LOZIDE SEV 0.2980

* 2.5MG TABLET02153483 MYLAN-INDAPAMIDE MYL $ 0.1706 02223597 NU-INDAPAMIDE NXP 0.1706 02223678 APO-INDAPAMIDE APX 0.1706 02231184 NOVO-INDAPAMIDE NOP 0.1706 02239620 PMS-INDAPAMIDE PMS 0.1706 02239917 DOM-INDAPAMIDE DOM 0.1706 02373912 JAMP-INDAPAMIDE JPC 0.1706 00564966 LOZIDE SEV 0.4874

METOLAZONE 2.5MG TABLET

00888400 ZAROXOLYN AVT $ 0.1937

40:28.10 POTASSIUM SPARING DIURETICS

AMILORIDE HCL 5MG TABLET

02249510 MIDAMOR AAP $ 0.2717

SPIRONOLACTONE* 25MG TABLET

00613215 NOVO-SPIROTON NOP $ 0.1057 00028606 ALDACTONE PFI 0.1307

* 100MG TABLET00613223 NOVO-SPIROTON NOP $ 0.2461 00285455 ALDACTONE PFI 0.3081

40:40.00 URICOSURIC DRUGS

PROBENECID 500MG TABLET

00294926 BENURYL VAE $ 0.1884

SULFINPYRAZONE 200MG TABLET

00441767 APO-SULFINPYRAZONE AAP $ 0.2997

62nd Edition 148 July 1, 2012

Page 171: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

ANTITUSSIVES, EXPECTORANTS AND MUCOLYTIC AGENTS

48:00

Page 172: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

48:00 ANTITUSSIVES, EXPECTORANTS AND MUCOLYTIC AGENTS

48:24.00 MUCOLYTIC AGENTS

ACETYLCYSTEINE* 20% SOLUTION (30ML)

02243098 ACETYLCYSTEINE SOLUTION SDZ $ 17.5500 02091526 MUCOMYST WEL 17.6500 02300435 ACETYLCYSTEINE INJECTION ALV 19.5100

DORNASE ALFA SEE APPENDIX A FOR EDS CRITERIA 1MG/ML INHALATION SOLUTION (2.5ML)

02046733 PULMOZYME (EDS) HLR $ 37.6887

62nd Edition 150 July 1, 2012

Page 173: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

EYE, EAR, NOSE AND THROAT PREPARATIONS

52:00

Page 174: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

52:00 EYE, EAR, NOSE AND THROAT PREPARATIONS

52:04.04 ANTI-INFECTIVES (ANTIBIOTICS)

FUSIDIC ACID SEE APPENDIX A FOR EDS CRITERIA 1% OPHTHALMIC DROPS (PRESERVATIVE FREE)

02243861 FUCITHALMIC (EDS) LEO $ 0.8584 1% OPHTHALMIC DROPS (G)

02243862 FUCITHALMIC (EDS) LEO $ 1.8460

GENTAMICIN SO4 GENTAMICIN SO4 5MG/ML IS EQUIVALENT TO 3MG/ML GENTAMICIN BASE.

* 5MG/ML OPHTHALMIC SOLUTION00512192 GARAMYCIN SCH $ 0.4060 02229440 SANDOZ GENTAMICIN SDZ 0.4060

* 5MG/ML OTIC SOLUTION02229441 SANDOZ GENTAMICIN SDZ $ 1.0320 00512184 GARAMYCIN SCH 1.1058

5MG/G OPHTHALMIC OINTMENT (3.5G)02230888 SANDOZ GENTAMICIN SDZ $ 5.2500

POLYMYXIN B SO4/NEOMYCIN SO4/GRAMICIDIN 10,000U/2.5MG/0.025MG PER ML EYE/EAR SOLUTION

00807435 OPTIMYXIN PLUS SDZ $ 0.7250

POLYMYXIN B SO4/TRIMETHOPRIM SO4* 10,000U/1MG PER ML OPHTHALMIC SOLUTION

02240363 PMS-POLYTRIMETHOPRIM PMS $ 2.3187 02011956 POLYTRIM ALL 3.0430

TOBRAMYCIN SEE APPENDIX A FOR EDS CRITERIA

* 0.3% OPHTHALMIC SOLUTION02239577 PMS-TOBRAMYCIN (EDS) PMS $ 0.5831 02241755 SANDOZ TOBRAMYCIN (EDS) SDZ 0.5831 00513962 TOBREX (EDS) ALC 1.7440

0.3% OPHTHALMIC OINTMENT (3.5G)00614254 TOBREX (EDS) ALC $ 8.6500

52:04.06 ANTI-INFECTIVES (ANTIVIRALS)

TRIFLURIDINE* 1% OPHTHALMIC SOLUTION (7.5ML)

00687456 VIROPTIC THM $ 22.7900 02248529 SANDOZ TRIFLURIDINE SDZ 22.7900

52:04.08 ANTI-INFECTIVES (SULFONAMIDES)

SULFACETAMIDE (SODIUM) 10% OPHTHALMIC SOLUTION

00028053 SODIUM SULAMYD SDZ $ 0.4933

62nd Edition 152 July 1, 2012

Page 175: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

52:00 EYE, EAR, NOSE AND THROAT PREPARATIONS

52:04.12 ANTI-INFECTIVES (MISCELLANEOUS)

ALUMINUM ACETATE/BENZETHONIUM CHLORIDE 0.5%/0.03% OTIC SOLUTION

00674222 BURO-SOL-OTIC GSK $ 0.2767

CIPROFLOXACIN SEE APPENDIX A FOR EDS CRITERIA

* 0.3% OPHTHALMIC SOLUTION02253933 PMS-CIPROFLOXACIN (EDS) PMS $ 0.7620 01945270 CILOXAN (EDS) ALC 2.0300

0.3% OPHTHALMIC OINTMENT (3.5G)02200864 CILOXAN (EDS) ALC $ 10.1500

MOXIFLOXACIN HCL SEE APPENDIX A FOR EDS CRITERIA 0.5% OPHTHALMIC SOLUTION

02252260 VIGAMOX (EDS) ALC $ 4.2400

OFLOXACIN SEE APPENDIX A FOR EDS CRITERIA

* 0.3% OPHTHALMIC SOLUTION02248398 APO-OFLOXACIN (EDS) APX $ 0.8561 02252570 PMS-OFLOXACIN (EDS) PMS 0.8561 02143291 OCUFLOX (EDS) ALL 2.4460

52:08.00 ANTI-INFLAMMATORY AGENTS

BECLOMETHASONE DIPROPIONATE* 50UG/DOSE AQUEOUS NASAL SPRAY (PACKAGE)

02172712 MYLAN-BECLOMETHASONE AQ MYL $ 12.2600 02238577 NU-BECLOMETHASONE NXP 12.2600 02238796 APO-BECLOMETHASONE APX 12.2600

BUDESONIDE* 64UG/DOSE NASAL SPRAY (PACKAGE)

02241003 MYLAN-BUDESONIDE AQ MYL $ 10.1200 02231923 RHINOCORT AQUA AST 10.7200

100UG/DOSE NASAL SPRAY (PACKAGE)02230648 MYLAN-BUDESONIDE AQ MYL $ 15.8100

100UG POWDER FOR INHALATION (PACKAGE)02035324 RHINOCORT TURBUHALER AST $ 23.8400

CICLESONIDE 50MCG/DOSE METERED DOSE NASAL SPRAY

02303671 OMNARIS NYC $ 25.2300

62nd Edition 153 July 1, 2012

Page 176: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

52:00 EYE, EAR, NOSE AND THROAT PREPARATIONS52:08.00 ANTI-INFLAMMATORY AGENTS

DEXAMETHASONE 0.1% OPHTHALMIC SUSPENSION

00042560 MAXIDEX ALC $ 1.6120 0.1% OPHTHALMIC/OTIC SOLUTION

00739839 SANDOZ DEXAMETHASONE SDZ $ 1.4060 0.1% OPHTHALMIC OINTMENT (3.5G)

00042579 MAXIDEX ALC $ 8.7400

FLUNISOLIDE 0.025% NASAL SOLUTION (PACKAGE)

02239288 APO-FLUNISOLIDE APX $ 14.8500

FLUOROMETHOLONE* 0.1% OPHTHALMIC SUSPENSION

02238568 PMS-FLUOROMETHOLONE PMS $ 1.7880 00247855 FML ALL 3.0580

FLUOROMETHOLONE ACETATE 0.1% OPHTHALMIC SUSPENSION

00756784 FLAREX ALC $ 1.8200

FLUTICASONE PROPIONATE* 50UG/DOSE AQUEOUS NASAL SPRAY (PACKAGE)

02294745 APO-FLUTICASONE APX $ 21.9700 02296071 RATIO-FLUTICASONE RPH 21.9700 02213672 FLONASE GSK 30.6100

KETOROLAC TROMETHAMINE SEE APPENDIX A FOR EDS CRITERIA

* 0.5% OPHTHALMIC SOLUTION02245821 APO-KETOROLAC (EDS) APX $ 1.6000 02247461 RATIO-KETOROLAC (EDS) RPH 1.6000 01968300 ACULAR (EDS) ALL 3.3600

MOMETASONE FUROATE MONOHYDRATE 0.05% AQUEOUS NASAL SPRAY

02238465 NASONEX SCH $ 28.9100

PREDNISOLONE ACETATE* 0.12% OPHTHALMIC SUSPENSION

01916181 SANDOZ PREDNISOLONE SDZ $ 1.3450 00299405 PRED MILD ALL 1.7960

* 1.0% OPHTHALMIC SUSPENSION00700401 RATIO-PREDNISOLONE RPH $ 1.9400 01916203 SANDOZ PREDNISOLONE SDZ 1.9400 02023768 DIOPRED SDZ 1.9400 00301175 PRED FORTE ALL 5.2880

TRIAMCINOLONE ACETONIDE AQUEOUS NASAL SPRAY (PACKAGE)

02213834 NASACORT AQ AVT $ 24.0000

62nd Edition 154 July 1, 2012

Page 177: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

52:00 EYE, EAR, NOSE AND THROAT PREPARATIONS

52:08.00 COMBINATION ANTI-INFECTIVE/ ANTI-INFLAMMATORY AGENTS

CIPROFLOXACIN HCL/DEXAMETHASONE SEE APPENDIX A FOR EDS CRITERIA 0.3%/0.1% OTIC SUSPENSION

02252716 CIPRODEX (EDS) ALC $ 3.8072

FRAMYCETIN SO4/GRAMICIDIN/DEXAMETHASONE BASE* 5MG/50UG/0.5MG PER ML EYE/EAR SOLUTION

02247920 SANDOZ OPTICORT SDZ $ 0.9800 02224623 SOFRACORT AVT 1.8663

GENTAMICIN SO4/BETAMETHASONE SODIUM PHOSPHATE* 0.3%/0.1% OTIC/OPHTHALMIC SOLUTION

02244999 SANDOZ PENTASONE SDZ $ 1.1960 00682217 GARASONE SCH 1.3729

IODOCHLORHYDROXYQUIN/FLUMETHASONE PIVALATE 1%/0.02% OTIC SOLUTION

00074454 LOCACORTEN-VIOFORM PAL $ 1.4791

POLYMYXIN B SO4/BACITRACIN (ZINC)/NEOMYCIN SO4/HYDROCORTISONE 10000U/400U/5MG/10MG PER G OPHTHALMIC OINTMENT (3.5G)

02242485 SANDOZ CORTIMYXIN SDZ $ 12.6500

POLYMYXIN B SO4/NEOMYCIN SO4/DEXAMETHASONE 6,000U/5MG/1MG PER ML OPHTHALMIC SOLUTION

00042676 MAXITROL ALC $ 1.9920 6,000U/5MG/1MG PER G OPHTHALMIC OINTMENT (3.5G)

00358177 MAXITROL ALC $ 9.7200

POLYMYXIN B SO4/NEOMYCIN SO4/HYDROCORTISONE* 10,000U/5MG/10MG PER ML OTIC SOLUTION

02230386 SANDOZ CORTIMYXIN SDZ $ 1.1400 01912828 CORTISPORIN GSK 1.3080

SULFACETAMIDE SODIUM/PREDNISOLONE ACETATE 100MG/2MG PER G OPHTHALMIC OINTMENT (3.5G)

00307246 BLEPHAMIDE S.O.P. ALL $ 11.9200

TOBRAMYCIN/DEXAMETHASONE SEE APPENDIX A FOR EDS CRITERIA 0.3%/0.1% OPHTHALMIC SUSPENSION

00778907 TOBRADEX (EDS) ALC $ 2.0400 0.3%/0.1% OPHTHALMIC OINTMENT (3.5G)

00778915 TOBRADEX (EDS) ALC $ 10.5200

62nd Edition 155 July 1, 2012

Page 178: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

52:00 EYE, EAR, NOSE AND THROAT PREPARATIONS

52:10.00 CARBONIC ANHYDRASE INHIBITORS

ACETAZOLAMIDE 250MG TABLET

00545015 ACETAZOLAMIDE AAP $ 0.1237

BRINZOLAMIDE 1% OPHTHALMIC SUSPENSION

02238873 AZOPT ALC $ 3.2840

DORZOLAMIDE HCL* 2% OPHTHALMIC SOLUTION

02316307 SANDOZ DORZOLAMIDE SDZ $ 1.3125 02216205 TRUSOPT MRK 3.8580

METHAZOLAMIDE 50MG TABLET

02245882 METHAZOLAMIDE AAP $ 0.4817

52:20.00 MIOTICS

CARBACHOL 1.5% OPHTHALMIC SOLUTION

00000655 ISOPTO CARBACHOL ALC $ 0.7047 3% OPHTHALMIC SOLUTION

00000663 ISOPTO CARBACHOL ALC $ 0.8480

PILOCARPINE HCL 1% OPHTHALMIC SOLUTION

00000841 ISOPTO CARPINE ALC $ 0.2140 2% OPHTHALMIC SOLUTION

00000868 ISOPTO CARPINE ALC $ 0.2467 4% OPHTHALMIC SOLUTION

00000884 ISOPTO CARPINE ALC $ 0.2794 4% OPHTHALMIC GEL (5G)

00575240 PILOPINE-HS ALC $ 13.0700

52:24.00 MYDRIATICS

ATROPINE SO4 1% OPHTHALMIC SOLUTION

00035017 ISOPTO ATROPINE ALC $ 0.6285

HOMATROPINE HYDROBROMIDE 2% OPHTHALMIC SOLUTION

00000779 ISOPTO HOMATROPINE ALC $ 0.6387 5% OPHTHALMIC SOLUTION

00000787 ISOPTO HOMATROPINE ALC $ 0.7607

62nd Edition 156 July 1, 2012

Page 179: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

52:00 EYE, EAR, NOSE AND THROAT PREPARATIONS

52:36.00 MISCELLANEOUS E.E.N.T. DRUGS

APRACLONIDINE HCL 0.5% OPHTHALMIC SOLUTION (5ML)

02076306 IOPIDINE ALC $ 22.2600 1% OPHTHALMIC SOLUTION (1 TREATMENT)

00888354 IOPIDINE ALC $ 10.9800

BETAXOLOL HCL 0.25% OPHTHALMIC SUSPENSION

01908448 BETOPTIC S ALC $ 2.3000

BIMATOPROST 0.01% OPHTHALMIC SOLUTION (ML)

02324997 LUMIGAN RC ALL $ 10.8200

BRIMONIDINE TARTRATE* 0.15% OPHTHALMIC SOLUTION

02301334 APO-BRIMONIDINE P APX $ 1.7330 02248151 ALPHAGAN P ALL 2.3100

* 0.2% OPHTHALMIC SOLUTION02243026 RATIO-BRIMONIDINE RPH $ 1.1550 02246284 PMS-BRIMONIDINE PMS 1.1550 02260077 APO-BRIMONIDINE APX 1.1550 02305429 SANDOZ BRIMONIDINE SDZ 1.1550 02236876 ALPHAGAN ALL 3.3000

BRIMONIDINE TARTRATE/TIMOLOL MALEATE 0.2%/0.5% OPHTHALMIC SOLUTION

02248347 COMBIGAN ALL $ 4.0120

BRINZOLAMIDE/TIMOLOL MALEATE 1%/0.5% OPHTHALMIC SUSPENSION

02331624 AZARGA ALC $ 4.2840

DICLOFENAC SODIUM SEE APPENDIX A FOR EDS CRITERIA 0.1% OPHTHALMIC SOLUTION (ML)

01940414 VOLTAREN OPHTHA (EDS) ALC $ 3.0300

DORZOLAMIDE HCL/TIMOLOL MALEATE* 2%/0.5% OPHTHALMIC SOLUTION (ML)

02320525 TEVA-DORZOTIMOL TEV $ 1.9887 02344351 SANDOZ DORZOLAMIDE-TIMOLO SDZ 1.9887 02240113 COSOPT MRK 5.8450

2%/0.5% OPHTHALMIC SOLUTION PF (PKG)02258692 COSOPT-PRESERVATIVE FREE MRK $ 28.4100

62nd Edition 157 July 1, 2012

Page 180: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

52:00 EYE, EAR, NOSE AND THROAT PREPARATIONS

52:36.00 MISCELLANEOUS E.E.N.T. DRUGS

GATIFLOXACIN SEE APPENDIX A FOR EDS CRITERIA 0.3% OPHTHALMIC SOLUTION

02257270 ZYMAR (EDS) ALL $ 2.5200

IPRATROPIUM BROMIDE* 21UG/DOSE NASAL SPRAY (PACKAGE)

02239627 PMS-IPRATROPIUM PMS $ 17.5400 02163705 ATROVENT NASAL SPRAY BOE 29.7900

LATANOPROST* 50UG/ML OPHTHALMIC SOLUTION (2.5ML)

02254786 CO LATANOPROST COB $ 9.4640 02296527 APO-LATANOPROST APX 9.4640 02367335 SANDOZ LATANOPROST SDZ 9.4640 02373041 GD-LATANOPROST GDI 9.4640 02231493 XALATAN PFI 27.5300

LATANOPROST/TIMOLOL MALEATE 50UG/5MG PER ML OPHTHALMIC SOLUTION (2.5ML)

02246619 XALACOM PFI $ 31.1500

LEVOBUNOLOL HCL 0.25% OPHTHALMIC SOLUTION

02031159 RATIO-LEVOBUNOLOL RPH $ 0.9330 * 0.5% OPHTHALMIC SOLUTION

02031167 RATIO-LEVOBUNOLOL RPH $ 1.1515 02237991 PMS-LEVOBUNOLOL PMS 1.1515 02241716 SANDOZ LEVOBUNOLOL SDZ 1.1515 00637661 BETAGAN ALL 3.2900

LODOXAMIDE TROMETHAMINE 0.1% OPHTHALMIC SOLUTION

00893560 ALOMIDE ALC $ 1.0730

SODIUM CROMOGLYCATE 2% NASAL METERED DOSE MIST (PACKAGE)

01950541 RHINARIS-CS PMS $ 13.7600

62nd Edition 158 July 1, 2012

Page 181: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

52:00 EYE, EAR, NOSE AND THROAT PREPARATIONS

52:36.00 MISCELLANEOUS E.E.N.T. DRUGS

TIMOLOL MALEATE* 0.25% OPHTHALMIC SOLUTION

00755826 APO-TIMOP APX $ 0.9678 02083353 PMS-TIMOLOL PMS 0.9678 02166712 SANDOZ TIMOLOL SDZ 0.9678

* 0.5% OPHTHALMIC SOLUTION00755834 APO-TIMOP APX $ 1.2145 02083345 PMS-TIMOLOL PMS 1.2145 02166720 SANDOZ TIMOLOL SDZ 1.2145 00451207 TIMOPTIC MRK 3.8260

* 0.25% OPHTHALMIC GEL FORMING SOLUTION02242275 TIMOLOL MALEATE-EX ALC $ 2.2820 02171880 TIMOPTIC-XE MRK 4.0840

* 0.5% OPHTHALMIC GEL FORMING SOLUTION02242276 TIMOLOL MALEATE-EX ALC $ 2.1520 02290812 APO-TIMOP GEL APX 2.1520 02171899 TIMOPTIC-XE MRK 4.8860

TRAVOPROST 0.004% OPHTHALMIC SOLUTION

02318008 TRAVATAN Z ALC $ 55.4000

TRAVOPROST/TIMOLOL MALEATE 0.004%/0.5% OPHTHALMIC SOLUTION

02278251 DUOTRAV ALC $ 31.2100

62nd Edition 159 July 1, 2012

Page 182: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...
Page 183: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

GASTROINTESTINAL DRUGS56:00

Page 184: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

56:00 GASTROINTESTINAL DRUGS

56:08.00 ANTIDIARRHEA AGENTS

DIPHENOXYLATE HCL 2.5MG TABLET

00036323 LOMOTIL PFI $ 0.4450

LOPERAMIDE HCL* 2MG CAPLET

02132591 NOVO-LOPERAMIDE NOP $ 0.2225 02212005 APO-LOPERAMIDE APX 0.2225 02228351 PMS-LOPERAMIDE PMS 0.2225 02239535 DOM-LOPERAMIDE DOM 0.2225 02257564 SANDOZ LOPERAMIDE SDZ 0.2225 02183862 IMODIUM MCL 0.7734

0.2MG/ML ORAL SOLUTION02016095 PMS-LOPERAMIDE HCL PMS $ 0.0988

56:12.00 CATHARTICS AND LAXATIVES

LACTULOSE SEE APPENDIX A FOR EDS CRITERIA

* 667MG/ML SOLUTION00703486 PMS-LACTULOSE (EDS) PMS $ 0.0145 00854409 RATIO-LACTULOSE (EDS) RPH 0.0145 02242814 APO-LACTULOSE (EDS) APX 0.0145 02247383 EURO-LAC (EDS) EUR 0.0145 02295881 JAMP-LACTULOSE (EDS) JPC 0.0145 02331551 TEVA-LACTULOSE (EDS) TEV 0.0145

56:14.00 CHOLELITHOLYTIC AGENTS

URSODIOL SEE APPENDIX A FOR EDS CRITERIA

* 250MG TABLET02273497 PMS-URSODIOL C (EDS) PMS $ 0.9119 02238984 URSO (EDS) AXC 1.3701

* 500MG TABLET02273500 PMS-URSODIOL C (EDS) PMS $ 1.7298 02245894 URSO DS (EDS) AXC 2.5988

62nd Edition 162 July 1, 2012

Page 185: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

56:00 GASTROINTESTINAL DRUGS

56:16.00 DIGESTANTS

PANCRELIPASE (LIPASE/AMYLASE/PROTEASE) 4000U/12000U/12000U CAPSULE CONTAINING ENTERIC COATED PARTICLES

00789445 PANCREASE MT 4 JAN $ 0.4936 4500U/20000U/25000U CAPSULE CONTAINING ENTERIC COATED PARTICLES

02203324 ULTRASE MS4 AXC $ 0.2266 5000U/16600U/18750U CAPSULE CONTAINING ENTERIC COATED PARTICLES

02239007 CREON 5 SLV $ 0.1703 6000U/30000U/19000U CAPSULE CONTAINING ENTERIC COATED PARTICLES

80025653 CREON 6 ABB $ 0.1703 8000U/30000U/30000U CAPSULE

00263818 COTAZYM SCH $ 0.1866 8000U/30000U/30000U CAPSULE CONTAINING ENTERIC COATED PARTICLES

00502790 COTAZYM ECS 8 SCH $ 0.3368 10000U/30000U/30000U CAPSULE CONTAINING ENTERIC COATED PARTICLES

00789437 PANCREASE MT 10 JAN $ 1.2337 10000U/33200U/37500U CAPSULE CONTAINING ENTERIC COATED PARTICLES

02200104 CREON 10 SLV $ 0.2723 12000U/39000U/39000U CAPSULE CONTAINING ENTERIC COATED PARTICLES

02045834 ULTRASE MT12 AXC $ 0.4432 16000U/48000U/48000U CAPSULE CONTAINING ENTERIC COATED PARTICLES

00789429 PANCREASE MT 16 JAN $ 1.9738 20000U/55000U/55000U CAPSULE CONTAINING ENTERIC COATED PARTICLES

00821373 COTAZYM ECS 20 SCH $ 0.8830 20000U/65000U/65000U CAPSULE CONTAINING ENTERIC COATED PARTICLES

02045869 ULTRASE MT20 AXC $ 0.7679 25000U/74000U/62500U CAPSULE CONTAINING ENTERIC COATED PARTICLES

01985205 CREON 25 SLV $ 0.8507 8000U/30000U/30000U TABLET

02230019 VIOKASE AXC $ 0.2314 16000U/60000U/60000U TABLET

02241933 VIOKASE AXC $ 0.3551

62nd Edition 163 July 1, 2012

Page 186: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

56:00 GASTROINTESTINAL DRUGS

56:22.00 ANTI-EMETICS

DIMENHYDRINATE* 50MG TABLET

00363766 APO-DIMENHYDRINATE APX $ 0.0226 00013803 GRAVOL CDC 0.1283

3MG/ML ORAL LIQUID00230197 GRAVOL CDC $ 0.0708

* 50MG/ML INJECTION SOLUTION (5ML)00392537 DIMENHYDRINATE IM SDZ $ 4.3000 00013579 GRAVOL CDC 5.7550 02300648 DIMENHYDRINATE INJ ALV 12.2120

100MG SUPPOSITORY00013609 GRAVOL CDC $ 0.5380

DOXYLAMINE SUCCINATE/PYRIDOXINE HCL 10MG/10MG DELAYED RELEASE TABLET

00609129 DICLECTIN DUI $ 1.2471

MECLIZINE HCL 25MG TABLET

00220442 BONAMINE MCL $ 0.4400

NABILONE SEE APPENDIX A FOR EDS CRITERIA

* 0.5MG CAPSULE02358085 RAN-NABILONE (EDS) RAN $ 1.0860 02380900 PMS-NABILONE (EDS) PMS 1.0860 02384884 TEVA-NABILONE (EDS) TEV 1.0860 02256193 CESAMET (EDS) VAE 3.1026

* 1MG CAPSULE02358093 RAN-NABILONE (EDS) RAN $ 2.1718 02380919 PMS-NABILONE (EDS) PMS 2.1718 02384892 TEVA-NABILONE (EDS) TEV 2.1718 00548375 CESAMET (EDS) VAE 6.2050

SCOPOLAMINE* 1.5MG TRANSDERMAL THERAPEUTIC SYSTEM

00550094 TRANSDERM-V PMS $ 3.9300 80024336 TRANSDERM-V NVR 3.9300

62nd Edition 164 July 1, 2012

Page 187: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

56:00 GASTROINTESTINAL DRUGS

56:40.00 MISCELLANEOUS GASTROINTESTINAL DRUGS

BUDESONIDE SEE APPENDIX A FOR EDS CRITERIA 3MG CONTROLLED ILEAL RELEASE CAPSULE

02229293 ENTOCORT (EDS) AST $ 1.6025

CIMETIDINE* 300MG TABLET

00487872 APO-CIMETIDINE APX $ 0.0860 00582417 NOVO-CIMETINE NOP 0.0860 00865818 NU-CIMET NXP 0.0860 02227444 MYLAN-CIMETIDINE MYL 0.0860

* 400MG TABLET00600059 APO-CIMETIDINE APX $ 0.1350 00603678 NOVO-CIMETINE NOP 0.1350 00865826 NU-CIMET NXP 0.1350 02227452 MYLAN-CIMETIDINE MYL 0.1350

* 600MG TABLET00600067 APO-CIMETIDINE APX $ 0.1702 00603686 NOVO-CIMETINE NOP 0.1702 00865834 NU-CIMET NXP 0.1702 02227460 MYLAN-CIMETIDINE MYL 0.1702

DOMPERIDONE MALEATE* 10MG TABLET

01912070 RATIO-DOMPERIDONE RPH $ 0.0831 02103613 APO-DOMPERIDONE APX 0.0831 02157195 TEVA-DOMPERIDONE NOP 0.0831 02231477 NU-DOMPERIDONE NXP 0.0831 02236466 PMS-DOMPERIDONE PMS 0.0831 02238315 DOM-DOMPERIDONE DOM 0.0831 02268078 RAN-DOMPERIDONE RAN 0.0831 02278669 MYLAN-DOMPERIDONE MYL 0.0831 02350440 DOMPERIDONE SAN 0.0831 02364271 AVA-DOMPERIDONE AVA 0.0831

ESOMEPRAZOLE MAGNESIUM TRIHYDRATE (MAC) SEE APPENDIX A FOR EDS CRITERIA SEE APPENDIX I FOR MAC POLICY 20MG DELAYED RELEASE TABLET

02244521 NEXIUM (EDS) AST $ 2.1780 40MG DELAYED RELEASE TABLET

02244522 NEXIUM (EDS) AST $ 2.1780

FAMOTIDINE* 20MG TABLET

01953842 APO-FAMOTIDINE APX $ 0.3721 02022133 NOVO-FAMOTIDINE NOP 0.3721 02024195 NU-FAMOTIDINE NXP 0.3721 02196018 MYLAN-FAMOTIDINE MYL 0.3721 02351102 FAMOTIDINE SAN 0.3721 00710121 PEPCID MRK 1.1318

62nd Edition 165 July 1, 2012

Page 188: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

56:00 GASTROINTESTINAL DRUGS

56:40.00 MISCELLANEOUS GASTROINTESTINAL DRUGS

* 40MG TABLET01953834 APO-FAMOTIDINE APX $ 0.6768 02022141 NOVO-FAMOTIDINE NOP 0.6768 02024209 NU-FAMOTIDINE NXP 0.6768 02196026 MYLAN-FAMOTIDINE MYL 0.6768 02351110 FAMOTIDINE SAN 0.6768 00710113 PEPCID MRK 2.0911

LANSOPRAZOLE (MAC) SEE APPENDIX A FOR EDS CRITERIA SEE APPENDIX I FOR MAC POLICY

* 15MG DELAYED RELEASE CAPSULE02280515 NOVO-LANSOPRAZOLE (EDS) NOP $ 0.7000 02293811 APO-LANSOPRAZOLE (EDS) APX 0.7000 02353830 MYLAN-LANSOPRAZOLE (EDS) MYL 0.7000 02357682 LANSOPRAZOLE (EDS) SAN 0.7000 02165503 PREVACID (EDS) ABB 2.0000

* 30MG DELAYED RELEASE CAPSULE02280523 NOVO-LANSOPRAZOLE (EDS) NOP $ 0.7000 02293838 APO-LANSOPRAZOLE (EDS) APX 0.7000 02353849 MYLAN-LANSOPRAZOLE (EDS) MYL 0.7000 02357690 LANSOPRAZOLE (EDS) SAN 0.7000 02165511 PREVACID (EDS) ABB 2.0000

15MG ORALLY DISINTEGRATING TABLET02249464 PREVACID FASTAB (EDS) ABB $ 2.0000

30MG ORALLY DISINTEGRATING TABLET02249472 PREVACID FASTAB (EDS) ABB $ 2.0000

LANSOPRAZOLE/CLARITHROMYCIN/AMOXICILLIN SEE APPENDIX A FOR EDS CRITERIA 30MG/500MG/500MG 7-DAY PACKAGE

02238525 HP-PAC (EDS) ABB $ 84.2700

METOCLOPRAMIDE HCL 5MG TABLET

02230431 PMS-METOCLOPRAMIDE PMS $ 0.0556 * 10MG TABLET

00842834 APO-METOCLOP APX $ 0.0583 02143283 NU-METOCLOPRAMIDE NXP 0.0583 02230432 PMS-METOCLOPRAMIDE PMS 0.0583

1MG/ML ORAL SOLUTION02230433 PMS-METOCLOPRAMIDE PMS $ 0.0448

MISOPROSTOL 100UG TABLET

02244022 APO-MISOPROSTOL AAP $ 0.2584 200UG TABLET

02244023 APO-MISOPROSTOL AAP $ 0.4303

62nd Edition 166 July 1, 2012

Page 189: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

56:00 GASTROINTESTINAL DRUGS

56:40.00 MISCELLANEOUS GASTROINTESTINAL DRUGS

NIZATIDINE* 150MG CAPSULE

02177714 PMS-NIZATIDINE PMS $ 0.2937 02185814 DOM-NIZATIDINE DOM 0.2937 02220156 APO-NIZATIDINE APX 0.2937 02240457 NOVO-NIZATIDINE NOP 0.2937 02247051 NU-NIZATIDINE NXP 0.2937 00778338 AXID MMT 0.9085

* 300MG CAPSULE02177722 PMS-NIZATIDINE PMS $ 0.5323 02220164 APO-NIZATIDINE APX 0.5323 02240458 NOVO-NIZATIDINE NOP 0.5323 02247052 NU-NIZATIDINE NXP 0.5323 00778346 AXID MMT 1.5206

OLSALAZINE SODIUM 250MG CAPSULE

02063808 DIPENTUM UCB $ 0.5289

OMEPRAZOLE (MAC) SEE APPENDIX A FOR EDS CRITERIA SEE APPENDIX I FOR MAC POLICY

* 10MG CAPSULE/TABLET02296438 SANDOZ OMEPRAZOLE (EDS) SDZ $ 0.8166 02329425 MYLAN-OMEPRAZOLE (EDS) MYL 0.8166 02230737 LOSEC (EDS) AST 1.8400

* 20MG CAPSULE/TABLET02245058 APO-OMEPRAZOLE (EDS) APX $ 0.7700 02260867 RATIO-OMEPRAZOLE (EDS) RPH 0.7700 02295415 NOVO-OMEPRAZOLE (EDS) NOP 0.7700 02296446 SANDOZ OMEPRAZOLE (EDS) SDZ 0.7700 02310260 PMS-OMEPRAZOLE DR (EDS) PMS 0.7700 02320851 PMS-OMEPRAZOLE DR (EDS) PMS 0.7700 02329433 MYLAN-OMEPRAZOLE (EDS) MYL 0.7700 02348691 OMEPRAZOLE (EDS) SAN 0.7700 02374870 RAN-OMEPRAZOLE (EDS) RAN 0.7700 00846503 LOSEC (CAP) (EDS) AST 1.1000 02190915 LOSEC (TAB) (EDS) AST 2.3140

PANTOPRAZOLE MAGNESIUM (MAC) SEE APPENDIX A FOR EDS CRITERIA SEE APPENDIX I FOR MAC POLICY 40MG ENTERIC COATED TABLET

02267233 TECTA (EDS) NYC $ 0.7500

62nd Edition 167 July 1, 2012

Page 190: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

56:00 GASTROINTESTINAL DRUGS

56:40.00 MISCELLANEOUS GASTROINTESTINAL DRUGS

PANTOPRAZOLE SODIUM (MAC) SEE APPENDIX A FOR EDS CRITERIA SEE APPENDIX I FOR MAC POLICY

* 20MG ENTERIC COATED TABLET02285479 NOVO-PANTOPRAZOLE (EDS) NOP $ 1.2750 02292912 APO-PANTOPRAZOLE (EDS) APX 1.2750 02301075 SANDOZ PANTOPRAZOLE (EDS) SDZ 1.2750 02305038 RAN-PANTOPRAZOLE (EDS) RAN 1.2750 02363410 AVA-PANTOPRAZOLE (EDS) AVA 1.2750

* 40MG ENTERIC COATED TABLET02285487 NOVO-PANTOPRAZOLE (EDS) NOP $ 0.7055 02292920 APO-PANTOPRAZOLE (EDS) APX 0.7055 02299585 MYLAN-PANTOPRAZOLE (EDS) MYL 0.7055 02300486 CO PANTOPRAZOLE (EDS) COB 0.7055 02301083 SANDOZ PANTOPRAZOLE (EDS) SDZ 0.7055 02305046 RAN-PANTOPRAZOLE (EDS) RAN 0.7055 02307871 PMS-PANTOPRAZOLE (EDS) PMS 0.7055 02363429 AVA-PANTOPRAZOLE (EDS) AVA 0.7055 02370808 PANTOPRAZOLE (EDS) SAN 0.7055 02229453 PANTOLOC (EDS) NYC 2.0803

RABEPRAZOLE SODIUM (MAC) SEE APPENDIX A FOR EDS CRITERIA SEE APPENDIX I FOR MAC POLICY

* 10MG ENTERIC COATED TABLET02296632 TEVA-RABEPRAZOLE EC (EDS) NOP $ 0.2275 02298074 RAN-RABEPRAZOLE (EDS) RAN 0.2275 02310805 PMS-RABEPRAZOLE EC (EDS) PMS 0.2275 02314177 SANDOZ RABEPRAZOLE (EDS) SDZ 0.2275 02345579 APO-RABEPRAZOLE (EDS) APX 0.2275 02356511 RABEPRAZOLE EC (EDS) SAN 0.2275 02243796 PARIET (EDS) JAN 0.6855

* 20MG ENTERIC COATED TABLET02296640 TEVA-RABEPRAZOLE EC (EDS) NOP $ 0.4550 02298082 RAN-RABEPRAZOLE (EDS) RAN 0.4550 02310813 PMS-RABEPRAZOLE EC (EDS) PMS 0.4550 02314185 SANDOZ RABEPRAZOLE (EDS) SDZ 0.4550 02345587 APO-RABEPRAZOLE (EDS) APX 0.4550 02356538 RABEPRAZOLE EC (EDS) SAN 0.4550 02243797 PARIET (EDS) JAN 1.3711

62nd Edition 168 July 1, 2012

Page 191: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

56:00 GASTROINTESTINAL DRUGS

56:40.00 MISCELLANEOUS GASTROINTESTINAL DRUGS

RANITIDINE* 150MG TABLET

00733059 APO-RANITIDINE APX $ 0.1800 00828564 NOVO-RANIDINE NOP 0.1800 00828823 RATIO-RANITIDINE RPH 0.1800 00865737 NU-RANIT NXP 0.1800 02207761 MYLAN-RANITIDINE MYL 0.1800 02242453 PMS-RANITIDINE PMS 0.1800 02243038 DOM-RANITIDINE DOM 0.1800 02243229 SANDOZ RANITIDINE SDZ 0.1800 02248570 CO RANITIDINE COB 0.1800 02336480 RAN-RANITIDINE RAN 0.1800 02353016 RANITIDINE SAN 0.1800 02367378 MYL-RANITIDINE MYL 0.1800 02212331 ZANTAC GSK 1.1675

* 300MG TABLET00733067 APO-RANITIDINE APX $ 0.3600 00828556 NOVO-RANIDINE NOP 0.3600 00865745 NU-RANIT NXP 0.3600 02207788 MYLAN-RANITIDINE MYL 0.3600 02242454 PMS-RANITIDINE PMS 0.3600 02243230 SANDOZ RANITIDINE SDZ 0.3600 02248571 CO RANITIDINE COB 0.3600 02336502 RAN-RANITIDINE RAN 0.3600 02353024 RANITIDINE SAN 0.3600 02367386 MYL-RANITIDINE MYL 0.3600 02212358 ZANTAC GSK 2.1977

* 15MG/ML ORAL SOLUTION02242940 NOVO-RANIDINE NOP $ 0.0932 02280833 APO-RANITIDINE APX 0.0932

SUCRALFATE* 1G TABLET

02045702 NOVO-SUCRALATE NOP $ 0.1832 02125250 APO-SUCRALFATE APX 0.1832 02134829 NU-SUCRALFATE NXP 0.1832 02100622 SULCRATE AXC 0.5710

200MG/ML ORAL SUSPENSION02103567 SULCRATE SUSPENSION PLUS AXC $ 0.1038

62nd Edition 169 July 1, 2012

Page 192: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

56:00 GASTROINTESTINAL DRUGS

56:40.00 MISCELLANEOUS GASTROINTESTINAL DRUGS

SULFASALAZINE (SALICYLAZOSULFAPYRIDINE)* 500MG TABLET

00598461 PMS-SULFASALAZINE PMS $ 0.2221 02064480 SALAZOPYRIN PFI 0.2557

* 500MG ENTERIC TABLET00598488 PMS-SULFASALAZINE PMS $ 0.3382 02064472 SALAZOPYRIN PFI 0.4027

5-AMINOSALICYLIC ACID (MESALAMINE) 400MG ENTERIC COATED TABLET

02171929 NOVO-5-ASA NOP $ 0.4039 01997580 ASACOL WCI 0.5440

500MG DELAYED RELEASE TABLET02099683 PENTASA FEI $ 0.5569

500MG ENTERIC COATED TABLET02112787 SALOFALK AXC $ 0.5376 01914030 MESASAL GSK 0.6274

800MG DELAYED RELEASE TABLET02267217 ASACOL 800 WCI $ 1.0410

1.2G DELAYED & EXTENDED RELEASE TABLET02297558 MEZAVANT SCI $ 1.5623

1.0G/100ML RETENTION ENEMA02153521 PENTASA FEI $ 3.7000

2.0G/60G RETENTION ENEMA02112795 SALOFALK RETENTION ENEMA AXC $ 3.8286

4.0G/60G RETENTION ENEMA02112809 SALOFALK RETENTION ENEMA AXC $ 6.5000

4.0G/100ML RETENTION ENEMA02153556 PENTASA FEI $ 4.4600

500MG SUPPOSITORY02112760 SALOFALK AXC $ 1.1880

1.0G SUPPOSITORY02153564 PENTASA FEI $ 1.6000 02242146 SALOFALK AXC 1.7454

62nd Edition 170 July 1, 2012

Page 193: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

GOLD COMPOUNDS60:00

Page 194: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

60:00 GOLD COMPOUNDS

60:00.00 GOLD COMPOUNDS

AURANOFIN 3MG CAPSULE

01916823 RIDAURA XED $ 6.0141

SODIUM AUROTHIOMALATE* 10MG/ML INJECTION SOLUTION (1ML)

02245456 SODIUM AUROTHIOMALATE SDZ $ 7.4000 01927620 MYOCHRYSINE AVT 11.9000

* 25MG/ML INJECTION SOLUTION (1ML)02245457 SODIUM AUROTHIOMALATE SDZ $ 9.0000 01927612 MYOCHRYSINE AVT 14.4600

* 50MG/ML INJECTION SOLUTION (1ML)02245458 SODIUM AUROTHIOMALATE SDZ $ 14.0000 01927604 MYOCHRYSINE AVT 22.4800

62nd Edition 172 July 1, 2012

Page 195: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

HEAVY METAL ANTAGONISTS64:00

Page 196: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

64:00 HEAVY METAL ANTAGONISTS

64:00.00 HEAVY METAL ANTAGONISTS

DEFERASIROX SEE APPENDIX A FOR EDS CRITERIA 125MG TABLET FOR SUSPENSION

02287420 EXJADE (EDS) NVR $ 10.1347 250MG TABLET FOR SUSPENSION

02287439 EXJADE (EDS) NVR $ 20.2697 500MG TABLET FOR SUSPENSION

02287447 EXJADE (EDS) NVR $ 40.5400

DEFEROXAMINE MESYLATE SEE APPENDIX A FOR EDS CRITERIA

* 500MG/VIAL POWDER FOR SOLUTION02241600 DESFERRIOXAMINE MES (EDS) HOS $ 7.0600 01981242 DESFERAL (EDS) NVR 13.9860

* 2G/VIAL POWDER FOR SOLUTION02247022 DESFERRIOXAMINE MES (EDS) HOS $ 28.3500 01981250 DESFERAL (EDS) NVR 56.1800

PENICILLAMINE 250MG CAPSULE

00016055 CUPRIMINE VAL $ 3.2965

62nd Edition 174 July 1, 2012

Page 197: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

HORMONES AND SYNTHETIC SUBSTITUTES

68:00

Page 198: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

68:00 HORMONES AND SYNTHETIC SUBSTITUTES68:04.00 ADRENAL CORTICOSTEROIDS

BECLOMETHASONE DIPROPIONATE 50UG/INHALATION AEROSOL (PACKAGE) (CFC-FREE)

02242029 QVAR MDC $ 30.0200 100UG/INHALATION AEROSOL (PACKAGE) (CFC-FREE)

02242030 QVAR MDC $ 59.8600

BETAMETHASONE ACETATE/BETAMETHASONE SODIUM PHOSPHATE* 3MG/3MG PER ML INJECTION SUSPENSION (1ML)

02237835 BETAJECT SDZ $ 9.5300 00028096 CELESTONE SOLUSPAN SCH 10.9950

BUDESONIDE 0.125MG/ML INHALATION SOLUTION (2ML)

02229099 PULMICORT NEBUAMP AST $ 0.4340 0.25MG/ML INHALATION SOLUTION (2ML)

01978918 PULMICORT NEBUAMP AST $ 0.8680 0.5MG/ML INHALATION SOLUTION (2ML)

01978926 PULMICORT NEBUAMP AST $ 1.7360 100UG POWDER FOR INHALATION (PACKAGE)

00852074 PULMICORT TURBUHALER AST $ 31.2700 200UG POWDER FOR INHALATION (PACKAGE)

00851752 PULMICORT TURBUHALER AST $ 63.8600 400UG POWDER FOR INHALATION (PACKAGE)

00851760 PULMICORT TURBUHALER AST $ 112.6500

CICLESONIDE 100UG METERED DOSE INHALER

02285606 ALVESCO NYC $ 44.5600 200UG METERED DOSE INHALER

02285614 ALVESCO NYC $ 73.6600

CORTISONE ACETATE 25MG TABLET

00280437 CORTISONE VAE $ 0.3118

62nd Edition 176 July 1, 2012

Page 199: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

68:00 HORMONES AND SYNTHETIC SUBSTITUTES

68:04.00 ADRENAL CORTICOSTEROIDS

DEXAMETHASONE* 0.5MG TABLET

01964976 PMS-DEXAMETHASONE PMS $ 0.1094 02240684 RATIO-DEXAMETHASONE RPH 0.1094 02261081 APO-DEXAMETHASONE APX 0.1094

0.75MG TABLET01964968 PMS-DEXAMETHASONE PMS $ 0.4635

2MG TABLET02279363 PMS-DEXAMETHASONE PMS $ 0.4389

* 4MG TABLET01964070 PMS-DEXAMETHASONE PMS $ 0.4264 02240687 RATIO-DEXAMETHASONE RPH 0.4264 02250055 APO-DEXAMETHASONE APX 0.4264 00489158 DEXASONE VAE 0.7679

DEXAMETHASONE PHOSPHATE* 4MG/ML INJECTION SOLUTION (5ML)

00664227 DEXAMETHASONE SOD PHO INJ SDZ $ 8.0300 01977547 DEXAMETHASONE SOD PHO INJ CYT 8.0300 02204266 DEXAMETHASONE OMEGA OMG 8.0300

FLUDROCORTISONE ACETATE 0.1MG TABLET

02086026 FLORINEF PAL $ 0.2468

FLUTICASONE PROPIONATE 50UG/INHALATION AEROSOL (PACKAGE)

02244291 FLOVENT HFA GSK $ 23.9300 125UG/INHALATION AEROSOL (PACKAGE)

02244292 FLOVENT HFA GSK $ 41.2800 250UG/INHALATION AEROSOL (PACKAGE)

02244293 FLOVENT HFA GSK $ 82.5400 50UG/DOSE POWDER FOR INHALATION (PACKAGE)

02237244 FLOVENT DISKUS GSK $ 15.1300 100UG/DOSE POWDER FOR INHALATION (PACKAGE)

02237245 FLOVENT DISKUS GSK $ 23.9300 250UG/DOSE POWDER FOR INHALATION (PACKAGE)

02237246 FLOVENT DISKUS GSK $ 41.2800 500UG/DOSE POWDER FOR INHALATION (PACKAGE)

02237247 FLOVENT DISKUS GSK $ 82.5400

62nd Edition 177 July 1, 2012

Page 200: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

68:00 HORMONES AND SYNTHETIC SUBSTITUTES

68:04.00 ADRENAL CORTICOSTEROIDS

HYDROCORTISONE 10MG TABLET

00030910 CORTEF PFI $ 0.1527 20MG TABLET

00030929 CORTEF PFI $ 0.2756

HYDROCORTISONE SODIUM SUCCINATE 100MG INJECTION POWDER

00030600 SOLU-CORTEF PFI $ 3.4990 250MG INJECTION POWDER

00030619 SOLU-CORTEF PFI $ 6.0800

METHYLPREDNISOLONE 4MG TABLET

00030988 MEDROL PFI $ 0.3454 16MG TABLET

00036129 MEDROL PFI $ 0.9954

METHYLPREDNISOLONE ACETATE* 40MG/ML INJECTION SUSPENSION (1ML)

02245400 METHYLPREDNISOLONE ACETATE SDZ $ 4.1000 02245407 METHYLPREDNISOLONE ACETATE SDZ 4.1000 00030759 DEPO-MEDROL PFI 5.1820

* 80MG/ML INJECTION SUSPENSION (1ML)02245406 METHYLPREDNISOLONE SDZ $ 8.2000 00030767 DEPO-MEDROL PFI 9.9400

PREDNISOLONE SODIUM PHOSPHATE* 1MG/ML ORAL LIQUID

02245532 PMS-PREDNISOLONE PMS $ 0.0863 02230619 PEDIAPRED AVT 0.1270

PREDNISONE* 1MG TABLET

00271373 WINPRED VAE $ 0.1035 00598194 APO-PREDNISONE APX 0.1035

* 5MG TABLET00021695 NOVO-PREDNISONE NOP $ 0.0401 00312770 APO-PREDNISONE APX 0.0401

* 50MG TABLET00232378 NOVO-PREDNISONE NOP $ 0.1735 00550957 APO-PREDNISONE APX 0.1735

62nd Edition 178 July 1, 2012

Page 201: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

68:00 HORMONES AND SYNTHETIC SUBSTITUTES

68:04.00 ADRENAL CORTICOSTEROIDS

TRIAMCINOLONE ACETONIDE* 10MG/ML INJECTION SUSPENSION (5ML)

02229540 TRIAMCINOLONE ACETONIDE SDZ $ 12.2500 01999761 KENALOG 10 BMY 16.8200

* 40MG/ML INJECTION SUSPENSION (1ML)01977563 TRIAMCINOLONE ACETONIDE CYT $ 4.7700 02229550 TRIAMCINOLONE SDZ 4.7700 01999869 KENALOG 40 BMY 7.7600

TRIAMCINOLONE HEXACETONIDE SEE APPENDIX A FOR EDS CRITERIA 20MG/ML INJECTION SUSPENSION

02194155 ARISTOSPAN (EDS) VAL $ 6.1700

68:08.00 ANDROGENS

DANAZOL 50MG CAPSULE

02018144 CYCLOMEN AVT $ 0.9047 100MG CAPSULE

02018152 CYCLOMEN AVT $ 1.3425 200MG CAPSULE

02018160 CYCLOMEN AVT $ 2.1453

TESTOSTERONE CYPIONATE* 100MG/ML OILY INJECTION SOLUTION (10ML)

02246063 TESTOSTERONE CYPIONATE SDZ $ 23.5800 00030783 DEPO-TESTOSTERONE PFI 26.9800

TESTOSTERONE ENANTHATE 200MG/ML OILY INJECTION SOLUTION (ML)

00029246 DELATESTRYL THM $ 9.5500

TESTOSTERONE UNDECANOATE 40MG CAPSULE

00782327 ANDRIOL SCH $ 0.9400

62nd Edition 179 July 1, 2012

Page 202: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

68:00 HORMONES AND SYNTHETIC SUBSTITUTES

68:12.00 CONTRACEPTIVES

ETHINYL ESTRADIOL/DESOGESTREL* 0.03MG/0.15MG (21 TABLET)

02317192 APRI APX $ 11.4200 02042487 MARVELON SCH 15.5400

* 0.03MG/0.15MG (28 TABLET)02317206 APRI APX $ 11.4200 02042479 MARVELON SCH 15.5400

0.03MG/0.15MG (28 TABLET)02042533 ORTHO-CEPT JAN $ 18.5000

0.1MG/0.025MG/0.125MG/0.025MG/0.15MG/0.025MG (21 TABLET)

02272903 LINESSA SCH $ 14.8500 0.1MG/0.025MG/0.125MG/0.025MG/0.15MG/0.025MG (28 TABLET)

02257238 LINESSA SCH $ 14.8500

ETHINYL ESTRADIOL/DROSPIRENONE 0.020MG/3.0MG (28 TABLET)

02321157 YAZ (28) BAY $ 15.1500 0.030MG/3.0MG (21 TABLET)

02261723 YASMIN 21 BAY $ 11.8400 0.030MG/3.0MG (28 TABLET)

02261731 YASMIN 28 BAY $ 11.8400

ETHINYL ESTRADIOL/ETHYNODIOL DIACETATE 0.03MG/2MG (21 TABLET)

00469327 DEMULEN 30 PFI $ 12.3900 0.03MG/2MG (28 TABLET)

00471526 DEMULEN 30 PFI $ 13.2500

ETHINYL ESTRADIOL/ETONORGESTREL 2.GMG/11.4MG SLOW-RELEASE VAGINAL RING

02253186 NUVARING MRK $ 14.7200

62nd Edition 180 July 1, 2012

Page 203: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

68:00 HORMONES AND SYNTHETIC SUBSTITUTES68:12.00 CONTRACEPTIVES

ETHINYL ESTRADIOL/L-NORGESTREL* 0.02MG/0.1MG (21 TABLET)

02298538 AVIANE APX $ 9.7400 02236974 ALESSE PFI 14.7600

* 0.02MG/0.1MG (28 TABLET)02298546 AVIANE APX $ 9.7400 02236975 ALESSE PFI 14.7600

0.03MG/0.05MG(6)0.04MG/0.075MG(5) 0.03MG/0.125MG(10) (21 TABLET)

00707600 TRIQUILAR BAY $ 14.6600 0.03MG/0.05MG(6)0.04MG/0.075MG(5) 0.03MG/0.125MG(10) INERT (7) (28 TABLET)

00707503 TRIQUILAR BAY $ 14.6600 * 0.03MG/0.15MG (21 TABLET)

02295946 PORTIA 21 APX $ 9.7400 02042320 MIN-OVRAL PFI 14.7600

* 0.03MG/0.15MG (28 TABLET)02295954 PORTIA 28 APX $ 9.7400 02042339 MIN-OVRAL PFI 14.7600

ETHINYL ESTRADIOL/NORETHINDRONE 0.035MG/0.5MG (21 TABLET)

02187086 BREVICON PFI $ 11.3500 00317047 ORTHO 0.5/35 JAN 18.5000

0.035MG/0.5MG (28 TABLET)02187094 BREVICON PFI $ 11.3500 00340731 ORTHO 0.5/35 JAN 18.5000

0.035MG/0.5MG (7) 0.035MG/0.75MG (7) 0.035/1.0MG (7) (21 TABLET)

00602957 ORTHO 7/7/7 JAN $ 18.5000 0.035MG/0.5MG (7) 0.035MG/0.75MG (7) 0.035MG/1.0MG (7) INERT (7) (28 TABLET)

00602965 ORTHO 7/7/7 JAN $ 18.5000 0.035MG/0.5MG(7)0.035MG/1.0MG(9) 0.035MG/0.5MG(5) (21 TABLET)

02187108 SYNPHASIC PFI $ 10.4300 0.035MG/0.5MG(7)0.035MG/1.0MG(9) 0.035MG/0.5MG(5) INERT (7) (28 TABLET)

02187116 SYNPHASIC PFI $ 10.4300 0.035MG/1MG (21 TABLET)

02197502 SELECT 1/35 PFI $ 7.6700 02189054 BREVICON 1/35 PFI 11.3500 00372846 ORTHO 1/35 JAN 18.5000

0.035MG/1MG (28 TABLET)02199297 SELECT 1/35 PFI $ 7.6700 02189062 BREVICON 1/35 PFI 11.3500 00372838 ORTHO 1/35 JAN 18.5000

62nd Edition 181 July 1, 2012

Page 204: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

68:00 HORMONES AND SYNTHETIC SUBSTITUTES

68:12.00 CONTRACEPTIVES

ETHINYL ESTRADIOL/NORETHINDRONE ACETATE 0.02MG/1MG (21 TABLET)

00315966 MINESTRIN 1/20 PAL $ 13.0300 0.02MG/1MG (28 TABLET)

00343838 MINESTRIN 1/20 PAL $ 13.0300 0.03MG/1.5MG (21 TABLET)

00297143 LOESTRIN 1.5/30 PAL $ 13.0300 0.03MG/1.5MG (28 TABLET)

00353027 LOESTRIN 1.5/30 PAL $ 13.0300

ETHINYL ESTRADIOL/NORGESTIMATE 0.025MG/0.18MG (7) 0.025MG/0.215MG (7) 0.025MG/0.25MG (7) (21 TABLET)

02258560 TRI-CYCLEN LO JAN $ 12.2700 0.025MG/0.18MG (7) 0.025MG/0.215MG (7) 0.025MG/0.25MG (7) INERT (7) (28 TABLET)

02258587 TRI-CYCLEN LO JAN $ 12.2700 0.035MG/0.18MG (7) 0.035MG/0.215MG (7) 0.035MG/0.25MG (7) (21 TABLET)

02028700 TRI-CYCLEN JAN $ 18.5000 0.035MG/0.18MG (7) 0.035MG/0.215MG (7) 0.035MG/0.25MG (7) INERT (7) (28 TABLET)

02029421 TRI-CYCLEN JAN $ 18.5000 0.035MG/0.25MG (21 TABLET)

01968440 CYCLEN JAN $ 18.5000 0.035MG/0.25MG (28 TABLET)

01992872 CYCLEN JAN $ 18.5000

LEVONORGESTREL 0.75MG TABLET

02241674 PLAN B PAL $ 8.6000 02285576 NORLEVO BAY 8.6000

52MG EXTENDED RELEASE INTRAUTERINE INSERT02243005 MIRENA BAY $ 329.6100

NORETHINDRONE 0.35MG (28 TABLET)

00037605 MICRONOR JAN $ 18.5000

62nd Edition 182 July 1, 2012

Page 205: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

68:00 HORMONES AND SYNTHETIC SUBSTITUTES68:16.00 ESTROGENS

CONJUGATED ESTROGENS 0.3MG TABLET

02043394 PREMARIN PFI $ 0.2900 0.625MG TABLET

00265470 C.E.S. VAE $ 0.0988 02043408 PREMARIN PFI 0.2900

1.25MG TABLET02043424 PREMARIN PFI $ 0.2900

0.625MG/G VAGINAL CREAM02043440 PREMARIN PFI $ 0.6379

ESTRADIOL SEE APPENDIX A FOR EDS CRITERIA 0.5MG TABLET

02225190 ESTRACE SCI $ 0.1287 1MG TABLET

02148587 ESTRACE SCI $ 0.2486 2MG TABLET

02148595 ESTRACE SCI $ 0.4390 0.06% TRANSDERMAL GEL SPRAY (PACKAGE)

02238704 ESTROGEL (EDS) SCH $ 28.9800 2MG VAGINAL RING (7.5UG/24 HOURS)

02168898 ESTRING PAL $ 67.1100 10UG VAGINAL TABLET

02325462 VAGIFEM 10 NOO $ 3.2134 25UG TRANSDERMAL THERAPEUTIC SYSTEM (PKG)

02247499 CLIMARA 25 (EDS) BAY $ 19.6700 02245676 ESTRADOT (EDS) NVR 20.8800 02243722 OESCLIM (EDS) TPI 21.0500 00756849 ESTRADERM (EDS) NVR 26.5900

37.5UG TRANSDERMAL THERAPEUTIC SYSTEM (PKG)02243999 ESTRADOT (EDS) NVR $ 21.0200

* 50UG TRANSDERMAL PATCH (PKG)02246967 SANDOZ ESTRADIOL DERM (EDS) SDZ $ 16.8000 02244000 ESTRADOT (EDS) NVR 22.4000

50UG TRANSDERMAL THERAPEUTIC SYSTEM (PKG)02231509 CLIMARA 50 (EDS) BAY $ 21.0100 02243724 OESCLIM (EDS) TPI 21.0500

* 75UG TRANSDERMAL PATCH (PKG)02246968 SANDOZ ESTRADIOL DERM (EDS) SDZ $ 17.9000 02244001 ESTRADOT (EDS) NVR 24.0200

75UG TRANSDERMAL THERAPEUTIC SYSTEM (PKG)02247500 CLIMARA 75 (EDS) BAY $ 22.4000

* 100UG TRANSDERMAL PATCH (PKG)02246969 SANDOZ ESTRADIOL DERM (EDS) SDZ $ 18.7000 02244002 ESTRADOT (EDS) NVR 25.3800

100UG TRANSDERMAL THERAPEUTIC SYSTEM (PKG)02231510 CLIMARA 100 (EDS) BAY $ 23.6900 00756792 ESTRADERM (EDS) NVR 32.0900

62nd Edition 183 July 1, 2012

Page 206: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

68:00 HORMONES AND SYNTHETIC SUBSTITUTES

68:16.00 ESTROGENS

ESTRADIOL/NORETHINDRONE ACETATE SEE APPENDIX A FOR EDS CRITERIA 50UG/140UG TRANSDERMAL THERAPEUTIC SYSTEM (8 )

02241835 ESTALIS (EDS) NVR $ 24.6800 50UG/250UG TRANSDERMAL THERAPEUTIC SYSTEM (8 )

02241837 ESTALIS (EDS) NVR $ 24.6800

68:16.12 ESTROGEN AGONIST-ANTAGONISTS

RALOXIFENE HCL SEE APPENDIX A FOR EDS CRITERIA

* 60MG TABLET02279215 APO-RALOXIFENE (EDS) APX $ 0.8457 02312298 NOVO-RALOXIFINE (EDS) NOP 0.8457 02239028 EVISTA (EDS) LIL 1.8804

68:18.00 GONADOTROPINS

BUSERELIN ACETATE SEE APPENDIX A FOR EDS CRITERIA 1MG/ML INJECTION

02225166 SUPREFACT (EDS) AVT $ 122.5800 1MG/ML INTRANASAL SOLUTION

02225158 SUPREFACT (EDS) AVT $ 78.2000

GOSERELIN ACETATE SEE APPENDIX A FOR EDS CRITERIA 3.6MG/SYRINGE

02049325 ZOLADEX (EDS) AST $ 390.5000

62nd Edition 184 July 1, 2012

Page 207: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

68:00 HORMONES AND SYNTHETIC SUBSTITUTES

68:18.00 GONADOTROPINS

LEUPROLIDE ACETATE SEE APPENDIX A FOR EDS CRITERIA 3.75MG/ML INJECTION

00884502 LUPRON DEPOT (EDS) ABB $ 347.1800 7.5MG/ML INJECTION

00836273 LUPRON DEPOT (EDS) ABB $ 387.9700 11.25MG (3-MONTH SR) DEPOT INJECTION

02239834 LUPRON DEPOT (EDS) ABB $ 1034.4100

NAFARELIN ACETATE SEE APPENDIX A FOR EDS CRITERIA 2MG/ML NASAL SOLUTION

02188783 SYNAREL (EDS) PFI $ 285.9000

68:20.08 ANTI-DIABETIC DRUGS (INSULINS-PORK)

INSULIN (ISOPHANE) PORK 100U/ML INJECTION SUSPENSION (10ML)

02275864 HYPURIN NPH WCK $ 88.0000

INSULIN (REGULAR) PORK 100U/ML INJECTION SOLUTION (10ML)

02275872 HYPURIN REGULAR WCK $ 88.0000

68:20.08 ANTI-DIABETIC DRUGS (INSULINS-HUMAN BIOSYNTHETIC)

INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC 100U/ML INJECTION SUSPENSION (10ML)

00587737 HUMULIN-N LIL $ 21.6700 02024225 NOVOLIN GE NPH NOO 21.9300

100U/ML INJECTION SUSPENSION (5X3ML)01959239 HUMULIN-N CARTRIDGE LIL $ 42.5200 02024268 NOVOLIN GE NPH PENFILL NOO 42.8700

62nd Edition 185 July 1, 2012

Page 208: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

68:00 HORMONES AND SYNTHETIC SUBSTITUTES

68:20.08 ANTI-DIABETIC DRUGS (INSULINS-HUMAN BIOSYNTHETIC)

INSULIN (REGULAR) ASPART SEE APPENDIX A FOR EDS CRITERIA 100U/ML INJECTION SOLUTION (10ML)

02245397 NOVORAPID (EDS) NOO $ 27.9200 100U/ML INJECTION SOLUTION (5X3ML)

02244353 NOVORAPID (EDS) NOO $ 56.6000

INSULIN (REGULAR) HUMAN BIOSYNTHETIC 100U/ML INJECTION SOLUTION (10ML)

00586714 HUMULIN-R LIL $ 21.6700 02024233 NOVOLIN GE TORONTO NOO 21.9300

100U/ML INJECTION SOLUTION (5X3ML)01959220 HUMULIN-R CARTRIDGE LIL $ 42.5200 02024284 NOVOLIN GE TORONTO PENFIL NOO 43.0300

INSULIN (REGULAR) LISPRO SEE APPENDIX A FOR EDS CRITERIA 100U/ML INJECTION SOLUTION (10ML)

02229704 HUMALOG (EDS) LIL $ 27.1100 100U/ML INJECTION SOLUTION (5X3ML)

02229705 HUMALOG CART./KWIKPEN (EDS) LIL $ 54.4500

INSULIN (REGULAR/ISOPHANE) HUMAN BIOSYNTHETIC 100U/ML INJECTION SUSPENSION 30%/70% (10ML)

00795879 HUMULIN 30/70 LIL $ 21.6700 02024217 NOVOLIN GE 30/70 NOO 21.9300

100U/ML INJECTION SUSPENSION 30%/70% (5X3ML)

01959212 HUMULIN 30/70 CARTRIDGE LIL $ 42.5200 02025248 NOVOLIN GE 30/70 PENFILL NOO 42.8300

100U/ML INJECTION SUSPENSION 40%/60% (5X3ML)

02024314 NOVOLIN GE 40/60 PENFILL NOO $ 43.8600 100U/ML INJECTION SUSPENSION 50%/50% (5X3ML)

02024322 NOVOLIN GE 50/50 PENFILL NOO $ 43.8600

INSULIN DETEMIR 100U/ML INJECTION SOLUTION

02271842 LEVEMIR PENFILL NOO $ 100.1800

62nd Edition 186 July 1, 2012

Page 209: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

68:00 HORMONES AND SYNTHETIC SUBSTITUTES

68:20.08 ANTI-DIABETIC DRUGS (INSULINS-HUMAN BIOSYNTHETIC)

INSULIN GLARGINE 100U/ML INJECTION SOLUTION (10ML)

02245689 LANTUS AVT $ 59.8200 * 100U/ML INJECTION SOLUTION (5X3ML)

02251930 LANTUS AVT $ 90.0400 02294338 LANTUS SOLOSTAR AVT 90.0400

INSULIN GLULISINE SEE APPENDIX A FOR EDS CRITERIA 100U/ML INJECTION SOLUTION (10ML)

02279460 APIDRA (EDS) AVT $ 24.5000 * 100U/ML INJECTION SOLUTION (5X3ML)

02279479 APIDRA (EDS) AVT $ 48.4500 02294346 APIDRA SOLOSTAR (EDS) AVT 49.0000

68:20.20 ANTI-DIABETIC DRUGS (ORAL HYPOGLYCEMICS)

ACARBOSE 50MG TABLET

02190885 GLUCOBAY BAY $ 0.2642 100MG TABLET

02190893 GLUCOBAY BAY $ 0.3659

CHLORPROPAMIDE 100MG TABLET

00399302 APO-CHLORPROPAMIDE APX $ 0.0745 250MG TABLET

00312711 APO-CHLORPROPAMIDE APX $ 0.0760

GLICLAZIDE* 30MG MODIFIED RELEASE TABLET

02242987 DIAMICRON MR SEV $ 0.1405 02297795 GLICLAZIDE MR AAP 0.1405

60MG MODIFIED RELEASE TABLET02356422 DIAMICRON MR SEV $ 0.2529

62nd Edition 187 July 1, 2012

Page 210: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

68:00 HORMONES AND SYNTHETIC SUBSTITUTES

68:20.20 ANTI-DIABETIC DRUGS (ORAL HYPOGLYCEMICS)

GLYBURIDE* 2.5MG TABLET

00808733 MYLAN-GLYBE MYL $ 0.0393 01900927 RATIO-GLYBURIDE RPH 0.0393 01913654 APO-GLYBURIDE APX 0.0393 01913670 TEVA-GLYBURIDE NOP 0.0393 02020734 NU-GLYBURIDE NXP 0.0393 02248008 SANDOZ GLYBURIDE SDZ 0.0393 02350459 GLYBURIDE SAN 0.0393 02363704 AVA-GLYBURIDE AVA 0.0393 02224550 DIABETA AVT 0.1337

* 5MG TABLET00720941 EUGLUCON PMS $ 0.0683 00808741 MYLAN-GLYBE MYL 0.0683 01900935 RATIO-GLYBURIDE RPH 0.0683 01913662 APO-GLYBURIDE APX 0.0683 01913689 TEVA-GLYBURIDE NOP 0.0683 02020742 NU-GLYBURIDE NXP 0.0683 02234514 DOM-GLYBURIDE DOM 0.0683 02236734 PMS-GLYBURIDE PMS 0.0683 02248009 SANDOZ GLYBURIDE SDZ 0.0683 02350467 GLYBURIDE SAN 0.0683 02363712 AVA-GLYBURIDE AVA 0.0683 02224569 DIABETA AVT 0.2394

62nd Edition 188 July 1, 2012

Page 211: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

68:00 HORMONES AND SYNTHETIC SUBSTITUTES

68:20.20 ANTI-DIABETIC DRUGS (ORAL HYPOGLYCEMICS)

METFORMIN* 500MG TABLET

02229516 GLYCON VAE $ 0.0605 *02167786 APO-METFORMIN APX 0.0936 02242974 RATIO-METFORMIN RPH 0.0936 02269031 RAN-METFORMIN RAN 0.0936 02045710 NOVO-METFORMIN NOP 0.0936 02148765 MYLAN-METFORMIN MYL 0.0936 02162822 NU-METFORMIN NXP 0.0936 02223562 PMS-METFORMIN PMS 0.0936 02229994 DOM-METFORMIN DOM 0.0936 02242794 METFORMIN MLP 0.0936 02246820 SANDOZ METFORMIN FC SDZ 0.0936 02257726 CO METFORMIN COB 0.0936 02353377 METFORMIN SAN 0.0936 02364506 AVA-METFORMIN AVA 0.0936 02378620 MAR-METFORMIN MPI 0.0936 02378841 METFORMIN MPI 0.0936 02379767 SEPTA-METFORMIN SPT 0.0936 02099233 GLUCOPHAGE AVT 0.2717

* 850MG TABLET02239214 GLYCON VAE $ 0.1100 *02269058 RAN-METFORMIN RAN 0.1186 02229656 MYLAN-METFORMIN MYL 0.1186 02246821 SANDOZ METFORMIN FC SDZ 0.1186 02257734 CO METFORMIN COB 0.1186 02364514 AVA-METFORMIN AVA 0.1186 02378639 MAR-METFORMIN MPI 0.1186 02378868 METFORMIN MPI 0.1186 02379775 SEPTA-METFORMIN SPT 0.1186 02162849 GLUCOPHAGE AVT 0.3538

NATEGLINIDE SEE APPENDIX A FOR EDS CRITERIA 60MG TABLET

02245438 STARLIX (EDS) NVR $ 0.5500 120MG TABLET

02245439 STARLIX (EDS) NVR $ 0.5500

62nd Edition 189 July 1, 2012

Page 212: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

68:00 HORMONES AND SYNTHETIC SUBSTITUTES

68:20.20 ANTI-DIABETIC DRUGS (ORAL HYPOGLYCEMICS)

PIOGLITAZONE HCL SEE APPENDIX B FOR ONLINE ADJUDICATION

* 15MG TABLET02303442 ACCEL PIOGLITAZONE (EDS) ACC $ 0.6300 *02274914 NOVO-PIOGLITAZONE (EDS) NOP 0.8133 02297906 SANDOZ PIOGLITAZONE (EDS) SDZ 0.8133 02298279 MYLAN-PIOGLITAZONE (EDS) MYL 0.8133 02301423 RATIO-PIOGLITAZONE (EDS) RPH 0.8133 02302861 CO PIOGLITAZONE (EDS) COB 0.8133 02302942 APO-PIOGLITAZONE (EDS) APX 0.8133 02303124 PMS-PIOGLITAZONE (EDS) PMS 0.8133 02326477 MINT-PIOGLITAZONE (EDS) MNT 0.8133 02363232 AVA-PIOGLITAZONE (EDS) AVA 0.8133 02375850 RAN-PIOGLITAZONE (EDS) RAN 0.8133 02242572 ACTOS (EDS) TAK 2.4533

* 30MG TABLET02303450 ACCEL PIOGLITAZONE (EDS) ACC $ 0.8900 *02274922 NOVO-PIOGLITAZONE (EDS) NOP 1.1394 02297914 SANDOZ PIOGLITAZONE (EDS) SDZ 1.1394 02298287 MYLAN-PIOGLITAZONE (EDS) MYL 1.1394 02301431 RATIO-PIOGLITAZONE (EDS) RPH 1.1394 02302888 CO PIOGLITAZONE (EDS) COB 1.1394 02302950 APO-PIOGLITAZONE (EDS) APX 1.1394 02303132 PMS-PIOGLITAZONE (EDS) PMS 1.1394 02326485 MINT-PIOGLITAZONE (EDS) MNT 1.1394 02339587 PIOGLITAZONE (EDS) AHI 1.1394 02363240 AVA-PIOGLITAZONE (EDS) AVA 1.1394 02375869 RAN-PIOGLITAZONE (EDS) RAN 1.1394 02242573 ACTOS (EDS) TAK 3.4369

* 45MG TABLET02303469 ACCEL PIOGLITAZONE (EDS) ACC $ 1.3400 *02274930 NOVO-PIOGLITAZONE (EDS) NOP 1.7132 02297922 SANDOZ PIOGLITAZONE (EDS) SDZ 1.7132 02298295 MYLAN-PIOGLITAZONE (EDS) MYL 1.7132 02301458 RATIO-PIOGLITAZONE (EDS) RPH 1.7132 02302896 CO PIOGLITAZONE (EDS) COB 1.7132 02302977 APO-PIOGLITAZONE (EDS) APX 1.7132 02303140 PMS-PIOGLITAZONE (EDS) PMS 1.7132 02326493 MINT-PIOGLITAZONE (EDS) MNT 1.7132 02339595 PIOGLITAZONE (EDS) AHI 1.7132 02363259 AVA-PIOGLITAZONE (EDS) AVA 1.7132 02375877 RAN-PIOGLITAZONE (EDS) RAN 1.7132 02242574 ACTOS (EDS) TAK 5.1678

62nd Edition 190 July 1, 2012

Page 213: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

68:00 HORMONES AND SYNTHETIC SUBSTITUTES

68:20.20 ANTI-DIABETIC DRUGS (ORAL HYPOGLYCEMICS)

REPAGLINIDE SEE APPENDIX A FOR EDS CRITERIA

* 0.5MG TABLET02321475 CO REPAGLINIDE (EDS) COB $ 0.1042 02354926 PMS-REPAGLINIDE (EDS) PMS 0.1042 02355663 APO-REPAGLINIDE (EDS) APX 0.1042 02357453 SANDOZ REPAGLINIDE (EDS) SDZ 0.1042 02239924 GLUCONORM (EDS) NOO 0.3126

* 1MG TABLET02321483 CO REPAGLINIDE (EDS) COB $ 0.1083 02354934 PMS-REPAGLINIDE (EDS) PMS 0.1083 02355671 APO-REPAGLINIDE (EDS) APX 0.1083 02357461 SANDOZ REPAGLINIDE (EDS) SDZ 0.1083 02239925 GLUCONORM (EDS) NOO 0.3250

* 2MG TABLET02321491 CO REPAGLINIDE (EDS) COB $ 0.1125 02354942 PMS-REPAGLINIDE (EDS) PMS 0.1125 02355698 APO-REPAGLINIDE (EDS) APX 0.1125 02357488 SANDOZ REPAGLINIDE (EDS) SDZ 0.1125 02239926 GLUCONORM (EDS) NOO 0.3376

ROSIGLITAZONE MALEATE SEE APPENDIX A FOR EDS CRITERIA 2MG TABLET

02241112 AVANDIA (EDS) GSK $ 1.3755 4MG TABLET

02241113 AVANDIA (EDS) GSK $ 2.1584 8MG TABLET

02241114 AVANDIA (EDS) GSK $ 3.0865

ROSIGLITAZONE MALEATE/METFORMIN HCL SEE APPENDIX A FOR EDS CRITERIA 1MG/500MG TABLET

02247085 AVANDAMET (EDS) GSK $ 0.6421 2MG/500MG TABLET

02247086 AVANDAMET (EDS) GSK $ 1.1611 4MG/500MG TABLET

02247087 AVANDAMET (EDS) GSK $ 1.5946 2MG/1000MG TABLET

02248440 AVANDAMET (EDS) GSK $ 1.2682 4MG/1000MG TABLET

02248441 AVANDAMET (EDS) GSK $ 1.7337

SAXAGLIPTIN SEE APPENDIX B FOR ONLINE ADJUDICATION 5MG TABLET

02333554 ONGLYZA (EDS) BMY $ 2.7560

62nd Edition 191 July 1, 2012

Page 214: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

68:00 HORMONES AND SYNTHETIC SUBSTITUTES

68:20.20 ANTI-DIABETIC DRUGS (ORAL HYPOGLYCEMICS)

SITAGLIPTIN PHOSPHATE SEE APPENDIX B FOR ONLINE ADJUDICATION 100MG TABLET

02303922 JANUVIA (EDS) MRK $ 2.8948

SITAGLIPTIN PHOSPHATE/METFORMIN HCL SEE APPENDIX B FOR ONLINE ADJUDICATION 50MG/500MG TABLET

02333856 JANUMET (EDS) MRK $ 1.5687 50MG/850MG TABLET

02333864 JANUMET (EDS) MRK $ 1.5687 50MG/1000MG TABLET

02333872 JANUMET (EDS) MRK $ 1.5687

TOLBUTAMIDE 500MG TABLET

00312762 TOLBUTAMIDE AAP $ 0.1089

68:24.00 PARATHYROID

CALCITONIN SALMON SEE APPENDIX A FOR EDS CRITERIA 100IU/ML INJECTION (1ML)

02007134 CALTINE 100 (EDS) FEI $ 7.8200 200IU/ML INJECTION (2ML)

01926691 CALCIMAR (EDS) AVT $ 55.2500 * 200IU/DOSE NASAL SPRAY (BOTTLE)

02247585 APO-CALCITONIN (EDS) APX $ 19.6000 02261766 SANDOZ CALCITONIN NS (EDS) SDZ 19.6000 02240775 MIACALCIN (EDS) NVR 30.6450

62nd Edition 192 July 1, 2012

Page 215: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

68:00 HORMONES AND SYNTHETIC SUBSTITUTES

68:28.00 PITUITARY AGENTS

COSYNTROPIN ZINC HYDROXIDE 1MG/ML INJECTION SUSPENSION (1ML)

00253952 SYNACTHEN DEPOT NVR $ 32.2800

DESMOPRESSIN SEE APPENDIX A FOR EDS CRITERIA

* 0.1MG TABLET02284030 APO-DESMOPRESSIN (EDS) APX $ 0.4626 02287730 NOVO-DESMOPRESSIN (EDS) NOP 0.4626 02304368 PMS-DESMOPRESSIN (EDS) PMS 0.4626 00824305 D.D.A.V.P. (EDS) FEI 1.3217

* 0.2MG TABLET02284049 APO-DESMOPRESSIN (EDS) APX $ 0.9252 02287749 NOVO-DESMOPRESSIN (EDS) NOP 0.9252 02304376 PMS-DESMOPRESSIN (EDS) PMS 0.9252 00824143 D.D.A.V.P. (EDS) FEI 2.6434

60UG ORALLY DISINTEGRATING TABLET02284995 DDAVP MELT (EDS) FEI $ 0.9910

120UG ORALLY DISINTEGRATING TABLET02285002 DDAVP MELT (EDS) FEI $ 1.9824

240UG ORALLY DISINTEGRATING TABLET02285010 DDAVP MELT (EDS) FEI $ 3.5684

4UG/ML INJECTION (1ML)00873993 D.D.A.V.P. (EDS) FEI $ 10.0600

10UG/DOSE INTRANASAL SOLUTION00402516 D.D.A.V.P. (EDS) FEI $ 47.2000

* 10UG/DOSE INTRANASAL SOLUTION (SPRAY PUMP)02242465 DESMOPRESSIN (EDS) AAP $ 70.8000 00836362 D.D.A.V.P. (EDS) FEI 94.4000

150UG/DOSE INTRANASAL SOLUTION (SPRAY PUMP)02237860 OCTOSTIM (EDS) FEI $ 386.0000

SOMATROPIN SEE APPENDIX A FOR EDS CRITERIA 3.33MG INJECTION (VIAL)

02215136 SAIZEN (EDS) SRO $ 144.9000 5MG INJECTION (VIAL)

02325063 OMNITROPE (EDS) SDZ $ 155.8000 02237971 SAIZEN (EDS) SRO 217.5200 00745626 HUMATROPE (EDS) LIL 233.3500

6MG INJECTION (CARTRIDGE)02350122 SAIZEN (EDS) SRO $ 261.0000 02243077 HUMATROPE CARTRIDGE (EDS) LIL 280.0200

8.8MG INJECTION (VIAL)02272083 SAIZEN (EDS) SRO $ 348.0300

62nd Edition 193 July 1, 2012

Page 216: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

68:00 HORMONES AND SYNTHETIC SUBSTITUTES 10MG INJECTION (VIAL)

02325071 OMNITROPE (EDS) SDZ $ 311.6000 02229722 NUTROPIN AQ (EDS) HLR 389.4400 02216191 NUTROPIN (EDS) HLR 389.4400

10MG INJECTION (CARTRIDGE)02249002 NUTROPIN AQ PEN (EDS) HLR $ 389.4400

12MG INJECTION (CARTRIDGE)02350130 SAIZEN (EDS) SRO $ 522.0000 02243078 HUMATROPE CARTRIDGE (EDS) LIL 560.0400

20MG INJECTION (CARTRIDGE)02350149 SAIZEN (EDS) SRO $ 870.0000

24MG INJECTION (CARTRIDGE)02243079 HUMATROPE (EDS) LIL $ 1120.0800

68:32.00 PROGESTINS

ESTRADIOL/NORETHINDRONE ACETATE SEE SECTION 68:16.00 (ESTROGENS)

MEDROXYPROGESTERONE ACETATE* 2.5MG TABLET

02221284 NOVO-MEDRONE NOP $ 0.0562 02244726 APO-MEDROXY APX 0.0562 02252740 NU-MEDROXY NXP 0.0562 00708917 PROVERA PFI 0.1635

* 5MG TABLET02221292 NOVO-MEDRONE NOP $ 0.1108 02244727 APO-MEDROXY APX 0.1108 02252759 NU-MEDROXY NXP 0.1108 00030937 PROVERA PFI 0.3232

* 10MG TABLET02221306 NOVO-MEDRONE NOP $ 0.2237 02277298 APO-MEDROXY APX 0.2237 00729973 PROVERA PFI 0.6559

50MG/ML INJECTION SUSPENSION (5ML)00030848 DEPO-PROVERA PFI $ 26.6900

150MG/ML INJECTION SUSPENSION (1ML)00585092 DEPO-PROVERA PFI $ 27.5420

PROGESTERONE (MICRONIZED) SEE APPENDIX A FOR EDS CRITERIA 100MG CAPSULE

02166704 PROMETRIUM (EDS) SCH $ 1.2840

62nd Edition 194 July 1, 2012

Page 217: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

68:00 HORMONES AND SYNTHETIC SUBSTITUTES

68:36.04 THYROID AGENTS

LEVOTHYROXINE (SODIUM) 0.025MG TABLET

02172062 SYNTHROID ABB $ 0.0865 * 0.05MG TABLET

02213192 ELTROXIN TPI $ 0.0289 02172070 SYNTHROID ABB 0.0595

0.075MG TABLET02172089 SYNTHROID ABB $ 0.0935

0.088MG TABLET02172097 SYNTHROID ABB $ 0.0935

* 0.1MG TABLET02213206 ELTROXIN TPI $ 0.0354 02172100 SYNTHROID ABB 0.0733

0.112MG TABLET02171228 SYNTHROID ABB $ 0.0987

0.125MG TABLET02172119 SYNTHROID ABB $ 0.0999

* 0.15MG TABLET02213214 ELTROXIN TPI $ 0.0393 02172127 SYNTHROID ABB 0.0785

0.175MG TABLET02172135 SYNTHROID ABB $ 0.1072

* 0.2MG TABLET02213222 ELTROXIN TPI $ 0.0416 02172143 SYNTHROID ABB 0.0837

* 0.3MG TABLET02213230 ELTROXIN TPI $ 0.0636 02172151 SYNTHROID ABB 0.1155

THYROID 30MG TABLET

00023949 THYROID ERF $ 0.1285 60MG TABLET

00023957 THYROID ERF $ 0.2704 125MG TABLET

00023965 THYROID ERF $ 0.4242

62nd Edition 195 July 1, 2012

Page 218: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

68:00 HORMONES AND SYNTHETIC SUBSTITUTES

68:36.08 ANTITHYROID AGENTS

METHIMAZOLE 5MG TABLET

00015741 TAPAZOLE PAL $ 0.2503

PROPYLTHIOURACIL 50MG TABLET

00010200 PROPYL-THYRACIL PAL $ 0.2160 100MG TABLET

00010219 PROPYL-THYRACIL PAL $ 0.3380

62nd Edition 196 July 1, 2012

Page 219: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

SKIN AND MUCOUS MEMBRANE AGENTS

84:00

Page 220: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

84:00 SKIN AND MUCOUS MEMBRANE AGENTS

84:04.04 ANTI-INFECTIVES (ANTIBIOTICS)

CLINDAMYCIN PHOSPHATE* 1% TOPICAL SOLUTION

02266938 TARO-CLINDAMYCIN TAR $ 0.2262 00582301 DALACIN T PFI 0.3237

FRAMYCETIN SO4 1% GAUZE (10CM X 10CM)

01988840 SOFRA-TULLE ERF $ 1.5533 1% GAUZE (30CM X 10CM)

01987682 SOFRA-TULLE ERF $ 3.6230

FUSIDIC ACID 2% TOPICAL CREAM

00586668 FUCIDIN LEO $ 0.6247

MUPIROCIN 2% CREAM

02239757 BACTROBAN GCH $ 0.5500 * 2% OINTMENT

02279983 TARO-MUPIROCIN TAR $ 0.3453 01916947 BACTROBAN GCH 0.5500

POLYMYXIN B SO4/NEOMYCIN SO4/BACITRACIN (ZINC) 5,000U/5MG/400U PER G TOPICAL OINTMENT

00666122 NEOSPORIN GSK $ 0.4680

SODIUM FUSIDATE 2% TOPICAL OINTMENT

00586676 FUCIDIN LEO $ 0.6247

84:04.08 ANTI-INFECTIVES (ANTI-FUNGALS)

CICLOPIROX OLAMINE 1% TOPICAL CREAM

02221802 LOPROX AVT $ 0.4730

62nd Edition 198 July 1, 2012

Page 221: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

84:00 SKIN AND MUCOUS MEMBRANE AGENTS

84:04.08 ANTI-INFECTIVES (ANTI-FUNGALS)

CLOTRIMAZOLE 200MG VAGINAL TABLET

02264099 CANESTEN COMBI-PAK 3 BCD $ 13.3100 * 1% TOPICAL CREAM

00812382 CLOTRIMADERM TAR $ 0.1073 02150867 CANESTEN BCD 0.3693

* 1% VAGINAL CREAM00812366 CLOTRIMADERM TAR $ 0.1750 02150891 CANESTEN-6 BCD 0.2438

* 2% VAGINAL CREAM00812374 CLOTRIMADERM TAR $ 0.3500 02150905 CANESTEN-3 BCD 0.4876

500MG VAGINAL SUPPOSITORY/1% TOPICAL CREAM (COMBINATION PACKAGE)

02264102 CANESTEN COMBI-PAK 1 BCD $ 13.3100

KETOCONAZOLE 2% TOPICAL CREAM

02245662 KETODERM TPM $ 0.3167

MICONAZOLE NITRATE 100MG VAGINAL SUPPOSITORY/2% TOPICAL CREAM (COMBINATION PACKAGE)

02126257 MONISTAT 7 COMBINATION MCL $ 13.7600 400MG VAGINAL OVULES

02126605 MONISTAT-3 MCL $ 4.0067 400MG VAGINAL OVULES/2% TOPICAL CREAM (COMBINATION PACKAGE)

02126249 MONISTAT 3 COMBINATION MCL $ 13.7600 * 2% VAGINAL CREAM

02231106 MICOZOLE TAR $ 0.1511 02084309 MONISTAT-7 MCL 0.3435

2% TOPICAL CREAM02085852 MICATIN WEL $ 0.2977

62nd Edition 199 July 1, 2012

Page 222: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

84:00 SKIN AND MUCOUS MEMBRANE AGENTS

84:04.08 ANTI-INFECTIVES (ANTI-FUNGALS)

NYSTATIN* 100,000U/G TOPICAL CREAM

00716871 NYADERM TAR $ 0.0633 02194236 RATIO-NYSTATIN RPH 0.0633

100,000U/G TOPICAL OINTMENT02194228 RATIO-NYSTATIN RPH $ 0.1129

25,000U/G VAGINAL CREAM00716901 NYADERM TAR $ 0.0492

100,000U/G VAGINAL CREAM02194163 RATIO-NYSTATIN RPH $ 0.3191

TERBINAFINE HCL 1% TOPICAL CREAM

02031094 LAMISIL NVR $ 0.5184 1% TOPICAL SPRAY SOLUTION

02238703 LAMISIL NVR $ 0.5264

TERCONAZOLE 80MG VAGINAL OVULES/0.8% CREAM (DUAL-PAK)

02130874 TERAZOL-3 DUAL-PAK JAN $ 25.1300 * 0.4% VAGINAL CREAM (PKG)

02247651 TARO-TERCONAZOLE TAR $ 12.2700 00894729 TERAZOL-7 JAN 23.9000

84:04.12 ANTI-INFECTIVES (SCABICIDES AND PEDICULICIDES)

CROTAMITON 10% TOPICAL CREAM

00623377 EURAX CLC $ 0.3584

ISOPROPYL MYRISTATE 50% TOPICAL SOLUTION

02279592 RESULTZ NYC $ 0.1021

PERMETHRIN* 1% CREME RINSE

00771368 NIX CREME RINSE IPC $ 0.1233 02231480 KWELLADA-P CREME RINSE GCH 0.1238

5% TOPICAL CREAM02219905 NIX DERMAL CREAM GCH $ 0.4977

5% TOPICAL LOTION02231348 KWELLADA-P LOTION GCH $ 0.2688

PYRETHINS/PIPERONYL BUTOXIDE/PETROLEUM DISTILLATE 0.33%/3.0%/1.2% SHAMPOO/CONDITIONER

02125447 R&C SHAMPOO/CONDITIONER GCH $ 0.1208

62nd Edition 200 July 1, 2012

Page 223: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

84:00 SKIN AND MUCOUS MEMBRANE AGENTS84:04.16 MISCELLANEOUS ANTI-INFECTIVES

HEXACHLOROPHENE 3% TOPICAL EMULSION

02017733 PHISOHEX AVT $ 0.0681

METRONIDAZOLE 1% TOPICAL GEL

02297809 METROGEL GAC $ 0.6149 0.75% TOPICAL CREAM

02226839 METROCREAM GAC $ 0.6600 0.75% TOPICAL LOTION

02248206 METROLOTION GAC $ 0.6600 1% TOPICAL CREAM

02156091 NORITATE AVT $ 0.5409 1% TOPICAL CREAM (WITH SUNSCREEN)

02242919 ROSASOL GSK $ 0.5184 0.75% VAGINAL GEL

02125226 NIDAGEL MDC $ 0.2890 10% VAGINAL CREAM

01926861 FLAGYL AVT $ 0.2322

SULFACETAMIDE (SODIUM)/COLLOIDAL SULPHUR 10%/5% TOPICAL LOTION

02220407 SULFACET-R AVT $ 0.9628

84:06.00 ANTI-INFLAMMATORY AGENTS

AMCINONIDE* 0.1% TOPICAL CREAM

02247098 RATIO-AMCINONIDE RPH $ 0.1909 02192284 CYCLOCORT GSK 0.5467

* 0.1% TOPICAL OINTMENT02247096 RATIO-AMCINONIDE RPH $ 0.3151 02192268 CYCLOCORT GSK 0.5467

* 0.1% TOPICAL LOTION02247097 RATIO-AMCINONIDE RPH $ 0.2611 02192276 CYCLOCORT GSK 0.4590

BECLOMETHASONE DIPROPIONATE 0.025% TOPICAL CREAM

02089602 PROPADERM PAL $ 0.4372

62nd Edition 201 July 1, 2012

Page 224: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

84:00 SKIN AND MUCOUS MEMBRANE AGENTS

84:06.00 ANTI-INFLAMMATORY AGENTS

BETAMETHASONE DIPROPIONATE* 0.05% TOPICAL CREAM

00323071 DIPROSONE SCH $ 0.2047 01925350 TARO-SONE TAR 0.2047

* 0.05% TOPICAL OINTMENT00344923 DIPROSONE SCH $ 0.2152 00805009 RATIO-TOPISONE RPH 0.2152

* 0.05% TOPICAL LOTION00417246 DIPROSONE SCH $ 0.1980 00809187 RATIO-TOPISONE RPH 0.1980

* 0.05% TOPICAL GLYCOL CREAM00688622 DIPROLENE SCH $ 0.5187 00849650 RATIO-TOPILENE RPH 0.5187

* 0.05% TOPICAL GLYCOL OINTMENT00629367 DIPROLENE SCH $ 0.5187 00849669 RATIO-TOPILENE RPH 0.5187

* 0.05% TOPICAL GLYCOL LOTION00862975 DIPROLENE SCH $ 0.2697 01927914 RATIO-TOPILENE RPH 0.4683

BETAMETHASONE DIPROPIONATE/SALICYLIC ACID 0.05%/3% TOPICAL OINTMENT

00578436 DIPROSALIC SCH $ 0.9447 * 0.05%/2% TOPICAL LOTION

02245688 RATIO-TOPISALIC RPH $ 0.4228 00578428 DIPROSALIC SCH 0.4694

BETAMETHASONE DISODIUM PHOSPHATE 5MG/100ML ENEMA (100ML)

02060884 BETNESOL ENEMA PAL $ 9.5200

BETAMETHASONE VALERATE* 0.05% TOPICAL CREAM

00535427 RATIO-ECTOSONE RPH $ 0.0606 00716618 BETADERM TAR 0.0606

* 0.1% TOPICAL CREAM00535435 RATIO-ECTOSONE RPH $ 0.0991 00716626 BETADERM TAR 0.0991

0.05% TOPICAL OINTMENT00716642 BETADERM TAR $ 0.0606

0.1% TOPICAL OINTMENT00716650 BETADERM TAR $ 0.0903

62nd Edition 202 July 1, 2012

Page 225: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

84:00 SKIN AND MUCOUS MEMBRANE AGENTS

84:06.00 ANTI-INFLAMMATORY AGENTS

0.05% TOPICAL LOTION00653209 RATIO-ECTOSONE MILD RPH $ 0.2530

0.1% TOPICAL LOTION00750050 RATIO-ECTOSONE RPH $ 0.2550

* 0.1% SCALP LOTION00027944 VALISONE VAL $ 0.0853 00653217 RATIO-ECTOSONE RPH 0.0853 00716634 BETADERM TAR 0.0853

BUDESONIDE 0.02MG/ML ENEMA (100ML)

02052431 ENTOCORT AST $ 8.3400

CLOBETASOL PROPIONATE* 0.05% TOPICAL CREAM

01910272 RATIO-CLOBETASOL RPH $ 0.2623 02024187 MYLAN-CLOBETASOL MYL 0.2623 02093162 NOVO-CLOBETASOL NOP 0.2623 02232191 PMS-CLOBETASOL PMS 0.2623 02245523 TARO-CLOBETASOL CREAM TAR 0.2623 02309521 PMS-CLOBETASOL PMS 0.2623 02213265 DERMOVATE TPM 0.7714

* 0.05% TOPICAL OINTMENT01910280 RATIO-CLOBETASOL RPH $ 0.2623 02026767 MYLAN-CLOBETASOL MYL 0.2623 02126192 NOVO-CLOBETASOL NOP 0.2623 02232193 PMS-CLOBETASOL PMS 0.2623 02245524 TARO-CLOBETASOL OINTMENT TAR 0.2623 02309548 PMS-CLOBETASOL PMS 0.2623 02213273 DERMOVATE TPM 0.7714

* 0.05% SCALP APPLICATION01910299 RATIO-CLOBETASOL RPH $ 0.2527 02216213 MYLAN-CLOBETASOL MYL 0.2527 02232195 PMS-CLOBETASOL PMS 0.2527 02245522 TARO-CLOBETASOL SOLUTION TAR 0.2527 02213281 DERMOVATE TPM 0.5850

CLOBETASONE BUTYRATE 0.05% TOPICAL CREAM

02214415 SPECTRO ECZEMA CARE GCH $ 0.3817

DESONIDE 0.05% TOPICAL CREAM

02229315 PMS-DESONIDE PMS $ 0.3087 * 0.05% TOPICAL OINTMENT

02229323 PMS-DESONIDE PMS $ 0.2928 02115522 DESOCORT GAC 0.6667

62nd Edition 203 July 1, 2012

Page 226: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

84:00 SKIN AND MUCOUS MEMBRANE AGENTS84:06.00 ANTI-INFLAMMATORY AGENTS

DESOXIMETASONE 0.05% TOPICAL CREAM

02221918 TOPICORT MILD AVT $ 0.4670 0.25% TOPICAL CREAM

02221896 TOPICORT AVT $ 0.6730 0.05% TOPICAL GEL

02221926 TOPICORT AVT $ 0.4615 0.25% TOPICAL OINTMENT

02221934 TOPICORT AVT $ 0.5949

DIFLUCORTOLONE VALERATE 0.1% TOPICAL CREAM

00587826 NERISONE GSK $ 0.3860 0.1% TOPICAL OILY CREAM

00587818 NERISONE GSK $ 0.3860 0.1% TOPICAL OINTMENT

00587834 NERISONE GSK $ 0.3860

FLUOCINOLONE ACETONIDE 0.01% TOPICAL OIL

00873292 DERMA-SMOOTHE/FS HDI $ 0.2471 0.01% SHAMPOO

02242738 CAPEX SHAMPOO GAC $ 0.7204

FLUOCINONIDE* 0.05% TOPICAL CREAM

00716863 LYDERM TPM $ 0.2443 02161923 LIDEX VAL 0.2443

* 0.05% TOPICAL GEL02161974 LIDEX VAL $ 0.3418 02236997 LYDERM TPM 0.3418

* 0.05% TOPICAL OINTMENT02161966 LIDEX VAL $ 0.3035 02236996 LYDERM TPM 0.3370

0.05% IN EMOLLIENT BASE02163152 LIDEMOL VAL $ 0.1980

HYDROCORTISONE* 0.5% TOPICAL CREAM

00513288 CORTATE MRK $ 0.1334 00716820 HYDERM TAR 0.1667

* 1% TOPICAL CREAM00716839 HYDERM TAR $ 0.0364 00192597 EMO-CORT GSK 0.1685

2.5% TOPICAL CREAM00595799 EMO-CORT GSK $ 0.2267

62nd Edition 204 July 1, 2012

Page 227: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

84:00 SKIN AND MUCOUS MEMBRANE AGENTS

84:06.00 ANTI-INFLAMMATORY AGENTS

* 0.5% TOPICAL OINTMENT00513261 CORTATE MRK $ 0.1334 00716685 CORTODERM TAR 0.1400

1% TOPICAL OINTMENT00716693 CORTODERM TAR $ 0.0390

1% TOPICAL LOTION00578541 SARNA HC GSK $ 0.0917 00192600 EMO-CORT GSK 0.1519

2.5% TOPICAL LOTION00856711 SARNA HC GSK $ 0.1772 00595802 EMO-CORT GSK 0.2054

* 100MG/60ML ENEMA (60ML)00230316 HYCORT VAE $ 5.1429 02112736 CORTENEMA AXC 6.7200

HYDROCORTISONE ACETATE 10% RECTAL AEROSOL FOAM (15G)

00579335 CORTIFOAM PAL $ 92.0500

HYDROCORTISONE VALERATE 0.2% TOPICAL CREAM

02242984 HYDROVAL TPM $ 0.1212 0.2% TOPICAL OINTMENT

02242985 HYDROVAL TPM $ 0.1212

HYDROCORTISONE/UREA 1%/10% TOPICAL CREAM

00503134 UREMOL-HC GSK $ 0.1686 1%/10% TOPICAL LOTION

00560022 UREMOL-HC GSK $ 0.0968

MOMETASONE FUROATE 0.1% TOPICAL CREAM

00851744 ELOCOM SCH $ 0.7520 * 0.1% TOPICAL OINTMENT

02248130 RATIO-MOMETASONE RPH $ 0.2252 02264749 TARO-MOMETASONE OINTMENT TAR 0.2252 00851736 ELOCOM SCH 0.6754

0.1% TOPICAL LOTION00871095 ELOCOM SCH $ 0.5037

TRIAMCINOLONE ACETONIDE* 0.1% TOPICAL CREAM

00716960 TRIADERM TAR $ 0.0585 02194058 ARISTOCORT R VAL 0.1300

0.1% TOPICAL OINTMENT02194031 ARISTOCORT R VAL $ 0.1300

0.1% ORAL TOPICAL OINTMENT01964054 ORACORT DENTAL PASTE TAR $ 1.0800

62nd Edition 205 July 1, 2012

Page 228: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

84:00 SKIN AND MUCOUS MEMBRANE AGENTS

84:06.00 COMBINATION ANTI-INFECTIVE/ ANTI-INFLAMMATORY AGENTS

BETAMETHASONE DIPROPIONATE/CLOTRIMAZOLE 0.05%/1% TOPICAL CREAM

00611174 LOTRIDERM SCH $ 0.8234

FUSIDIC ACID/HYDROCORTISONE ACETATE 2%/1% TOPICAL CREAM

02238578 FUCIDIN H LEO $ 1.0954

NEOMYCIN/GRAMICIDIN/NYSTATIN/TRIAMCINOLONE ACETONIDE* 2.5MG/0.25MG/100,000U/1MG PER G TOPICAL CREAM

00550507 RATIO-TRIACOMB RPH $ 0.3833 00717002 VIADERM-KC TAR 0.4142

2.5MG/0.25MG/100,000U/1MG PER G TOPICAL OINTMENT

00717029 VIADERM-KC TAR $ 0.4233

POLYMYXIN B SO4/BACITRACIN (ZINC)/NEOMYCIN SO4/HYDROCORTISONE 5000U/400U/5MG/10MG PER G TOPICAL OINTMENT

00666246 CORTISPORIN GSK $ 0.7880

84:12.00 ASTRINGENTS

ALUMINUM ACETATE/BENZETHONIUM CHLORIDE 0.35%/0.023% POWDER (2.36G PACKAGE)

00579947 BURO-SOL GSK $ 0.7320

84:16.00 CELL STIMULANTS AND PROLIFERANTS

ADAPALENE 0.1% TOPICAL CREAM

02231592 DIFFERIN GAC $ 1.4600 0.1% TOPICAL GEL

02148749 DIFFERIN GAC $ 1.4600

62nd Edition 206 July 1, 2012

Page 229: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

84:00 SKIN AND MUCOUS MEMBRANE AGENTS

84:16.00 CELL STIMULANTS AND PROLIFERANTS

TRETINOIN SEE APPENDIX A FOR EDS CRITERIA 0.01% TOPICAL CREAM

00657204 STIEVA-A GSK $ 0.2980 * 0.01% TOPICAL GEL

01926462 VITAMIN A ACID AVT $ 0.2964 00870013 RETIN A VAE 0.3737

0.025% TOPICAL CREAM00578576 STIEVA-A GSK $ 0.2980

* 0.025% TOPICAL GEL01926470 VITAMIN A ACID AVT $ 0.2964 00587966 STIEVA-A GSK 0.2980 00443816 RETIN A VAE 0.3737

* 0.05% TOPICAL CREAM00518182 STIEVA-A GSK $ 0.2980 00443794 RETIN A VAE 0.3737

* 0.05% TOPICAL GEL01926489 VITAMIN A ACID AVT $ 0.2964 00641863 STIEVA-A GSK 0.2980

* 0.1% TOPICAL CREAM00662348 STIEVA-A FORTE (EDS) GSK $ 0.2980 00870021 RETIN A (EDS) VAE 0.3737

84:28.00 KERATOLYTIC AGENTS

BENZOYL PEROXIDE 10% WASH

01925199 BENZAC W GAC $ 0.1334 10% TOPICAL GEL (ALCOHOL BASE)

00263699 PANOXYL-10 GSK $ 0.1427 10% TOPICAL GEL (AQUEOUS BASE)

01912437 BENZAC AC GAC $ 0.3334 20% TOPICAL GEL (ALCOHOL BASE)

00373036 PANOXYL-20 GSK $ 0.1864

CLINDAMYCIN PHOSPHATE/BENZOYL PEROXIDE* 1%/5% TOPICAL GEL

02248472 BENZACLIN AVT $ 0.8918 02243158 CLINDOXYL GEL GSK 0.9007

62nd Edition 207 July 1, 2012

Page 230: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

84:00 SKIN AND MUCOUS MEMBRANE AGENTS

84:28.00 KERATOLYTIC AGENTS

DITHRANOL 0.1% TOPICAL CREAM

00537594 ANTHRANOL MTI $ 0.5616 0.2% TOPICAL CREAM

00537608 ANTHRANOL MTI $ 0.5920 0.4% TOPICAL LOTION

00695351 ANTHRASCALP MTI $ 0.7000 1% TOPICAL OINTMENT

00566756 ANTHRAFORTE-1 MTI $ 0.7646 2% TOPICAL OINTMENT

00566748 ANTHRAFORTE-2 MTI $ 0.8066

ERYTHROMYCIN/BENZOYL PEROXIDE 3%/5% TOPICAL GEL

02225271 BENZAMYCIN AVT $ 1.0346

PODOFILOX 0.5% TOPICAL SOLUTION (PACKAGE)

01945149 CONDYLINE CDX $ 37.0000 02074788 WARTEC PAL 42.7800

84:36.00 MISCELLANEOUS SKIN & MUCOUS MEMBRANE AGENTS

ACITRETIN SEE APPENDIX A FOR EDS CRITERIA 10MG CAPSULE

02070847 SORIATANE (EDS) TRI $ 2.0434 25MG CAPSULE

02070863 SORIATANE (EDS) TRI $ 3.5884

AZELAIC ACID 15% TOPICAL GEL

02270811 FINACEA SEV $ 0.6000

CALCIPOTRIOL 50UG/G TOPICAL CREAM

02150956 DOVONEX LEO $ 0.7560 50UG/G TOPICAL OINTMENT

01976133 DOVONEX LEO $ 0.7337 50UG/ML SCALP SOLUTION

02194341 DOVONEX LEO $ 0.7594

62nd Edition 208 July 1, 2012

Page 231: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

84:00 SKIN AND MUCOUS MEMBRANE AGENTS84:36.00 MISCELLANEOUS SKIN & MUCOUS MEMBRANE AGENTS

CALCIPOTRIOL/BETAMETHASONE DIPROPIONATE 50UG/0.5MG/G TOPICAL OINTMENT

02244126 DOVOBET LEO $ 1.4360 50UG/0.5MG/G SCALP GEL

02319012 XAMIOL LEO $ 1.4402

CYCLOSPORINE NOTE: THE IDENTIFICATION NUMBERS LISTED FOR THIS PRODUCT HAVE BEEN GENERATED BY THE PRESCRIPTION DRUG PLAN FOR BILLING PURPOSES ONLY. SEE APPENDIX A FOR EDS CRITERIA 10MG CAPSULE

00950792 NEORAL (EDS) NVR $ 0.6239 25MG CAPSULE

00950793 NEORAL (EDS) NVR $ 1.4500 50MG CAPSULE

00950807 NEORAL (EDS) NVR $ 2.8270 100MG CAPSULE

00950815 NEORAL (EDS) NVR $ 5.6560 100MG/ML LIQUID

00950823 NEORAL (EDS) NVR $ 5.0276

FLUOROURACIL 5% TOPICAL CREAM

00330582 EFUDEX VAE $ 0.8350

IMIQUIMOD SEE APPENDIX A FOR EDS CRITERIA 5% TOPICAL CREAM (5G SACHET)

02239505 ALDARA (EDS) MDC $ 12.7884

ISOTRETINOIN* 10MG CAPSULE

00582344 ACCUTANE HLR $ 0.9314 02257955 CLARUS MYL 0.9314

* 40MG CAPSULE00582352 ACCUTANE HLR $ 1.9004 02257963 CLARUS MYL 1.9004

METHOTREXATE* 2.5MG TABLET

02170698 METHOTREXATE PFI $ 0.6325 02182963 APO-METHOTREXATE HOS 0.6325 02244798 RATIO-METHOTREXATE RPH 0.6325

10MG TABLET02182750 METHOTREXATE HOS $ 2.4541

62nd Edition 209 July 1, 2012

Page 232: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

84:00 SKIN AND MUCOUS MEMBRANE AGENTS

84:36.00 MISCELLANEOUS SKIN & MUCOUS MEMBRANE AGENTS

PIMECROLIMUS SEE APPENDIX A FOR EDS CRITERIA 1% TOPICAL CREAM

02247238 ELIDEL (EDS) VAE $ 2.2100

TACROLIMUS SEE APPENDIX A FOR EDS CRITERIA 0.03% TOPICAL OINTMENT

02244149 PROTOPIC (EDS) APC $ 2.1500 0.1% TOPICAL OINTMENT

02244148 PROTOPIC (EDS) APC $ 2.3000

TAZAROTENE 0.05% TOPICAL CREAM

02243894 TAZORAC ALL $ 1.3214 0.05% TOPICAL GEL

02230784 TAZORAC ALL $ 1.3214 0.1% TOPICAL CREAM

02243895 TAZORAC ALL $ 1.3214 0.1% TOPICAL GEL

02230785 TAZORAC ALL $ 1.3214

84:50.06 DEPIGMENTING & PIGMENTING AGENTS (PIGMENTING AGENTS)

METHOXSALEN SEE APPENDIX A FOR EDS CRITERIA 10MG CAPSULE

00252654 OXSORALEN ULTRA (EDS) VAE $ 0.4300 01946374 OXSORALEN (EDS) VAE 0.5773

1% LOTION01907476 OXSORALEN (EDS) VAE $ 1.4690

62nd Edition 210 July 1, 2012

Page 233: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

SMOOTH MUSCLE RELAXANTS86:00

Page 234: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

86:00 SMOOTH MUSCLE RELAXANTS

86:12.00 GENITOURINARY SMOOTH MUSCLE RELAXANTS

DARIFENACIN SEE APPENDIX A FOR EDS CRITERIA 7.5MG EXTENDED RELEASE TABLET

02273217 ENABLEX (EDS) NVR $ 1.5025 15MG EXTENDED RELEASE TABLET

02273225 ENABLEX (EDS) NVR $ 1.5025

OXYBUTYNIN CHLORIDE SEE APPENDIX A FOR EDS CRITERIA

* 5MG TABLET02158590 NU-OXYBUTYN NXP $ 0.1508 02163543 APO-OXYBUTYNIN APX 0.1508 02230394 NOVO-OXYBUTYNIN NOP 0.1508 02230800 MYLAN-OXYBUTYNIN MYL 0.1508 02240550 PMS-OXYBUTYNIN PMS 0.1508 02241285 DOM-OXYBUTYNIN DOM 0.1508 02350238 OXYBUTYNIN SAN 0.1508

10MG CONTROLLED RELEASE TABLET02273578 UROMAX (EDS) PFR $ 1.3655

15MG CONTROLLED RELEASE TABLET02273586 UROMAX (EDS) PFR $ 1.4710

1MG/ML SYRUP02223376 PMS-OXYBUTYNIN PMS $ 0.1183

SOLIFENACIN SUCCINATE SEE APPENDIX A FOR EDS CRITERIA 5MG TABLET

02277263 VESICARE (EDS) APC $ 1.5000 10MG TABLET

02277271 VESICARE (EDS) APC $ 1.5000

TOLTERODINE L-TARTRATE SEE APPENDIX A FOR EDS CRITERIA 2MG EXTENDED-RELEASE CAPSULE

02244612 DETROL LA (EDS) PFI $ 1.9124 4MG EXTENDED-RELEASE CAPSULE

02244613 DETROL LA (EDS) PFI $ 1.9124

TROSPIUM CHLORIDE SEE APPENDIX A FOR EDS CRITERIA 20MG TABLET

02275066 TROSEC (EDS) SNV $ 0.7635

62nd Edition 212 July 1, 2012

Page 235: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

86:00 SMOOTH MUSCLE RELAXANTS86:16.00 RESPIRATORY SMOOTH MUSCLE RELAXANTS

OXTRIPHYLLINE* 20MG/ML ELIXIR

00792942 PMS-OXTRIPHYLLINE PMS $ 0.0325 00476366 CHOLEDYL ERF 0.0384

THEOPHYLLINE (ANHYDROUS)⌧ 100MG SUSTAINED RELEASE TABLET

00692689 APO-THEO-LA APX $ 0.1300 02230085 NOVO-THEOPHYL SR NOP 0.1300

⌧ 200MG SUSTAINED RELEASE TABLET00692697 APO-THEO-LA APX $ 0.0907 02230086 NOVO-THEOPHYL SR NOP 0.0907

⌧ 300MG SUSTAINED RELEASE TABLET00692700 APO-THEO-LA APX $ 0.1400 02230087 NOVO-THEOPHYL SR NOP 0.1400

400MG SUSTAINED RELEASE TABLET02014165 UNIPHYL PFR $ 0.4980

600MG SUSTAINED RELEASE TABLET02014181 UNIPHYL PFR $ 0.6032

5.33MG/ML SOLUTION01966219 THEOLAIR LIQUID MDC $ 0.0253

62nd Edition 213 July 1, 2012

Page 236: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...
Page 237: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

VITAMINS88:00

Page 238: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

88:00 VITAMINS

88:08.00 VITAMIN B

CYANOCOBALAMIN* 1MG/ML INJECTION SOLUTION (10ML)

00521515 VITAMIN B12 SDZ $ 3.0700 01987003 CYANOCOBALAMIN CYT 3.0700

FOLIC ACID* 5MG TABLET

00426849 APO-FOLIC APX $ 0.0198 02285673 EURO-FOLIC EUR 0.0198 02366061 JAMP-FOLIC ACID JPC 0.0198

LEUCOVORIN CALCIUM (FOLINIC ACID) SEE APPENDIX A FOR EDS CRITERIA 5MG TABLET

02170493 LEUCOVORIN (EDS) PFI $ 6.1959

NIACIN 100MG TABLET

00268585 NIACIN VAE $ 0.0292 * 500MG TABLET

00557412 NIACIN JPC $ 0.0450 00294950 NIACIN VAE 0.0495

500MG EXTENDED RELEASE FILM COATED TABLET02309254 NIASPAN FCT SNV $ 1.2700

750MG EXTENDED RELEASE FILM COATED TABLET02309262 NIASPAN FCT SNV $ 1.2700

1000MG EXTENDED RELEASE FILM COATED TABLET02309289 NIASPAN FCT SNV $ 1.2700

PYRIDOXINE HCL* 25MG TABLET

80002890 JAMP-VITAMIN B6 JPC $ 0.0183 01943200 VITAMIN B6 ODN 0.0293

THIAMINE HCL 50MG TABLET

80009633 JAMP-VITAMIN B1 JPC $ 0.0700 100MG TABLET

80009588 JAMP-VITAMIN B1 JPC $ 0.1260 * 100MG/ML INJECTION SOLUTION (10ML)

00816078 VITAMIN B1 SDZ $ 11.8800 02193221 THIAMIJECT OMG 11.8800

62nd Edition 216 July 1, 2012

Page 239: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

88:00 VITAMINS

88:16.00 VITAMIN D

ALFACALCIDOL SEE APPENDIX A FOR EDS CRITERIA 0.25UG CAPSULE

00474517 ONE-ALPHA (EDS) LEO $ 0.4475 1.0UG CAPSULE

00474525 ONE-ALPHA (EDS) LEO $ 1.3396 2UG/ML ORAL DROPS (ML)

02240329 ONE-ALPHA (EDS) LEO $ 5.1170

CALCIFEROL* 8,288IU/ML ORAL SOLUTION

80003615 ERDOL/DRISODAN ODN $ 0.4200 02017598 DRISDOL AVT 0.4269

CALCITRIOL SEE APPENDIX A FOR EDS CRITERIA 0.25UG CAPSULE

00481823 ROCALTROL (EDS) HLR $ 0.9280 0.5UG CAPSULE

00481815 ROCALTROL (EDS) HLR $ 1.4758 1UG/ML ORAL SOLUTION

00824291 ROCALTROL (EDS) HLR $ 2.9560

62nd Edition 217 July 1, 2012

Page 240: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...
Page 241: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

UNCLASSIFIED THERAPEUTIC AGENTS92:00

Page 242: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

92:00 UNCLASSIFIED THERAPEUTIC AGENTS

92:00.00 UNCLASSIFIED THERAPEUTIC AGENTS

ABATACEPT SEE APPENDIX A FOR EDS CRITERIA 250MG POWDER FOR SOLUTION

02282097 ORENCIA (EDS) BMY $ 469.1500

ADALIMUMAB SEE APPENDIX A FOR EDS CRITERIA

* 40MG/0.8ML PRE-FILLED SYRINGE02258595 HUMIRA (EDS) ABB $ 729.4200 97799756 HUMIRA PF SYRINGE (EDS) ABB 729.4200

40MG/0.8ML PRE-FILLED PEN97799757 HUMIRA PEN (EDS) ABB $ 729.4200

ALENDRONATE SODIUM SEE APPENDIX A FOR EDS CRITERIA

* 10MG TABLET02247373 TEVA-ALENDRONATE (EDS) NOP $ 0.6981 02248728 APO-ALENDRONATE (EDS) APX 0.6981 02270129 MYLAN-ALENDRONATE (EDS) MYL 0.6981 02288087 SANDOZ ALENDRONATE (EDS) SDZ 0.6981 02381486 ALENDRONATE SODIUM (EDS) AHI 0.6981

* 40MG TABLET02258102 CO ALENDRONATE (EDS) COB $ 2.0370 02201038 FOSAMAX (EDS) MRK 4.0743

* 70MG TABLET02248730 APO-ALENDRONATE (EDS) APX $ 3.5201 02258110 CO ALENDRONATE (EDS) COB 3.5201 02261715 NOVO-ALENDRONATE (EDS) NOP 3.5201 02275279 RATIO-ALENDRONATE (EDS) RPH 3.5201 02284006 PMS-ALENDRONATE FC (EDS) PMS 3.5201 02286335 MYLAN-ALENDRONATE (EDS) MYL 3.5201 02288109 SANDOZ ALENDRONATE (EDS) SDZ 3.5201 02352966 ALENDRONATE (EDS) SAN 3.5201 02381494 ALENDRONATE SODIUM (EDS) AHI 3.5201 02245329 FOSAMAX (EDS) MRK 10.2375

ALENDRONATE SODIUM/VITAMIN D3 (CHOLECALCIFEROL) SEE APPENDIX A FOR EDS CRITERIA 70MG/5600IU TABLET

02314940 FOSAVANCE 70/5600 (EDS) MRK $ 4.5650

ALFUZOSIN* 10MG EXTENDED-RELEASE TABLET

02304678 SANDOZ ALFUZOSIN SDZ $ 0.4966 02314282 NOVO-ALFUZOSIN PR NOP 0.4966 02315866 APO-ALFUZOSIN APX 0.4966 02245565 XATRAL AVT 1.0251

62nd Edition 220 July 1, 2012

Page 243: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

92:00 UNCLASSIFIED THERAPEUTIC AGENTS

92:00.00 UNCLASSIFIED THERAPEUTIC AGENTS

ALGLUCOSIDASE ALFA SEE APPENDIX A FOR EDS CRITERIA 50MG/VIAL

02284863 MYOZYME (EDS) GZY $ 840.3100

ALLOPURINOL 100MG TABLET

00402818 ZYLOPRIM AAP $ 0.0780 200MG TABLET

00479799 ZYLOPRIM AAP $ 0.1300 300MG TABLET

00402796 ZYLOPRIM AAP $ 0.2125

ANAGRELIDE HCL* 0.5MG CAPSULE

02253054 MYLAN-ANAGRELIDE MYL $ 2.6361 02260107 SANDOZ ANAGRELIDE SDZ 2.6361 02274949 PMS-ANAGRELIDE PMS 2.6361 02281287 DOM-ANAGRELIDE DOM 2.6361 02236859 AGRYLIN SCI 5.5524

ANAKINRA SEE APPENDIX A FOR EDS CRITERIA 100MG/0.67ML PRE-FILLED SYRINGE

02245913 KINERET (EDS) BIO $ 46.7700

ATOMOXETINE HCL SEE APPENDIX A FOR EDS CRITERIA 10MG CAPSULE

02262800 STRATTERA (EDS) LIL $ 2.6000 18MG CAPSULE

02262819 STRATTERA (EDS) LIL $ 2.9800 25MG CAPSULE

02262827 STRATTERA (EDS) LIL $ 3.2900 40MG CAPSULE

02262835 STRATTERA (EDS) LIL $ 3.7500 60MG CAPSULE

02262843 STRATTERA (EDS) LIL $ 4.1600 80MG CAPSULE

02279347 STRATTERA (EDS) LIL $ 4.4900 100MG CAPSULE

02279355 STRATTERA (EDS) LIL $ 4.8900

62nd Edition 221 July 1, 2012

Page 244: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

92:00 UNCLASSIFIED THERAPEUTIC AGENTS

92:00.00 UNCLASSIFIED THERAPEUTIC AGENTS

AZATHIOPRINE* 50MG TABLET

02231491 MYLAN-AZATHIOPRINE MYL $ 0.3366 02236819 TEVA-AZATHIOPRINE NOP 0.3366 02242907 APO-AZATHIOPRINE APX 0.3366 02248843 NU-AZATHIOPRINE NXP 0.3366 02343002 AZATHIOPRINE SAN 0.3366 00004596 IMURAN TPI 0.9897

BETAINE ANHYDROUS 1G/SCOOP POWDER FOR ORAL SOLUTION

02238526 CYSTADANE RDT $ 4.1293

BOCEPREVIR SEE APPENDIX A FOR EDS CRITERIA 200MG CAPSULES

02370816 VICTRELIS (EDS) MRK $ 12.5000

BOCEPREVIR/RIBAVIRIN/PEGINTERFERON ALFA-2B SUBMIT QTY IN TERMS OF MCG OF PEGINTERFERON SEE APPENDIX A FOR EDS CRITERIA 80MCG REDIPENS PLUS CAPSULES PER KIT

02371448 VICTRELIS TRIPLE (EDS) MRK $ 16.5785 100MCG REDIPENS PLUS CAPSULES PER KIT

02371456 VICTRELIS TRIPLE (EDS) MRK $ 13.2628 120MCG REDIPENS PLUS CAPSULES PER KIT

02371464 VICTRELIS TRIPLE (EDS) MRK $ 11.3584 150MCG REDIPENS PLUS CAPSULES PER KIT

02371472 VICTRELIS TRIPLE (EDS) MRK $ 9.0867

BOTULINUM TOXIN TYPE A SEE APPENDIX A FOR EDS CRITERIA 100IU/VIAL INJECTION

01981501 BOTOX (EDS) ALL $ 3.5700

BROMOCRIPTINE MESYLATE 5MG CAPSULE

02230454 APO-BROMOCRIPTINE APX $ 1.4644 2.5MG TABLET

02087324 APO-BROMOCRIPTINE APX $ 0.9782

CABERGOLINE SEE APPENDIX A FOR EDS CRITERIA

* 0.5MG TABLET02301407 CO CABERGOLINE (EDS) COB $ 8.8550 02242471 DOSTINEX (EDS) PAL 13.6900

62nd Edition 222 July 1, 2012

Page 245: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

92:00 UNCLASSIFIED THERAPEUTIC AGENTS

92:00.00 UNCLASSIFIED THERAPEUTIC AGENTS

CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A SEE APPENDIX A FOR EDS CRITERIA 100U/VIAL POWDER FOR SOLUTION

02324032 XEOMIN (EDS) MRZ $ 330.0000

COLCHICINE 0.6MG TABLET

00287873 COLCHICINE EUR $ 0.2565 00572349 COLCHICINE-ODAN ODN 0.2565

1MG TABLET00206032 COLCHICINE EUR $ 0.5080 00621374 COLCHICINE-ODAN ODN 0.5080

CYCLOSPORINE (TRANSPLANT) SEE APPENDIX A FOR EDS CRITERIA 10MG CAPSULE

02237671 NEORAL (EDS) NVR $ 0.6239 25MG CAPSULE

02150689 NEORAL (EDS) NVR $ 1.4500 50MG CAPSULE

02150662 NEORAL (EDS) NVR $ 2.8270 100MG CAPSULE

02150670 NEORAL (EDS) NVR $ 5.6560 100MG/ML LIQUID

02150697 NEORAL (EDS) NVR $ 5.0276

DENOSUMAB SEE APPENDIX A FOR EDS CRITERIA 60MG/ML PRE-FILLED SYRINGE

02343541 PROLIA (EDS) AMG $ 340.5600 60MG/ML VIAL

02343568 PROLIA (EDS) AMG $ 340.5600

DUTASTERIDE 0.5MG CAPSULE

02247813 AVODART GSK $ 1.6570

ETANERCEPT SEE APPENDIX A FOR EDS CRITERIA 25MG/VIAL POWDER FOR INJECTION (VIAL)

02242903 ENBREL (EDS) AMG $ 189.4200 50MG/ML PRE-FILLED SYRINGE/AUTOINJECTOR

02274728 ENBREL (EDS) AMG $ 378.9500

62nd Edition 223 July 1, 2012

Page 246: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

92:00 UNCLASSIFIED THERAPEUTIC AGENTS

92:00.00 UNCLASSIFIED THERAPEUTIC AGENTS

ETIDRONATE DISODIUM* 200MG TABLET

02245330 MYLAN-ETIDRONATE MYL $ 0.4996 02248686 CO ETIDRONATE COB 0.4996

ETIDRONATE DISODIUM/CALCIUM CARBONATE* 400MG/1250MG TABLET (PACKAGE)

02247323 MYLAN-ETI-CAL CAREPAC MYL $ 19.9900 02263866 CO ETIDROCAL COB 19.9900 02324199 NOVO-ETIDRONATECAL NOP 19.9900 02353210 ETIDROCAL SAN 19.9900 02176017 DIDROCAL WCI 43.8300

FEBUXOSTAT SEE APPENDIX A FOR EDS CRITERIA 80MG TABLET

02357380 ULORIC (EDS) TAK $ 1.5900

FINASTERIDE* 5MG TABLET

02306905 RATIO-FINASTERIDE RPH $ 0.6486 02310112 PMS-FINASTERIDE PMS 0.6486 02322579 SANDOZ FINASTERIDE SDZ 0.6486 02348500 NOVO-FINASTERIDE NOP 0.6486 02354462 CO FINASTERIDE COB 0.6486 02355043 FINASTERIDE TABLETS USP AHI 0.6486 02356058 MYLAN-FINASTERIDE MYL 0.6486 02357224 JAMP-FINASTERIDE JPC 0.6486 02365383 APO-FINASTERIDE APX 0.6486 02371820 RAN-FINASTERIDE RAN 0.6486 02010909 PROSCAR MRK 1.9184

FINGOLIMOD HYDROCHLORIDE SEE APPENDIX D FOR EDS CRITERIA 0.5MG CAPSULE

02365480 GILENYA (EDS) NVR $ 85.1648

GLATIRAMER ACETATE SEE APPENDIX D FOR EDS CRITERIA 20MG INJECTION (PRE-FILLED SYRINGE)

02245619 COPAXONE (EDS) TVM $ 43.2000

GLUCAGON 1MG INJECTION POWDER (RDNA ORIGIN)

02243297 GLUCAGON LIL $ 86.3500

62nd Edition 224 July 1, 2012

Page 247: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

92:00 UNCLASSIFIED THERAPEUTIC AGENTS

92:00.00 UNCLASSIFIED THERAPEUTIC AGENTS

GOLIMUMAB SEE APPENDIX A FOR EDS CRITERIA 50MG/0.5ML PRE-FILLED SYRINGE (MG)

02324776 SIMPONI (EDS) JJI $ 28.9400 50MG/0.5ML AUTO-INJECTOR (MG)

02324784 SIMPONI (EDS) JJI $ 28.9400

INFLIXIMAB WHEN BILLING, SUBMIT QUANTITY IN TERMS OF MILLIGRAMS. SEE APPENDIX A FOR EDS CRITERIA 100MG/VIAL INJECTION (MG)

02244016 REMICADE (EDS) JJI $ 9.4000

INTERFERON BETA-1A SEE APPENDIX D FOR EDS CRITERIA 8.8UG (6) 22UG (6) PRE-FILLED SYRINGE

02281708 REBIF INITIATION PAC (EDS) SRO $ 125.0900 22UG (6 MILLION IU) PRE-FILLED SYRINGE

02237319 REBIF (EDS) SRO $ 125.0900 44UG (12 MILLION IU) PRE-FILLED SYRINGE

02237320 REBIF (EDS) SRO $ 152.2900 66UG/1.5ML (3 DOSES/22UG) PF CARTRIDGE

02318253 REBIF (EDS) SRO $ 375.2700 132UG/1.5ML (3 DOSES/44UG) PF CARTRIDGE

02318261 REBIF (EDS) SRO $ 456.8500 30UG POWDER FOR IM INJECTION (VIAL)

02237770 AVONEX (EDS) BGN $ 392.7900 30UG (30 MILLION IU) PF SYRINGE/PEN AUTO-INJ

02269201 AVONEX PS/PEN (EDS) BGN $ 392.7900

INTERFERON BETA-1B SEE APPENDIX D FOR EDS CRITERIA 0.3MG POWDER FOR INJECTION (VIAL)

02337819 EXTAVIA (EDS) NVR $ 99.3600 02169649 BETASERON (EDS) BAY 110.0000

KETOTIFEN FUMARATE SEE APPENDIX A FOR EDS CRITERIA 1MG TABLET

00577308 ZADITEN (EDS) TEV $ 1.6722 0.2MG/ML SYRUP

02176084 NOVO-KETOTIFEN (EDS) NOP $ 0.1330

62nd Edition 225 July 1, 2012

Page 248: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

92:00 UNCLASSIFIED THERAPEUTIC AGENTS

92:00.00 UNCLASSIFIED THERAPEUTIC AGENTS

LANREOTIDE ACETATE WHEN BILLING, SUBMIT QUANTITY IN TERMS OF MILLIGRAMS. SEE APPENDIX A FOR EDS CRITERIA 60MG/UNIT SYRINGE

02283395 SOMATULINE AUTOGEL (EDS) SRO $ 19.3700 90MG/UNIT SYRINGE

02283409 SOMATULINE AUTOGEL (EDS) SRO $ 16.3400 120MG/UNIT SYRINGE

02283417 SOMATULINE AUTOGEL (EDS) SRO $ 15.3400

LEFLUNOMIDE SEE APPENDIX A FOR EDS CRITERIA

* 10MG TABLET02256495 APO-LEFLUNOMIDE (EDS) APX $ 3.7006 02261251 NOVO-LEFLUNOMIDE (EDS) NOP 3.7006 02283964 SANDOZ LEFLUNOMIDE (EDS) SDZ 3.7006 02288265 PMS-LEFLUNOMIDE (EDS) PMS 3.7006 02319225 MYLAN-LEFLUNOMIDE (EDS) MYL 3.7006 02351668 LEFLUNOMIDE (EDS) SAN 3.7006 02241888 ARAVA (EDS) AVT 10.9044

* 20MG TABLET02256509 APO-LEFLUNOMIDE (EDS) APX $ 3.7006 02261278 NOVO-LEFLUNOMIDE (EDS) NOP 3.7006 02283972 SANDOZ LEFLUNOMIDE (EDS) SDZ 3.7006 02288273 PMS-LEFLUNOMIDE (EDS) PMS 3.7006 02319233 MYLAN-LEFLUNOMIDE (EDS) MYL 3.7006 02351676 LEFLUNOMIDE (EDS) SAN 3.7006 02241889 ARAVA (EDS) AVT 10.9044

MARAVIROC SEE APPENDIX A FOR EDS CRITERIA 150MG TABLET

02299844 CELSENTRI (EDS) VII $ 16.5000 300MG TABLET

02299852 CELSENTRI (EDS) VII $ 16.5000

MONTELUKAST SODIUM SEE APPENDIX A FOR EDS CRITERIA

* 4MG CHEWABLE TABLET02330385 SANDOZ MONTELUKAST (EDS) SDZ $ 0.5044 02354977 PMS-MONTELUKAST (EDS) PMS 0.5044 02355507 TEVA-MONTELUKAST (EDS) TEV 0.5044 02377608 APO-MONTELUKAST (EDS) APX 0.5044 02380749 MYLAN-MONTELUKAST (EDS) MYL 0.5044 02243602 SINGULAIR (EDS) MRK 1.4904

62nd Edition 226 July 1, 2012

Page 249: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

92:00 UNCLASSIFIED THERAPEUTIC AGENTS

92:00.00 UNCLASSIFIED THERAPEUTIC AGENTS

* 5MG CHEWABLE TABLET02330393 SANDOZ MONTELUKAST (EDS) SDZ $ 0.5565 02354985 PMS-MONTELUKAST (EDS) PMS 0.5565 02355515 TEVA-MONTELUKAST (EDS) TEV 0.5565 02377616 APO-MONTELUKAST (EDS) APX 0.5565 02380757 MYLAN-MONTELUKAST (EDS) MYL 0.5565 02238216 SINGULAIR (EDS) MRK 1.6504

* 10MG TABLET02328593 SANDOZ MONTELUKAST (EDS) SDZ $ 0.8195 02355523 TEVA-MONTELUKAST (EDS) TEV 0.8195 02373947 PMS-MONTELUKAST (EDS) PMS 0.8195 02379236 MONTELUKAST SODIUM (EDS) AHI 0.8195 02238217 SINGULAIR (EDS) MRK 2.4237

* 4MG ORAL GRANULE02358611 SANDOZ MONTELUKAST (EDS) SDZ $ 0.5044 02247997 SINGULAIR (EDS) MRK 1.4904

MYCOPHENOLATE MOFETIL SEE APPENDIX A FOR EDS CRITERIA

* 250MG CAPSULE02320630 SANDOZ MYCOPHENOLATE (EDS) SDZ $ 0.7217 02352559 APO-MYCOPHENOLATE (EDS) APX 0.7217 02364883 NOVO-MYCOPHENOLATE (EDS) TEV 0.7217 02371154 MYLAN-MYCOPHENOLATE (EDS) MYL 0.7217 02192748 CELLCEPT (EDS) HLR 2.0620

* 500MG TABLET02313855 SANDOZ MYCOPHENOLATE (EDS) SDZ $ 1.4434 02348675 NOVO-MYCOPHENOLATE (EDS) TEV 1.4434 02352567 APO-MYCOPHENOLATE (EDS) APX 1.4434 02370549 MYLAN-MYCOPHENOLATE (EDS) MYL 1.4434 02378574 MYCOPHENOLATE MOFETIL (EDS) AHI 1.4434 02379996 CO MYCOPHENOLATE (EDS) COB 1.4434 02237484 CELLCEPT (EDS) HLR 4.1240

200MG/ML SUSPENSION02242145 CELLCEPT (EDS) HLR $ 1.6496

MYCOPHENOLATE SODIUM SEE APPENDIX A FOR EDS CRITERIA 180MG ENTERIC COATED TABLET

02264560 MYFORTIC (EDS) NVR $ 1.9977 360MG ENTERIC COATED TABLET

02264579 MYFORTIC (EDS) NVR $ 3.9954

NATALIZUMAB SEE APPENDIX D FOR EDS CRITERIA 20MG/ML INJECTION SOLUTION (ML)

02286386 TYSABRI (EDS) BGN $ 173.1000

62nd Edition 227 July 1, 2012

Page 250: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

92:00 UNCLASSIFIED THERAPEUTIC AGENTS

92:00.00 UNCLASSIFIED THERAPEUTIC AGENTS

OCTREOTIDE WHEN BILLING LAR FORM, SUBMIT QUANTITY IN TERMS OF MILLIGRAMS. SEE APPENDIX A FOR EDS CRITERIA

* 50UG INJECTION (1ML)02248639 OCTREOTIDE ACETATE (EDS) OMG $ 1.7500 00839191 SANDOSTATIN (EDS) NVR 5.0700

* 100UG INJECTION (1ML)02248640 OCTREOTIDE ACETATE (EDS) OMG $ 3.3000 00839205 SANDOSTATIN (EDS) NVR 9.5700

* 200UG/ML INJECTION (5ML)02248642 OCTREOTIDE ACETATE (EDS) OMG $ 31.7100 02049392 SANDOSTATIN (EDS) NVR 92.0500

* 500UG INJECTION (1ML)02248641 OCTREOTIDE ACETATE (EDS) OMG $ 15.5000 00839213 SANDOSTATIN (EDS) NVR 44.9800

10MG/VIAL POWDER FOR INJECTION (MG)02239323 SANDOSTATIN LAR (EDS) NVR $ 131.5800

20MG/VIAL POWDER FOR INJECTION (MG)02239324 SANDOSTATIN LAR (EDS) NVR $ 85.0000

30MG/VIAL POWDER FOR INJECTION (MG)02239325 SANDOSTATIN LAR (EDS) NVR $ 72.7000

PAMIDRONATE DISODIUM SEE APPENDIX A FOR EDS CRITERIA

* 30MG INJECTION02244550 PAMIDRONATE DISODIUM(EDS) HOS $ 56.7800 02059762 AREDIA (EDS) NVR 166.9300

60MG INJECTION02244551 PAMIDRONATE DISODIUM(EDS) HOS $ 95.0600

* 90MG INJECTION02244552 PAMIDRONATE DISODIUM(EDS) HOS $ 170.3400 02059789 AREDIA (EDS) NVR 500.7900

PENTOSAN POLYSULFATE SO4 SEE APPENDIX A FOR EDS CRITERIA 100MG CAPSULE

02029448 ELMIRON (EDS) JAN $ 1.7930

62nd Edition 228 July 1, 2012

Page 251: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

92:00 UNCLASSIFIED THERAPEUTIC AGENTS

92:00.00 UNCLASSIFIED THERAPEUTIC AGENTS

PREGABALIN SEE APPENDIX A FOR EDS CRITERIA 25MG CAPSULE

02268418 LYRICA (EDS) PFI $ 0.7990 50MG CAPSULE

02268426 LYRICA (EDS) PFI $ 1.2534 75MG CAPSULE

02268434 LYRICA (EDS) PFI $ 1.6219 150MG CAPSULE

02268450 LYRICA (EDS) PFI $ 2.2357 300MG CAPSULE

02268485 LYRICA (EDS) PFI $ 2.2357

QUINAGOLIDE HCL SEE APPENDIX A FOR EDS CRITERIA 0.075MG TABLET

02223767 NORPROLAC (EDS) FEI $ 1.0900 0.150MG TABLET

02223775 NORPROLAC (EDS) FEI $ 1.6300

RANIBIZUMAB WHEN BILLING, SUBMIT QUANTITY IN TERMS OF MILLIGRAMS. SEE APPENDIX A FOR EDS CRITERIA 10MG/ML INJECTION SOLUTION (MCG)

02296810 LUCENTIS (EDS) NVR $ 0.6848

RASAGILINE MESYLATE 0.5MG TABLET

02284642 AZILECT TVM $ 7.0000 1MG TABLET

02284650 AZILECT TVM $ 7.0000

RIFABUTIN SEE APPENDIX A FOR EDS CRITERIA 150MG CAPSULE

02063786 MYCOBUTIN (EDS) PFI $ 3.9821

62nd Edition 229 July 1, 2012

Page 252: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

92:00 UNCLASSIFIED THERAPEUTIC AGENTS

92:00.00 UNCLASSIFIED THERAPEUTIC AGENTS

RISEDRONATE SODIUM SEE APPENDIX A FOR EDS CRITERIA

* 5MG TABLET02298376 NOVO-RISEDRONATE (EDS) NOP $ 1.3661 02242518 ACTONEL (EDS) WCI 1.8800

* 30MG TABLET02298384 NOVO-RISEDRONATE (EDS) NOP $ 5.9000 02239146 ACTONEL (EDS) WCI 12.1800

* 35MG TABLET02298392 NOVO-RISEDRONATE (EDS) NOP $ 3.4003 02302209 PMS-RISEDRONATE (EDS) PMS 3.4003 02319861 RATIO-RISEDRONATE (EDS) RPH 3.4003 02327295 SANDOZ RISEDRONATE (EDS) SDZ 3.4003 02353687 APO-RISEDRONATE (EDS) APX 3.4003 02357984 MYLAN-RISEDRONATE (EDS) MYL 3.4003 02370255 RISEDRONATE (EDS) SAN 3.4003 02246896 ACTONEL (EDS) WCI 10.2850

150MG TABLET02316838 ACTONEL (EDS) WCI $ 54.6000

RITUXIMAB SEE APPENDIX A FOR EDS CRITERIA 10MG/ML INJECTION SOLUTION (ML)

02241927 RITUXAN (EDS) HLR $ 45.3100

SEVELAMER HCL SEE APPENDIX A FOR EDS CRITERIA 800MG TABLET

02244310 RENAGEL (EDS) GZY $ 1.6357

SIROLIMUS SEE APPENDIX A FOR EDS CRITERIA 1MG/ML ORAL SOLUTION

02243237 RAPAMUNE (EDS) PFI $ 7.7275 1MG TABLET

02247111 RAPAMUNE (EDS) PFI $ 7.7275

SODIUM CROMOGLYCATE SEE APPENDIX A FOR EDS CRITERIA 100MG CAPSULE

00500895 NALCROM (EDS) AVT $ 1.4276 10MG/ML INHALATION SOLUTION (2ML)

02046113 PMS-SODIUM CROMOGLYCATE PMS $ 0.7696

62nd Edition 230 July 1, 2012

Page 253: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

92:00 UNCLASSIFIED THERAPEUTIC AGENTS92:00.00 UNCLASSIFIED THERAPEUTIC AGENTS

TACROLIMUS SEE APPENDIX A FOR EDS CRITERIA 0.5MG CAPSULE

02243144 PROGRAF (EDS) APC $ 1.9700 1MG CAPSULE

02175991 PROGRAF (EDS) APC $ 2.5200 5MG CAPSULE

02175983 PROGRAF (EDS) APC $ 12.6200 5MG/ML AMPOULE

02176009 PROGRAF (EDS) APC $ 124.5000 0.5MG EXTENDED RELEASE CAPSULE

02296462 ADVAGRAF (EDS) APC $ 1.9700 1MG EXTENDED RELEASE CAPSULE

02296470 ADVAGRAF (EDS) APC $ 2.5200 3MG EXTENDED RELEASE CAPSULE

02331667 ADVAGRAF (EDS) APC $ 7.5600 5MG EXTENDED RELEASE CAPSULE

02296489 ADVAGRAF (EDS) APC $ 12.6200

TAMSULOSIN HCL* 0.4MG SUSTAINED RELEASE CAPSULE

02281392 NOVO-TAMSULOSIN NOP $ 0.3415 02298570 MYLAN-TAMSULOSIN MYL 0.3415

* 0.4MG CR TABLET/SR CAPSULE02294265 RATIO-TAMSULOSIN RPH $ 0.2100 02295121 SANDOZ TAMSULOSIN SDZ 0.2100 02340208 SANDOZ TAMSULOSIN CR SDZ 0.2100 02362406 APO-TAMSULOSIN CR APX 0.2100 02366231 AVA-TAMSULOSIN CR AVA 0.2100 02368242 TEVA-TAMSULOSIN CR TEV 0.2100 02270102 FLOMAX CR BOE 0.6190

TELAPREVIR SEE APPENDIX A FOR EDS CRITERIA 375MG TABLET

02371553 INCIVEK (EDS) VER $ 69.3810

TETRABENAZINE 25MG TABLET

02199270 NITOMAN VAE $ 6.6457

62nd Edition 231 July 1, 2012

Page 254: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

92:00 UNCLASSIFIED THERAPEUTIC AGENTS

92:00.00 UNCLASSIFIED THERAPEUTIC AGENTS

TOCILIZUMAB SEE APPENDIX A FOR EDS CRITERIA 20MG/ML SOLUTION FOR INFUSION (4ML)

02350092 ACTEMRA (EDS) HLR $ 179.2000 20MG/ML SOLUTION FOR INFUSION (10ML)

02350106 ACTEMRA (EDS) HLR $ 448.0000 20MG/ML SOLUTION FOR INFUSION (20ML)

02350114 ACTEMRA (EDS) HLR $ 896.0000

TRIMEPRAZINE TARTRATE 2.5MG TABLET

01926306 PANECTYL ERF $ 0.3484 5MG TABLET

01926292 PANECTYL ERF $ 0.4292

USTEKINUMAB WHEN BILLING, SUBMIT QUANTITY IN TERMS OF MILLIGRAMS. SEE APPENDIX A FOR EDS CRITERIA 45MG/0.5ML INJECTION SOLUTION (MG)

02320673 STELARA (EDS) JAN $ 99.4987

ZAFIRLUKAST SEE APPENDIX A FOR EDS CRITERIA 20MG TABLET

02236606 ACCOLATE (EDS) AST $ 0.7580

ZOLEDRONIC ACID SEE APPENDIX A FOR EDS CRITERIA 5MG/100ML INJECTION SOLUTION (VIAL)

02269198 ACLASTA (EDS) NVR $ 670.8000

62nd Edition 232 July 1, 2012

Page 255: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

DIABETIC SUPPLIES94:00

Page 256: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

94:00 DIABETIC SUPPLIES

94:00.00 DIABETIC SUPPLIES

NOTE: SOME OF THE IDENTIFICATION NUMBERS LISTED IN THISSECTION HAVE BEEN GENERATED BY THE PRESCRIPTION DRUG PLANFOR BILLING PURPOSES ONLY.

ISOPROPYL ALCOHOL 70% SWAB

00795232 WEBCOL ALCOHOL PREP TYC $ 0.0099 80002455 ALCOHOL SWAB NDI 0.0122 00480452 ALCOHOL PREP NHP 0.0150 02240759 BD ALCOHOL SWAB BDC 0.0169

LANCET LANCET

97799807 MPD ULTRA THIN MPD $ 0.0387 97799810 MPD THIN MPD 0.0387 00977659 BD ULTRA FINE II LANCET BDC 0.0505 00906190 PRECISION THIN ABC 0.0532 00950913 EQUATE THIN MPD 0.0546 99401063 FREESTYLE ABC 0.0560 00950914 EQUATE ULTRATHIN MPD 0.0598 00906239 MICROLET BAY 0.0636 00901359 ONE TOUCH ULTRA SOFT LSN 0.0650 97799466 BGSTAR AVT 0.0650 97799501 ONE TOUCH DELICA LSN 0.0670 97799540 EZ HEALTH ORACLE THI 0.0688 00000165 SOFTCLIX ROC 0.0770 00950927 BD ULTRAFINE 33 BDC 0.0831 00950944 ACCU-CHEK MULTICLIX ROC 0.0932 97799494 ACCU-CHEK FASTCLIX MOBILE ROC 0.0932 00995965 GLUCOLET FINGERSTIX BAY 0.1269 00950915 SOFTCLIX PRO ROC 0.1300

NEEDLE 28G NEEDLE

99221028 NOVOFINE 12MM NOO $ 0.3301 29G NEEDLE

00964344 UNIFINE 12MM ACM $ 0.1680 97799566 INSUPEN 12MM DRX 0.2100 97799561 SUPER-FINE STANDARD/12.7 PMS 0.2440 97799543 ULTICARE PEN 29G 12MM ULT 0.2518 00977101 BD ULTRA FINE 12.7MM BDC 0.3050

30G NEEDLE97799567 INSUPEN 8MM DRX $ 0.2100 00908169 NOVOFINE 8MM NOO 0.3301 97799467 NOVOTWIST TIP NEEDLE NOO 0.3301 99117796 NOVOFINE 6MM NOO 0.3301

62nd Edition 234 July 1, 2012

Page 257: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

94:00 DIABETIC SUPPLIES

94:00.00 DIABETIC SUPPLIES

31G NEEDLE00964220 UNIFINE 8MM ACM $ 0.1895 00964271 UNIFINE 6MM ACM 0.1895 97799568 INSUPEN 8MM DRX 0.2100 97799569 INSUPEN 6MM DRX 0.2100 97799562 SUPER-FINE MICRO 5MM PMS 0.2440 97799563 SUPER-FINE XTRA 8MM PMS 0.2440 97799544 ULTICARE PEN 31G 8MM ULT 0.2518 97799545 ULTICARE PEN 31G 6MM ULT 0.2518 00977011 BD ULTRAFINE 5MM 8MM BDC 0.2771

32G NEEDLE97799570 INSUPEN 8MM DRX $ 0.2500 97799571 INSUPEN 6MM DRX 0.2500 97799527 BD ULTRA-FINE NANO BDC 0.2850 97799468 NOVOTWIST TIP NEEDLE NOO 0.3403 97799764 NOVOFINE ETW 32G NOO 0.3403

SYRINGE 0.3CC SYRINGE

00977951 MONOJECT ULTRACOMFORT 29G TYC $ 0.1145 99254011 MONOJECT ULTRACOMFORT 30G TYC 0.1212 00964018 ULTICARE 29G ACM 0.1980 00964174 ULTICARE 30G ACM 0.2080 97799516 ULTICARE 30G 1/2 ULT 0.2144 97799513 ULTICARE 31G 5/16 ULT 0.2171 97799509 ULTICARE 29G 1/2 ULT 0.2610 97799506 ULTICARE 30G 5/16 ULT 0.2750 97799551 ULTICARE 30G 1/2 ULT 0.2750 97799548 ULTICARE 31G 5/16 ULT 0.2850 00920193 BD ULTRA FINE-29G BDC 0.3091 00950959 BD ULTRAFINE 11 1/2 U 31G BDC 0.3091

0.5CC SYRINGE00920355 MONOJECT ULTRACOMFORT 30G TYC $ 0.1178 99432799 MONOJECT ULTRACOMFORT 29G TYC 0.1178 97799518 ULTICARE 28G 1/2 ULT 0.1950 00963941 ULTICARE 29G ACM 0.1980 00964115 ULTICARE 30G ACM 0.2080 97799515 ULTICARE 30G 1/2 ULT 0.2144 97799512 ULTICARE 31G 5/16 ULT 0.2171 97799508 ULTICARE 29G 1/2 ULT 0.2610 97799505 ULTICARE 30G 5/16 ULT 0.2750 97799550 ULTICARE 30G 1/2 ULT 0.2750 97799547 ULTICARE 31G 5/16 ULT 0.2850 00920207 BD ULTRA FINE-29G BDC 0.3091 97799885 BD ULTRAFINE 11 1/2U 30G BDC 0.3091

62nd Edition 235 July 1, 2012

Page 258: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

94:00 DIABETIC SUPPLIES

94:00.00 DIABETIC SUPPLIES

1CC SYRINGE99433383 MONOJECT ULTRACOMFORT 29G TYC $ 0.1279 00920045 MONOJECT ULTRACOMFORT 30G TYC 0.1313 97799517 ULTICARE 28G/1/2 ULT 0.1950 00963895 ULTICARE 29G ACM 0.1980 00964069 ULTICARE 30G ACM 0.2080 97799514 ULTICARE 30G/1/2 ULT 0.2144 97799511 ULTICARE 31G 5/16 ULT 0.2171 97799507 ULTICARE 29G 1/2 ULT 0.2610 97799504 ULTICARE 30G 5/16 ULT 0.2750 97799549 ULTICARE 30G 1/2 ULT 0.2750 97799546 ULTICARE 31G 5/16 ULT 0.2850 00909238 BD ULTRAFINE II SHORT-30G BDC 0.3091 00920215 BD ULTRAFINE-29G BDC 0.3091

94:00.00 INSULIN PUMP SUPPLIES

NOTE: THE IDENTIFICATION NUMBERS LISTED IN THIS SECTIONHAVE BEEN GENERATED BY THE PRESCRIPTION DRUG PLAN FOR BILLINGPURPOSES ONLY.

CARTRIDGE/RESERVOIR 1.8ML SYRINGE RESERVOIR

97799707 PARADIGM RESERVOIR (EDS) MOC $ 4.3500 2.0ML CARTRIDGE

00951039 ANIMAS CARTRIDGE (EDS) ANC $ 6.3710 3.0ML RESERVOIR/CARTRIDGE

97799706 PARADIGM RESERVOIR (EDS) MOC $ 4.3500 00951010 COZMO CARTRIDGE (EDS) ACM 5.2500

3.15ML PLASTIC CARTRIDGE00950971 ACCU-CHEK SPIRIT (EDS) DIS $ 3.8000

OMNIPOD AUTOMATED DELIVERY DEVICE00951173 OMNIPOD DEL DEVICE (EDS) GSK $ 30.0000

INFUSION SET 6MM CANNULA/18" TUBING

97799521 SURE T (EDS) MOC $ 16.8000 97799486 PARADIGM QUICK-SET (EDS) MOC 20.5000 97799491 PARADIGM MIO/BLUE (EDS) MOC 21.5000 97799492 PARADIGM MIO/PINK (EDS) MOC 21.5000

6MM CANNULA/23" TUBING00951042 CONTACT DETACH (EDS) ANC $ 15.5000 97799520 SURE T (EDS) MOC 16.8000 00951043 INSET 11 (EDS) ANC 19.5000 97799744 PARADIGM QUICK-SET (EDS) MOC 20.5000

6MM CANNULA/24" TUBING00951012 CONTACT DETACH (EDS) ACM $ 10.5000 00950973 ACCU-CHEK RAPID D (EDS) DIS 11.6700 00951015 CLEO 90 (EDS) ACM 15.5000 00951014 THINSET 90 (EDS) ACM 17.5000 97799732 PARADIGM SOF-SET MICRO (EDS) MOC 19.2000

62nd Edition 236 July 1, 2012

Page 259: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

94:00 DIABETIC SUPPLIES

94:00.00 INSULIN PUMP SUPPLIES

6MM CANNULA/31" TUBING00950974 ACCU-CHEK RAPID D (EDS) DIS $ 11.6700 00951016 CLEO 90 (EDS) ACM 15.5000

6MM CANNULA/32" TUBING97799487 PARADIGM QUICK-SET (EDS) MOC $ 20.5000 97799490 PARADIGM MIO (EDS) MOC 21.5000

6MM CANNULA/42" TUBING00951019 CLEO 90 (EDS) ACM $ 15.5000 00951018 THINSET 90 (EDS) ACM 17.5000 97799733 PARADIGM SOF-SET MICRO (EDS) MOC 19.2000

6MM CANNULA/43" TUBING00950975 ACCU-CHEK RAPID D (EDS) DIS $ 11.6700 00951044 INSET 11 (EDS) ANC 19.5000 97799743 PARADIGM QUICK-SET (EDS) MOC 20.5000

8MM CANNULA/23" TUBING97799519 SURE T (EDS) MOC $ 16.8000

8MM CANNULA/24" TUBING00950976 ACCU-CHEK RAPID D (EDS) DIS $ 11.6700 00950983 ACCU-CHEK ULTRAFLEX 2 (EDS) DIS 14.5000 00950982 ACCU-CHEK ULTRAFLEX 1 (EDS) DIS 17.5000

8MM CANNULA/31" TUBING00950977 ACCU-CHEK RAPID D (EDS) DIS $ 11.6700 00950985 ACCU-CHEK ULTRAFLEX 2 (EDS) DIS 14.5000 00950984 ACCU-CHEK ULTRAFLEX 1 (EDS) DIS 17.5000

8MM CANNULA/43" TUBING00950978 ACCU-CHEK RAPID D (EDS) DIS $ 11.6700 00950987 ACCU-CHEK ULTRAFLEX 2 (EDS) DIS 14.5000 00950986 ACCU-CHEK ULTRAFLEX 1 (EDS) DIS 17.5000

9MM CANNULA/23" TUBING00951045 INSET 11 (EDS) ANC $ 19.5000 97799742 PARADIGM QUICK-SET (EDS) MOC 20.5000

9MM CANNULA/24" TUBING00951021 CLEO 90 (EDS) ACM $ 15.5000 00951020 THINSET 90 (EDS) ACM 17.5000 97799734 PARADIGM SOF-SET QR (EDS) MOC 19.0000

9MM CANNULA/31" TUBING00951022 CLEO 90 (EDS) ACM $ 15.5000

9MM CANNULA/32" TUBING97799488 PARADIGM QUICK-SET (EDS) MOC $ 20.5000 97799489 PARADIGM MIO (EDS) MOC 21.5000

9MM CANNULA/42" TUBING00951024 CLEO 90 (EDS) ACM $ 15.5000 00951023 THINSET 90 (EDS) ACM 17.5000 97799735 PARADIGM SOF-SET QR (EDS) MOC 19.0000

9MM CANNULA/43" TUBING00951046 INSET 11 (EDS) ANC $ 19.5000 97799741 PARADIGM QUICK-SET (EDS) MOC 20.5000

62nd Edition 237 July 1, 2012

Page 260: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

94:00 DIABETIC SUPPLIES

94:00.00 INSULIN PUMP SUPPLIES

10MM CANNULA/24" TUBING00950979 ACCU-CHEK RAPID D (EDS) DIS $ 11.6700 00950989 ACCU-CHEK ULTRAFLEX 2 (EDS) DIS 14.5000 00950988 ACCU-CHEK ULTRAFLEX 1 (EDS) DIS 17.5000

10MM CANNULA/31" TUBING00950980 ACCU-CHEK RAPID D (EDS) DIS $ 11.6700 00950991 ACCU-CHEK ULTRAFLEX 2 (EDS) DIS 14.5000 00950990 ACCU-CHEK ULTRAFLEX 1 (EDS) DIS 17.5000

10MM CANNULA/43" TUBING00950981 ACCU-CHEK RAPID D (EDS) DIS $ 11.6700 00950993 ACCU-CHEK ULTRAFLEX 2 (EDS) DIS 14.5000 00950992 ACCU-CHEK ULTRAFLEX 1 (EDS) DIS 17.5000

13MM CANNULA/23" TUBING00951048 COMFORT SHORT COMBO (EDS) ANC $ 14.9800 00951047 COMFORT SHORT ANGLED (EDS) ANC 19.1300 00951060 INSET 30 (EDS) ANC 19.5000 97799716 PARADIGM SIL. FULL (EDS) MOC 20.5000

13MM CANNULA/24" TUBING00950995 ACCU-CHEK 2 MINI (EDS) DIS $ 14.5000 00951025 COMFORT SHORT (EDS) ACM 14.5000 00950994 ACCU-CHEK 1 MINI (EDS) DIS 17.5000

13MM CANNULA/31" TUBING00950997 ACCU-CHEK 2 MINI (EDS) DIS $ 11.6000 00951027 COMFORT SHORT (EDS) ACM 14.5000 00950996 ACCU-CHEK 1 MINI (EDS) DIS 17.5000

13MM CANNULA/42" TUBING00951029 COMFORT SHORT (EDS) ACM $ 14.5000

13MM CANNULA/43" TUBING00950999 ACCU-CHEK 2 MINI (EDS) DIS $ 14.5000 00951050 COMFORT SHORT COMBO (EDS) ANC 14.9800 00950998 ACCU-CHEK 1 MINI (EDS) DIS 17.5000 00951049 COMFORT SHORT ANGLED (EDS) ANC 19.1300 00951061 INSET 30 (EDS) ANC 19.5000 97799715 PARADIGM SIL. FULL (EDS) MOC 20.5000

13MM CANNULA00951031 COMFORT SHORT (EDS) ACM $ 12.2500 97799529 SILHOUETTE (EDS) MOC 16.8000

17MM CANNULA/23" TUBING00951052 COMFORT ANGLED COMBO (EDS) ANC $ 14.0000 00951051 COMFORT ANGLED (EDS) ANC 17.8800 97799718 PARADIGM SIL. FULL (EDS) MOC 20.5000

17MM CANNULA/24" TUBING00951001 ACCU-CHEK TENDER 2 (EDS) DIS $ 14.5000 00951032 COMFORT (EDS) ACM 14.5000 00951000 ACCU-CHEK TENDER 1 (EDS) DIS 17.5000

17MM CANNULA/31" TUBING00951003 ACCU-CHEK TENDER 2 (EDS) DIS $ 14.5000 00951034 COMFORT (EDS) ACM 14.5000 00951002 ACCU-CHEK TENDER 1 (EDS) DIS 17.5000

62nd Edition 238 July 1, 2012

Page 261: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

94:00 DIABETIC SUPPLIES

94:00.00 INSULIN PUMP SUPPLIES

17MM CANNULA/42" TUBING00951036 COMFORT (EDS) ACM $ 14.5000

17MM CANNULA/43" TUBING00951054 COMFORT ANGLED COMBO (EDS) ANC $ 14.0000 00951005 ACCU-CHEK TENDER 2 (EDS) DIS 14.5000 00951004 ACCU-CHEK TENDER 1 (EDS) DIS 17.5000 00951053 COMFORT ANGLED (EDS) ANC 17.8800 97799719 PARADIGM SIL. FULL (EDS) MOC 20.5000

17MM CANNULA00951038 COMFORT (EDS) ACM $ 12.2500 97799528 SILHOUETTE (EDS) MOC 16.8000

24" QUICK RELEASE97799721 PARADIGM POLYFIN (EDS) MOC $ 6.8000

42" QUICK RELEASE97799722 PARADIGM POLYFIN (EDS) MOC $ 6.8000

DISPOSABLE INFUSION SET97799694 PARADIGM SURE-T (EDS) MOC $ 16.8000

INSERTION DEVICE INSERTER

00950970 ACCU-CHEK LINKASSIST (EDS) DIS $ 28.0000 00951006 SEN-SERTER (EDS) MOC 36.7500 00951007 PARADIGM QUICK-SERTER (EDS) MOC 36.7500 00951008 SIL-SERTER (EDS) MOC 36.7500 00951009 SOF-SERTER (EDS) MOC 36.7500

SKIN PREPARATION SKIN PREPARATION

00950972 IV SKIN PREPARATION (EDS) DIS $ 0.2400 00951072 IV SKIN PREPARATION (EDS) MOC 0.3798 00951011 IV SKIN PREPARATION (EDS) ACM 0.4198 00951041 ADHESIVE WIPES (EDS) ANC 0.5190

62nd Edition 239 July 1, 2012

Page 262: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...
Page 263: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

APPENDICES

APPENDIX A - EXCEPTION DRUG STATUS PROGRAM

APPENDIX B - ONLINE ADJUDICATION

APPENDIX C - MAXIMUM ALLOWABLE COST (MAC) POLICY

APPENDIX D - SASKATCHEWAN MS DRUGS PROGRAM

Page 264: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

APPENDIX A

EXCEPTION DRUG STATUS PROGRAM NOTES REGARDING THE EXCEPTION DRUG STATUS (EDS) PROGRAM • Duly licensed practitioners prescribing within their scope of practice (or authorized

office staff) may apply for EDS. • Requests can be submitted by telephone, by mail or by fax. A toll-free line with an

electronic message system is available exclusively for requests on a 24-hour basis. The telephone number to access this line is 1-800-667-2549; the Drug Plan EDS Unit fax number is (306) 798-1089.

• Patients are notified by letter if coverage has been approved and the time period for which coverage has been approved.

• If a request has been denied, letters are sent to the patient and prescriber notifying them of the reason for the denial. In most cases, the Drug Plan requires more information to determine the patient's eligibility for coverage, and will reconsider coverage at such time as further information is received.

• If the drug requested is not a benefit under the Drug Plan, the patient and prescriber are notified. Payment for the medication is the responsibility of the patient in these cases. It is important to note that not all medications currently available on the market in Canada are benefits under the Saskatchewan Drug Plan or under the Exception Drug Status Program of the Drug Plan.

• The majority of EDS requests are routinely backdated 30 days from the time the Drug Plan receives the request. Provision can be made for further backdating of EDS coverage on a case-by-case basis by staff in the Operations Unit. However, there is no provision or backdating further than one year from the current date. Requests for backdating can be made by a health professional or the patient. Patients are expected to meet EDS criteria within the dates requested.

• The Drug Plan policy does not allow a fee to be charged to clients for Exception Drug Status applications made to the Drug Plan on the client's behalf.

• See NOTES CONCERNING THE FORMULARY, pages viii-xiii for additional general information regarding Exception Drug Status coverage.

• Coverage may be provided for other products in certain instances. REQUIREMENTS FOR REVIEW OF DRUGS FOR NON-APPROVED INDICATIONS On rare occasions drugs are required for non-approved indications on a case by case basis. In order to conduct a timely review of these requests the drug review committee requests the following information be provided by the prescriber: ● the disease or problem being treated ● list of previous therapies tried and the response achieved ● other non-exception options available and why not appropriate ● name of the drug being requested ● clinical evidence to strongly support the use of the drug for the condition being

treated ● outcome measures that will be followed to assess the effect of the drug ● dose of the drug and length of time to be used CRITERIA FOR COVERAGE UNDER EXCEPTION DRUG STATUS Following are the criteria for coverage of certain drugs under Exception Drug Status. Professional staff at the Drug Plan can provide further information.

242

Page 265: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

The following information is required to process all Exception Drug Status requests: • Patient name; patient Health Services Number (9 digits); name of drug;

diagnosis* relevant to use of drug; prescriber name and phone number. *For pharmacist-initiated EDS requests: The diagnosis, which must be obtained from the physician or physician's agent, is to be consistently documented within the pharmacy, whether the documentation is on the original prescription, computer file, or EDS fax form.

abacavir SO4, oral solution, 20mg/mL; tablet, 300mg (Ziagen-VII)

For management of HIV disease. This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

abacavir SO4/lamivudine, tablet, 600mg/300mg (Kivexa-VII) For management of HIV disease. This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

abacavir SO4/lamivudine/zidovudine, tablet, 300mg/150mg/300mg (Trizivir-VII)

For management of HIV disease. This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

abatacept, powder for solution, 250mg/vial (Orencia-BMY) (a) For the treatment of active rheumatoid arthritis in patients who have failed or

are intolerant to methotrexate and leflunomide. Note: This drug should NOT be used in combination with anti-TNF agents.

(b) For treatment of juvenile idiopathic arthritis in children who are intolerant to, or have not had an adequate response from etanercept. Initial treatment should be limited to a maximum of 16 weeks. Retreatment should only be permitted for children who had an adequate initial treatment response and subsequently experience a disease flare.

Abilify - see aripiprazole Accel Pioglitazone - see pioglitazone Accolate - see zafirlukast acitretin, capsule, 10mg, 25mg (Soriatane-HLR)

For treatment of: (a) Severe intractable psoriasis (b) Darier’s disease (c) Ichthyosiform dermatoses (d) Palmoplantar pustulosis and other disorders of keratization.

Aclasta - see zoledronic acid Actemra - see tocilizumab Actonel - see risedronate sodium Actos - see pioglitazone HCl Acular - see ketorolac tromethamine adalimumab, pre-filled syringe, 40mg/0.8mL (Humira-ABB); pre-filled pen, 40mg/0.8mL (Humira Pen-ABB)

For treatment of: (a) active rheumatoid arthritis in patients who have failed methotrexate and

leflunomide. (b) active rheumatoid arthritis in patients intolerant to methotrexate and

leflunomide.

243

Page 266: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

(c) psoriatic arthritis in patients who have failed methotrexate and one other DMARD.

(d) psoriatic arthritis in patients who are intolerant to methotrexate and one other DMARD.

Note: Treatment should be combined with an immunosuppressant. This product should be used in consultation with a specialist in this area. Exceptions can be considered in cases where methotrexate or leflunomide are contraindicated. (e) For treatment of ankylosing spondylitis (A.S.) according to the following

criteria: 1) For patients who have already been treated conventionally with two or

more NSAIDs taken sequentially at maximum tolerated or recommended doses for four weeks without symptom control. AND

2) Satisfy New York diagnostic criteria: a score > 4 on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) AND a score of > 4 cm on the 0-10cm spinal pain VAS on two occasions at least 12 weeks apart without any change of treatment. AND

3) Adequate response to treatment assessed at 12 weeks defined as at least 50% reduction in pre-treatment baseline BASDAI score or by > 2 units AND a reduction of > 2 cm in the spinal pain VAS.

NOTE: Coverage will not be provided when a patient switches to another anti-TNF agent if the patient fails to respond or if there is loss of response to the first agent. Requests for coverage for this indication must be made by a rheumatologist. A second application would also be required after 12 weeks to assess and would need to show an improvement to the patient’s condition on either of these medications. Please refer to the Formulary website for the application form. Subsequent annual renewal requests (beyond 15 months) will be considered for patients whose BASDAI scores do not worsen (i.e. remains within two points of the second assessment).

(f) Crohn’s disease as follows: Initially for a 6 month period: For the treatment of moderate to severely active Crohn’s disease in patients refractory to or with contraindications to an adequate course of 5-aminosalicylic acid and corticosteroids and other immunosuppressive therapy. Eligible patients should receive an induction dose of 160mg followed by 80mg two weeks later. Clinical response to adalimumab should be assessed after the induction dose. Ongoing coverage: Adalimumab maintenance therapy should only be provided for responders, as noted above, and for a dose not exceeding 40mg every two weeks. Patients undergoing this treatment should be reviewed every 6 months by a specialist.

(g) For treatment of adult patients with severe debilitating plaque psoriasis who meet all of the following criteria:

i) failure to respond to, contraindications to, or intolerant of methotrexate and cyclosporine; AND

ii) failure to respond to, intolerant to or unable to access phototherapy. Coverage will be approved initially for the induction phase of up to 16 weeks. Coverage can be renewed in patients who have responded to therapy. This product should be used in consultation with a specialist in this area.

Adcirca - see tadalafil

adefovir dipivoxil, tablet, 10mg (Hepsera-GSI) For treatment of hepatitis B when used in combination with lamivudine, in patients who have developed failure to lamivudine, as defined by an increase in HBV DNA of > 1 log10 IU/mL above the nadir, measured on two separate occasions within a interval of at least 1 month, after the first three months of lamivudine therapy, and when failure to lamivudine is not due to poor adherance to therapy.

Advagraf - see tacrolimus Advair - see salmeterol xinafoate/fluticasone propionate Advair Diskus - see salmeterol xinafoate/fluticasone propionate

244

Page 267: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

Aggrenox - see dipyridamole/acetylsalicylic acid Aldara - see imiquimod Alendronate - see alendronate sodium *alendronate sodium, tablet, 10mg (Apo-Alendronate-APX) (Novo-Alendronate-NOP) (Mylan-Alendronate-MYL) (Sandoz Alendronate-SDZ) (Alendronate Sodium Tablets-AHI) (Ran-Alendronate-RAN); tablet, 70mg (Fosamax-MSD) (CO Alendronate-COB) (pms-Alendronate-PMS) (Apo-Alendronate-APX) (Novo-Alendronate-NOP) (ratio-Alendronate-RPH) (Mylan-Alendronate-MYL) (pms-Alendronate-FC-PMS) (Alendronate-SAN) (Alendronate Sodium Tablets-AHI)

For treatment of: (a) Osteoporosis in patients unresponsive to etidronate disodium/calcium

(Didrocal) after receiving it for one year. (b) Osteoporosis in patients intolerant to etidronate disodium/calcium (Didrocal). (c) Osteoporosis in patients with pre-existing and/or recent fractures, and: (d) Glucocorticoid-induced osteoporosis in patients who have received systemic

glucocorticoid treatment for at least 3 months.

*alendronate sodium, tablet, 40mg (Fosamax-MSD) (CO Alendronate-COB) For treatment of symptomatic Paget’s disease of the bone. alendronate sodium/vitamin D3 (cholecalciferol), tablet, 70mg/5600IU (Fosavance-MSD) For treatment of osteoporosis. Alertec - see modafinil alfacalcidol, capsule, 0.25ug, 1ug; oral drops, 2ug/mL (One-Alpha-LEO)

For management of: (a) Hypocalcemia in chronic renal disease patients prior to initiation of dialysis. (b) Osteodystrophy in chronic renal disease patients prior to initiation of dialysis.

Note: Coverage for dialysis patients is provided under the Saskatchewan Aids to Independent Living (S.A.I.L.) Program. Exception Drug Status coverage is not required for S.A.I.L. patients.

alglucosidase alfa, powder for solution, 50mg/vial (Myozyme-GZY)

For patients with infantile onset Pompe disease, as demonstrated by onset of symptoms and confirmed cardiomyopathy within the first 12 months of life. The Committee approved the following monitoring and withdrawal criteria, which received approval from the Canadian Expert Drug Advisory Committee (CEDAC): The monitoring of markers of disease severity and response to treatment must include at least: - Weight, length and head circumference. - Need for ventilatory assistance, including supplementary oxygen, CPAP, BiPAP, or endotracheal intubation and ventilation. - Left ventricular mass index (LVMI) as determined by echocardiography (not ECG alone). - Periodic consultation with cardiology. - Periodic consultation with respirology. Withdrawal of therapy: - Patients to be considered for reimbursement of drug costs for alglucosidase alfa treatment must be willing to participate in the long-term evaluation of the efficacy of treatment by periodic medical assessment. Failure to comply with recommended medical assessment and investigations may result in withdrawal of financial support of drug therapy. - The development of the need for continuing invasive ventilatory support after the initiation of enzyme-replacement therapy (ERT) should be considered a treatment failure. Funding for ERT should not be continued for infants who fail to achieve ventilator-free status, or who deteriorate further, within 6 months after the initiation of ventilatory support.

245

Page 268: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

- Deterioration of cardiac function, as shown by failure of LV hypertrophy (as indicated by LV mass index) to regress by more than Z=1 unit, or persistent clinical or echocardiographic findings of cardiac systolic or diastolic failure without evidence of improvement, in spite of 24 weeks of ERT, should be considered a treatment failure and funding for ERT should be discontinued.

almotriptan malate, tablet, 6.25mg, 12.5mg (Axert-JAN) For treatment of migraine headaches in patients over 18 years of age.

The maximum quantity that can be claimed through the Drug plan is limited to 6 doses per 30 days within a 60-day period. Patients requiring more than 12 doses in a consecutive 60-day period should be considered for migraine prophylaxis therapy if they are not already receiving such therapy.

ambrisentan, tablet, 5mg, 10mg (Volibris-GSK) For the treatment of pulmonary arterial hypertension, on the recommendation of a specialist.

Amerge - see naratriptan HCl amoxicillin trihydrate/potassium clavulanate, oral suspension, 40mg/5.3mg/mL (Clavulin-GXK) *oral suspension, 80mg/11.4mg/mL (Clavulin-GSK) (Apo-Amoxi Clav-APX) *oral suspension, 25mg/6.25mg (Apo-Amoxi Clav-APX); 50mg/12.5mg/mL (Clavulin-GSK) (Apo-Amoxi Clav-APX); *tablet, 250mg/125mg, 500mg/125mg (Clavulin-GSK) (Apo-Amoxi Clav-APX) *tablet, 875mg/125mg (Clavulin-GSK) (Apo-Amoxi Clav-APX) (Novo-Clavamoxin-NOP) (ratio-Aclavulante-RPH)

For treatment of: (a) Upper and lower respiratory tract infections in patients unresponsive to first-

line antibiotics. (b) Infections caused by organisms known to be resistant or unresponsive to

alternative antibiotics. (c) Infections in patients allergic to alternative antibiotics. (d) Respiratory tract infections in nursing home patients. (e) Pneumonia in patients in the community with comorbidity e.g. chronic

underlying lung disease (excluding asthma), diabetes mellitus, renal insufficiency, heart failure, stroke.

(f) Infections in patients with neutropenia. (g) Pneumonia caused by aspiration. (h) For human, cat and dog bites. (i) Diabetic foot infections, and: (j) For completion of treatment initiated in hospital.

anakinra, subcutaneous injection (pre-filled syringe), 100mg/0.67mL (Kineret-BIO)

For treatment of: (a) Active rheumatoid arthritis in patients who have failed methotrexate and

leflunomide. (b) Active rheumatoid arthritis in patients intolerant to methotrexate and leflunomide.

(Note - exceptions can be considered in cases where methotrexate or leflunomide are contraindicated). This product should be used in consultation with a specialist in this area.

Note: Coverage will not be provided when used in combination with TNF blocking agents (i.e. adalimumab, etanercept and infliximab) due to the significantly higher risk of adverse events. Treatment should be combined with an immunosuppressant.

Androcur - see cyproterone acetate Apidra - see insulin glulisine Apo-Alendronate - see alendronate sodium Apo-Amoxi Clav - see amoxicillin trihydrate/potassium clavulanate Apo-Calcitonin - see calcitonin salmon

246

Page 269: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

Apo-Carvedilol - see carvedilol Apo-Cefprozil - see cefprozil Apo-Cefuroxime - see cefuroxime axetil Apo-Ciproflox - see ciprofloxacin Apo-Clarithromycin - see clarithromycin Apo-Clopidogrel - see clopidogrel bisulfate Apo-Clozapine - see clozapine Apo-Cyclobenzaprine - see cyclobenzaprine HCl Apo-Desmopressin - see desmopressin Apo-Etodolac - see etodolac Apo-Fluconazole - see fluconazole Apo-Flunarizine - see flunarizine Apo-Ketoconazole - see ketoconazole Apo-Ketorolac - see ketorolac tromethamine Apo-Lactulose - see lactulose Apo-Lansoprazole - see lansoprazole Apo-Leflunomide - see leflunomide Apo-Levofloxacin - see levofloxacin Apo-Megestrol - see megestrol acetate tablet Apo-Meloxicam - see meloxicam Apo-Midodrine - see midodrine HCl Apo-Minocycline - see minocycline HCl Apo-Modafinil - see modafinil Apo-Montelukast - see monelukast sodium Apo-Mycophenolate - see mycophenolate mofetil Apo-Nabumetone - see nabumetone Apo-Norflox - see norfloxacin Apo-Ofloxacin - see ofloxacin Apo-Olanzapine - see olanzapine Apo-Omeprazole - see omeprazole Apo-Oxcarbazepine - see oxcarbazepine Apo-Pantoprazole - see pantoprazole sodium Apo-Pioglitazone - see pioglitazone HCl Apo-Rabeprazole - see rabeprazole sodium Apo-Raloxifene - see raloxefene HCl Apo-Repaglinide - see repaglinide Apo-Risedronate - see risedronate sodium Apo-Rivastigmine - see rivastigmine Apo-Selegiline - see selegiline HCl Apo-Sumatriptan - see sumatriptan Apo-Ticlopidine - see ticlopidine HCl Apo-Tizanidine - see tizanidine HCl Apo-Zidovudine - see zidovudine Apo-Zolmitriptan - see zolmitriptan Aptivus - see tipranavir Aranesp - see darbepoetin alfa Arava - see leflunomide Aredia - see pamidronate Aricept - see donepezil HCl aripiprazole, tablet, 2mg, 5mg, 10mg, 15mg, 20mg, 30mg (Abilify-BMY) For the treatment of schizophrenia. Aristospan - see triamcinolone/hexacetonide atazanavir SO4, capsule, 150mg, 200mg, 300mg (Reyataz-BMY)

For management of HIV disease. This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

247

Page 270: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

atomoxetine HCl, capsule, 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg (Strattera-LIL)

For treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients who meet all of the following criteria:

• Has failed or is intolerant to treatment with methylphenidate and an amphetamine.

• Treatment with Strattera must be recommended by or in consultation with a specialist in psychiatry, pediatrics or a general practitioner with expertise in ADHD.

• Evidence of benefit from a one month trial with Strattera. atovaquone, suspension, 150mg/mL (Mepron-GSK) For treatment of Pneumocystis carinii pneumonia (PCP) in patients intolerant to

trimethoprim/sulfamethoxazole. Atripla - see efavirenz/emtricitabine/tenofovir disoproxil fumarate Auro-Cefprozil - see cefprozil Auro-Cefuroxime - see cefuroxime axetil Auro-Cyclobenzaprine - see cyclobenzaprine Ava-Azithromycin - see azithromycin Ava-Clarithromycin - see clarithromycin Ava-Levofloxacin - see levofloxacin Ava-Meloxicam - see meloxicam Ava-Pantoprazole - see pantoprazole sodium Ava-Pioglitazone - see pioglitazone HCl Ava-Sumatriptan - see sumatriptan Avandamet - see rosiglitazone maleate/metformin HCl Avandia - see rosiglitazone maleate Avelox - see moxifloxacin HCl Avonex - see Appendix D Avonex PS - see Appendix D Axert - see almotriptan malate Azithromycin - see azithromycin *azithromycin, tablet, 250mg (Zithromax-PFI) (Apo-Azithromycin-APX) (Novo-Azithromycin-NOP) (CO Azithromycin-COB) (pms-Azithromycin-PMS) (Sandoz Azithromycin-SDZ) (ratio-Azithromycin-RPH) (Mylan-Azithromycin-MYL) (Dom-Azithromycin-DOM) (Azithromycin-SAN) (GD-Azithromycin-GDI) (Ava-Azithromycin-AVA); 600mg (CO Azithromycin-COB) (pms-Azithromycin-PMS) (Dom-Azithromycin-DOM) (Zithromax-PFI) (Azithromycin-SAN) *oral suspension, 20mg/mL, 40mg/mL (Zithromax-PFI) (pms-Azithromycin-PMS) (Novo-Azithromycin-NOP) (Sandoz Azithromycin-SDZ) (Ava-Azithromycin-AVA) For treatment of:

(a) Pneumonia. (b) Upper and lower respiratory tract bacterial infections known to be resistant

or unresponsive to alternative antibiotics. (c) Infections in patients allergic to alternative antibiotics. (d) Infection (and prophylaxis) in patients with non-tuberculous Mycobacterium. (e) Chlamydia trachomatis infections, and: (f) For completion of treatment initiated in hospital with macrolides or

quinolones. (g) For patients intolerant to erythromycin and/or other antibiotics.

*azithromycin, tablet, 600mg (Zithromax-PFI) (CO Azithromycin-COB) (pms-Azithromycin-PMS) (Dom-Azithromycin-DOM)

For treatment and prophylaxis in patients with non-tuberculous Mycobacterium.

248

Page 271: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

aztreonam, inhalation powder for solution, 75mg/vial (Cayston-GSI) For the treatment of Pseudomonas aeruginosa infections when used as cyclic treatment (28 day cycles) in patients with moderate to severe cystic fibrosis (CF) and deteriorating clinical condition despite treatment with inhaled tobramycin. Notes:

This product has not been studied in patients under the age of six.

• Previous EDS approvals for inhaled tobramycin will be discontinued prior to authorizing EDS approval of Cayston.

• This product should not be used in mild CF disease. baclofen, injection, 0.05mg/mL, 0.5mg/mL, 2mg/mL (Lioresal Intrathecal-NVR)

See Appendix B for online adjudication criteria. Baraclude - see entecavir +Betaseron - see Appendix D bezafibrate, tablet, 200mg (pms-Bezafibrate-PMS); sustained release tablet, 400mg (Bezalip SR-HLR)

For treatment of: (a) Hyperlipidemia in patients unresponsive to gemfibrozil or fenofibrate. (b) Hyperlipidemia in patients who have experienced side effects with

gemfibrozil or fenofibrate.

Bezalip SR - see bezafibrate Biaxin - see clarithromycin Biaxin XL - see clarithromycin

boceprevir, capsule, 200mg (Victrelis-MRK) For the treatment of chronic hepatitis C genotype 1 infection in patients with

compensated liver disease, in combination with peginterferon alpha/ribavirin when all of the following criteria are met:

• detectable levels of hepatitis C virus (HCV) RNA in the last six months

• a fibrosis stage of F2, F3, or F4 • patient not co-infected with HIV • one course of treatment only (up to 44 weeks duration).

boceprevir/ribavirin plus peginterferon alfa 2b, combination kit, 200mg/200mg capsule/80mcg/0.5ml sol, 200mg/200mg/100mcg/0.5ml sol, 200mg/200mg/120mcg/0.5ml sol, 200mg/200mg/150mcg/0.5ml sol (Victrelis Triple-MRK)

For the treatment of chronic hepatitis C genotype 1 infection in patients with compensated liver disease, in combination with peginterferon alpha/ribavirin when all of the following criteria are met:

• detectable levels of hepatitis C virus (HCV) RNA in the last six months • a fibrosis stage of F2, F3, or F4 • patient not co-infected with HIV • one course of treatment only (up to 44 weeks duration).

bosentan, tablet, 62.5mg, 125mg (Tracleer-ACT)

For treatment of pulmonary arterial hypertension on the recommendation of a specialist.

Botox - see botulinum toxin type A

249

Page 272: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

botulinum toxin type A, injection, 100IU/vial (Botox-ALL) For treatment of:

(a) Eye dystonias, that is, blepharospasm and strabismus. (b) Cervical dystonia, that is, torticollis.

(c) Other forms of severe spasticity. (d) Hyperhidrosis of the axilla. (e) Children with non-neurologic functional outflow obstruction due to external

sphincter over-activity who are not candidates for or who have not responded to other options.

(f) Spinal cord injury patients with chronic urinary retention who are not candidates for or who have not responded to other options. Note: This criteria does not apply to patients with multiple sclerosis.

(g) Severe neurogenic bladder dysfunction in patients who have failed treatment with two anticholinergic drugs, who are unable to take these drugs because of adverse effects, who have definite evidence of detrusor hyperactivity on cystometrogram done by a qualified urodynamicist.

Brilinta - see ticagrelor budesonide, controlled ileal release capsule, 3mg (Entocort-AST) (a) For treatment of mild to moderate Crohn's Disease affecting the ileum

and/or ascending colon. Coverage will be provided for up to 8 weeks. (b) Maintenance treatment in Crohn’s Disease will be approved for patients

unresponsive or intolerant to other agents. bumetanide, tablet, 1mg, 2mg, 5mg (Burinex-LEO) See Appendix B for online adjudication criteria. buprenorphine/naloxone, sublingual tablet, 2mg/0.5, 8mg/2mg (Suboxone-SPC) For treatment of opioid dependency in patients for whom methadone is

contraindicated, (e.g. patients at high risk of, or with QT prolongation, or hypersensitivity to methadone).

Burinex - see bumetanide buserelin acetate, intranasal solution, 1.05mg/mL; injection, 1.05mg/mL (Suprefact-HRU)

For treatment of: (a) Endometriosis. (Coverage may be repeated after a six month lapse, for

another 6 month course). (b) Menorrhagia in preparation for endometrial ablation, and: (c) For pre-treatment of uterine fibroids prior to surgical removal.

*cabergoline, tablet, 0.5mg (Dostinex-PFI) (CO Cabergoline-COB) See Appendix B for online adjudication criteria.

Calcimar - see calcitonin salmon

calcitonin salmon, injection, 100IU/mL (Caltine-FEI); *injection, 200IU/mL (Calcimar-AVT)

For treatment of: (a) Osteoporosis with bone pain due to crush fracture. Coverage will be

provided for a maximum of 3 months. (b) Osteogenesis imperfecta, and: (c) For symptomatic treatment of Paget's disease of the bone. *calcitonin salmon, nasal spray, 200IU/dose (Miacalcin-NVR) (Apo-Calcitonin-APX) (Sandoz Calcitonin NS-SDZ)

For treatment of: (a) Osteoporosis in patients intolerant to listed bisphosphonates.

250

Page 273: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

(b) Osteoporosis in patients unresponsive to listed bisphosphonates after treatment for one year, and:

(c) Osteoporosis with bone pain due to crush fracture. Coverage will be provided for a maximum of 3 months as an alternative to the subcutaneous dosage form.

calcitriol, capsule, 0.25ug, 0.5ug; oral solution, 1ug/mL (Rocaltrol-HLR)

(a) For management of hypocalcemia and osteodystrophy in patients with chronic renal failure undergoing renal dialysis. Note: Coverage for dialysis patients is provided under the Saskatchewan Aids to Independent Living (SAIL) Program. Exception Drug Status coverage is NOT required for SAIL patients.

(b) For management of hypocalcemia and clinical manifestations associated with post-surgical hypoparathyroidism, idiopathic hypoparathyroidism, pseudohypoparathyroidism, or vitamin D resistant rickets.

calcium acetate, tablet, 667mg (PhosLo-FMC) For treatment of:

(a) End-stage renal disease in patients intolerant to aluminum or calcium carbonate containing phosphate-binding agents.

(b) End-stage renal disease in patients where aluminum or calcium carbonate containing phosphate-binding agents are inappropriate.

Caltine - see calcitonin salmon Carvedilol - see carvedilol *carvedilol, tablet, 3.125mg, 6.25mg, 12.5mg, 25mg (Apo-Carvedilol-APX) (pms-Carvedilol-PMS) (Nu-Carvedilol-NXP) (ratio-Carvedilol-RPH) (Ran-Carvedilol-RAN) (Mylan-Carvedilol-MYL) (Carvedilol-SAN)

For treatment of: (a) Stable symptomatic heart failure in patients taking an ACE inhibitor. (b) Stable symptomatic heart failure in patients Intolerant to an ACE inhibitor.

Cayston - see aztreonam cefixime, tablet, 400mg; suspension, 20mg/mL (Suprax-AVT) For treatment of:

(a) Infections in patients allergic to alternative antibiotics. (Note: patients who have had an anaphylactic reaction to penicillin should not receive cephalosporins.)

(b) Infections caused by organisms known to be: • Resistant to alternative antibiotics. • Unresponsive to alternative antibiotics.

(c) Uncomplicated gonorrhea. (d) For completion of antibiotic treatment initiated in hospital.

*cefprozil, tablet, 250mg, 500mg (Cefzil-BMY)(Apo-Cefprozil-APX) (Ran-Cefprozil-RAN) (Sandoz Cefprozil-SDZ) (Auro-Cefprozil-API) *oral suspension, 25mg/mL (Cefzil-BMY)(Apo-Cefprozil-APX) (Sandoz Cefprozil-SDZ) (Ran-Cefprozil-RAN) (Auro-Cefprozil-API) *oral suspension, 50mg/mL (Cefzil-BMY)(Apo-Cefprozil-APX) (Ran-Cefprozil-RPH) (Sandoz Cefprozil-SDZ) (Auro-Cefprozil-API) For treatment of:

(a) Upper and lower respiratory tract infections in patients unresponsive to first-line antibiotics.

(b) Infections caused by organisms known to be resistant or unresponsive to alternative antibiotics.

(c) Infections in patients allergic to alternative antibiotics. (Note: patients who have had an anaphylactic reaction to penicillin should not receive cephalosporins.)

251

Page 274: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

(d) Respiratory tract infections in nursing home patients. (e) Pneumonia in patients in the community with comorbidity e.g. chronic

underlying lung disease (excluding asthma), diabetes mellitus, renal insufficiency, heart failure, stroke, and:

(f) For completion of antibiotic treatment initiated in hospital. Ceftin - see cefuroxime axetil cefuroxime axetil, suspension, 25mg/mL (Ceftin-GSK) *tablet, 250mg, 500mg (Ceftin-GSK) (ratio-Cefuroxime-RPH) (Apo-Cefuroxime-APX) (Auro-Cefuroxime-API) For treatment of:

(a) Upper and lower respiratory tract infections in patients unresponsive to first-line antibiotics.

(b) Infections caused by organisms known to be resistant or unresponsive to alternative antibiotics.

(c) Infections in patients allergic to alternative antibiotics. (Note: patients who have had an anaphylactic reaction to penicillin should not receive cephalosporins.)

(d) Respiratory tract infections in nursing home patients. (e) Pneumonia in patients in the community with comorbidity i.e. chronic

underlying lung disease (excluding asthma), diabetes mellitus, renal insufficiency, heart failure, stroke, and:

(f) For completion of antibiotic treatment initiated in hospital. Cefzil - see cefprozil Celsentri - see maraviroc Celebrex - see celecoxib celecoxib, capsule, 100mg, 200mg (Celebrex-PFI)

See Appendix B for online adjudication criteria.

CellCept - see mycophenolate mofetil Cesamet - see nabilone Ciloxan - see ciprofloxacin Cipro - see ciprofloxacin tablet Ciprodex - see ciprofloxacin HCl/dexamethasone Cipro XL - see ciprofloxacin Ciprofloxacin - see ciprofloxacin *ciprofloxacin, ophthalmic solution, 0.3% (Ciloxan-ALC) (pms-Ciprofloxacin-PMS); ophthalmic ointment, 0.3% (Ciloxan-ALC)

For treatment of: (a) Ophthalmic infections caused by gram-negative organisms. (b) Ophthalmic infections unresponsive to alternative agents.

*ciprofloxacin, tablet, 250mg, 500mg (Apo-Ciproflox-APX) (CO Ciprofloxacin-COB) (Mylan-Ciprofloxacin-MYL) (Novo-Ciprofloxacin-NOP) (pms-Ciprofloxacin-PMS) (ratio-Ciprofloxacin-RPH) (Sandoz Ciprofloxacin-SDZ) (Dom-Ciprofloxacin-DOM) (Nu-Ciprofloxacin-NXP) (Ran-Ciproflox-RAN) (Taro-Ciprofloxacin-TAR) (Mint-Ciprofloxacin-MNT) (Ciprofloxacin-SAN) (Mar-Ciprofloxacin) (Septa-Ciprofloxacin-SPT); *tablet, 750mg (Apo-Ciproflox-APX) (CO Ciprofloxacin-COB) (Mylan-Ciprofloxacin-MYL) (Novo-Ciprofloxacin-NOP) (pms-Ciprofloxacin-PMS) (ratio-Ciprofloxacin-RPH) (Sandoz Ciprofloxacin-SDZ) (Dom-Ciprofloxacin-DOM) (Nu-Ciprofloxacin-NXP) (Ran-Ciproflox-RAN) (Mint-Ciprofloxacin-MNT) (Ciprofloxacin-SAN) (Septa-Ciprofloxacin-SPT); oral suspension100mg/mL (Cipro-BAY)

252

Page 275: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

For treatment of: (a) Infections caused by Pseudomonas aeruginosa. (b) Infections in patients allergic to two or more alternative antibiotics. (c) Infections known to be resistant to alternative antibiotics. Resistance must

be determined by culture and sensitivity testing (C&S). (d) Patients with severe diabetic foot infections in combination with other

antibiotics. (e) Infection (and prophylaxis) in patients with prolonged neutropenia. (f) Genitourinary tract infections in patients allergic or unresponsive to

alternative antibiotics. (g) Patients with bronchiectasis or cystic fibrosis. (h) Gonorrhea, and: (i) For completion of antibiotic treatment initiated in hospital when alternatives

are not appropriate.

ciprofloxacin, extended release tablet, 500mg (Cipro XL-BAY) For treatment of uncomplicated urinary tract infections in females unresponsive or allergic to first-line agents.

ciprofloxacin, extended release tablet, 1000mg (Cipro XL-BAY)

For treatment of complicated urinary tract infections in patients unresponsive or allergic to first-line agents.

ciprofloxacin HCl/dexamethasone, otic suspension, 0.3%/0.1% (Ciprodex-ALC)

(a) For acute otitis media with otorrhea through tympanostomy tubes in patients who require treatment.

(b) For acute otitis externa in the presence of a tympanostomy tube or a known perforation of the tympanic membrane.

*clarithromycin, tablet, 250mg, 500mg (Biaxin-ABB) (Apo-Clarithromycin-APX) (Mylan-Clarithromycin-MYL) (pms-Clarithromycin-PMS) (ratio-Clarithromycin-RPH) (Sandoz Clarithromycin-SDZ) (Ran-Clarithromycin-RAN) (Ava-Clarithromycin-AVA); oral suspension, 25mg/mL, 50mg/mL (Biaxin-ABB); extended-release tablet, 500mg (Biaxin XL-ABB)

For treatment of: (a) Pneumonia. (b) Upper and lower respiratory tract bacterial infections known to be resistant

to alternative antibiotics. (c) Upper and lower respiratory tract bacterial infections unresponsive to

alternative antibiotics. (d) Infections in patients allergic to alternative antibiotics. (e) For treatment (and prophylaxis) in patients with non-tuberculous

Mycobacterium. (f) For one week for eradication of H. pylori-related infections when used in

combination treatment regimens for the treatment of peptic ulcer disease. (g) For completion of treatment initiated in hospital with macrolides or quinolones. (h) For patients intolerant to erythromycin and/or other antibiotics.

Clavulin - see amoxicillin trihydrate/potassium clavulanate Climara - see estradiol *clonidine HCl, tablet, 0.025mg (Dixarit-BOE) (Novo-Clonidine-NOP)

For treatment of: (a) Menopausal flushing.

(b) Attention Deficit Hyperactivity Disorder.

*clopidogrel bisulfate, tablet, 75mg (Plavix-BMY) (Apo-Clopidogrel-APX) (CO Clopidogrel-COB) (Mylan-Clopidogrel-MYL) (Sandoz Clopidogrel-SDZ) (Teva-Clopidogrel-TEV) (pms-Clopidogrel-PMS) (Ran-Clopidogrel-RAN)

(a) For treatment of patients who have experienced a transient ischemic attack, stroke, or a myocardial infarction while on acetylsalicylic acid.

253

Page 276: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

(b) For treatment of patients who have experienced a transient ischemic attack, stroke, or who have had a myocardial infarction and have a clearly demonstrated allergy to acetylsalicylic acid (manifested by asthma or nasal polyps).

(c) For treatment of patients who have experienced a transient ischemic attack, stroke, or a myocardial infarction and are intolerant to acetylsalicylic acid (manifested by gastrointestinal hemorrhage).

(d) When prescribed following intracoronary stent placement. Coverage will be provided for a period of 1 year. In patients intolerant or allergic to ASA coverage may be renewed.

(e) For reduction of atherothrombotic events in patients with acute coronary syndrome (i.e. unstable angina or non-Q-wave myocardial infarction without ST segment elevation) concurrently with acetylsalicylic acid. Coverage will also be considered for patients intolerant or allergic to acetylsalicylic acid. Coverage will be provided for a period of 1 year. In patients intolerant or allergic to ASA coverage may be renewed.

(f) For treatment of peripheral arterial disease in patients intolerant/allergic to ASA.

Clopixol - see zuclopenthixol clostridium botulinum neurotoxin type A, 100U/vial, powder for solution (Xeomin-MRZ)

(a) For treatment of blepharospasm. (b) For treatment of cervical dystonia, that is spasmodic torticollis.

*clozapine, tablet, 25mg, 100mg (Clozaril-NVR) (Gen-Clozapine-MYL) (Apo-Clozapine-APX) tablet, 50mg, 200mg (Gen-Clozapine-MYL) For treatment of schizophrenia in patients who are either treatment resistant or

treatment intolerant and have no other medical contraindications. Clozaril - see clozapine CO Azithromycin - see azithromycin CO Cabergoline - see cabergoline CO Ciprofloxacin - see ciprofloxacin CO Clopidogrel - see clopidogrel bisulfate CO Fluconazole - see fluconazole CO Levofloxacin - see levofloxacin CO Meloxicam - see meloxicam CO Mycophenolate - see mycophenolate mofetil CO Norfloxacin - see norfloxacin CO Olanzapine - see olanzapine CO Olanzapaine ODT - see olanzapine CO Pantoprazole - see pantoprazole sodium CO Pioglitazone - see pioglitazone HCl CO Repaglinide - see repaglinide CO Rizatriptan ODT - see rizatriptan benzoate CO Sumatriptan - see sumatriptan codeine, controlled release tablet, 50mg, 100mg, 150mg, 200mg (Codeine Contin-PFR)

For treatment of : (a) Palliative and chronic pain patients as an alternative to ASA/codeine

combination products or acetaminophen/codeine combination products. (b) Palliative and chronic pain patients as an alternative to regular release tablet

when large doses are required. In non-palliative patients, coverage will only be approved for a 6 month course of

therapy, subject to review.

254

Page 277: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

Codeine Contin - see codeine Combivir - see lamivudine/zidovudine Copaxone - see Appendix D Crixivan - see indinavir SO4

Cyclobenzaprine - see cyclobenzaprine HCl

*cyclobenzaprine HCl, tablet, 10mg (Apo-Cyclobenzaprine-APX) (Novo-Cycloprine-NOP) (Nu-Cyclobenzaprine-NXP) (pms-Cyclobenzaprine-PMS) (Mylan-Cyclobenzaprine-MYL) (Dom-Cyclobenzaprine-DOM) (Cyclobenzaprine-SAN) (Auro-Cyclobenzaprine-API) As an adjunct to rest and physical therapy for relief of muscle spasm associated

with acute, painful musculoskeletal conditions in patients unresponsive to alternative therapy or who are experiencing severe adverse reactions to alternative therapy.

Coverage will be provided for up to a 3 week period. Coverage can be renewed for a 3 week period every 3 months.

cyclosporine, capsule, 10mg, 25mg, 50mg, 100mg; liquid, 100mg/mL (Neoral-NVR)

For treatment of: (a) Nephrotic syndrome. (b) Severe active rheumatoid arthritis in patients for whom classical slow-acting

anti-rheumatic agents are inappropriate or ineffective, and: (c) For induction and maintenance of remission of severe psoriasis in patients

for whom conventional therapy is ineffective or inappropriate. For the above indications prescriptions are subject to deductible (where

applicable) and co-payment as for other drugs covered under the Drug Plan. Pharmacies note: claims on behalf of these patients must use the following identifying numbers (not the DIN):

10mg - 00950792 100mg - 00950815 25mg - 00950793 100mg/mL - 00950823 50mg - 00950807

cyclosporine, capsule, 10mg, 25mg, 50mg, 100mg; liquid, 100mg/mL (Neoral-NVR) For prophylaxis of graft rejection following solid organ transplant and in bone

marrow transplant procedures. In such cases, the cost is covered at 100% and the deductible (where applicable) does not apply.

Cymbalta - see duloxetine hydrochloride Cyproterone - see cyproterone acetate cyproterone acetate, injection, 100mg/mL (Androcur-PMS); *tablet, 50mg (Androcur-PMS) (Mylan-Cyproterone-MYL) (Cyproterone-AAP) For treatment of hirsuitism. dabigatran, tablet, 110mg, 150mg (Pradax-BOE) Inclusion Criteria: At-risk patients with non-valvular atrial fibrillation (AF) who require the Drug Product for the prevention of stroke and systemic embolism AND in whom:

(a) Anticoagulation is inadequate following a reasonable trial on warfarin; OR (b) Anticoagulation with warfarin is contraindicated or not possible due to

inability to regularly monitor via International Normalized Ratio (INR)

255

Page 278: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

testing (i.e. no access to INR testing services at a laboratory, clinic, pharmacy, and at home).

Exclusion Criteria: Patients with impaired renal function (creatinine clearance or estimated glomerular filtration rate < 30 mL/min) OR ≥ 75 years of age and without documented stable renal function OR hemodynamically significant rheumatic valvular heart disease, especially mitral stenosis; OR prosthetic heart valves. Notes:

(a) Documented stable renal function is defined as creatinine clearance or estimated glomerular filtration rate that is maintained for at least three months (i.e. 30-49 mL/min for 110 mg twice daily dosing or ≥ 50 mL/min for 150 mg twice daily dosing).

(b) At-risk patients with atrial fibrillation are defined as those with a CHADS2

score of ≥ 1. (c) Inadequate anticoagulation is defined as INR testing results that are

outside the desired INR range for at least 35% of the tests during the monitoring period (i.e. adequate anticoagulation is defined as INR test results that are within the desired INR range for at least 65% of the tests during the monitoring period).

(d) A reasonable trial on warfarin is defined as at least two months of therapy. (e) Since renal impairment can increase bleeding risk, renal function should be

regularly monitored. Other factors that increase bleeding risk should also be assessed and monitored (see product monograph).

(f) Patients starting dabigatran should have ready access to appropriate medical services to manage a major bleeding event.

(g) There is currently no data to support that dabigatran provides adequate anticoagulation in patients with rheumatic valvular disease or those with prosthetic heart valves, so dabigatran is not recommended in these populations.

dalteparin sodium, syringe, 2,500IU/mL (0.2mL), 7,500IU/mL (0.3mL), pre-filled syringe, 10,000IU/mL (0.4mL), 12,500IU/mL (0.5mL), 15,000IU/mL (0.6mL), 18,000IU/mL (0.72mL): injection solution, 5,000IU/mL (0.2mL), 10,000IU/mL (1mL), 25,000IU/mL (3.8mL) (Fragmin-PFI)

(a) For treatment of venous thromboembolism for up to 10 days. (b) For prophylaxis following total knee arthroplasty for up to 35 days. (c) For major orthopedic trauma for up to10 days (treatment duration may be

reassessed). (d) For long-term outpatient prophylaxis in patients who are pregnant. (e) For long-term outpatient prophylaxis in patients who have a contraindication

to, are intolerant to, or have failed, warfarin therapy. (f) For long-term outpatient prophylaxis in patients who have lupus

anticoagulant syndrome. (g) Prophylaxis in patients undergoing total hip replacement or following hip

fracture surgery for up to 35 days following the procedure.

darbepoetin alfa, pre-filled syringe, 25ug/mL (0.4mL), 40ug/mL (0.5mL), 100ug/mL (0.3mL, 0.4mL, 0.5mL, 0.65mL), 200ug/mL (0.3mL, 0.4mL, 0.5mL), 500ug/mL (0.3mL, 0.4mL) (Aranesp-AMG)

For treatment of anemia in chronic renal disease patients prior to initiation of dialysis. Note: Coverage for dialysis patients is provided under the S.A.I.L. Program. EDS coverage is not required for S.A.I.L. patients.

256

Page 279: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

darifenacin, extended release tablet, 7.5mg, 15mg (Enablex-NVR) See Appendix B for online adjudication criteria. darunavir, tablet, 75mg, 400mg, 600mg (Prezista-JAN)

For management of HIV disease. This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

DDAVP - see desmopressin DDAVP Melt - see desmopressin deferasirox, tablet for oral suspension, 125mg, 250mg, 500mg (Exjade-NVR)

For treatment of chronic iron overload in patients with transfusion dependent anemias who have a contraindication to the injectable deferoxamine.

*deferoxamine mesylate, powder for solution, 500mg/vial, 2g/vial (Desferal-NVR) (Desferrioxamine Mesilate-HOS) For treatment of iron overload in patients with transfusion-dependent anemias. delavirdine mesylate, tablet, 100mg (Rescriptor-VII) For management of HIV disease. This drug, as with other antivirals in the

treatment of HIV, should be used under the direction of an infectious disease specialist.

denosumab, solution for injection, pre-filled syringe, 60mg/1.0mL (Prolia-AMG)

For the treatment of postmenopausal osteoporosis in women who would otherwise meet the current EDS criteria for oral bisphosphonates, but for whom oral bisphosphonates are contraindicated due to hypersensitivity (i.e. an allergic reaction) or abnormalities of the esophagus (e.g., esophageal stricture or achalasia) and have at least two of the following: (a) age > 75 years (b) a prior fragility fracture (c) a bone mineral density (BMD) T-score ≤ -2.5

Desferal - see deferoxamine mesylate Desferrioxamine Mesilate - see deferoxamine mesylate *desmopressin, tablet, 0.1mg, 0.2mg; (DDAVP-FEI) (Apo-Desmopressin-APX) (Novo-Desmopressin-NOP) (pms-Desmopressin-PMS); orally disintegrating tablet, 60ug, 120ug, 240ug (DDAVP Melt-FEI)

For treatment of: (a) Diabetes insipidus. (b) Enuresis in children over 5 years of age refractory to bed-wetting alarms or

alternative agents listed in the Formulary. (c) Nocturia in patients with a recognized neurologic disorder which causes

detrusor over-activity confirmed by cystogram in the absence of obstruction, who have not responded or are intolerant to at least two anticholinergic drugs.

*desmopressin, intranasal solution, 10ug/dose (DDAVP-FEI) (Apo-Desmopressin-APX) (Novo-Desmopressin-NOP)

For treatment of: (a) Diabetes insipidus. (b) Nocturia in patients with a recognized neurologic disorder which causes

detrusor over-activity confirmed by cystogram in the absence of obstruction, who have not responded or are intolerant to at least two anticholinergic drugs.

desmopressin, injection, 4ug/mL (DDAVP-FEI); intranasal solution, 150ug/dose (Octostim-FEI) For prophylaxis of mild hemophilia A and mild von Willebrand's disease.

257

Page 280: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

Detrol LA - see tolterodine L-tartrate DexIron - see iron dextran diclofenac sodium, ophthalmic solution, 0.1% (Voltaren Ophtha-ALC)

For treatment of: (a) Post-operative ocular inflammation in patients undergoing cataract surgery. (b) Long-term inflammatory conditions unresponsive to short-term topical

steroids, and: (c) For prophylaxis of aphakic macular edema following cataract surgery.

didanosine, capsule (enteric coated beadlet), 125mg, 200mg, 250mg, 400mg (Videx EC-BMY) For management of HIV disease. This drug, as with other antivirals in the

treatment of HIV, should be used under the direction of an infectious disease specialist.

Diflucan - see fluconazole

dipyridamole/acetylsalicylic acid, capsule, 200mg/25mg (Aggrenox-BOE) For treatment of patients who have had a: (a) Stroke while on acetylsalicylic acid. (b) Transient ischemic attack while on acetylsalicylic acid.

Dixarit - see clonidine HCl Dom-Azithromycin - see azithromycin Dom-Ciprofloxacin - see ciprofloxacin Dom-Cyclobenzaprine - see cyclobenzaprine HCl Dom-Fluconazole - see fluconazole Dom-Meloxicam - see meloxicam Dom-Sumatriptan - see sumatriptan Dom-Ursodiol C - see ursodiol donepezil HCl, tablet, 5mg, 10mg (Aricept-PFI)

(a) A diagnosis of probable Alzheimer's disease as per DSM-IV criteria. (b) A mild to moderate stage of the disease with a MMSE score of 10-26

established within 60-days prior to application for coverage by a clinician or nurse practitioner.

(c) A Functional Activities Questionnaire (FAQ) must be completed within 60-days prior to initial application for coverage by a clinician or nurse practitioner.

(d) Patients must discontinue all drugs with anticholinergic activity at least 14 days before the MMSE and FAQ are administered. Drugs with anticholinergic activity are not to be used concurrently with donepezil therapy. List all current medications patient was taking at the time of assessment.

(e) Patients intolerant to one drug may be switched to another drug in this class. Intolerance should be observed within the first month of treatment.

• Eligible patients currently taking donepezil would require assessment at

6 month intervals. To continue receiving donepezil, patients must not have both a greater than 2 point reduction in MMSE and a 1 point increase in FAQ in a 6 month evaluation period. Scores are compared to the most recent test results.

• Eligible new patients will enter a 3 month treatment period with donepezil. During the 3 month trial, patients must exhibit an improvement from the initial MMSE or FAQ to continue treatment with donepezil. The improvement must be at least 2 MMSE points or -1 FAQ. Patients who meet these requirements will be re-evaluated at 6 month intervals. To continue receiving donepezil, patients must not have both a greater than 2 point reduction in MMSE and a 1 point increase in FAQ in a 6 month evaluation period. Scores are compared to the most recent test results.

258

Page 281: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

• The MMSE score must remain at 10 or greater at all times to be eligible for coverage.

• Patients who do not meet criteria to continue donepezil can be re-evaluated within 3 months to confirm deterioration before coverage is discontinued.

• Donepezil does not need to be discontinued prior to MMSE or FAQ testing. • A patient intolerant of one drug and switching to a second will be considered

a "new" patient and will be assessed as such.

• Coverage will not be considered for patients who have failed on other drugs in this class.

Initial EDS applications for donepezil (Aricept) will only be accepted from physicians on the Aricept/Exelon/Reminyl EDS application form. This form is available online at http://formulary.drugplan.health.gov.sk.ca or by calling the Drug Plan. EDS renewals can be submitted either by telephone, mail or fax.

dornase alfa, inhalation solution, 1mg/mL (Pulmozyme-HLR) For treatment of cystic fibrosis patients who meet the following criteria:

(a) At least 5 years of age. (b) Lung function greater than 40% (as measured by FVC). (c) Physicians will be requested to provide evidence of the beneficial effect of

this drug in their patients after 6 months of therapy before additional coverage is granted.

Renewal of coverage will be provided for a 6 month period if any of the following criteria are met: (a) FEV1 has improved by 10% from pre-treatment value. (b) Decreased antibiotic utilization. (c) Decreased hospitalizations. (d) Decreased absenteeism from school or work. (e) If the individual deteriorates upon discontinuation of Pulmozyme therapy.

Physicians must provide appropriate documentation to establish benefit. Dostinex - see cabergoline duloxetine hydrochloride, delayed release capsule, 30mg, 60mg (Cymbalta-LIL)

(a) For the treatment of neuropathic pain in diabetic patients unresponsive following treatment with adequate doses of tricyclic antidepressants (TCA) as indicated on the patient profile by 2 consecutive prescriptions for a TCA within 6 months of the EDS request, or

(b) For the treatment of neuropathic pain in diabetic patients intolerant or contraindicated to tricyclic antidepressants.

Coverage will be provided to a maximum daily dose of 60mg.

Duragesic - see fentanyl Duragesic Mat - see fentanyl Edecrin - see ethacrynic acid efavirenz, capsule, 50mg, 200mg; tablet, 600mg (Sustiva-BMY)

For management of HIV disease. This drug, as with other antivirals in treatment of HIV, should be used under the direction of an infectious disease specialist.

efavirenz/emtricitabine/tenofovir disoproxil fumarate, tablet, 600mg/200mg/300mg (Atripla-BMY)

For treatment of HIV-1 infection where the virus is susceptible to each of tenofovir and emtricitabine and efavirenz and:

(a) Atripla is used to replace existing therapy with its component drugs, or (b) The patient is treatment naive, or (c) The patient has established viral suppression but requires antiretroviral

therapy modification due to intolerance or adverse effects.

259

Page 282: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

This drug as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

Effient - see prasugrel Eldepryl - see selegiline HCl Elidel - see pimecrolimus Elmiron - see pentosan polysulfate sodium emtricitabine/tenofovir disoproxil fumarate, tablet, 200mg/300mg (Truvada-GSI)

For treatment of HIV patients where: (a) The virus is susceptible to tenofovir and emtricitabine, AND (b) Efavirenz is not indicated due to adverse effects or antiretroviral resistance. This drug as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

Enablex - see darifenacin Enbrel - see etanercept enfuvirtide, powder for solution, 108mg/vial (vial) (Fuzeon-HLR)

For management of HIV disease on a case-by-case basis, following committee review of each case. (It was noted that enfuvirtide is not first-line therapy. The most appropriate use of this product is for “salvage therapy”). This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

enoxaparin, syringe, 30mg/mL, 40mg/mL, 60mg/mL, 80mg/mL, 100mg/mL (Lovenox-AVT); injection solution, 100mg/mL (3mL); 150mg/mL (Lovenox HP-AVT)

(a) For treatment of venous thromboembolism for up to 10 days. (b) For prophylaxis following total knee arthroplasty for up to 35 days. (c) For major orthopedic trauma for up to 10 days (treatment duration may be

reassessed). (d) For long-term outpatient prophylaxis in patients who are pregnant. (e) For long-term outpatient prophylaxis in patients who have a contraindication

to, are intolerant to, or have failed, warfarin therapy. (f) For long-term outpatient prophylaxis in patients who have lupus

anticoagulant syndrome. (g) For treatment of pediatric patients where anticoagulant therapy is required

and warfarin therapy cannot be administered. (h) Prophylaxis in patients undergoing total hip replacement or following hip

fracture surgery for up to 35 days following the procedure. entecavir, tablet, 0.5mg (Baraclude-BMY)

For treatment of chronic hepatitis B infection in patients with cirrhosis documented on radiologic or histologic grounds and a HBV DNA concentration above 2000IU/mL.

Entocort - see budesonide epoetin alfa, pre-filled syringe, 1,000 IU/0.5mL, 2,000IU/0.5mL, 3,000IU/0.3mL, 4,000IU/0.4mL, 5,000IU/0.5mL, 6,000IU/0.6mL, 8,000IU/0.8mL, 10,000IU/mL, 20,000IU/0.5mL, 30,000IU/0.75mL, 40,000IU/mL (Eprex-JAN)

For treatment of: (a) Anemia in chronic renal disease patients prior to initiation of dialysis. Note:

Coverage for dialysis patients is provided under the Saskatchewan Aids to Independent Living (S.A.I.L.) Program. Exception Drug Status coverage is not required for S.A.I.L. patients.

(b) Anemia in AIDS patients. (c) Anemia in transplant patients.

260

Page 283: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

epoprostenol, powder for solution, 0.5mg/vial, 1.5mg/vial (Flolan-GSK) For treatment of pulmonary hypertension on the recommendation of a specialist.

Please contact the Drug Plan for billing information. Eprex - see epoetin alfa esomeprazole magnesium trihydrate, delayed release tablet, 20mg, 40mg (Nexium-AST)

(a) For a maximum of 8 weeks in treatment of peptic ulcer disease, which includes gastric and duodenal ulcers, in patients not responding or experiencing unusual or severe adverse reactions to a reasonable trial with H2 blockers, sucralfate or misoprostol. Coverage for a repeat treatment will be approved only after a 3-6 month period of no treatment or prophylaxis with an H2 blocker, sucralfate or misoprostol.

(b) For treatment of symptoms of gastroesophageal reflux disease (GERD). It was noted that patients with non-erosive GERD could potentially be reduced to stop-down therapy with an H2 antagonist depending on symptom resolution.

(c) For treatment of severe erosive esophagitis and Zollinger-Ellison Syndrome. (d) For one week for eradication of H. pylori-related infections in individuals with

peptic ulcer disease. Provision will be made for additional coverage in treatment failures.

(e) For first-line prevention of gastroduodenal hemorrhage in high risk patients with prior history of gastroduodenal bleeds for whom anticoagulant, glucocorticosteroid or NSAID therapy cannot be avoided. Coverage is renewable on a yearly basis for patients if discontinuation of offending agents or replacement with less damaging alternatives is not feasible.

(f) For a maximum of 8 weeks in patients discharged from hospital, on a proton pump inhibitor, following a gastroduodenal bleed.

Estalis - see estradiol/norethindrone acetate Estraderm - see estradiol estradiol, transdermal gel (metered dose pump), 0.06% (Estrogel-SCH); +transdermal therapeutic system, 25ug, 100ug (Estraderm-NVR), 25ug, 50ug, 75ug, 100ug (Climara-BEX), 25ug, 50ug (Oesclim-PAL) *transdermal therapeutic system, 25ug, 37.5ug, 50ug, 75ug, 100ug (Estradot-NVR) (Sandoz Estradiol Derm-SDZ)

For treatment of patients: (a) Intolerant to oral estrogen. (b) With a fasting plasma triglyceride level of 4.5 mmol/L or more.

estradiol/norethindrone acetate, transdermal therapeutic system (8), 50ug/140ug; 50ug/250ug (Estalis-NVR)

For treatment of patients: (a) Intolerant to oral hormone replacement therapy (either estrogen or

progesterone). (b) With a fasting plasma triglyceride level of 4.5 mmol/L or more.

Estradot - see estradiol Estrogel - see estradiol etanercept, powder for injection (vial), 25mg/vial; pre-filled syringe, 50mg/mL (Enbrel-AMG)

For treatment of: (a) Active rheumatoid arthritis in patients who have failed or are intolerant to

methotrexate and leflunomide. (b) Active juvenile rheumatoid arthritis in pediatric patients who have failed one

DMARD.

261

Page 284: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

(c) Psoriatic arthritis in patients who have failed or are intolerant to methotrexate and one other DMARD.

Note: Exceptions can be considered in cases where methotrexate or leflunomide are contraindicated. Treatment should be combined with an immunosuppressant. (d) For treatment of ankylosing spondylitis (A.S.) according to the following criteria:

1) For patients who have already been treated conventionally with two or more NSAIDs taken sequentially at maximum tolerated or recommended doses for four weeks without symptom control. AND

2) Satisfy New York diagnostic criteria: a score > 4 on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) AND a score of > 4 cm on the 0-10cm spinal pain VAS on two occasions at least 12 weeks apart without any change of treatment. AND

3) Adequate response to treatment assessed at 12 weeks defined as at least 50% reduction in pre-treatment baseline BASDAI score or by > 2 units AND a reduction of > 2 cm in the spinal pain VAS.

NOTE: Coverage will not be provided when a patient switches to another anti-TNF agent if the patient fails to respond or if there is loss of response to the first agent. Requests for coverage for this indication must be made by the rheumatologist. A second application would also be required after 12 weeks to assess and would need to show an improvement to the patient’s condition on either of these medications. Please refer to the Formulary website for the application form. Subsequent annual renewal requests (beyond 15 months) will be considered for patients whose BASDAI scores do not worsen (i.e. remains within two points of the second assessment).

(e) For treatment of adult patients with severe debilitating plaque psoriasis who meet all of the following criteria: i) failure to respond to, contraindications to, or intolerant of methotrexate

and cyclosporine AND ii) failure to respond to, intolerant to or unable to access phototherapy. Coverage will be approved initially for the induction phase of up to 16 weeks. Coverage can be renewed in patients who have responded to therapy. This product should be used in consultation with a specialist in this area.

For all of the above indications this product should be used in consultation with a specialist in this area.

ethacrynic acid, tablet, 25mg (Edecrin-VAE) See Appendix B for online adjudication criteria. etodolac, capsule, 200mg, 300mg (Apo-Etodolac-APX) For treatment of patients intolerant to other NSAIDs listed in the Formulary. etravirine, tablet, 100mg, 200mg (Intelence-JAN)

For use in combination with other antiretroviral agents for the treatment of HIV-1 strains resistant to multiple antiretroviral agents, including non-nucleoside reverse transcriptase inhibitors. This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

Euro-Lac - see lactulose Evista - see raloxifene HCl Exelon - see rivastigmine Exjade - see deferasirox Extavia - see Appendix D

262

Page 285: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

febuxostat, tablet, 80mg (Uloric-TAK) For the treatment of symptomatic gout in patients with a documented hypersensitivity to allopurinol. Hypersensitivity to allopurinol is a rare condition that is characterized by a major skin manifestation, fever, multi-organ involvement, lymphadenopathy and hematological abnormalities (eosinophilia, atypical lymphocytes). NOTE: Intolerance or lack of response to allopurinol will not be covered by this criteria.

*fentanyl, transdermal system, 12ug/hr (ratio-Fentanyl-RPH) (Sandoz Fentanyl MTX-SDZ) (Ran-Fentanyl Matrix-RAN) (pms-Fentanyl MTX-PMS) 25ug/hr, 50ug/hr, 75ug/hr, 100ug/hr (ratio-Fentanyl-RPH) (Novo-Fentanyl-NOP) (Sandoz Fentanyl MTX-SDZ) (Duragesic Mat-JAN) (Ran-Fentanyl Matrix-RAN) (pms-Fentanyl MTX-PMS)

See Appendix B for online adjudication criteria.

Ferrlecit - see iron ferric sodium gluconate complex filgrastim, injection solution, 300ug/mL (Neupogen-AMG)

For treatment of: (a) Congenital, cyclic or idiopathic neutropenia in patients with absolute

neutrophil counts of less than or equal to 500. (b) Non-cancer patients who have undergone bone marrow transplantation. (c) AIDS patients with absolute neutrophil counts of less than 500.

fingolimod hydrochloride, capsule, 0.5mg (Gilenya-NVR) See Appendix D Flexitec - see cyclobenzaprine HCl Flolan - see epoprostenol fluconazole, powder for oral suspension, 10mg/mL (Diflucan-PFI); *tablet, 50mg, 100mg (Apo-Fluconazole-APX) (Mylan-Fluconazole-MYL) (pms-Fluconazole-PMS) (Novo-Fluconazole-NOP) (CO Fluconazole-COB) (Dom-Fluconazole-DOM)

For treatment of: (a) Fungal meningitis in immunocompromised patients. (b) Severe or life-threatening fungal infections. (c) Severe dermatophytoses unresponsive to other forms of therapy including

ketoconazole. (d) For fungal prophylaxis in post bone marrow/stem cell transplant patients or

severely immunocompromised malignant hematology patients (i.e. leukemia) Note: the 150mg capsule form of fluconazole is listed as a regular benefit in the

Saskatchewan Formulary. flunarizine HCl, capsule, 5mg (Apo-Flunarizine-APX) For prophylaxis of migraines in cases where alternative prophylactic agents have

not been effective. Foradil - see formoterol fumarate +formoterol fumarate, powder for inhalation (capsule), 12ug (Foradil-NVR); powder for inhalation (package), 6ug/dose, 12ug/dose (Oxeze Turbuhaler-AST)

For treatment of: (a) Asthma uncontrolled on concurrent inhaled steroid therapy. It is important

that these patients also have access to a short-acting beta-2 agonist for symptomatic relief.

263

Page 286: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

(b) COPD unresponsive to short-acting beta agonists or short-acting anticholinergic bronchodilators.

formoterol fumarate dihydrate/budesonide, powder for inhalation (package), 6ug/100ug, 6ug/200ug (Symbicort Turbuhaler-AST)

For treatment of: (a) Asthma in patients uncontrolled on inhaled steroid therapy (b) COPD in patients where there has been concurrent or past use of tiotropium

or a LABA (salmeterol or formoterol). Fosamax - see alendronate sodium fosamprenavir calcium, tablet, 700mg; oral suspension, 50mg/mL (Telzir-VII)

For the management of HIV disease. This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

Fosavance - see alendronate sodium/vitamin D3 (cholcalciferol)

fosfomycin tromethamine, oral powder (sachet), 3g (Monurol-AXX) For treatment of: (a) Urinary tract infections with organisms reistant to first line therapy. (b) Urinary tract infections in patients allergic to first line agents.

(c) Urinary tract infections in pregnancy when first line agents are inappropriate.

Fragmin - see dalteparin sodium Fraxiparine - see nadroparin calcium Fraxiparine Forte - see nadroparin calcium Fucithalmic - see fusidic acid fusidic acid, ophthalmic drops (preservative free), 1%; ophthalmic drops 1% (Fucithalmic-LEO)

For treatment of patients unresponsive to listed alternatives. Fuzeon - see enfuvirtide *galantamine hydrobromide, extended release capsule, 8mg, 16mg, 24mg (Reminyl ER-JAN) (Mylan-Galantamine ER-MYL) (Pat-Galantamine ER-PAT) (Teva-Galantamine ER-TEV)

(a) A diagnosis of probable Alzheimer's disease as per DSM-IV criteria. (b) A mild to moderate stage of the disease with a MMSE score of 10-26

established within 60-days prior to application for coverage by a clinician. (c) Functional Activities Questionnaire (FAQ) must be completed within 60-days prior to initiation for coverage by a clinician. (d) Patients must discontinue all drugs with anticholinergic activity at least

14 days before the MMSE and FAQ are administered. Drugs with nticholinergic activity are not to be used concurrently with galantamine hydrobromide therapy. List all current medications patient was taking at the time of assessment.

(e) Patients intolerant to one drug may be switched to another drug in this class. Intolerance should be observed within the first month of treatment.

• Eligible patients currently taking galantamine hydrobromide would require assessment at 6 month intervals. To continue receiving galantamine hydrobromide, patients must not have both a greater than 2 point reduction in MMSE and a 1 point increase in FAQ in a 6 month evaluation period. Scores are compared to the most recent test results.

264

Page 287: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

• Eligible new patients will enter a 3 month treatment period with galantamine hydrobromide. During the 3 month trial, patients must exhibit an improvement from the initial MMSE or FAQ to continue treatment with galantamine hydrobromide. The improvement must be at least 2 MMSE points or -1 FAQ. Patients who meet these requirements will be re-evaluated at 6 month intervals. To continue receiving galantamine hydrobromide, patients must not have both a greater than 2 point reduction in MMSE and a 1 point increase in FAQ in a 6 month evaluation period. Scores are compared to the most recent test results.

• The MMSE score must remain at 10 or greater at all times to be eligible for

coverage.

• Patients who do not meet criteria to continue galantamine hydrobromide can be re-evaluated within 3 months to confirm deterioration before coverage is discontinued.

• Galantamine hydrobromide does not need to be discontinued prior to MMSE

or FAQ testing.

• A patient intolerant of one drug and switching to a second will be considered a "new" patient and will be assessed as such.

• Coverage will not be considered for patients who have failed on other drugs

in this class.

Initial EDS applications for galantamine (Reminyl) will only be accepted from physicians on the Aricept/Exelon/Reminyl EDS application form. This form is available online at http://formulary.drugplan.health.gov.sk.ca or by calling the Drug Plan. EDS renewals can be submitted either by telephone, mail or fax.

gatifloxacin, ophthalmic solution, 0.3% (Zymar-ALL) For treatment of: (a) Ophthalmic infections caused by gram-negative organisms. (b) Ophthalmic infections unresponsive to alternative agents.

Gen-Clozapine - see clozapine Gilenya - see Appendix D glatiramer acetate, injection, 20mg (pre-filled syringe) (Copaxone-TVM) See Appendix D GlucoNorm - see repaglinide golimumab, 50mg/mL, pre-filled syringe; autoinjector (Simponi-MSD)

(a) For treatment of ankylosing spondylitis (A.S.) according to the following criteria:

Initial Application for a 12-week medication trial: 1) For patients who have already been treated conventionally with two or

more non-steroidal anti-inflammatory drugs (NSAIDs) taken sequentially at maximum tolerated or recommended doses for four weeks without symptom control. AND

2) Satisfy New York diagnostic criteria: a score > 4 on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) AND a score of > 4 cm on the 0-10cm spinal pain visual analogue scale (VAS) on two occasions at least 12 weeks apart without any change of treatment.

Second Application (following the initial 12 week approval, requests will be considered for a one year approval timeframe):

265

3) Adequate response to treatment assessed at 12 weeks defined as at least 50% reduction in pre-treatment baseline BASDAI score or by > 2 units AND a reduction of > 2 cm in the spinal pain VAS.

Page 288: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

Subsequent Annual Renewal Applications (beyond the first 15 months, requests are to be submitted annually for consideration of ongoing approval on a yearly basis):

4) The BASDAI score does not worsen (i.e. remains within two units of the second assessment) AND at least two units less than the initial application’s BASDAI score.

Notes: • Coverage will not be provided when a patient switches to another anti-TNF

agent if the patient fails to respond or if there is a loss of response to the first agent.

• Requests for coverage for this indication must be made by a rheumatologist. (b) For the treatment of psoriatic arthritis in patients who have failed or are intolerant to methotrexate and one other DMARD. (c) For the treatment of active rheumatoid arthritis in patients who have failed or are intolerant to methotrexate and leflunomide. Treatment should be combined with an immunosuppressant. This product should be used in consultation with a specialist in the area. (Note: Exceptions can be considered in cases where methotrexate or leflunomide are contraindicated). goserelin acetate, 3.6mg/syringe (Zoladex-AST) For treatment of:

(a) Endometriosis. (Coverage may be repeated after a six month lapse, for another 6 month course).

(b) Menorrhagia in preparation for endometrial ablation, and: (c) For pre-treatment of uterine fibroids prior to surgical removal. Coverage will be provided for a maximum of 6 months.

Hepsera - see adefovir dipivoxil Heptovir - see lamivudine Hp-PAC - see lansoprazole/clarithromycin/amoxicillin Humalog - see insulin lispro Humatrope - see somatropin Humira - see adalimumab Humira Pen - see adalimumab imiquimod, topical cream (single-use packet), 5% (Aldara-MDA)

For treatment of: (a) Genital warts in patients unresponsive to podofilox. (b) Genital warts in patients with a large wart area. (c) Biopsy-confirmed primary superficial basal cell carcinoma (sBCC) in patients

meeting the following criteria: • Tumour diameter of ≤ 2 cm, AND • Tumour location on the trunk, neck or extremities (excluding

hands and feet), AND • Surgery or irradiation therapy is not medically indicated (e.g.

recurrent lesions in previously irradiated area, number of lesions too numerous to irradiate or remove surgically).

Notes for the sBCC criteria: • Renewals for the same tumour will not be considered. • Requests approved for sBCC will be approved for six weeks. • Surgical management should be considered first-line for

superficial basal cell carcinoma in most patients, especially for isolated lesions.

Imitrex - see sumatriptan

266

Page 289: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

Incivek - see telaprevir indinavir SO4, capsule, 200mg, 400mg (Crixivan-MRK)

For management of HIV disease. This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

infliximab, injection (mg),100mg/vial (Remicade-MSD) (a) Moderate to severe Crohn's Disease:

• For treatment of patients who demonstrate continuing symptoms despite the use of optimal conventional therapies such as 5-ASA agents, glucocorticoids and immunosuppressive therapy.

• For treatment of patients who are intolerant to conventional therapy including 5-ASA agents, glucocorticoids and immunosuppressive therapy.

(b) Fistulizing Crohn's Disease: • For treatment of patients with symptomatic enterocutaneous or perineal

fistulae, enterovaginal fistulae or enterovesical fistulae (i.e. any type of fistulizing Crohn’s Disease). Clinical response should be assessed after the induction dose. Ongoing coverage will only be provided for those who respond to treatment. Patients undergoing this treatment should be reviewed every six months by a specialist in this area.

(c) Active rheumatoid arthritis in patients who have failed treatment with methotrexate and leflunomide.

(d) Active rheumatoid arthritis in patients intolerant to methotrexate and leflunomide. Treatment should be combined with an immunosuppressant. This product should be used in consultation with a specialist in this area. (Note: Exceptions can be considered in cases where methotrexate or leflunomide are contraindicated.

(e) For treatment of adult patients with severe debilitating plaque psoriasis who meet all of the following criteria:

i) failure to respond to, contraindications to, or intolerant of methotrexate and cyclosporine; AND

ii) failure to respond to, intolerant to or unable to access phototherapy.

Coverage will be approved initially for the induction phase of up to 16 weeks. Coverage can be renewed in patients who have responded to therapy. This product should be used in consultation with a specialist in this area.

(f) Psoriatic arthritis in patients who have failed or are intolerant to methotrexate and one other DMARD.

Note: Exceptions can be considered in cases where methotrexate or leflunomide are contraindicated. Treatment should be combined with an immunosuppressant. (g) For treatment of ankylosing spondylitis (A.S.) according to the following

criteria: 1) For patients who have already been treated conventionally with two or more NSAIDS taken sequentially at maximum tolerated or recommended doses for four weeks without symptom control. AND 2) Satisfy New York diagnostic critieria: a score > 4 on the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) AND a score of > 4cm on the 0-10cm spinal pain VAS on two occasions at least 12 weeks apart without any change of treatment. AND 3) Adequate response to treatment assessed at 12 weeks defined as at least 50% reduction in pre-treatment baseline BASDAI score or by > 2 units AND a reduction of > 2cm in the spinal pain VAS.

267

Page 290: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

NOTE: Coverage will not be provided when a patient switches to another anti-TNF agent if the patient fails to respond or if there is a loss of response to the first agent. Requests for coverage for this indication must be made by the rheumatologist. A second application would also be required after 12 weeks to assess and would need to show an improvement to the patient’s condition on either of these medications. Please refer to the Formulary website for the application form. Subsequent annual renewal requests (beyond 15 months) will be considered for patients whose BASDAI scores do not worsen (i.e. remains within two points of the second assessment). For all of the above indications this product should be used in consultation with a specialist in this area. (h) For treatment of ulcerative colitis in patients unresponsive to high dose

intravenous steroids. NOTE: Clinical response should be assessed after the three-dose induction phase before proceeding to maintenance therapy. Ongoing coverage will only be provided for those who respond to therapy. Patients undergoing this treatment should be reviewed every six months by a specialist in this area.

Infufer - see iron dextran Innohep - see tinzaparin sodium insulin aspart, injection solution, 100U/mL (5x3mL) (10mL) (NovoRapid-NOO)

(a) For treatment of Type 1 diabetes. (b) For treatment of difficult to control Type 2 diabetes in patients who have not

responded to alternative insulin agents listed in the Formulary. insulin glulisine, solution for injection, 100U/mL (5x3mL) (10mL); 100U/mL, pre-filled pen SoloStar (3mL) (Apidra-AVT)

(a) For treatment of Type 1 diabetes. (b) For treatment of difficult to control Type 2 diabetes in patients who have not

responded to alternative insulin agents listed in the Formulary. insulin lispro, injection solution, 100U/mL (5x3mL) (10mL) (Humalog-LIL)

(a) For treatment of Type 1 diabetes (b) For treatment of difficult to control Type 2 diabetes in patients who have not

responded to alternative insulin agents listed in the Formulary.

Intelence - see etravirine interferon alfa-2b, powder for injection, 10 million IU; injection solution albumin (human) free, 6 million IU/mL (0.5mL), 10 million IU/mL (0.5mL, 1mL); multi-dose pen (kit) albumin (human) free, 18 million IU/pen, 30 million IU/pen, 60 million IU/pen (Intron-A-SCH)

For treatment of: (a) Chronic active hepatitis B for a period of up to 6 months. (b) Chronic active hepatitis C. Coverage will be provided for a duration of up to

48 weeks therapy. Genotypes 2 and 3 may respond to 24 weeks therapy. Note: Interferons are not interchangeable. Pharmacists should dispense the

product specified by the physician. Intron A - see interferon alfa-2b interferon beta-1a, powder for IM injection, 30ug (Avonex-BGN); pre-filled syringe, 30ug (Avonex PS-BGN) See Appendix D

268

Page 291: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

interferon beta-1a, pre-filled syringe, 8.8ug/0.2mL (6)/22ug/0.5mL (6) (Rebif Initiation Pack-SRO) See Appendix D interferon beta-1a, pre-filled syringe,8.8 ug/0.2mL (6), 22ug (6 million IU), 44ug (12 million IU) (Rebif-SRO); pre-filled cartridge, 66ug/1.5mL (3 doses of 22ug), 132ug/1.5mL (3 doses of 44ug) (Rebif-SRO) See Appendix D +interferon beta-1b, powder for injection, 0.3mg (vial) (Betaseron-BAY) + (Extavia-NVR) See Appendix D

Intron A - see interferon alfa-2b Invega Sustenna - see paliperidone palmitate Invirase - see saquinavir

*iron dextran, injection, 50mg/mL (Infufer-SDZ) (DexIron-MYL) For treatment of iron deficiency when patients are intolerant to oral iron

replacement products. Note: Coverage for dialysis patients is provided under the Saskatchewan Aids to Independent Living (S.A.I.L.) Program. Exception Drug Status coverage is not required for S.A.I.L. patients.

iron ferric sodium gluconate complex, injection solution, 12.5mg/mL (Ferrlecit-JAN)

For treatment of: (a) Iron deficiency anemia in patients undergoing chronic hemodialysis who are

receiving supplemental erythropoetin. (b) Iron deficiency anemia in patients intolerant to oral iron replacement

products. Note: Coverage for dialysis patients is provided under the Saskatchewan Aids to

Independent Living (S.A.I.L.) Program. Exception Drug Status coverage is not required for S.A.I.L. patients.

iron sucrose, injection, 20mg/mL (Venofer-MYL)

See Appendix B for online adjudication criteria.

Isentress - see raltegravir

itraconazole, capsule, 100mg; oral solution, 10mg/mL (Sporanox-JAN) For treatment of: (a) Severe or life-threatening fungal infections. (b) Severe dermatophytoses unresponsive to other forms of therapy. (c) Onychomycosis.

Jamp-Lactulose - see lactulose Janumet - see sitagliptin and metformin hydrochloride Januvia - see sitagliptin phosphate Kaletra - see lopinavir/ritonavir *ketoconazole, tablet, 200mg (Apo-Ketoconazole-APX) (Nu-Ketocon-NXP) (Novo-Ketoconazole-NOP)

For treatment of: (a) Severe or life-threatening fungal infections. (b) Severe dermatophytoses. (c) Dermatophytoses unresponsive to other forms of therapy.

*ketorolac tromethamine, ophthalmic solution, 0.5% (Acular-ALL) (Apo-Ketoralac-APX) (ratio-Ketorolac-RPH)

For treatment of:

269 (a) Post-operative ocular inflammation in patients undergoing cataract surgery.

Page 292: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

(b) Long-term inflammatory conditions unresponsive to short-acting topical steroids, and:

(c) For prophylaxis of aphakic macular edema following cataract surgery. +ketotifen fumarate, tablet, 1mg (Zaditen-NVR) (Novo-Ketotifen-NOP) syrup, 0.2mg/mL) (Novo-Ketotifen-NOP)

For treatment of pediatric patients with asthma who are unresponsive to or unable to administer alternative prophylactic agents listed in the Formulary. Kineret - see anakinra Kivexa - see abacavir SO4/lamivudine lacosamide, tablet, 50mg, 100mg, 150mg, 200mg (Vimpat-UCB)

For the adjunctive treatment of refractory partial-onset seizures in patients who meet all of the following criteria:

• Are currently receiving two or more antiepileptic drugs; AND • All other antiepileptic drugs are ineffective or not appropriate; AND • The medication is being used under the direction of a neurologist.

*lactulose, solution, 667mg/mL (pms-Lactulose-PMS) (ratio-Lactulose-RPH) (Apo-Lactulose-APX) (Jamp-Lactulose-JPC) (Teva-Lacutlose-TEV) (Euro-Lac-EUR) For treatment of portal systemic encephalopathy. lamivudine, tablet, 100mg (Heptovir-GSK) For management of hepatitis B. lamivudine, tablet, 150mg, 300mg; oral solution, 10mg/mL (3TC-VII)

For management of HIV disease. This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

lamivudine/zidovudine, tablet, 150mg/300mg (Combivir-VII)

For management of HIV disease. This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

lanreotide acetate, injection, 60mg, 90mg, 120mg (Somatuline Autogel-TCI) For treatment of acromegaly.

*lansoprazole, delayed release capsule, 15mg, 30mg (Prevacid-ABB) (Apo-Lansoprazole-APX) (Novo-Lansoprazole-NOP) (Mylan-Lansoprazole-MYL) (Lansoprazole-SAN); delayed release tablet, 15mg, 30mg (Prevacid FasTab-ABB)

(a) For a maximum of 8 weeks in treatment of peptic ulcer disease, which includes gastric and duodenal ulcers, in patients not responding or experiencing unusual or severe adverse reactions to a reasonable trial with H2 blockers, sucralfate or misoprostol. Coverage for a repeat treatment will be approved only after a 3-6 month period of no treatment or prophylaxis with an H2 blocker, sucralfate or misoprostol.

(b) For treatment of symptoms of gastroesophageal reflux disease (GERD). It was noted that patients with non-erosive GERD could potentially be reduced to step-down therapy with an H2 antagonist depending on symptom resolution.

(c) For treatment of severe erosive esophagitis and Zollinger-Ellison Syndrome. (d) For one week for eradication of H. pylori-related infections in individuals with

peptic ulcer disease. Provision will be made for additional coverage in treatment failures.

270

(e) For first-line prevention of gastroduodenal hemorrhage in high risk patients with prior history of gastroduodenal bleeds for whom anticoagulant, glucocorticosteroid or NSAID therapy cannot be avoided. Coverage is renewable on a yearly basis for patients if discontinuation of offending agents or replacement with less damaging alternatives is not feasible.

Page 293: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

(f) For a maximum of 8 weeks in patients discharged from hospital, on a proton pump inhibitor, following a gastroduodenal bleed.

lansoprazole/clarithromycin/amoxicillin, 7 day package, 30mg/500mg/500mg (Hp-PAC-ABB)

For one week for eradication of H. pylori-related infections in individuals with peptic ulcer disease. Provision will be made for additional coverage in treatment failures.

Leflunomide - see leflunomide *leflunomide, tablet, 10mg, 20mg (Arava-AVT) (Apo-Leflunomide-APX) (Novo-Leflunomide-NOP) (Sandoz Leflunomide-SDZ) (pms-Leflunomide-PMS) (Mylan-Leflunomide-MYL) (Leflunomide-SAN)

For treatment of: (a) Active rheumatoid arthritis in patients who have failed methotrexate and at

least one other DMARD (e.g. sulfasalazine, azathioprine or hydroxychloroquine).

(b) Active rheumatoid arthritis in patients intolerant to methotrexate and at least one other DMARD (e.g. sulfasalazine, azathioprine or hydroxychloroquine).

Note: Leflunomide is contraindicated in patients with pre-existing impairment of liver function.

Leucovorin - see leucovorin calcium leucovorin calcium, tablet, 5mg (Leucovorin-PFI)

See Appendix B for online adjudication criteria. leuprolide acetate, injection, 3.75mg/mL, 7.5mg/mL; depot injection, 11.25mg (3-month SR) (Lupron Depot-ABB)

For treatment of: (a) Endometriosis. (Coverage may be repeated after a six month lapse, for

another 6 month course). (b) Menorrhagia in preparation for endometrial ablation, and: (c) For pre-treatment of uterine fibroids prior to surgical removal. Coverage will be provided for a maximum of 6 months.

Levaquin - see levofloxacin *levofloxacin, tablet, 250mg, 500mg (Levaquin-JAN) (Novo-Levofloxacin-NOP) (Apo-Levofloxacin) (CO Levofloxacin-COB) (Mylan-Levofloxacin-MYL) (pms-Levofloxacin-PMS) (Ava-Levofloxacin-AVA) (Sandoz Levofloxacin-SDZ) For treatment of:

(a) Pneumonia in patients with underlying lung disease (excluding asthma). (b) Pneumonia in nursing home patients. (c) Infections in patients allergic to two or more alternative antibiotics. (d) Infections known to be resistant to alternative antibiotics. Resistance must

be determined by C & S. Where C & S cannot be obtained coverage will be approved when a patient has failed at least 2 other classes of antibiotics, and:

(e) For completion of antibiotic treatment initiated in hospital when alternatives are not appropriate.

(f) For treatment of pelvic inflammatory disease. *levofloxacin, tablet, 750mg (Levaquin-JAN) (Novo-Levofloxacin-NOP) (Apo-Levofloxacin-APX) (CO Levofloxacin-COB) (pms-Levofloxacin-PMS) (Sandoz Levofloxacin-SDZ) EDS will only be approved for five days.

271

Page 294: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

For treatment of: (a) Pneumonia in patients with underlying lung disease (excluding asthma) (b) Pneumonia in patients in a nursing home. (c) Pneumonia in patients allergic to two or more alternative antibiotics. (d) Pneumonia known to be resistant to alternative antibiotics. Resistance must

be determined by C & S. Where C & S cannot be obtained coverage will be approved when a patient has failed at least 2 other classes of antibiotics, and:

(e) For completion of antibiotic treatment of pneumonia initiated in hospital when alternatives are not appropriate.

linezolid, tablet, 600mg; oral suspension, 100mg/5ml (Zyvoxam-PFI)

Following consultation with an infectious disease specialist For treatment of: (a) Gram-positive infections in patients resistant to vancomycin. (b) Gram positive infections in patients intolerant to or experiencing severe

adverse effects from vancomycin, and: (c) For completion of therapy initiated in hospital with intravenous vancomycin,

quinupristin/dalfopristin or linezolid for patients who can be discharged on oral therapy.

Lioresal Intrathecal - see baclofen Loniten - see minoxidil lopinavir/ritonavir, tablet, 100mg/25mg; 200mg/50mg; oral solution, 80mg/20mg(mL) (Kaletra-ABB)

For management of HIV disease. This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

Losec - see omeprazole magnesium Lovenox - see enoxaparin Lovenox HP - see enoxaparin Lucentis - see ranibizumab Lupron Depot - see leuprolide acetate Lyrica - see pregabalin Mar-Ciprofloxacin - see ciprofloxacin Mar-Rizatriptan - see rizatripatan benzoate maraviroc, tablet, 150mg, 300mg (Celsentri-VII)

For treatment of HIV-1 disease (in combination with other antiretroviral agents) in patients: (a) Who have CCR5 tropic viruses AND (b) Who have documented resistance to at least one agent from each of the

three major classes of antiretroviral agents (nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors).

Note: Testing for CCR5 tropic viruses is required for use of this agent. This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

Maxalt - see rizatriptan benzoate Maxalt RPD - see rizatriptan benzoate Megace OS - see megestrol acetate oral suspension

*megestrol acetate, tablet, 40mg, 160mg (Apo-Megestrol-APX) For treatment of anorexia, cachexia, or unexplained weight loss in patients with a diagnosis of acquired immunodeficiency (AIDS).

272

Page 295: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

megestrol acetate, oral suspension, 40mg/mL (Megace OS-BMY) For treatment of anorexia, cachexia, or unexplained weight loss in patients with a diagnosis of acquired immunodeficiency (AIDS).

Meloxicam - see meloxicam

*meloxicam, tablet, 7.5mg, 15mg (Mobicox-BOE) (pms-Meloxicam-PMS) (Apo-Meloxicam-APX) (Dom-Meloxicam-DOM) (CO Meloxicam-COB) (Mylan-Meloxicam-MYL) (Novo-Meloxicam-NOP) (Meloxicam-SAN) (Ava-Meloxicam-AVA) For treatment of patients intolerant to other NSAIDs listed in the formulary.

Mepron - see atovaquone

mercaptopurine, tablet, 50mg (Purinethol-NOP) For treatment of: (a) Crohn's disease. (b) Rheumatoid arthritis.

+methoxsalen, capsule, 10mg (Oxsoralen-ICN) (Oxsoralen Ultra-ICN) lotion, 1% (Oxsoralen-ICN) For treatment of psoriasis, for use prior to PUVA therapy. Miacalcin - see calcitonin salmon nasal spray midodrine HCl, tablet, 2.5mg, 5mg (Apo-Midodrine-APX) For treatment of orthostatic hypotension.

Minocycline - see minocycline HCl

*minocycline HCl, capsule, 50mg, 100mg (Apo-Minocycline-APX) (Novo-Minocycline-NOP) (Mylan-Minocycline-MYL) (Sandoz Minocycline-SDZ) (Minocycline-SAN) (pms-Minocycline-PMS) For treatment of acne unresponsive to tetracycline.

minoxidil, tablet, 2.5mg, 10mg (Loniten-PFI) For control of hypertension unresponsive to all other listed therapeutic agents. Mint-Ciprofloxacin - see ciprofloxacin Mint-Pioglitazone - see pioglitazone HCl Mobicox - see meloxicam *modafinil, tablet, 100mg (Alertec-DPY) (Apo-Modafinil-APX)

For treatment of: (a) Patients with sleep laboratory-confirmed diagnosis of narcolepsy. (b) Patients with sleep laboratory-confirmed diagnosis of idiopathic CNS

hypersomnia. Montelukast - see montelukast sodium Montelukast Sodium Tablets - see montelukast sodium *montelukast sodium, chewable tablet, 4mg, 5mg (Singulair-MSD) (Apo-Montelukast-APX) (pms-Montelukast-PMS) (Sandoz Montelukast-SDZ) (Teva-Montelukast-TEV) (Mylan-Montelukast-MYL); tablet, 10mg (Singulair-MSD) (pms-Montelukast-PMS) (Sandoz Montelukast-SDZ) (Teva-Montelukast-TEV) (Montelukast Sodium Tablets-AHI) (Mylan-Montelukast-MYL); oral granules, 4mg (Singulair-MSD) (Sandoz Montelukast-SDZ)

(a) For treatment of asthma patients under the age of six years.

273

Page 296: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

(b) For asthma patients who cannot manage the use of an inhalation device despite assistance with a spacer (eg. physically or mentally challenged patients or pediatric patients).

(c) For adjunctive treatment in patients up to the age of 18 concurrently on an inhaled steroid who have failed a long acting beta-2 agonist (LABA).

Monurol - see fosfomycin tromethamine moxifloxacin HCl, tablet, 400mg (Avelox-BAY) For treatment of:

(a) Pneumonia in patients with underlying lung disease (excluding asthma) or pneumonia in nursing home patients.

(b) Infections in patients allergic to two or more alternative antibiotics. (c) Infections known to be resistant to alternative antibiotics. Resistance must

be determined by C & S. Where a C & S cannot be obtained coverage will be approved when a patient has failed at least 2 other classes of antibiotics, and:

(d) For completion of antibiotic treatment initiated in hospital when alternatives are not appropriate.

moxifloxacin HCl, ophthalmic solution, 0.5% (Vigamox-ALC) For treatment of ophthalmic infections unresponsive to alternative agents. Mycobutin - see rifabutin Mycopenolate Mofetil – see mycophenolate mofetil *mycophenolate mofetil, capsule, 250mg (CellCept-HLR) (Apo-Mycophenolate-APX) (Mylan-Mycophenolate-MYL) (Novo-Mycophenolate-TEV) (Sandoz Mycophenolate-SDZ); *tablet, 500mg (CellCept-HLR) (Apo-Mycophenolate-APX) (Mylan-Mycophenolate-MYL) (Novo-Mycophenolate-TEV) (Sandoz Mycophenolate-SDZ) (CO Mycophenolate-COB) (Mycophenolate Mofetil-AHI); powder for oral suspension, 200mg/mL (CellCept-HLR)

(a) For prevention of acute rejection in transplant patients. (b) For treatment of nephrotic syndrome in cases of biopsy-proven evidence of

severe proliferative lesions or sclerosis, which have not responded after a 6 month course of cyclophosphamide, or in patients unable to tolerate cyclophosphamide.

mycophenolate sodium, enteric coated tablet, 180mg, 360mg (Myfortic-NVR) For prevention of acute rejection in renal transplant patients. Myfortic - see mycophenolate sodium Mylan-Alendronate - see alendronate sodium Mylan-Azithromycin - see azithromycin Mylan-Carvedilol - see carvediolol Mylan-Ciprofloxacin - see ciprofloxacin Mylan-Clarithromycin - see clarithromycin Mylan-Clopidogrel - see clopidogrel bisulfate Mylan-Cycloprine - see cyclobenzaprine HCl Mylan-Cyproterone - see cyproterone acetate Mylan-Fluconazole - see fluconazole Mylan-Galantamine ER - see galantamine hydrobromide Mylan-Lansoprazole - see lansoprazole Mylan-Leflunomide - see leflunomide Mylan-Levofloxcin - see levofloxacin Mylan-Meloxicam - see meloxicam Mylan-Minocycline - see minocycline HCl Mylan-Montelukast - see montelukast sodium

274

Page 297: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

Mylan-Mycophenolate - see mycophenolate mofetil Mylan-Nabumetone - see nabumetone Mylan-Olanzapine - see olanzapine Mylan-Olanzapine ODT - see olanzapine Mylan-Omeprazole - see omeprazole Mylan-Pantoprazole - see pantoprazole sodium Mylan-Pioglitazone - see pioglitazone HCl Mylan-Risedronate - see risedronate sodium Mylan-Rizatriptan ODT - see rizatriptan benzoate Mylan-Selegiline - see selegiline HCl Mylan-Sumatriptan - see sumatriptan Mylan-Ticlopidine - see ticlopidine HCl Mylan-Tizanidine - see tizandine HCl Myozyme - see alglucosidase alfa *nabilone, capsule, 0.5mg, 1mg (Cesamet-VAE) (pms-Nabilone-PMS) (Ran-Nabilone-RAN) (Teva-Nabilone-TEV) For treatment of nausea and anorexia in AIDS patients. *nabumetone, tablet, 500mg (Apo-Nabumetone-APX) (Mylan-Nabumetone-MYL) (Novo-Nabumetone-NOP); 750mg (Novo-Nabumetone-NOP) For treatment of patients intolerant to other NSAIDs listed in the Formulary.

nadroparin calcium, syringe, 9,500IU/mL (0.3mL, 0.4mL, 0.6mL, 0.8mL, 1.0mL) (Fraxiparine-AVT); syringe, 19,000IU/mL (0.6mL, 0.8mL, 1mL) (Fraxiparine Forte-AVT)

(a) For treatment of venous thromboembolism for up to 10 days. (b) For prophylaxis following total knee arthroplasty for up to 35 days. (c) For major orthopedic trauma for up to 10 days (treatment duration may be

reassessed). (d) For long-term outpatient prophylaxis in patients who are pregnant. (e) For long-term outpatient prophylaxis in patients who have a

contracindication to, are intolerant to, or have failed, warfarin therapy. (f) For long-term outpatient prophylaxis in patients who have lupus

anticoagulant syndrome. (g) Prophylaxis in patients undergoing total hip replacement or following hip

fracture surgery for up to 35 days following the procedure.

nafarelin acetate, intranasal solution, 2mg/mL (Synarel-HLR) For treatment of: (a) Endometriosis. (Coverage may be repeated after a six month lapse, for

another 6 month course). (b) Menorrhagia in preparation for endometrial ablation, and: (c) For pre-treatment of uterine fibroids prior to surgical removal. Coverage will be provided for a maximum of 6 months

Nalcrom - see sodium cromoglycate *naratriptan HCl, tablet, 1mL (Amerge-GSK) (Novo-Naratriptan-NOP); 2.5mg (Amerge-GSK) (Novo-Naratriptan-NOP) (Sandoz Naratriptan-SDZ) For treatment of migraine headaches in patients over 18 years of age.

The maximum quantity that can be claimed through the Drug Plan is limited to 6 doses per 30 days within a 60-day period. Patients requiring more than 12 doses in a consecutive 60-day period should be considered for migraine prophylaxis therapy if they are not already receiving such therapy.

natalizumab, solution for IV infusion, 20mg/mL (Tysabri-BGN) See Appendix D nateglinide, tablet, 60mg, 120mg (Starlix-NVR)

275 For treatment of :

Page 298: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

(a) Diabetes in patients uncontrolled on sulfonylureas. (b) Diabetes in patients intolerant to sulfonylureas.

nelfinavir mesylate, tablet, 250mg, 625mg (Viracept-PFI)

For management of HIV disease. This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

Neoral - see cyclosporine Neupogen - see filgrastim *nevirapine, tablet, 200mg (Viramune-BOE) (Teva-Nevirapine-TVM) (Auro-Nevirapine-API)

For management of HIV disease. This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

Nexium - see esomeprazole magnesium trihydrate nimodipine, tablet, 30mg (Nimotop-BAY) For treatment of subarachnoid hemorrhage to complete a 3 week course of

treatment in cases where a patient is discharged from hospital before completion of the treatment period.

Nimotop - see nimodipine Nizoral - see ketoconazole *norfloxacin, tablet, 400mg (Apo-Norflox-APX) (Novo-Norfloxacin-NOP) (pms-Norfloxacin-PMS) (CO Norfloxacin-COB) For treatment of:

(a) Genitourinary tract infections caused by Pseudomonas aeruginosa. (b) Genitourinary tract infections in patients allergic to alternative agents. (c) Genitourinary tract infections in patients with organisms known to be

resistant to alternative antibiotics, and: (d) For adults with gonoccoccal urethritis or cervicitis.

Norprolac - see quinagolide HCl Norvir - see ritonavir Norvir SEC - see ritonavir Novo-Alendronate - see alendronate sodium Novo-Azithromycin - see azithromycin Novo-Ciprofloxacin - see ciprofloxacin Novo-Clavamoxin - see amoxicillin trihydrate/potassium clavulanate Novo-Clonidine - see clonidine HCl Novo-Cycloprine - see cyclobenzaprine HCl Novo-Desmopressin - see desmopressin Novo-Fentanyl - see fentanyl Novo-Fluconazole - see fluconazole Novo-Ketoconazole - see ketoconazole Novo-Ketotifen - see ketotifen fumarate Novo-Lansoprazole - see lansoprazole Novo-Leflunomide - see leflunomide Novo-Levofloxacin - see levofloxacin Novo-Meloxicam - see meloxicam Novo-Minocycline - see minocycline HCl Novo-Mycophenolate - see mycophenolate mofetil Novo-Nabumetone - see nabumetone Novo-Naratriptan - see naratriptan HCl

276

Page 299: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

Novo-Norfloxacin - see norfloxacin Novo-Olanzapine - see olanzapine Novo-Olanzapine OD - see olanzapine Novo-Omeprazole - see omeprazole Novo-Pantoprazole - pantoprazole sodium Novo-Pioglitazone - see pioglitazone HCl Novo-Rabeprazole EC - see rabeprazole sodium Novo-Raloxifene - see raloxifene HCl NovoRapid - see insulin aspart Novo-Risedronate - see risedronate sodium Novo-Selegiline - see selegiline HCl Novo-Sumatriptan - see sumatriptan Novo-Sumatriptan DF - see sumatriptan Novo-Ticlopidine - see ticlopidine Nu-Carvedilol - see carvedilol Nu-Ciprofloxacin - see ciprofloxacin Nu-Cyclobenzaprine - see cyclobenzaprine HCl Nu-Ketocon - see ketoconazole Nu-Megestrol - see megestrol acetate tablet Nu-Selegiline - see selegiline HCl Nu-Ticlopidine - see ticlopidine HCl Nutropin - see somatropin Nutropin AQ - see somatropin Nutropin AQ Pen - see somatropin Octostim - see desmopressin *octreotide, injection, 50ug/mL (1mL), 100ug/mL (1mL), 200ug/mL (5mL), 500ug/mL (1mL) (Sandostatin-NVR) (Octreotide Acetate-OMG); powder for injection, 10mg/vial, 20mg/vial, 30mg/vial (Sandostatin LAR-NVR) (a) For management of terminal malignant bowel obstruction in palliative

patients. (b) For treatment of acromegaly. Note: Coverage for federally approved cancer indications is provided under the

Saskatchewan Cancer Agency according to their guidelines. Octreotide Acetate - see octreotide Ocuflox - see ofloxacin ophthalmic solution Oesclim - see estradiol *ofloxacin, ophthalmic solution, 0.3% (Ocuflox-ALL) (Apo-Ofloxacin-APX) (pms-Ofloxacin-PMS)

For the treatment of: (a) Ophthalmic infections caused by gram-negative organisms. (b) Ophthalmic infections unresponsive to alternative agents, and: (c) Infiltrative corneal infections.

Olanzapine - see olanzapine *olanzapine, tablet, 2.5mg, 5mg, 7.5mg, 10mg, 15mg (Zyprexa-LIL) (Novo-Olanzapine-NOP) (pms-Olanzapine-PMS) (Apo-Olanzapine-APX) (CO Olanzapine-COB) (Olanzapine-SAN) (Mylan-Olanzapine-MYL); *orally disintegrating tablet, 5mg, 10mg, 15mg (Zyprexa Zydis-LIL) (Novo-Olanzapine OD-NOP) (PMS-Olanzapine ODT-PMS) (CO Olanzapine ODT-COB) (Sandoz Olanzapine ODT-SDZ) (Apo-Olanzapine ODT-APX) (Olanzapine ODT-SAN) (Mylan-Olanzapine ODT-MYL)

For treatment of: (a) Schizophrenia.

277

Page 300: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

(b) Other psychotic conditions where there has been: • Treatment failure to other atypical anti-psychotic agents. • Intolerance to other atypical anti-psychotic agents.

(c) Patients with acute mania of bi-polar affective disorder for an additional 4 weeks following hospital discharge, and:

(d) For maintenance treatment of bipolar disorder in patients who are unresponsive to other first line agents (lithium, divalproex and lamotrigine).

Omeprazole - see omeprazole *omeprazole, capsule/tablet, 20mg (Losec-AST) (Apo-Omeprazole-APX) (ratio-Omeprazole-RPH) (Sandoz Omeprazole-SDZ) (pms-Omeprazole DR-PMS) (Mylan-Omeprazole-MYL) (Omeprazole-SAN) (Novo-Omeprazole-NOP) (Ran-Omeprazole-RAN)

(a) For a maximum of 8 weeks in treatment of peptic ulcer disease, which includes gastric and duodenal ulcers, in patients not responding or experiencing unusual or severe adverse reactions to a reasonable trial with H2 blockers, sucralfate or misoprostol. Coverage for a repeat treatment will be approved only after a 3-6 month period of no treatment or prophylaxis with an H2 blocker, sucralfate or misoprostol.

(b) For treatment of symptoms of gastroesophageal reflux disease (GERD). It was noted that patients with non-erosive GERD could potentially be reduced to step-down therapy with an H2 antagonist depending on symptom resolution.

(c) For treatment of severe erosive esophagitis and Zollinger-Ellison Syndrome. (d) For one week for eradication of H. pylori-related infections in individuals with

peptic ulcer disease. Provision will be made for additional coverage in treatment failures.

(e) For first-line prevention of gastroduodenal hemorrhage in high risk patients with prior history of gastroduodenal bleeds for whom anticoagulant, glucocorticosteroid or NSAID therapy cannot be avoided. Coverage is renewable on a yearly basis for patients if discontinuation of offending agents or replacement with less damaging alternatives is not feasible.

(f) For a maximum of 8 weeks in patients discharged from hospital, on a proton pump inhibitor, following a gastroduodenal bleed.

*omeprazole, capsule/tablet 10mg (Losec-AST) (Sandoz Omeprazole-SDZ) (Mylan-Omeprazole-MYL)

For treatment of: (a) Symptoms of gastroesophageal reflux disease (GERD). It was noted that

patients with non-erosive GERD could potentially be reduced to step-down therapy with an H2 antagonist depending on symptom resolution.

(b) Severe erosive esophagitis and Zollinger-Ellison syndrome. This is renewable on a yearly basis, and:

(c) For maintenance therapy of healed reflux esophagitis. This is renewable on a yearly basis.

Omnitrope - see somatropin One-Alpha - see alfacalcidol Onglyza - see saxagliptin Orencia - see abatacept *oxcarbazepine, tablet, 150mg, 300mg, 600mg (Trileptil-NVR) (Apo-Oxcarbazepine-APX); oral suspension, 60mg/mL (Trileptil-NVR) See Appendix B for online adjudication criteria.

278

Page 301: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

Oxeze Turbuhaler - see formoterol fumarate Oxsoralen - see methoxsalen oxybutynin chloride, controlled release tablet, 10mg, 15mg (Uromax-PFR) See Appendix B for online adjudication criteria. oxycodone HCl, controlled release tablet, 10mg, 15mg, 20mg, 30mg, 40mg, 60mg, 80mg (Oxyneo-PFR) For the treatment of pain in palliative and cancer patients. Oxyneo - see oxycodone HCl paliperidone palmitate, pre-filled syringe, 50mg, 75mg, 100mg, 150mg (Invega Sustenna-JAN)

For the treatment of patients exhibiting a compliance problem with an oral antipsychotic and in whom the administration of a conventional injectable extended action antipsychotic is ineffective or poorly tolerated.

*pamidronate disodium, injection, 30mg, (Aredia-NVR) (Pamidronate Disodium Injection-DBU) (pms-Pamidronate-PMS); *injection, 60mg (Pamidronate Disodium Injection-DBU) (Pamidronate Disodium Omega-OMG) *injection, 90mg (Aredia-NVR) (Pamidronate Disodium Injection-DBU) (pms-Pamidronate-PMS)

For treatment of osteoporosis in patients intolerant to oral bisphosphonates.

Pantoprazole - see pantolprazole sodium

*pantoprazole sodium, enteric-coated tablet, 20mg (Sandoz Pantoprazole-SDZ) (Apo-Pantoprazole-APX) (Ava-Pantoprazole-AVA) (Novo-Pantoprazole-NOP) (Ran-Pantoprazole-RAN); 40mg (Pantoloc-NYC) (Apo-Pantoprazole-APX) (Novo-Pantoprazole-NOP) (Ran-Pantoprazole-RAN) (CO Pantoprazole-COB) (Mylan-Pantoprazole-MYL) (pms-Pantoprazole-PMS) (Sandoz Pantoprazole-SDZ) (Ava-Pantoprazole-AVA) (Pantoprazole-SAN)

(a) For a maximum of 8 weeks in treatment of peptic ulcer disease, which includes gastric and duodenal ulcers, in patients not responding or experiencing unusual or severe adverse reactions to a reasonable trial with H2 blockers, sucralfate or misoprostol. Coverage for a repeat treatment will be approved only after a 3-6 month period of no treatment or prophylaxis with an H2 blocker, sucralfate or misoprostol.

(b) For treatment of symptoms of gastroesophageal reflux disease (GERD). It was noted that patients with non-erosive GERD could potentially be reduced to step-down therapy with an H2 antagonist depending on symptom resolution.

(c) For treatment of severe erosive esophagitis and Zollinger-Ellison Syndrome. (d) For one week for eradication of H. pylori-related infections in individuals with

peptic ulcer disease. Provision will be made for additional coverage in treatment failures.

(e) For first-line prevention of gastroduodenal hemorrhage in high risk patients with prior history of gastroduodenal bleeds for whom anticoagulant, glucocorticosteroid or NSAID therapy cannot be avoided. Coverage is renewable on a yearly basis for patients if discontinuation of offending agents or replacement with less damaging alternatives is not feasible.

(f) For a maximum of 8 weeks in patients discharged from hospital, on a proton pump inhibitor, following a gastroduodenal bleed.

279

Page 302: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

pantoprazole magnesium, enteric-coated tablet, 40mg (Tecta-NYC) (a) For a maximum of 8 weeks in treatment of peptic ulcer disease, which

includes gastric and duodenal ulcers, in patients not responding or experiencing unusual or severe adverse reactions to a reasonable trial with H2 blockers, sucralfate or misoprostol. Coverage for a repeat treatment will be approved only after a 3-6 month period of no treatment or prophylaxis with an H2 blocker, sucralfate or misoprostol.

(b) For treatment of symptoms of gastroesophageal reflux disease (GERD). It was noted that patients with non-erosive GERD could potentially be reduced to step-down therapy with an H2 antagonist depending on symptom resolution.

(c) For treatment of severe erosive esophagitis and Zollinger-Ellison Syndrome. (d) For one week for eradication of H. pylori-related infections in individuals with

peptic ulcer disease. Provision will be made for additional coverage in treatment failures.

(e) For first-line prevention of gastroduodenal hemorrhage in high risk patients with prior history of gastroduodenal bleeds for whom anticoagulant, glucocorticosteriod or NSAID therapy cannot be avoided. Coverage is renewable on a yearly basis for patients if discontinuation of offending agents or replacement with less damaging alternatives is not feasible.

(f) For a maximum of 8 weeks in patients discharged from hospital, on a proton pump inhibitor, following a gastroduodenal bleed.

Pantoloc - see pantoprazole sodium Pariet - see rabeprazole sodium Pat-Galantamine ER - see galantamine hydrobromide Pegetron - see peginterferon alfa-2b/ribavirin peginterferon alfa-2a, injection (pre-filled syringe), 180ug/0.5mL (Pegasys-HLR)

(a) For treatment of chronic active hepatitis C. Coverage will be provided for a duration of up to 48 weeks. Genotypes 2 and 3 may respond to 24 weeks of therapy.

(b) For the management of hepatitis B for up to 48 weeks. peginterferon alfa-2a/ribavirin, injection (pre-filled syringe)/tablet, 180ug/1mL/200mg (Pegasys RBV-HLR)

For treatment of chronic active hepatitis C. Coverage will be provided for a duration of up to 48 weeks. Genotypes 2 and 3 may respond to 24 weeks of therapy.

peginterferon alfa-2b/ribavirin, powder for solution/capsule, 50ug/0.5mL/200mg, 150ug/0.5mL/200mg (Pegetron-SCH) 80ug/0.5mL/200mg, 100ug/0.5mL/200mg, 120ug/0.5mL/200mg, 150ug/0.5mL/200mg (Pegetron Redipen-SCH)

For treatment of chronic active hepatitis C. Coverage will be provided for a duration of up to 48 weeks. Genotypes 2 and 3 may respond to 24 weeks of therapy.

peginterferon alfa-2b/ribavirin, powder for solution/capsule, 50ug/200mg, 80ug/200mg, 100ug/200mg, 120ug/200mg, 150ug/200mg (Pegetron-SCH)

For treatment of chronic active hepatitis C. Coverage will be provided for a duration of up to 48 weeks. Genotypes 2 and 3 may respond to 24 weeks of therapy.

pentosan polysulfate sodium, capsule, 100mg (Elmiron-JAN) For treatment of interstitial cystitis where other treatments have failed.

280

Page 303: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PhosLo - see calcium acetate pimecrolimus, topical cream, 1% (Elidel-NVR)

For treatment of: (a) Atopic dermatitis in patients unresponsive to topical steroids tried within the

last 3 months. (b) Atopic dermatitis in patients intolerant to topical steroids tried within the last

3 months.

Pioglitazone - see pioglitazone HCl *pioglitazone HCl, tablet, 15mg, 30mg, 45mg (Actos-TAK) (Apo-Pioglitazone-APX) (CO Pioglitazone-COB) (Mylan-Pioglitazone-MYL) (Novo-Pioglitazone-NOP) (pms-Pioglitazone-PMS) (ratio-Pioglitazone-RPH) (Sandoz Pioglitazone-SDZ) (Accel Pioglitazone-ACC) (Mint-Pioglitazone-MNT) (Pioglitazone-AHI) (Ava-Pioglitazone-AVA) (Ran-Pioglitazone-RAN)

See Appendix B for online adjudication criteria. Plavix - see clopidogrel bisulfate pms-Alendronate - see alendronate sodium pms-Alendronate-FC - see alendronate sodium pms-Azithromycin - see azithromycin pms-Bezafibrate - see bezafibrate pms-Carvedilol - see carvedilol pms-Ciprofloxacin - see ciprofloxacin pms-Clarithromycin - see clarithromycin pms-Clopidogrel - see clopidogrel bisulfate pms-Cyclobenzaprine - see cyclobenzaprine HCl pms-Desmopressin - see desmopressin pms-Fentanyl MTX - see fentanyl pms-Fluconazole - see fluconazole pms-Ketotifen - see ketotifen pms-Lactulose - see lactulose pms-Leflunomide - see leflunomide pms-Levofloxacin - see levofloxacin pms-Meloxicam - see meloxicam pms-Montelukast - see montelukast sodium pms-Nabilone - see nabilone pms-Norfloxacin - see norfloxacin pms-Ofloxacin - see ofloxacin pms-Olanzapine - see olanzapine pms-Olanzapine ODT - see olanzapine pms-Omeprazole DR - see omeprazole pms-Pantoprazole - see pantoprazole sodium pms-Pioglitazone - see pioglitazone HCl pms-Rabeprazole - see rabeprazole sodium pms-Raloxifene - see raloxifene HCl pms-Repaglinide - see repaglinide pms-Risedronate - see risedronate sodium pms-Rivastigmine - see rivastigmine pms-Sumatriptan - see sumatriptan pms-Tobramycin - see tobramycin pms-Ursodiol C - see ursodiol pms-Vancomycin - see vancomycin HCl pms-Zolmitriptan - see zolmitriptan Pradax - see dabigatran

281

Page 304: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

prasugrel, tablet, 10mg (Effient-LIL) For treatment initiated by a cardiologist in patients under 75 years of age and over 60kg with stent thrombosis while on clopidogrel in the preceding 28 days.

pregabalin, capsule, 25mg, 50mg, 75mg, 150mg, 300mg (Lyrica-PFI) (a) For the treatment of neuropathic pain in patients unresponsive following

treatment with adequate doses of tricyclic antidepressants (TCA) as indicated on the patient profile by 2 consecutive prescriptions for a TCA within 6 months of the EDS request, or

(b) For the treatment of neuropathic pain in patients intolerant or contraindicated to tricyclic antidepressants.

Note: Coverage is not approved for the treatment of pain associated with conditions such as fibromyalgia, Multiple Sclerosis, Trigeminal Neuralgia and others.

Prevacid - see lansoprazole Prevacid FasTab - see lansoprazole Prezista - see darunavir progesterone (micronized), capsule, 100mg (Prometrium-SCH)

For treatment of patients: (a) Intolerant to medroxyprogesterone acetate (Provera). (b) Having low high-density lipoproteins. Prograf - see tacrolimus Prolia - see denosumab Prometrium - see progesterone (micronized) Protopic - see tacrolimus Pulmozyme - see dornase alfa Purinethol - see mercaptopurine quinagolide HCl, tablet, 0.075mg, 0.150mg (Norprolac-FEI)

See Appendix B for online adjudication criteria.

*rabeprazole sodium, enteric coated tablet, 10mg, 20mg (Pariet-JAN) (Novo-Rabeprazole EC-NOP) (Ran-Rabeprazole-RAN) (pms-Rabeprazole EC-PMS) (Sandoz Rabeprazole-SDZ) (Apo-Rabeprazole-APX) (Rabeprazole-SAN)

(a) For a maximum of 8 weeks in treatment of peptic ulcer disease, which includes gastric and duodenal ulcers, in patients not responding or experiencing unusual or severe adverse reactions to a reasonable trial with H2 blockers, sucralfate or misoprostol. Coverage for a repeat treatment will be approved only after a 3-6 month period of no treatment or prophylaxis with an H2 blocker, sucralfate or misoprostol.

(b) For treatment of symptoms of gastroesophageal reflux disease (GERD). It was noted that patients with non-erosive GERD could potentially be reduced to step-down therapy with an H2 antagonist depending on symptom resolution.

(c) For treatment of severe erosive esophagitis and Zollinger-Ellison Syndrome. (d) For one week for eradication of H. pylori-related infections in individuals with

peptic ulcer disease. Provision will be made for additional coverage in treatment failures.

(e) First-line prevention of gastroduodenal hemorrhage in high-risk patients with prior history of gastroduodenal bleeds for whom anticoagulant, glucocorticosteroid or NSAID therapy cannot be avoided. Coverage is renewable on a yearly basis for patients if discontinuation of offending agents or replacement with less damaging alternatives is not feasible.

(f) For a maximum of 8 weeks in patients discharged from hospital, on a proton pump inhibitor, following a gastroduodenal bleed.

282

Page 305: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

*raloxifene HCl, tablet, 60mg (Evista-LIL) (Apo-Raloxifene-APX) (Novo-Raloxifene-NOP) (pms-Raloxifene-PMS)

For treatment of: (a) Osteoporosis in patients unresponsive to etidronate disodium/calcium

(Didrocal) after receiving it for 1 year. (b) Osteoporosis in patients intolerant to etidronate disodium/calcium (Didrocal).

raltegravir, tablet, 400mg (Isentress-MSD)

For the treatment of HIV-1 infection in treatment-experienced patients who have evidence of viral replication and HIV-1 strains resistant to three classes of HIV agents. This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

Ran-Carvedilol - see carvedilol Ran-Cefprozil - see cefprozil Ran-Ciproflox - see ciprofloxacin Ran-Clarithromycin - see clarithromycin Ran-Clopidogrel - see clopidogrel bisulfate Ran-Fentanyl - see fentanyl Ran-Fentanyl Matrix - see fentanyl Ran-Nabilone - see nabilone Ran-Omeprazole - see omeprazole Ran-Pantoprazole - see pantoprazole sodium Ran-Pioglitazone - see pioglitazone HCl Ran-Rabeprazole - see rabeprazole sodium ranibizumab, injection solution, 10mg/mL (mcg) (Lucentis-NVR)

For the treatment of neovascular (wet) age-related macular degeneration (AMD) if all of the following circumstances apply to the eye to be treated: (a) The best corrected visual acuity (BCVA) is between 6/12 and 6/96 (b) The lesion size is less than or equal to 12 disc areas in greatest linear

dimension (c) There is evidence of recent (< 3 months) presumed disease progression

(blood vessel growth, as indicated by fluorescein angiography, optical coherence tomography (OCT) or recent visual acuity changes)

(d) Injection will be by a qualified ophthalmologist with experience in intravitreal injections

Coverage will not be provided for patients: (a) With permanent structural damage to the central fovea or no active disease

(as defined in the Royal College of Ophthalmology guidelines). (b) Receiving concurrent verteporfin PDT treatment.

The interval between the doses should be no shorter than one month. Treatment with ranibizumab should be continued only in people who maintain adequate response to therapy. Ranibizumab should be permanently discontinued if any one of the following occurs: (a) Reduction in BCVA in the treated eye to less than 15 letters (absolute) on 2

consecutive visits in the treated eye, attributed to AMD in the absence of other pathology.

(b) Reduction in BCVA of 30 letters or more compared to either baseline and/or best recorded level since baseline and/or best recorded level since baseline as this may indicate either poor treatment effect or adverse event or both.

(c) There is evidence of deterioration of the lesion morphology despite optimum treatment over 3 consecutive visits.

283

Page 306: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

Rapamune - see sirolimus ratio-Aclavulanate - see amoxicillin trihydrate/potassium clavulanate ratio-Alendronate - see alendronate sodium ratio-Azithromycin - see azithromycin ratio-Carvedilol - see carvedilol ratio-Cefuroxime - see cefuroxime axetil ratio-Ciprofloxacin - see ciprofloxacin ratio-Clarithromycin - see clarithromycin ratio-Fentanyl - see fentanyl ratio-Ketorolac - see ketorolac tromethamine ratio-Lactulose - see lactulose ratio-Omeprazole - see omeprazole ratio-Pioglitazone - see pioglitazone HCl ratio-Risedronate - see risedronate sodium ratio-Rivastigmine see rivastigmine Rebif - see Appendix D Rebif Initiation Pack - see Appendix D Remicade - see infliximab Reminyl ER - see galantamine hydrobromide Remodulin - see treprostinil Renagel - see sevelamer HCl *repaglinide, tablet, 0.5mg, 1mg, 2mg (GlucoNorm-NOO) (Apo-Repaglinide-APX) (CO Repaglinide-COB) (pms-Repaglinide-PMS) (Sandoz Repaglinide-SDZ)

See Appendix B for online adjudication criteria. Rescriptor - see delavirdine mesylate Retin A - see tretinoin Retrovir - see zidovudine Revatio - see sildenafil citrate Reyataz - see atazanavir SO4 rifabutin, capsule, 150mg (Mycobutin-PFI) For prevention of disseminated Mycobacterium avium complex (MAC) in patients

with advanced human immunodeficiency virus (HIV) infection. Risedronate - see risedronate sodium *risedronate sodium, tablet, 5mg, 150mg (Actonel-WCI) (Novo-Risedronate-NOP); 35mg (Apo-Risedronate-APX) (pms-Risedronate-PMS) (ratio-Risedronate-RPH) (Sandoz Risedronate-SDZ) (Mylan-Risedronate-MYL) (Risedronate-SAN);

For treatment of: (a) Osteoporosis in patients unresponsive to etidronate disodium/calcium

(Didrocal) after receiving it for one year. (b) Osteoporosis in patients intolerant to etidronate disodium/calcium (Didrocal). (c) Osteoporosis in patients who have pre-existing and/or recent fractures, (d) Glucocorticoid-induced osteoporosis in patients who have received systemic

glucocorticoid treatment for at least 3 months.

*risedronate sodium, tablet, 30mg (Actonel-WCI) (Novo-Risedronate-NOP) For treatment of symptomatic Paget's disease of the bone. Risperdal Consta - see risperidone

284

Page 307: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

risperidone, powder for suspension sustained-release, 12.5mg/vial, 25mg/vial, 37.5mg/vial, 50mg/vial (Risperdal Consta-JAN)

For treatment of patients exhibiting a compliance problem with an oral antipsychotic and in whom the administration of a conventional injectable extended action antipsychotic is ineffective or poorly tolerated.

ritonavir, oral solution, 80mg/mL (Norvir-ABB); soft elastic capsule, 100mg (Norvir SEC-ABB); tablet, 100mg (Norvir-ABB)

For management of HIV disease. This drug, as with other antivirals in treatment of HIV, should be used under the direction of an infectious disease specialist.

Rituxan - see rituximab rituximab, injection solution, 10mg/mL (Rituxan-HLR)

For treatment of severe rheumatoid arthritis when used in combination with methotrexate in adult patients who have failed to respond to an adequate trial of an anti-TNF agent. Rituxan should not be used concomitantly with anti-TNF agents. Please contact the Drug Plan for billing information.

rivaroxaban, tablet, 10mg (Xarelto-BAY)

(a) For prophylaxis following total knee arthroplasty for up to 14 days following the procedure.

(b) For prophylaxis in patients undergoing total hip replacement for up to 35 days following the procedure.

*rivastigmine, capsule, 1.5mg, 3mg, 4.5mg, 6mg (Exelon-NVR) (Sandoz Rivastigmine-SDZ) (pms-Rivastigmine-PMS) (ratio-Rivastigmine-RPH) (Apo-Rivastigmine-APX) oral solution, 2mg/mL (Exelon-NVR)

(a) A diagnosis of probable Alzheimer's disease as per DSM-IV criteria. (b) A mild to moderate stage of the disease with a MMSE score of 10-26

established within 60-days prior to application for coverage by a clinician. (c) A Functional Activities Questionnaire (FAQ) must be completed. (d) Patients must discontinue all drugs with anticholinergic activity at least 14

days before the MMSE and FAQ are administered. Drugs with anticholinergic activity are not to be used concurrently with rivastigmine therapy. List all current medications patient was taking at the time of assessment.

(e) Patients intolerant to one drug may be switched to another drug in this class. Intolerance should be observed within the first month of treatment.

• Eligible patients currently taking rivastigmine would require assessment at 6 month intervals. To continue receiving rivastigmine, patients must not have both a greater than 2 point reduction in MMSE and a 1 point increase in FAQ in a 6 month evaluation period. Scores are compared to the most recent test results.

• Eligible new patients will enter a 3 month treatment period with

rivastigmine. During the 3 month trial, patients must exhibit an improvement from the initial MMSE or FAQ to continue treatment with rivastigmine. The improvement must be at least 2 MMSE points or -1 FAQ. Patients who meet these requirements will be re-evaluated at 6 month intervals. To continue receiving rivastigmine, patients must not have both a greater than 2 point reduction in MMSE and a 1 point increase in FAQ in a 6 month evaluation period. Scores are compared to the most recent test results.

The MMSE score must remain at 10 or greater at all times to be eligible for coverage. • Patients who do not meet criteria to continue rivastigmine can be

re-evaluated within 3 months to confirm deterioration before coverage is discontinued.

285

Page 308: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

• Rivastigmine does not need to be discontinued prior to MMSE or FAQ

testing.

• A patient intolerant of one drug and switching to a second will be considered a "new" patient and will be assessed as such.

• Coverage will not be considered for patients who have failed on other drugs

in this class.

Initial EDS application for rivastigmine (Exelon) will only be accepted from physicians on the Aricept/Exelon/Reminyl EDS application form. This form is available online at http://formulary.drugplan.health.gov.sk.ca or by calling the Drug Plan. EDS renewals can be submitted either by telephone, mail or fax.

*rizatriptan benzoate, tablet, 5mg,10mg (Maxalt-MRK) (Mar-Rizatriptan-MPI); *orally disintegrating tablet, 5mg, 10mg (Maxalt RPD-MSD) (CO Rizatriptan ODT-COB) (Mylan-Rizatriptan ODT-MYL) (Sandoz Rizatriptan ODT-SDZ) For treatment of migraine headaches in patients over 18 years of age. The maximum quantity that can be claimed through the Drug Plan is limited

to 6 doses per 30 days within a 60-day period. Patients requiring more than 12 doses in a consecutive 60-day period should be considered for migraine prophylaxis therapy if they are not already receiving such therapy.

Rocaltrol - see calcitriol rosiglitazone maleate, tablet, 2mg, 4mg, 8mg (Avandia-GSK)

For the treatment of patients with Type 2 diabetes who are not adequately controlled on or are intolerant to metformin and a sulfonylurea. Note: Precribers are reminded to ensure that the Patient Informed Consent form is completed prior to prescribing this medication.

rosiglitazone maleate/metformin HCl, tablet, 1mg/500mg, 2mg/500mg, 4mg/500mg, 2mg/1000mg, 4mg/1000mg (Avandamet-GSK)

For the convenience of patients who have been stabilized on metformin and rosiglitazone. Note: Precribers are reminded to ensure that the Patient Informed Consent form is completed prior to prescribing this medication.

Saizen - see somatropin salmeterol xinafoate, powder disk, 50ug/blister (Serevent-GSK); powder for inhalation (package), 50ug/dose (Serevent Diskus-GSK)

For treatment of: (a) Asthma uncontrolled on concurrent inhaled steroid therapy.

It is important that these patients also have access to a short-acting beta-2 agonist for symptomatic relief.

(b) COPD unresponsive to short-acting beta agonists or short-acting anticholinergic bronchodilators.

salmeterol xinafoate/fluticasone propionate, metered dose inhaler (package), 25ug/125ug, 25ug/250ug (Advair-GSK); powder for inhalation (package), 50ug/100ug, 50ug/250ug, 50ug/500ug (Advair Diskus-GSK)

For treatment of: (a) Asthma in patients uncontrolled on inhaled steroid therapy. It is important

that these patients also have access to a short-acting beta-2 agonist for symptomatic relief.

(b) COPD in patients where there has been concurrent or past use of tiotropium or a LABA (salmeterol or formoterol).

286

Page 309: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

Sandostatin - see octreotide Sandostatin LAR - see octreotide Sandoz Alendronate - see alendronate sodium Sandoz Azithromycin - see azithromycin Sandoz Calcitonin NS - see calcitonin salmon Sandoz Cefprozil - see cefprozil Sandoz Ciprofloxacin - see ciprofloxacin Sandoz Clarithromycin - see clarithromycin Sandoz Clopidogrel -see clopidogrel bisulfate Sandoz Estradiol Derm - see estradiol Sandoz Fentanyl MTX - fentanyl Sandoz Leflunomide - see leflunomide Sandoz Levofloxacin - see levofloxacin Sandoz Minocycline - see minocycline HCl Sandoz Montelukast - see montelukast sodium Sandoz Mycophenolate - see mycophenolate mofetil Sandoz Naratriptan - see naratriptan Sandoz Olanzapine - see olanzapine Sandoz Olanzapine ODT - see olanzapine Sandoz Omeprazole - see omeprazole Sandoz Pantoprazole - see pantoprazole sodium Sandoz Pioglitazone - see pioglitazone HCl Sandoz Rabeprazole - see rabeprazole sodium Sandoz Repaglinide - see repaglinide Sandoz Risedronate - see risedronate sodium Sandoz Rizatriptan ODT - see rizatriptan benzoate Sandoz Rivastigmine - see rivastigmine Sandoz Sumatriptan - see sumatriptan Sandoz Tobramycin - see tobramycin ophthalmic solution Sandoz Zolmitriptan - see zolmitriptan saquinavir, capsule, 200mg, 500mg (Invirase-HLR)

For management of HIV disease. This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

saxagliptin, tablet, 2.5mg, 5mg (Onglyza-BMY) See Appendix B for online adjudication criteria.

*selegiline HCl, tablet, 5mg (Novo-Selegiline-NOP) (Apo-Selegiline-APX) (Mylan-Selegiline-MYL) (Nu-Selegiline-NXP) See Appendix B for online adjudication criteria Septa-Ciprofloxacin - see ciprofloxacin Serevent - see salmeterol xinafoate Serevent Diskus - see salmeterol xinafoate sevelamer HCl, tablet, 800mg (Renagel-GZY)

For treatment of: (a) End-stage renal disease in patients intolerant to aluminum or calcium

containing phosphate-binding agents. (b) End-stage renal disease in patients where aluminum or calcium containing

phosphate-binding agents are inappropriate.

287

Page 310: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

sildenafil citrate, tablet, 20mg (Revatio-PFI) For treatment of pulmonary arterial hypertension on the recommendation of a specialist. Note: The maximum dose that will be provided as a benefit is 20mg three times daily.

Simponi - see golimumab Singulair - see montelukast sodium

sirolimus, tablet, 1mg; oral solution, 1mg/mL (Rapamune-WYA) For prophylaxis of graft rejection in transplant patients.

sitagliptin and metformin hydrochloride, tablet, 50mg/500mg, 50mg/850mg, 50mg/1000mg (Janumet-MRK)

See Appendix B for online adjudication criteria. sitagliptin phosphate, tablet, 100mg (Januvia-MRK)

See Appendix B for online adjudication criteria. sodium cromoglycate, capsule, 100mg (Nalcrom-AVT)

For treatment of: (a) Patients who experience severe reactions to foods which cannot be

avoided. (b) Crohn's Disease unresponsive to traditional therapy.

(c) Ulcerative colitis in patients unresponsive to traditional therapy. solifenacin succinate, tablet, 5mg, 10mg (Vesicare-APC)

See Appendix B for online adjudication criteria. +somatropin, injection, 5mg (Humatrope-LIL) 5mg cartridge (Omnitrope), 6mg, 12mg, 24mg (Humatrope Cartridge-LIL, Saizen-SRO)

For treatment of children who have growth failure due to inadequate secretion of normal endogenous growth hormone. (Note: These products are not interchangeable)

+somatropin, injection, 3.33mg, 8.8mg (Saizen-SRO), 5mg (Saizen-SRO), 10mg (Nutropin AQ-HLR); cartridge, 10 mg (Nutropin AQ Pen-HLR)

For treatment of: (a) Children who have growth failure due to inadequate secretion of normal

endogenous growth hormone. (b) Children who have growth failure associated with chronic renal insufficiency.

Note Exception Drug Status coverage is not required for S.A.I.L. patients. Coverage is provided under Saskatchewan Aids to Independent Living (S.A.I.L.) Program.

Somatuline Autogel - see lanreotide acetate Soriatane - see acitretin Spiriva - see tiotropium bromide monohydrate Sporanox - see itraconazole Starlix - see nateglinide stavudine, capsule, 15mg, 20mg, 30mg, 40mg (Zerit-BMY)

For management of HIV disease. This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

Stelara - see ustekinumab Stieva-A Forte - see tretinoin Strattera - see atomoxetine HCl Suboxone - see buprenorphine/naloxone Sumatriptan - see sumatriptan

288

Page 311: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

*sumatriptan, tablet, 25mg) (CO Sumatriptan-COB) (Mylan-Sumatriptan-MYL) (pms-Sumatriptan-PMS) (Dom-Sumatriptan-DOM) (Novo-Sumatriptan DF-NOP) (Sumatriptan-SAN); 50mg (Imitrex DF-GSK) (Apo-Sumatriptan-APX) (CO Sumatriptan-COB) (Mylan-Sumatriptan-MYL) (pms-Sumatriptan-PMS) (Sandoz Sumatriptan-SDZ) (ratio-Sumatriptan-RPH) (Dom-Sumatriptan-DOM) (Novo-Sumatriptan DF-NOP) (Sumatriptan-SAN) (Ava-Sumatriptan-AVA); 100mg (Imitrex DF-GSK) (Apo-Sumatriptan-APX) (CO Sumatriptan-COB) (Mylan-Sumatriptan-MYL) (Novo-Sumatriptan-NOP) (pms-Sumatriptan-PMS) (Sandoz Sumatriptan-SDZ) (ratio-Sumatriptan-RPH) (Dom-Sumatriptan-DOM) (Novo-Sumpatriptan DF-NOP) (Sumatriptan-SAN) (Ava-Sumatriptan-AVA); nasal spray, 5mg, 20mg (Imitrex-GSK) For treatment of migraine headaches in patients over 18 years of age. The maximum quantity that can be claimed through the Drug Plan is limited

to 6 doses per 30 days within a 60-day period. Patients requiring more than 12 doses in a consecutive 60-day period should be considered for migraine prophylaxis therapy if they are not already receiving such therapy.

Suprax - see cefixime Suprefact - see buserelin acetate Sustiva - see efavirenz Symbicort Turbuhaler - see formoterol fumarate dihydrate/budesonide Synarel - see nafarelin acetate 3TC - see lamivudine

tacrolimus, capsule, 0.5mg, 1mg, 5mg (Prograf-APC); extended-release capsule, ampoule, 0.5mg, 1mg, 3mg, 5mg; (Advagraf-APC), 5mg/mL (Prograf-APC)

For prophylaxis of graft rejection and to prevent rejection in post bone marrow/stem cell transplant patients.

tacrolimus, topical ointment, 0.03%, 0.1% (Protopic-FUJ)

For treatment: (a) Atopic dermatitis in patients unresponsive to topical steroids tried within the

last 3 months. (b) Atopic dermatitis in patients intolerant to topical steroids tried within the last

3 months. tadalafil, tablet, 20mg (Adcirca-LIL)

For the treatment of pulmonary arterial hypertension on the recommendation of a specialist. Note: The maximum dose that will be provided as a benefit is 40mg once daily.

Taro-Ciprofloxacin - see ciprofloxacin Tecta - see pantoprazole magnesium telaprevir, tablet, 375mg (Incivek-VER) For the treatment of chronic hepatitis C genotype 1 infection in patients with

compensated liver disease, in combination with peginterferon alpha/ribavirin when all of the following criteria are met: • detectable levels of hepatitis C virus (HCV) RNA in the last six months • a fibrosis stage of F2, F3, or F4 • patient not co-infected with HIV • one course of treatment only (12 weeks duration).

Telzir - see fosamprenavir calcium

289

Page 312: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

tenofovir disoproxil fumarate, tablet, 300mg (Viread-GSI) For treatment of:

(a) HIV in patients who have failed an alternative nucleoside reverse transcriptase inhibitor.

(b) HIV in patients intolerant to an alternative nucleoside reverse transcriptase inhibitor.

This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist. (c) Chronic hepatitis B infection in patients with cirrhosis documented on

radiologic or histologic grounds and a HBV DNA concentration above 2000IU/mL.

Teva-Clopidogrel - see clopidogrel bisulfate Teva-Galantamine ER - see galantamine hydrobromide Teva-Lactulose - see lactulose Teva-Montelukast - see montelukast sodium Teva-Nabilone - see nabilone Ticlopidine - see ticlopidine HCl *ticlopidine HCl, tablet, 250mg (Apo-Ticlopidine-APX) (Nu-Ticlopidine-NXP) (Mylan-Ticlopidine-MYL) (Novo-Ticlopidine-NOP) (Ticlopidine-SAN)

For treatment of patients who have experienced a: (a) Transient ischemic attack, stroke, or myocardial infarction while on

acetylsalicylic acid. (b) Transient ischemic attack, stroke or myocardial infarction and have clearly

demonstrated allergy to acetylsalicylic acid (manifested by asthma or nasal polyps).

(c) Transient ischemic attack, stroke or a myocardial infarction and are intolerant of acetylsalicylic acid (manifested by gastrointestinal hemorrhage).

tinzaparin sodium, syringe, 10,000IU/mL (0.25mL, 0.35mL, 0.45mL), 20,000IU/mL (0.5mL, 0.7mL, 0.9mL); injection solution, 10,000IU/mL (2mL), 20,000IU/mL (2mL) (Innohep-LEO)

(a) For treatment of venous thromboembolism for up to 10 days. (b) For prophylaxis following total knee arthroplasty for up to 35 days. (c) For major orthopedic trauma for up to 10 days (treatment duration may be

reassessed). (d) For long-term outpatient prophylaxis in patients who are pregnant. (e) For long-term outpatient prophylaxis in patients who have a contraindication

to, are intolerant to, or have failed, warfarin therapy. (f) For long-term outpatient prophylaxis in patients who have lupus

anticoagulant syndrome. (g) Prophylaxis in patients undergoing total hip replacement or following hip

fracture surgery for up to 35 days following the procedure.

tiotropium bromide monohydrate, powder capsule, 18ug/dose (Spiriva-BOE) (a) For treatment of COPD in patients unresponsive to short-acting beta

agonists or short-acting anticholinergic bronchodilators, or (b) For treatment of moderate to severe COPD (i.e. Medical Research Council

(MRC) dyspnea scale score 3 to 5), in conjunction with spirometry demonstrating moderate to severe airflow obstruction (i.e. FEV1 <60% and low FEV1/FVC <0.7), without a trial of short-acting agents.

tipranavir, capsule, 250mg (Aptivus-BOE)

For the management of HIV disease in patients who have been shown to be non-responsive or resistant to all currently listed protease inhibitors (except Prezista).

290

Page 313: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

This drug, as with all antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

*tizanidine HCl, tablet, 4mg (Zanaflex-DPY) (Apo-Tizanidine-APX) (Mylan-Tizanidine-MYL)

For treatment of : (a) Severe spasticity in patients unresponsive to baclofen or benzodiazepines. (b) Severe spasticity in patients intolerant to baclofen or benzodiazepines.

TOBI - see tobramycin inhalation solution TOBI PODHALER - see tobramycin inhalation powder Tobradex - see tobramycin/dexamethasone Tobramycin - see tobramycin ophthalmic solution tobramycin, inhalation powder capsule, 28mg (TOBI PODHALER-NVR) For the treatment of cystic fibrosis patients intolerant to injectable tobramycin when used for inhalation. tobramycin, inhalation solution, 60mg/mL (TOBI-CCL)

For treatment of cystic fibrosis patients intolerant to injectable tobramycin when used for inhalation.

tobramycin, ophthalmic ointment, 0.3% (Tobrex-ALC); *ophthalmic solution, 0.3% (Tobrex-ALC) (pms-Tobramycin-PMS) (Sandoz Tobramycin-SDZ) For treatment of ophthalmic infections in cases unresponsive to gentamicin

ophthalmic.

tobramycin/dexamethasone, ophthalmic suspension, 0.3%/0.1%; ophthalmic ointment, 0.3%/0.1% (Tobradex-ALC)

(a) For treatment of ophthalmic infections in cases unresponsive to therapeutic alternatives.

(b) For post-operative long-term (>7days) use.

Tobrex - see tobramycin tocilizumab, solution for IV infusion, 20mg/mL (4mL vial, 10mL vial, 20mL vial) (Actemra-HLR) For treatment of moderate to severe active rheumatoid arthritis, in combination

with methotrexate or other disease-modifying antirheumatic drugs (DMARDS), who have failed to respond to an adequate trial of both DMARDs and a tumour necrosis factor (TNF) alpha inhibitor.

Patients should be assessed after 16 weeks of treatment and therapy continued only if there is a clinical response to treatment.

Actemra should not be used concomitantly with TNF alpha inhibitors. This product should be used in consultation with a specialist in this area. tolterodine l-tartrate, extended-release capsule, 2mg, 4mg (Detrol LA-PFI) See Appendix B for online adjudication criteria. Tracleer - see bosentan treprostinil, injection solution, 1mg, 2mg, 5mg, 10mg (Remodulin-NTI)

For treatment of patients with primary pulmonary hypertension or pulmonary hypertension secondary to collagen vascular disease, with New York Heart association class 111 or 1V disease who have both:

291

(a) failed to respond to non-prostanoid therapies (i.e. calcium channel blockers, vasodilators, bosentan)

Page 314: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

and: (b) who are not candidates for epoprostenol therapy because of:

• prior recurrent complications with central line access (i.e. infection, thrombosis) or,

• they reside in an area without ready access to medical care, which could complicate problems associated with an abrupt interruption of epoprostenol theapy.

Please contact the Drug Plan for billing information.

*tretinoin, cream, 0.1% (Stieva-A Forte-STI) (Retin A-JAN) For treatment of acne unresponsive to alternative topical therapy. triamcinolone hexacetonide, injection suspension, 20mg/mL (Aristospan-STI) For intra-articular injection in the management of pediatric chronic inflammatory

arthropathies. tricagrelor, tablet, 90mg (Brilinta-AST) For treatment initiated by a cardiologists and internists in patients with stent

thrombosis while on clopidogrel in the preceding 28 days. Trileptal - see oxcarbazepine Trizivir - see abacavir SO4/lamivudine/zidovudine Trosec - see trospium chloride trospium chloride, tablet, 20mg (Trosec-SNV) See Appendix B for online adjudication criteria. Truvada - see emtricitabine/tenofovir disproxil fumarate Tysabri - see natalizumab Uloric - see febuxostat Urso - see ursodiol Uromax - see oxybutynin chloride *ursodiol, tablet, 250mg (Urso-AXC), 500mg (Urso DS-AXC) (pms-Ursodiol C-PMS) (Dom-Ursodiol C-DOM) For management of cholestatic liver diseases such as primary biliary cirrhosis. ustekinumab, solution for injection, 45mg/0.5mL (Stelara-JAN)

For treatment of adult patients with severe debilitating plaque psoriasis who meet all of the following criteria:

i) failure to respond to, contraindications to, or intolerant of methotrexate and cyclosporine and

ii) failure to respond to, intolerant to or unable to access phototherapy.

Coverage will be approved initially for the induction phase of up to 16 weeks. Coverage can be renewed in patients who have responded to therapy. This product should be used in consultation with a specialist in this area. Val-Vanco - see vacomycin HCL Valcyte - see valganciclovir HCl valganciclovir HCl, tablet, 450mg (Valcyte-HLR); powder for oral solution, 50mg/mL (Valcyte-HLR)

(a) For treatment of retinitis arising from CMV infection in patients with HIV infection.

292

Page 315: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

(b) For treatment and prophylaxis of CMV infection in transplant patients. Coverage will be approved for a six month period.

Vancocin - see vancomycin HCl vancomycin HCl, capsule, 125mg, 250mg (Vancocin-LIL); *injection, 500mg, 1g (pms-Vancomycin-PMS) (Val-Vanco-VAL)

For treatment of Clostridium difficile infections for up to two consecutive two week periods after no response, allergies or intolerance to a course of metronidazole. Repeat approvals will only be granted with laboratory evidence of C. difficile toxin.

Venofer - see iron sucrose Vesicare - see solifenacin succinate Vfend - see voriconazole Victrelis - see boceprevir Victrelis Triple - see boceprevir/ribavirin plus peginterferon alfa-2b Videx EC - see didanosine Vigamox - see moxifloxacin HCl Vimpat - see lacosamide Viracept - see nelfinavir Viramune - see nevirapine Viread - see tenofovir disoproxil fumarate Vitamin A Acid - see tretinoin Volibris - see ambrisentan Voltaren Ophtha - see diclofenac sodium voriconazole, tablet, 50mg, 200mg; (Vfend-PFI)

For step-down treatment of patients treated in hospital for invasive aspergillosis or other serious fungal infections in consultation with an infectious disease specialist.

Xarelto - see rivaroxaban Xeomin - see clostridium botulinum neurotoxin type A Zaditen - see ketotifen fumarate zafirlukast, tablet, 20mg (Accolate-AST)

(a) For asthma patients who cannot manage the use of an inhalation device despite assistance with a spacer (eg. physically or mentally challenged patients or pediatric patients.

(b) For adjunctive treatment in patients between the ages of 12 and 17 concurrently on an inhaled steroid who have failed a long acting beta-2 agonist (LABA).

Zanaflex - see tizanidine HCl Zerit - see stavudine Ziagen - see abacavir SO4

zidovudine, syrup, 10mg/mL; injection, 10mg/mL (Retrovir-GSK) *capsule, 100mg (Retrovir-GSK) (Apo-Zidovudine-APX)

For management of HIV disease. This drug, as with other antivirals in the treatment of HIV, should be used under the direction of an infectious disease specialist.

Zithromax - see azithromycin Zoladex - see goserelin acetate

293

Page 316: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

zoledronic acid, solution, 5mg/100mL (Aclasta-NVR) (a) For symptomatic treatment of Paget’s disease of the bone. (b) For the treatment of postmenopausal osteoporosis in women who would otherwise meet the current EDS criteria for oral bisphosphonates, but for whom oral bisphosphonates are contraindicated due to abnormalities of the esophagus (e.g. esophageal stricture or achalasia) and have at least two of the following: i) age > 75 years ii) a prior fragility fracture iii) a bone mineral density (BMD) T-score < -2.5 Note: Only one treatment per year is required.

zolmitriptan, *tablet, 2.5mg (Zomig-AST) (Mylan-Zolmitriptan-MYL) (Sandoz Zolmitriptan-SDZ) (pms-Zolmitriptan-PMS) (Teva-Zolmitriptan-TEV) (Apo-Zolmitripan-APX); *orally dispersible tablet, 2.5mg (Zomig Rapimelt-AST) (Sandoz Zolmitriptan-SDZ) (pms-Zolmitriptan-PMS) (Teva-Zolmitriptan-TEV); nasal spray, 5mg (Zomig Nasal Spray-AST) For treatment of migraine headaches in patients over 18 years of age. The maximum quantity that can be claimed through the Drug Plan is limited

to 6 doses per 30 days within a 60-day period. Patients requiring more than 12 doses in a consecutive 60-day period should be considered for migraine prophylaxis therapy if they are not already receiving such therapy.

Zomig - see zolmitriptan Zomig Nasal Spray - see zolmitriptan Zomig Rapimelt - see zolmitriptan zuclopenthixol, acetate injection, 50mg/mL (Clopixol-Acuphase-AVT); decanoate injection, 200mg/mL (Clopixol-Depot-AVT); dihydrochloride tablet, 10mg, 25mg, (Clopixol-AVT) For treatment of schizophrenia in patients unresponsive to other neuroleptic

medications. Zymar - see gatifloxacin Zyprexa - see olanzapine Zyprexa Zydis - see olanzapine Zyvoxam - see linezolid

LEGEND: *These brands of products have been approved as interchangeable. +These brands of products have NOT been approved as interchangeable.

294

Page 317: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

APPENDIX B

ONLINE ADJUDICATION CRITERIA

Online Adjudication Approval of certain criteria based medication is available online. Claims for the medications noted below can be submitted and adjudicated automatically through the online computer system. For these specific medications, the Drug Plan computer system checks the patient’s online drug profile and if the necessary alternate drugs appear on the Drug Plan profile the coverage and approval letter are automatically generated for the patient. This means the prescriber or pharmacist will not need to apply for coverage for these specific medications via phone, fax or mail. Please Note: Requests for these medications are still accepted by telephone, mail or fax. This may be required if for some reason the patient’s computer profile is incomplete or if there are unusual circumstances surrounding the application. Online Adjudication Medications baclofen, injection, 0.05mg/mL, 0.5mg/mL, 2mg/mL (Lioresal Intrathecal-NVR)

For treatment of: (a) Severe spastic conditions in patients unresponsive to oral baclofen. (b) Severe spastic conditions in patients intolerant to oral baclofen.

bumetanide, tablet, 1mg, 2mg, 5mg (Burinex-LEO) For treatment of patients intolerant to furosemide. *cabergoline, tablet, 0.5mg (Dostinex-PFI) (CO Cabergoline-COB)

For treatment of: (a) Hyperprolactinemic disorders in patients unresponsive to bromocriptine. (b) Hyperprolactinemic disorders in patients intolerant to bromocriptine.

celecoxib, capsule, 100mg, 200mg (Celebrex-PFI)

For treatment of: (a) Patients age 65 and over (approved automatically through the online computer

system). (b) Rheumatoid arthritis and osteoarthritis in patients who have one of the following

factors: • past history of ulcers; • concurrent prednisone therapy; • concurrent warfarin therapy.

(c) Patients intolerant to other NSAIDs listed in the Formulary. darifenacin, extended release tablet, 7.5mg, 15mg (Enablex-NVR) For treatment of patients intolerant to oxybutynin chloride. ethacrynic acid, tablet, 25mg (Edecrin-VAE) For treatment of patients intolerant to furosemide.

295

Page 318: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

*fentanyl, transdermal system, 12ug/hr, 25ug/hr, 50ug/hr, 75ug/hr 100ug/hr (Duragesic Mat-JAN) (ratio-Fentanyl-RPH) (Sandoz Fentanyl Patch-SDZ) (Novo-Fentanyl-NOP) (Ran-Fentanyl Matrix-RAN) (pms-Fentanyl MTX-PMS) For treatment of patients:

(a) Intolerant to, or unable to take, oral sustained-release strong opioids; or (b) As an alternative to subcutaneous narcotic infusion therapy.

Pharmacists are not required to call the Drug Plan if a prescription has been filled for an oral sustained release or injectable opioid, such as hydromorphone, morphine, or oxycodone in the past 16 months. iron sucrose, injection, 20mg/mL (Venofer-MYL)

(a) For treatment of iron deficiency when patients are intolerant to oral iron replacement products and intravenous iron dextran.

(b) For treatment of patients who are intolerant to oral iron replacement products who require loading regimens of intravenous iron therapy.

leucovorin calcium, tablet, 5mg (Leucovorin-PFI)

For treatment of folic acid deficiency in patients who have been on long-term therapy with trimethoprim/sulfamethoxazole.

*oxcarbazepine, tablet, 150mg, 300mg, 600mg (Trileptil-NVR) (Apo-Oxcarbazepine-APX); oral suspension, 60mg/mL (Trileptil-NVR) For treatment of partial seizures in patients intolerant to carbamazepine. oxybutynin chloride, controlled release tablet, 10mg, 15mg (Uromax-PFR) For treatment of patients intolerant to immediate release oxybutynin chloride. *pioglitazone HCl, tablet, 15mg, 30mg, 45mg (Actos-TAK) (Accel-Pioglitazone-ACC) (Novo-Pioglitazone-NOP) (Sandoz Pioglitazone-SDZ) (Mylan-Pioglitazone-MYL) (ratio-Piogiltazone-RPH) (CO Pioglitazone-COB) (Apo-Pioglitazone-APX) (pms-Pioglitazone-PMS) (Mint-Pioglitazone-MNT) (Pioglitazone-SAN) (Ava-Pioglitazone-AVA) (Ran-Pioglitazone-RAN)

For treatment of patients with Type 2 diabetes who have had pervious prescriptions for metformin and a sulfonylurea.

Please Note: These products should be used in patients with diabetes who are not adequately controlled on or are intolerant to metformin and a sulfonylurea. quinagolide HCl, tablet, 0.075mg, 0.150mg (Norprolac-FEI)

For the treatment of hyperprolactineamia in patients who have failed or are intolerant to bromocriptine.

*repaglinide, tablet, 0.5mg, 1mg, 2mg (GlucoNorm-NOO) (Apo-Repaglinide-APX) (CO Repaglinide-COB) (pms-Repaglinide-PMS) (Sandoz Repaglinide-SDZ)

For treatment of : (a) Diabetes in patients uncontrolled on sulfonylureas. (b) Diabetes in patients intolerant to sulfonylureas.

saxagliptin, tablet, 5mg (Onglyza-BMY)

For treatment of patients with Type 2 diabetes who have had previous prescriptions for metformin and a sulfonylurea.

296

Page 319: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

Please Note: These products should be used in patients with diabetes who are not adequately controlled on or are intolerant to metformin and a sulfonylurea, and for whom insulin is not an option. *selegiline HCl, tablet, 5mg (Novo-Selegiline-NOP) (Apo-Selegiline-APX) (Mylan-Selegiline-MYL) (Nu-Selegiline-NXP) (a) For use as an adjunct in cases of Parkinson's disease being treated with

levodopa, levodopa/benzerazide, levodopa/carbidopa, or bromocriptine. (b) For prophylaxis in early Parkinsonism. sitagliptin and metformin hydrochloride, tablet, 50mg/500mg, 50mg/850mg, 50mg/1000mg (Janumet-MRK)

For the convenience of patients who have been stabilized on metformin and sitagliptin.

Please Note: These products should be used in patients with diabetes who are not adequately controlled on or are intolerant to metformin and a sulfonylurea, and for whom insulin is not an option. solifenacin succinate, tablet, 5mg, 10mg (Vesicare-APC)

For treatment of patients intolerant to oxybutynin chloride. sitagliptin phosphate, tablet, 100mg (Januvia-MRK)

For treatment of patients with Type 2 diabetes who have had previous prescriptions for metformin and a sulfonylurea.

Please Note: These products should be used in patients with diabetes who are not adequately controlled on or are intolerant to metformin and a sulfonylurea, and for whom insulin is not an option. tolterodine l-tartrate, extended-release capsule, 2mg, 4mg (Detrol LA-PFI))

For treatment of patients intolerant to oxybutynin chloride. trospium chloride, tablet, 20mg (Trosec-SNV) For treatment of patients intolerant to oxybutynin chloride.

297

Page 320: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

APPENDIX C

MAXIMUM ALLOWABLE COST (MAC) POLICY

For many common medical conditions, drug manufacturers market a wide variety of prescription drugs that often vary in price but achieve the same medical effect. Under the MAC policy, the Drug Plan obtains expert advice on which prescription drug products within a group of similar medications are safe and beneficial, and the most cost-effective. The price of the most cost-effective drugs are used as a guide to set the maximum allowable cost the Drug Plan will cover for other similar drugs used to treat the same condition. The price is not necessarily set at the lowest cost drug. Patients have two options if they are prescribed a drug whose price is above the MAC for the group; (1) they can either continue to take the higher priced drug and pay the difference in cost over the MAC or, (2) they can talk to their physician about switching to a drug that is within the MAC. If the patient wishes to switch medications they will need a new prescription from their physician. If the patient chooses to remain on a higher priced drug, then only the maximum allowable cost will go towards their deductible and/or calculation of their co-payment. The expert drug review committees assess the need for exemptions (and any exemption criteria) as they review each possible MAC group. Exemption criteria (where applicable) are noted in the chart below for each group. Exemption requests are considered on a case-by-case basis. Prescribers or pharmacists may make exemption requests, with supporting detailed information, to the Drug Plan via the Exception Drug Status process. The MAC policy applies equally to all Saskatchewan residents eligible for benefits under the Drug Plan and Extended Benefits Branch.

MAXIMUM ALLOWABLE COST GROUP(S) Proton Pump Inhibitors (PPIs)

Group includes esomeprazole, lansoprazole, omeprazole, pantoprazole magnesium, pantoprazole sodium, rabeprazole

Maximum Allowable Cost $1.51 per tablet or capsule (subject to the patient’s usual co-payment and deductible).

Exemption Criteria - Patients who are intolerant or refractory to at least two drugs priced within the MAC policy.

- Patients requiring administration of a PPI by nasogastric tube.

Notes - These drugs are available under the Exception Drug Status (EDS) program. Patients must meet EDS criteria to qualify for coverage. See Appendix A for information on EDS criteria for specific PPIs.

- HP-PAC prescriptions are not affected by this policy.

Please refer to formulary/website for actual prices.

298

Page 321: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

APPENDIX D

SASKATCHEWAN MS DRUGS PROGRAM

PROCEDURE FOR OBTAINING COVERAGE OF MS DRUGS

UNDER THE DRUG PLAN • Requests are initiated by a physician. The patient and physician complete the

application form and the physician forwards all relevant information to the Saskatchewan MS Drugs Program. For a copy of the application forms please refer to the website at: http://formulary.drugplan.health.gov.sk.ca/

• The MS Drug Advisory Panel reviews the application form and relevant

documentation and renders a decision based on the criteria for coverage. Note: A patient's eligibility for coverage is determined by the MS Drug Advisory Panel. The Drug Plan is notified of the decision and communicates the results to the patient and the physician. Please note, annual renewal applications are required for consideration of ongoing Exception Drug Status (EDS) approval by the MS Drug Advisory Panel. Renewal application forms are mailed by the Drug Plan to the prescribing physician one month before expiration of coverage.

• Questions regarding eligibility should be directed to: Saskatchewan MS Drugs Program Telephone: (306) 655-8400 Suite 7718-7th Floor FAX: (306) 655-8404 Saskatoon City Hospital Saskatoon, S7K 0M7 • Upon approval of coverage, patients are encouraged to apply for assistance with the

cost of these medications under the Drug Plan Special Support Program. For more detailed information regarding this program, see Special Coverages in Formulary Appendices, Indices & Other under http://formulary.drugplan.health.gov.sk.ca/.

1. CRITERIA FOR COVERAGE OF: • interferon beta-1b (Betaseron-BAY) (Extavia-NVR), • glatiramer acetate (Copaxone-TVM), • interferon beta-1a (Rebif-SRO), and • interferon beta-1a (Avonex-BGN) Approval for coverage will be given to patients who are assessed and meet the following criteria: • have clinical definite relapsing and remitting multiple sclerosis; • have had at least two documented attacks of MS during the previous two years (an

attack is defined as the appearance of new symptoms or worsening of old symptoms, lasting at least 24 hours in the absence of fever, preceded by stability for at least one month);

• are fully ambulatory for 100 meters without aids (canes, walkers or wheelchairs) - Extended Disability Status Scale (EDSS) 5.5 or less; • are age 18 or older (Note: Applications for patients under 18 will be considered.) Contraindications to Treatment • concurrent illness likely to alter compliance or substantially reduce life expectancy; • pregnancy, anticipated pregnancy or breast feeding within the next year; • active, severe depression.

299

Page 322: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

Physicians should also forward the following information: • documentation of attacks, date of onset, date of diagnosis; • neurological findings, Extended Disability Status Scale (EDSS); • MRI reports or other significant information; • list of current medications. 2. CRITERIA FOR COVERAGE OF: • natalizumab (Tysabri-BGN) For monotherapy treatment in patients with a diagnosis of multiple sclerosis who also meet ALL of the following criteria: a) Failure to respond to full and adequate courses of treatment with at least two disease-modifying therapies or have contraindications to, or be intolerant of these therapies, AND b) Significant increase in T2 lesion load compared to a previous MRI or at least one gadolinium-enhancing lesion, AND c) Two or more disabling relapses in the previous year. Contraindications to Treatment • any evidence of disease progression independent of relapses; • immune compromise due to immunosuppressant or anti-neoplastic therapy or due to

immunodeficiency (HIV, leukemia, lymphoma, etc.); • history of progressive multifocal leukoencephalopathy (PML); • concurrent malignancy; • pregnancy, anticipated pregnancy or breast-feeding within the next year; • active infectious disease (such as tuberculosis). Neurologists should also forward the following information: • name of previous disease-modifying therapies and duration of treatment; • details of intolerance or failure with previous disease-modifying therapies; • documentation of attacks including date of onset, duration of relapse, etc.; • neurological findings, including Extended Disability Status Scale (EDSS) scores; • MRI reports or other significant information; • list of current medications. Note: Applications for Tysabri must be initiated by a neurologist. 3. CRITERIA FOR COVERAGE OF: • fingolimod hydrochloride (Gilenya-NVR) For the treatment of relapsing-remitting multiple sclerosis where there has been: • Failure to respond to full and adequate courses of at least one interferon beta

formulation and glatiramer acetate, or contraindications to these therapies. • Two or more disabling relapses in the previous year. • Significant increase in T2 lesion load compared with that from a previous magnetic

resonance imaging (MRI) scan or at least one gadolinium-enhancing lesion.

In addition, fingolimod treatment should be stopped in patients with relapsing remitting MS who meet either of the following criteria: • Failure to achieve at least a 50% reduction from baseline in the average annual

relapse rate after two years. • Attainment of an Expanded Disability Status Scale (EDSS) score of greater than 5.0.

300

Page 323: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

MS DRUG APPROVAL PROCESS

Fax #: (306) 655-8404

(Patient consent)

(Special Support Approval)

Request for Drug Changesand Re-Applications

Physician

EDSApplication

MS Drug Advisory

Panel

ApprovedNot

Approved

Patient Education Schedule

Response to Physician

&Patient

Drug Plan Online Update

PhysicianLetter

PatientLetter

Follow-upAnnual Renewal

On-going Assessment

MS Drug Advisory

Panel

301

Page 324: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...
Page 325: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

INDICES

INDEX A - THERAPEUTIC CLASSIFICATION LIST

INDEX B - ALPHABETICAL LIST OF PHARMACEUTICAL PRODUCT NAMES

Page 326: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

INDEX A

THERAPEUTIC CLASSIFICATION LIST

08:00 ANTI-INFECTIVE AGENTS................................................................................................... . 208:04.00 AMEBICIDES................................................................................................................ . 208:08.00 ANTHELMINTICS.......................................................................................................... . 208:12.02 ANTIBIOTICS (AMINOGLYCOSIDES)......................................................................... . 208:12.04 ANTIBIOTICS (ANTIFUNGALS)................................................................................... . 308:12.06 ANTIBIOTICS (CEPHALOSPORINS)........................................................................... . 408:12.12 ANTIBIOTICS (MACROLIDES)..................................................................................... . 608:12.16 ANTIBIOTICS (PENICILLINS)....................................................................................... . 808:12.24 ANTIBIOTICS (TETRACYCLINES)............................................................................... . 1008:12.28 ANTIBIOTICS (MISCELLANEOUS ANTIBIOTICS)...................................................... . 1108:18.04 ADAMANTANES........................................................................................................... . 1208:18.08 ANTIRETROVIRAL AGENTS (HIV FUSION INHIBITORS).......................................... . 1208:18.08 ANTIRETROVIRAL AGENTS (NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS)........................................................................ . 1208:18.08 ANTIRETROVIRAL AGENTS (NUCLEOSIDE/NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS)........................................................................ . 1308:18.08 INTEGRASE INHIBITORS........…………………………............................................. . 1508:18.08 ANTIRETROVIRAL AGENTS (PROTEASE INHIBITORS)........................................... . 1508:18.20 INTERFERONS..................................................…………………………………………… . 1608:18.32 NUCLEOSIDES AND NUCLEOTIDES.......................................................................... . 1708:20.00 ANTIMALARIAL AGENTS............................................................................................. . 1908:22.00 QUINOLONES............................................................................................................... . 2008:26.00 SULFONES................................................................................................................... . 2208:36.00 URINARY ANTI-INFECTIVES....................................................................................... . 2208:40.00 MISCELLANEOUS ANTI-INFECTIVES........................................................................ . 22

10:00 ANTINEOPLASTIC AGENTS................................................................................................ . 2610:00.00 ANTINEOPLASTIC AGENTS........................................................................................ . 26

12:00 AUTONOMIC DRUGS........................................................................................................... . 2812:04.00 PARASYMPATHOMIMETIC (CHOLINERGIC) AGENTS............................................. . 2812:08.04 ANTIPARKINSONIAN AGENTS................................................................................... . 2912:08.08 ANTIMUSCARINICS/ANTISPASMODICS.................................................................... . 3012:12.00 SYMPATHOMIMETIC (ADRENERGIC) AGENTS........................................................ . 3112:16.00 SYMPATHOLYTIC AGENTS (ANTIMIGRAINE DRUGS)............................................. . 3312:20.00 SKELETAL MUSCLE RELAXANTS.............................................................................. . 3612:92.00 MISC. AUTONOMIC DRUGS.......................................................................................... 37

20:00 BLOOD FORMATION AND COAGULATION....................................................................... . 4020:04.04 IRON PREPARATIONS................................................................................................ . 4020:12.04 ANTICOAGULANTS...................................................................................................... . 4020:12.20 ANTIPLATELET DRUGS.............................................................................................. . 4420:16.00 HEMATOPOIETIC AGENTS......................................................................................... . 4420:24.00 HEMORRHEOLOGIC AGENTS.................................................................................... . 45

24:00 CARDIOVASCULAR DRUGS............................................................................................... . 4824:04.00 CARDIAC DRUGS........................................................................................................ . 4824:06.00 ANTILIPEMIC DRUGS.................................................................................................. . 6024:08.00 HYPOTENSIVE DRUGS............................................................................................... . 6724:12.00 VASODILATING DRUGS.............................................................................................. . 87

28:00 CENTRAL NERVOUS SYSTEM AGENTS........................................................................... . 9228:08.04 NON-STEROIDAL ANTI-INFLAMMATORY AGENTS.................................................. . 9228:08.08 OPIATE AGONISTS (NARCOTIC ANALGESICS)........................................................ . 9728:08.12 OPIATE PARTIAL AGONISTS ....................................................................…………… . 10428:08.92 MISCELLANEOUS ANALGESICS AND ANTIPYRETICS............................................ . 10428:12.04 ANTICONVULSANTS (BARBITURATES).................................................................... . 10428:12.08 ANTICONVULSANTS (BENZODIAZEPINES).............................................................. . 10528:12.12 ANTICONVULSANTS (HYDANTOINS)........................................................................ . 10628:12.20 ANTICONVULSANTS (SUCCINIMIDES)...................................................................... . 10628:12.92 MISCELLANEOUS ANTICONVULSANTS.................................................................... . 10728:16.04 PSYCHOTHERAPEUTIC AGENTS (ANTIDEPRESSANTS)........................................ . 11328:16.08 PSYCHOTHERAPEUTIC AGENTS (ANTIPSYCHOTIC AGENTS).............................. . 12328:20.00 RESPIRATORY AND CEREBRAL STIMULANTS........................................................ . 13328:24.04 ANXIOLYTICS, SEDATIVES AND HYPNOTICS (BARBITURATES)........................... . 13428:24.08 ANXIOLYTICS, SEDATIVES AND HYPNOTICS (BENZODIAZEPINES)..................... . 13428:24.92 MISCELLANEOUS ANXIOLYTICS, SEDATIVES AND HYPNOTICS.......................... . 13728:28.00 ANTIMANIC AGENTS................................................................................................... . 13828:92.00 MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS.................................... . 138

36:00 DIAGNOSTIC AGENTS......................................................................................................... . 14236:04.00 ADRENAL INSUFFICIENCY......................................................................................... . 14236:26.00 DIABETES MELLITUS.................................................................................................. . 14236:88.00 URINE CONTENTS....................................................................................................... . 143

304

Page 327: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

40:00 ELECTROLYTIC, CALORIC AND WATER BALANCE........................................................ . 14640:12.00 REPLACEMENT AGENTS............................................................................................ . 14640:18.00 ION-REMOVING RESINS.......................................................................................... . 14640:28.00 DIURETICS................................................................................................................... . 14640:28.10 POTASSIUM SPARING DIURETICS............................................................................ . 14840:40.00 URICOSURIC DRUGS.................................................................................................. . 148

48:00 ANTITUSSIVES, EXPECTORANTS AND MUCOLYTIC AGENTS...................................... . 15048:24.00 MUCOLYTIC AGENTS.................................................................................................. . 150

52:00 EYE, EAR, NOSE AND THROAT PREPARATIONS............................................................ . 15252:04.04 ANTI-INFECTIVES (ANTIBIOTICS).............................................................................. . 15252:04.06 ANTI-INFECTIVES (ANTIVIRALS)................................................................................ . 15252:04.08 ANTI-INFECTIVES (SULFONAMIDES)........................................................................ . 15252:04.12 ANTI-INFECTIVES (MISCELLANEOUS)...................................................................... . 15352:08.00 ANTI-INFLAMMATORY AGENTS................................................................................. . 15352:08.00 COMBINATION ANTI-INFECTIVE/ ANTI-INFLAMMATORY AGENTS........................ . 15552:10.00 CARBONIC ANHYDRASE INHIBITORS....................................................................... . 15652:20.00 MIOTICS........................................................................................................................ . 15652:24.00 MYDRIATICS................................................................................................................ . 15652:36.00 MISCELLANEOUS E.E.N.T. DRUGS........................................................................... . 157

56:00 GASTROINTESTINAL DRUGS............................................................................................. . 16256:08.00 ANTIDIARRHEA AGENTS............................................................................................ . 16256:12.00 CATHARTICS AND LAXATIVES.................................................................................. . 16256:14.00 CHOLELITHOLYTIC AGENTS...................................................................................... . 16256:16.00 DIGESTANTS................................................................................................................ . 16356:22.00 ANTI-EMETICS............................................................................................................. . 16456:40.00 MISCELLANEOUS GASTROINTESTINAL DRUGS..................................................... . 165

60:00 GOLD COMPOUNDS............................................................................................................ . 17260:00.00 GOLD COMPOUNDS.................................................................................................... . 172

64:00 HEAVY METAL ANTAGONISTS.......................................................................................... . 17464:00.00 HEAVY METAL ANTAGONISTS................................................................................... . 174

68:00 HORMONES AND SYNTHETIC SUBSTITUTES.................................................................. . 17668:04.00 ADRENAL CORTICOSTEROIDS.................................................................................. . 17668:08.00 ANDROGENS............................................................................................................... . 17968:12.00 CONTRACEPTIVES...................................................................................................... . 18068:16.00 ESTROGENS................................................................................................................ . 18368:16.12 ESTROGEN AGONIST-ANTAGONISTS...................................................................... . 18468:18.00 GONADOTROPINS....................................................................................................... . 18468:20.08 ANTI-DIABETIC DRUGS (INSULINS-PORK)............................................................... . 18568:20.08 ANTI-DIABETIC DRUGS (INSULINS-HUMAN BIOSYNTHETIC)................................. . 18568:20.20 ANTI-DIABETIC DRUGS (ORAL HYPOGLYCEMICS)................................................. . 18768:24.00 PARATHYROID............................................................................................................. . 19268:28.00 PITUITARY AGENTS.................................................................................................... . 19368:32.00 PROGESTINS............................................................................................................... . 19468:36.04 THYROID AGENTS....................................................................................................... . 19568:36.08 ANTITHYROID AGENTS.............................................................................................. . 196

84:00 SKIN AND MUCOUS MEMBRANE AGENTS....................................................................... . 19884:04.04 ANTI-INFECTIVES (ANTIBIOTICS).............................................................................. . 19884:04.08 ANTI-INFECTIVES (ANTI-FUNGALS).......................................................................... . 19884:04.12 ANTI-INFECTIVES (SCABICIDES AND PEDICULICIDES).......................................... . 20084:04.16 MISCELLANEOUS ANTI-INFECTIVES........................................................................ . 20184:06.00 ANTI-INFLAMMATORY AGENTS................................................................................. . 20184:06.00 COMBINATION ANTI-INFECTIVE/ ANTI-INFLAMMATORY AGENTS........................ . 20684:12.00 ASTRINGENTS............................................................................................................. . 20684:16.00 CELL STIMULANTS AND PROLIFERANTS................................................................. . 20684:28.00 KERATOLYTIC AGENTS.............................................................................................. . 20784:36.00 MISCELLANEOUS SKIN & MUCOUS MEMBRANE AGENTS..................................... . 20884:50.06 DEPIGMENTING & PIGMENTING AGENTS (PIGMENTING AGENTS)...................... . 210

86:00 SMOOTH MUSCLE RELAXANTS........................................................................................ . 21286:12.00 GENITOURINARY SMOOTH MUSCLE RELAXANTS................................................. . 21286:16.00 RESPIRATORY SMOOTH MUSCLE RELAXANTS...................................................... . 213

88:00 VITAMINS.............................................................................................................................. . 21688:08.00 VITAMIN B..................................................................................................................... . 21688:16.00 VITAMIN D.................................................................................................................... . 217

92:00 UNCLASSIFIED THERAPEUTIC AGENTS.......................................................................... . 22092:00.00 UNCLASSIFIED THERAPEUTIC AGENTS.................................................................. . 220

94:00 DIABETIC SUPPLIES........................................................................................................... . 23494:00.00 DIABETIC SUPPLIES................................................................................................... . 23494:00.00 INSULIN PUMP SUPPLIES.......................................................................................... . 236

305

Page 328: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

INDEX B

ALPHABETICAL LIST OF PHARMACEUTICAL PRODUCT NAMES

PRODUCT NAME Page PRODUCT NAME Page

292 97 ACYCLOVIR 173TC (EDS) 14 ACYCLOVIR 175-AMINOSALICYLIC ACID (MESALAMINE) 170 " 18ABACAVIR SO4 13 ADALAT XL 57ABACAVIR SO4/LAMIVUDINE 13 ADALIMUMAB 220ABACAVIR SO4/LAMIVUDINE/ZIDOVUDINE 13 ADAPALENE 206ABATACEPT 220 ADCIRCA (EDS) 89ABILIFY (EDS) 123 ADEFOVIR DIPIVOXIL 18ACARBOSE 187 ADHESIVE WIPES (EDS) 239ACCEL PIOGLITAZONE (EDS) 190 ADVAGRAF (EDS) 231ACCEL TOPIRAMATE 112 ADVAIR (EDS) 33ACCEL-CITALOPRAM 114 ADVAIR DISKUS (EDS) 33ACCOLATE (EDS) 232 AGGRENOX (EDS) 87ACCU-CHEK 1 MINI (EDS) 238 AGRYLIN 221ACCU-CHEK 2 MINI (EDS) 238 AIROMIR 32ACCU-CHEK ADVANTAGE 142 ALCOHOL PREP 234ACCU-CHEK AVIVA 142 ALCOHOL SWAB 234ACCU-CHEK COMPACT 142 ALDACTAZIDE-25 82ACCU-CHEK FASTCLIX MOBILE 234 ALDACTAZIDE-50 82ACCU-CHEK LINKASSIST (EDS) 239 ALDACTONE 148ACCU-CHEK MOBILE 142 ALDARA (EDS) 209ACCU-CHEK MULTICLIX 234 ALENDRONATE (EDS) 220ACCU-CHEK RAPID D (EDS) 236 ALENDRONATE SODIUM 220 " 237 ALENDRONATE SODIUM (EDS) 220 " 238 ALENDRONATE SODIUM/VITAMIN D3 ACCU-CHEK SPIRIT (EDS) 236 (CHOLECALCIFEROL) 220ACCU-CHEK TENDER 1 (EDS) 238 ALERTEC (EDS) 133 " 239 ALESSE 181ACCU-CHEK TENDER 2 (EDS) 238 ALFACALCIDOL 217 " 239 ALFUZOSIN 220ACCU-CHEK ULTRAFLEX 1 (EDS) 237 ALGLUCOSIDASE ALFA 221 " 238 ALLOPURINOL 221ACCU-CHEK ULTRAFLEX 2 (EDS) 237 ALMOTRIPTAN MALATE 33 " 238 ALOMIDE 158ACCUPRIL 79 ALPHAGAN 157ACCURETIC 80 ALPHAGAN P 157ACCUTANE 209 ALPRAZOLAM 134ACCUTREND 142 ALPRAZOLAM 134ACEBUTOLOL 48 ALTACE 80ACEBUTOLOL HCL 48 " 81 " 67 ALTACE HCT 81ACENOCOUMAROL 40 ALUMINUM ACETATE/ ACETAMINOPHEN/CAFFEINE/CODEINE 97 BENZETHONIUM CHLORIDE 153ACETAMINOPHEN/CODEINE 97 " 206ACETAZOLAMIDE 146 ALVESCO 176 " 156 AMANTADINE 12ACETAZOLAMIDE 156 AMBRISENTAN 87ACETYLCYSTEINE 150 AMCINONIDE 201ACETYLCYSTEINE INJECTION 150 AMERGE (EDS) 34ACETYLCYSTEINE SOLUTION 150 AMILORIDE HCL 148ACETYLSALICYLIC ACID 92 AMILORIDE HCL/ ACETYLSALICYLIC ACID/CAFFEINE/CODEINE 97 HYDROCHLOROTHIAZIDE 67ACITRETIN 208 AMIODARONE 48ACLASTA (EDS) 232 AMIODARONE 48ACTEMRA (EDS) 232 AMITRIPTYLINE 113ACTONEL (EDS) 230 AMLODIPINE 49ACTOS (EDS) 190 AMLODIPINE BESYLATE 49ACULAR (EDS) 154

306

Page 329: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

AMLODIPINE BESYLATE/ATORVASTATIN CALCIUM 50 APO-CILAZAPRIL/HCTZ 70AMLODIPINE-ODAN 49 APO-CIMETIDINE 165AMOXICILLIN 8 APO-CIPROFLOX (EDS) 20 " 9 APO-CITALOPRAM 114AMOXICILLIN (AMOXYCILLIN) 8 APO-CLARITHROMYCIN (EDS) 7AMOXICILLIN LS 9 APO-CLINDAMYCIN 11AMOXICILLIN TRIHYDRATE/ APO-CLOBAZAM 107 POTASSIUM CLAVULANATE 9 APO-CLOMIPRAMINE 115AMPICILLIN 10 APO-CLONAZEPAM 105ANAFRANIL 115 APO-CLONIDINE 70ANAGRELIDE HCL 221 APO-CLOPIDOGREL (EDS) 45ANAKINRA 221 APO-CLORAZEPATE 135ANDRIOL 179 APO-CLOZAPINE (EDS) 123ANDROCUR (EDS) 26 APO-CYCLOBENZAPRINE (EDS) 37ANIMAS CARTRIDGE (EDS) 236 APO-DESIPRAMINE 115ANTHRAFORTE-1 208 APO-DESMOPRESSIN (EDS) 193ANTHRAFORTE-2 208 APO-DEXAMETHASONE 177ANTHRANOL 208 APO-DIAZEPAM 135ANTHRASCALP 208 APO-DICLO 92APIDRA (EDS) 187 APO-DICLO SR 92APIDRA SOLOSTAR (EDS) 187 " 93APO-ACEBUTOLOL 48 APO-DIFLUNISAL 93APO-ACYCLOVIR 17 APO-DILTIAZ 52 " 18 APO-DILTIAZ CD 53APO-ALENDRONATE (EDS) 220 " 54APO-ALFUZOSIN 220 APO-DILTIAZEM TZ 53APO-ALPRAZ 134 " 54APO-AMILZIDE 67 APO-DIMENHYDRINATE 164APO-AMIODARONE 48 APO-DIVALPROEX 108APO-AMLODIPINE 49 APO-DOMPERIDONE 165APO-AMOX CLAV (EDS) 9 APO-DOXAZOSIN 71APO-AMOXI 8 APO-DOXEPIN 115 " 9 APO-DOXY 10APO-AMOXI CLAV (EDS) 9 APO-ENALAPRIL 71APO-ATENIDONE 68 " 72APO-ATENOL 50 APO-ENALAPRIL/HCTZ 72 " 51 APO-FAMCICLOVIR 18APO-ATORVASTATIN 60 APO-FAMOTIDINE 165 " 61 " 166APO-AZATHIOPRINE 222 APO-FENO-MICRO 62APO-AZITHROMYCIN (EDS) 6 APO-FINASTERIDE 224APO-BACLOFEN 36 APO-FLUCONAZOLE 3APO-BECLOMETHASONE 153 APO-FLUCONAZOLE (EDS) 3APO-BENAZEPRIL 68 APO-FLUNISOLIDE 154APO-BISOPROLOL 51 APO-FLUOXETINE 116APO-BRIMONIDINE 157 APO-FLUPHENAZINE 124APO-BRIMONIDINE P 157 APO-FLURAZEPAM 135APO-BROMAZEPAM 134 APO-FLURBIPROFEN 93APO-BROMOCRIPTINE 222 APO-FLUTICASONE 154APO-BUSPIRONE 137 APO-FLUVOXAMINE 116APO-CALCITONIN (EDS) 192 " 117APO-CANDESARTAN 68 APO-FOLIC 216 " 69 APO-FOSINOPRIL 73APO-CAPTO 69 APO-FUROSEMIDE 147APO-CARBAMAZEPINE 107 APO-GABAPENTIN 108APO-CARVEDILOL (EDS) 51 " 109 " 52 APO-GEMFIBROZIL 62APO-CEFPROZIL (EDS) 5 APO-GLYBURIDE 188APO-CEFUROXIME (EDS) 5 APO-HALOPERIDOL 124APO-CEPHALEX 6 APO-HYDRALAZINE 73APO-CHLORDIAZEPOXIDE 135 APO-HYDRO 147APO-CHLORPROPAMIDE 187 APO-HYDROMORPHONE 98APO-CILAZAPRIL 70 " 99

307

Page 330: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

APO-HYDROXYQUINE 19 APO-OLANZAPINE ODT (EDS) 126APO-HYDROXYZINE 137 APO-OMEPRAZOLE (EDS) 167APO-IBUPROFEN 94 APO-ORCIPRENALINE 32APO-INDAPAMIDE 148 APO-OXAZEPAM 136APO-IPRAVENT 30 APO-OXCARBAZEPINE (EDS) 111APO-ISMN 88 APO-OXYBUTYNIN 212APO-K 146 APO-PANTOPRAZOLE (EDS) 168APO-KETOCONAZOLE (EDS) 3 APO-PAROXETINE 119APO-KETOROLAC (EDS) 154 APO-PENTOXIFYLLINE SR 45APO-LACTULOSE (EDS) 162 APO-PEN-VK 10APO-LAMOTRIGINE 110 APO-PIMOZIDE 127APO-LANSOPRAZOLE (EDS) 166 APO-PINDOL 57APO-LATANOPROST 158 APO-PIOGLITAZONE (EDS) 190APO-LEFLUNOMIDE (EDS) 226 APO-PIROXICAM 96APO-LEVETIRACETAM 110 APO-PRAMIPEXOLE 139 " 111 " 140APO-LEVOCARB 138 APO-PRAVASTATIN 63APO-LEVOFLOXACIN (EDS) 21 " 64APO-LISINOPRIL 75 APO-PRAZO 79 " 76 APO-PREDNISONE 178APO-LISINOPRIL/HCTZ 76 APO-PROCHLORAZINE 127APO-LITHIUM CARBONATE 138 APO-PROPAFENONE 58APO-LOPERAMIDE 162 APO-PROPRANOLOL 58APO-LORAZEPAM 136 APO-QUETIAPINE 128APO-LOSARTAN 77 APO-QUININE 19APO-LOSARTAN/HCTZ 77 APO-RABEPRAZOLE (EDS) 168APO-LOVASTATIN 63 APO-RALOXIFENE (EDS) 184APO-MEDROXY 194 APO-RAMIPRIL 80APO-MEGESTROL (EDS) 26 " 81APO-MELOXICAM (EDS) 95 APO-RANITIDINE 169APO-METFORMIN 189 APO-REPAGLINIDE (EDS) 191APO-METHOPRAZINE 137 APO-RISEDRONATE (EDS) 230APO-METHOTREXATE 209 APO-RISPERIDONE 129APO-METHYLPHENIDATE 133 " 130APO-METHYLPHENIDATE SR 133 " 131APO-METOCLOP 166 APO-RIVASTIGMINE (EDS) 29APO-METOPROLOL 55 APO-ROPINIROLE 140 " 56 APO-ROSUVASTATIN 64APO-METOPROLOL SR 56 " 65APO-METOPROLOL-TYPE L 55 APO-SALVENT 32 " 56 APO-SALVENT CFC FREE 32APO-MIDODRINE (EDS) 32 APO-SELEGILINE (EDS) 140APO-MINOCYCLINE (EDS) 10 APO-SERTRALINE 120 " 11 APO-SIMVASTATIN 65APO-MIRTAZAPINE 117 " 66 " 118 " 67APO-MISOPROSTOL 166 APO-SOTALOL 59APO-MOCLOBEMIDE 118 APO-SUCRALFATE 169APO-MONTELUKAST (EDS) 226 APO-SULFATRIM 23 " 227 APO-SULFATRIM DS 23APO-MYCOPHENOLATE (EDS) 227 APO-SULFINPYRAZONE 148APO-NABUMETONE (EDS) 95 APO-SULIN 96APO-NADOL 56 APO-SUMATRIPTAN (EDS) 35APO-NAPROXEN 95 APO-TAMSULOSIN CR 231 " 96 APO-TEMAZEPAM 136APO-NIFED 57 APO-TERAZOSIN 83APO-NITRAZEPAM 105 APO-TERBINAFINE 4APO-NIZATIDINE 167 APO-THEO-LA 213APO-NORFLOX (EDS) 21 APO-TIAPROFENIC 96APO-NORTRIPTYLINE 118 APO-TICLOPIDINE (EDS) 45APO-OFLOXACIN (EDS) 153 APO-TIMOL 59APO-OLANZAPINE (EDS) 125 APO-TIMOP 159 " 126 APO-TIMOP GEL 159

308

Page 331: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

APO-TIZANIDINE (EDS) 37 AURO-LEVETRICETAM 111APO-TOPIRAMATE 112 AURO-MIRTAZAPINE OD 117APO-TRAZODONE 121 " 118APO-TRIAZIDE 84 AURO-NEVIRAPINE (EDS) 13APO-TRIAZO 136 AURO-TERBINAFINE 4APO-VALACYCLOVIR 18 AURO-TOPIRAMATE 112APO-VALPROIC 112 AVA-AMIODARONE 48 " 113 AVA-AZITHROMYCIN (EDS) 6APO-VALSARTAN 84 " 7 " 85 AVA-BUPROPION SR 113APO-VALSARTAN/HCTZ 85 AVA-CLARITHROMYCIN (EDS) 7 " 86 AVA-DOMPERIDONE 165APO-VASARTAN/HCTZ 86 AVA-FAMCICLOVIR 18APO-VENLAFAXINE XR 122 AVA-FUROSEMIDE 147APO-VERAP 86 AVA-GLYBURIDE 188APO-VERAP SR 86 AVA-LEVOFLOXACIN (EDS) 21APO-WARFARIN 42 AVALIDE 74 " 43 " 75APO-ZIDOVUDINE (EDS) 14 AVA-MELOXICAM (EDS) 95APO-ZOLMITRIPTAN (EDS) 36 AVA-METFORMIN 189APRACLONIDINE HCL 157 AVA-MIRTAZAPINE 117APRI 180 AVANDAMET (EDS) 191APTIVUS (EDS) 16 AVANDIA (EDS) 191ARANESP (EDS) 44 AVA-PANTOPRAZOLE (EDS) 168ARAVA (EDS) 226 AVA-PIOGLITAZONE (EDS) 190AREDIA (EDS) 228 AVA-PRAMIPEXOLE 139ARICEPT (EDS) 28 " 140ARIPIPRAZOLE 123 AVAPRO 74ARISTOCORT R 205 AVA-RAMIPRIL 80ARISTOSPAN (EDS) 179 " 81ARTHROTEC 93 AVA-RISPERIDONE 129ARTHROTEC 75 93 " 130ASACOL 170 " 131ASACOL 800 170 AVA-SOTALOL 59ATACAND 68 AVA-SUMATRIPTAN (EDS) 35 " 69 AVA-TAMSULOSIN CR 231ATACAND PLUS 69 AVA-VALSARTAN 84ATARAX 137 " 85ATASOL-15 97 AVA-VALSARTAN HCT 85ATASOL-30 97 " 86ATAZANAVIR SO4 15 AVELOX (EDS) 21ATENOLOL 50 AVENTYL 118 " 67 AVIANE 181ATENOLOL/CHLORTHALIDONE 68 AVODART 223ATIVAN 136 AVONEX (EDS) 225ATOMOXETINE HCL 221 AVONEX PS/PEN (EDS) 225ATORVASTATIN 60 AXERT (EDS) 33 " 61 AXID 167ATORVASTATIN CALCIUM 60 AZARGA 157ATOVAQUONE 22 AZATHIOPRINE 222ATRIPLA (EDS) 13 AZATHIOPRINE 222ATROPINE SO4 156 AZELAIC ACID 208ATROVENT HFA 30 AZILECT 229ATROVENT NASAL SPRAY 158 AZITHROMYCIN 6AURANOFIN 172 AZITHROMYCIN (EDS) 6AURO-CEFPROZIL (EDS) 5 " 7AURO-CEFUROXIME (EDS) 5 AZOPT 156AURO-CITALOPRAM 114 AZTREONAM 11AURO-CYCLOBENZAPRINE (EDS) 37 BACLOFEN 36AURO-GABAPENTIN 108 BACLOFEN 36 " 109 BACTROBAN 198AURO-LEVETIRACETAM 110 BARACLUDE (EDS) 18 " 111 BD ALCOHOL SWAB 234

309

Page 332: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

BD ULTRA FINE 12.7MM 234 BOTOX (EDS) 222BD ULTRA FINE II LANCET 234 BOTULINUM TOXIN TYPE A 222BD ULTRA FINE-29G 235 BREEZE 2 142BD ULTRAFINE 11 1/2 U 31G 235 BREVICON 181BD ULTRAFINE 11 1/2U 30G 235 BREVICON 1/35 181BD ULTRAFINE 33 234 BRICANYL TURBUHALER 33BD ULTRAFINE 5MM 8MM 235 BRILINTA (EDS) 45BD ULTRAFINE II SHORT-30G 236 BRIMONIDINE TARTRATE 157BD ULTRA-FINE NANO 235 BRIMONIDINE TARTRATE/TIMOLOL MALEATE 157BD ULTRAFINE-29G 236 BRINZOLAMIDE 156BECLOMETHASONE DIPROPIONATE 153 BRINZOLAMIDE/TIMOLOL MALEATE 157 " 176 BROMAZEPAM 134 " 201 BROMOCRIPTINE MESYLATE 222BENAZEPRIL 68 BUDESONIDE 153BENAZEPRIL HCL 68 " 165BENTYLOL 30 " 176BENURYL 148 " 203BENZAC AC 207 BUMETANIDE 146BENZAC W 207 BUPRENORPHINE/NALOXONE 104BENZACLIN 207 BUPROPION HCL 113BENZAMYCIN 208 BURINEX (EDS) 146BENZOYL PEROXIDE 207 BURO-SOL 206BENZTROPINE 29 BURO-SOL-OTIC 153BENZTROPINE MESYLATE 29 BUSCOPAN 30BENZTROPINE OMEGA 29 BUSERELIN ACETATE 184BETADERM 202 BUSPIRONE 137 " 203 C.E.S. 183BETAGAN 158 CABERGOLINE 222BETAHISTINE DIHYDROCHLORIDE 87 CADUET 50BETAINE ANHYDROUS 222 CALCIFEROL 217BETAJECT 176 CALCIMAR (EDS) 192BETAMETHASONE ACETATE/ CALCIPOTRIOL 208 BETAMETHASONE SODIUM PHOSPHATE 176 CALCIPOTRIOL/BETAMETHASONE BETAMETHASONE DIPROPIONATE 202 DIPROPIONATE 209BETAMETHASONE DIPROPIONATE/ CALCITONIN SALMON 192 CLOTRIMAZOLE 206 CALCITRIOL 217BETAMETHASONE DIPROPIONATE/ CALCIUM ACETATE 146 SALICYLIC ACID 202 CALCIUM POLYSTYRENE SULFONATE 146BETAMETHASONE DISODIUM PHOSPHATE 202 CALTINE 100 (EDS) 192BETAMETHASONE VALERATE 202 CANDESARTAN CILEXETIL 68BETASERON (EDS) 225 CANDESARTAN CILEXETIL 68BETAXOLOL HCL 157 " 69BETHANECHOL CHLORIDE 28 CANDESARTAN CILEXETIL/ BETNESOL ENEMA 202 HYDROCHLOROTHIAZIDE 69BETOPTIC S 157 CANDESARTEN CILEXETIL 68BEZAFIBRATE 61 CANESORAL 3BEZALIP SR (EDS) 61 CANESORAL COMBI-PAK 3BGSTAR 142 CANESTEN 199 " 234 CANESTEN COMBI-PAK 1 199BIAXIN (EDS) 7 CANESTEN COMBI-PAK 3 199BIAXIN BID (EDS) 7 CANESTEN-3 199BIAXIN XL (EDS) 7 CANESTEN-6 199BILTRICIDE 2 CAPEX SHAMPOO 204BIMATOPROST 157 CAPTOPRIL 51BIONIME RIGHTEST GS100 142 " 69BISOPROLOL FUMARATE 51 CARBACHOL 156BLEPHAMIDE S.O.P. 155 CARBAMAZEPINE 107BLOOD GLUCOSE TEST STRIP 142 CARBOLITH 138BOCEPREVIR 222 CARDIZEM CD 53BOCEPREVIR/RIBAVIRIN/ " 54 PEGINTERFERON ALFA-2B 222 CARDURA-1 71BONAMINE 164 CARDURA-2 71BOSENTAN 87 CARDURA-4 71

310

Page 333: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

CARTRIDGE/RESERVOIR 236 CLIMARA 100 (EDS) 183CARVEDILOL 51 CLIMARA 25 (EDS) 183CARVEDILOL (EDS) 51 CLIMARA 50 (EDS) 183 " 52 CLIMARA 75 (EDS) 183CATAPRES 70 CLINDAMYCIN HCL 11CAYSTON (EDS) 11 CLINDAMYCIN PALMITATE HCL 11CEFIXIME 4 CLINDAMYCIN PHOSPHATE 198CEFPROZIL 5 CLINDAMYCIN PHOSPHATE/BENZOYL PEROXIDE 207CEFTIN (EDS) 5 CLINDOXYL GEL 207CEFUROXIME AXETIL 5 CLINITEST 143CEFZIL (EDS) 5 CLOBAZAM 107CELEBREX (EDS) 92 CLOBETASOL PROPIONATE 203CELECOXIB 92 CLOBETASONE BUTYRATE 203CELESTONE SOLUSPAN 176 CLOMIPRAMINE HCL 115CELEXA 114 CLONAZEPAM 105CELLCEPT (EDS) 227 CLONIDINE HCL 70CELONTIN 106 CLOPIDOGREL BISULFATE 45CELSENTRI (EDS) 226 CLOPIXOL (EDS) 132CEPHALEXIN MONOHYDRATE 6 CLOPIXOL ACUPHASE (EDS) 132CESAMET (EDS) 164 CLOPIXOL DEPOT (EDS) 132CHAMPIX 37 CLORAZEPATE DIPOTASSIUM 135CHAMPIX (STARTER PACK) 37 CLOSTRIDIUM BOTULINUM CHEMSTRIP UG 5000K 143 NEUROTOXIN TYPE A 223CHLORAL HYDRATE 137 CLOTRIMADERM 199CHLORAL HYDRATE SYRUP 137 CLOTRIMAZOLE 199CHLORDIAZEPOXIDE 135 CLOXACILLIN 10CHLOROQUINE PHOSPHATE 19 CLOZAPINE 123CHLORPROMAZINE 123 CLOZARIL (EDS) 123CHLORPROMAZINE 123 CO ALENDRONATE (EDS) 220CHLORPROPAMIDE 187 CO AMLODIPINE 49CHLORTHALIDONE 147 CO ATENOLOL 50CHLORTHALIDONE 147 " 51CHOLEDYL 213 CO ATORVASTATIN 60CHOLESTYRAMINE RESIN 61 " 61CICLESONIDE 153 CO AZITHROMYCIN (EDS) 6 " 176 " 7CICLOPIROX OLAMINE 198 CO BETAHISTINE 87CILAZAPRIL 70 CO CABERGOLINE (EDS) 222CILAZAPRIL 70 CO CANDESARTAN 68CILAZAPRIL/HYDROCHLOROTHIAZIDE 70 " 69CILOXAN (EDS) 153 CO CILAZAPRIL 70CIMETIDINE 165 CO CIPROFLOXACIN (EDS) 20CIPRO (EDS) 20 CO CITALOPRAM 114 " 21 CO CLOMIPRAMINE 115CIPRO XL (EDS) 21 CO CLONAZEPAM 105CIPRODEX (EDS) 155 CO CLOPIDOGREL (EDS) 45CIPROFLOXACIN 20 CO DILTIAZEM CD 53 " 153 " 54CIPROFLOXACIN (EDS) 20 CO DILTIAZEM T 53CIPROFLOXACIN HCL/DEXAMETHASONE 155 " 54CITALOPRAM 114 CO ENALAPRIL 71CITALOPRAM HYDROBROMIDE 114 " 72CITALOPRAM-ODAN 114 CO ETIDROCAL 224CLARITHROMYCIN 7 CO ETIDRONATE 224CLARUS 209 CO FAMCICLOVIR 18CLAVULIN-125F (EDS) 9 CO FINASTERIDE 224CLAVULIN-200 (EDS) 9 CO FLUCONAZOLE (EDS) 3CLAVULIN-250F (EDS) 9 CO FLUOXETINE 116CLAVULIN-400 (EDS) 9 CO FLUVOXAMINE 116CLAVULIN-500 (EDS) 9 " 117CLAVULIN-875 (EDS) 9 CO GABAPENTIN 108CLEO 90 (EDS) 236 " 109 " 237

311

Page 334: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

CO IRBESARTAN 74 COMFORT (EDS) 239CO IRBESARTAN/HCT 74 COMFORT ANGLED (EDS) 238 " 75 " 239CO LATANOPROST 158 COMFORT ANGLED COMBO (EDS) 238CO LEVETIRACETAM 110 " 239 " 111 COMFORT SHORT (EDS) 238CO LEVOFLOXACIN (EDS) 21 COMFORT SHORT ANGLED (EDS) 238CO LISINOPRIL 75 COMFORT SHORT COMBO (EDS) 238 " 76 COMTAN 138CO LOSARTAN 77 CONCERTA 133CO LOVASTATIN 63 CONDYLINE 208CO MELOXICAM (EDS) 95 CONJUGATED ESTROGENS 183CO METFORMIN 189 CONTACT DETACH (EDS) 236CO MYCOPHENOLATE (EDS) 227 CONTOUR 142CO NORFLOXACIN (EDS) 21 COPAXONE (EDS) 224CO OLANZAPINE (EDS) 125 CORDARONE 48 " 126 CORTATE 204CO OLANZAPINE ODT (EDS) 126 " 205CO PANTOPRAZOLE (EDS) 168 CORTEF 178CO PAROXETINE 119 CORTENEMA 205CO PIOGLITAZONE (EDS) 190 CORTIFOAM 205CO PRAMIPEXOLE 139 CORTISONE 176 " 140 CORTISONE ACETATE 176CO PRAVASTATIN 63 CORTISPORIN 155 " 64 " 206CO QUETIAPINE 128 CORTODERM 205CO RAMIPRIL 80 COSOPT 157 " 81 COSOPT-PRESERVATIVE FREE 157CO RANITIDINE 169 COSYNTROPIN ZINC HYDROXIDE 142CO REPAGLINIDE (EDS) 191 " 193CO RISPERIDONE 129 COTAZYM 163 " 130 COTAZYM ECS 20 163 " 131 COTAZYM ECS 8 163CO RIZATRIPTAN ODT (EDS) 34 COUMADIN 42CO ROPINIROLE 140 " 43CO ROSUVASTATIN 64 COVERSYL 78 " 65 COVERSYL PLUS 79CO SERTRALINE 120 COVERSYL PLUS HD 79CO SIMVASTATIN 65 COZAAR 77 " 66 COZMO CARTRIDGE (EDS) 236 " 67 CREON 10 163CO SOTALOL 59 CREON 25 163CO SUMATRIPTAN (EDS) 35 CREON 5 163CO TEMAZEPAM 136 CREON 6 163CO TERBINAFINE 4 CRESTOR 64CO TOPIRAMATE 112 " 65CO VALACYCLOVIR 18 CRIXIVAN (EDS) 15CO VALSARTAN 84 CROTAMITON 200 " 85 CUPRIC SO4 REAGENT 143CO VENLAFAXINE XR 122 CUPRIMINE 174CODEINE 97 CYANOCOBALAMIN 216CODEINE CONTIN (EDS) 97 CYANOCOBALAMIN 216CODEINE PHOSPHATE 97 CYCLEN 182COLCHICINE 223 CYCLOBENZAPRINE (EDS) 37COLCHICINE 223 CYCLOBENZAPRINE HCL 37COLCHICINE-ODAN 223 CYCLOCORT 201COLESTID 61 CYCLOMEN 179COLESTIPOL HCL RESIN 61 CYCLOSPORINE 209COMBANTRIN 2 CYCLOSPORINE (TRANSPLANT) 223COMBIGAN 157 CYMBALTA (EDS) 116COMBIVENT 31 CYPROTERONE (EDS) 26COMBIVIR (EDS) 14 CYPROTERONE ACETATE 26COMFORT (EDS) 238 CYSTADANE 222

312

Page 335: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

D.D.A.V.P. (EDS) 193 DIFLUCORTOLONE VALERATE 204DABIGATRAN 40 DIFLUNISAL 93DALACIN C 11 DIGOXIN 52DALACIN T 198 DIHYDROERGOTAMINE 33DALTEPARIN SODIUM 41 DIHYDROERGOTAMINE MESYL. 33DANAZOL 179 DIHYDROERGOTAMINE MESYLATE 33DANTRIUM 37 DIIODOHYDROXYQUIN 2DANTROLENE SODIUM 37 DILANTIN 106DAPSONE 22 DILAUDID 98DAPSONE 22 " 99DARAPRIM 19 DILTIAZEM HCL 52DARBEPOETIN ALFA 44 " 71DARIFENACIN 212 DIMENHYDRINATE 164DARUNAVIR 15 DIMENHYDRINATE IM 164DDAVP MELT (EDS) 193 DIMENHYDRINATE INJ 164DEFERASIROX 174 DIODOQUIN 2DEFEROXAMINE MESYLATE 174 DIOPRED 154DELATESTRYL 179 DIOVAN 84DELAVIRDINE MESYLATE 12 " 85DEMEROL 100 DIOVAN-HCT 85DEMULEN 30 180 " 86DENOSUMAB 223 DIPENTUM 167DEPAKENE 112 DIPHENOXYLATE HCL 162 " 113 DIPROLENE 202DEPO-MEDROL 178 DIPROSALIC 202DEPO-PROVERA 194 DIPROSONE 202DEPO-TESTOSTERONE 179 DIPYRIDAMOLE 87DERMA-SMOOTHE/FS 204 DIPYRIDAMOLE/ACETYLSALICYLIC ACID 87DERMOVATE 203 DISOPYRAMIDE 55DESFERAL (EDS) 174 DITHRANOL 208DESFERRIOXAMINE MES (EDS) 174 DIVALPROEX SODIUM 108DESIPRAMINE HCL 115 DIXARIT (EDS) 70DESMOPRESSIN 193 DOM-AMANTADINE 12DESMOPRESSIN (EDS) 193 DOM-ANAGRELIDE 221DESOCORT 203 DOM-ATENOLOL 50DESONIDE 203 " 51DESOXIMETASONE 204 DOM-ATORVASTATIN 60DETROL LA (EDS) 212 " 61DEXAMETHASONE 154 DOM-AZITHROMYCIN (EDS) 6 " 177 " 7DEXAMETHASONE OMEGA 177 DOM-CARBAMAZEPINE CR 107DEXAMETHASONE PHOSPHATE 177 DOM-CIPROFLOXACIN (EDS) 20DEXAMETHASONE SOD PHO INJ 177 DOM-CITALOPRAM 114DEXASONE 177 DOM-CLOBAZAM 107DEXEDRINE 133 DOM-CLONAZEPAM 105DEXIRON (EDS) 40 DOM-CLONAZEPAM-R 105DEXTROAMPHETAMINE SO4 133 DOM-CYCLOBENZAPRINE (EDS) 37DIABETA 188 DOM-DICLOFENAC 92DIAMICRON MR 187 DOM-DICLOFENAC SR 92DIASTAT 135 " 93DIASTIX 143 DOM-DOMPERIDONE 165DIAZEPAM 135 DOM-FLUCONAZOLE (EDS) 3DICLECTIN 164 DOM-FLUOXETINE 116DICLOFENAC EC 92 DOM-FLUVOXAMINE 116DICLOFENAC SODIUM 92 " 117 " 157 DOM-FUROSEMIDE 147DICLOFENAC SODIUM/MISOPROSTOL 93 DOM-GABAPENTIN 108DICLOFENAC SR 92 " 109DICYCLOMINE HCL 30 DOM-GEMFIBROZIL 62DIDANOSINE 13 DOM-GLYBURIDE 188DIDROCAL 224 DOM-HYDROCHLOROTHIAZIDE 147DIFFERIN 206 DOM-INDAPAMIDE 148DIFLUCAN P.O.S. (EDS) 3 DOM-LEVETIRACETAM 110

313

Page 336: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

DOM-LEVETIRACETAM 111 EMO-CORT 205DOM-LOPERAMIDE 162 EMTRICITABINE/TENOFOVIR DOM-LORAZEPAM 136 DISOPROXIL FUMARATE 14DOM-LOVASTATIN 63 ENABLEX (EDS) 212DOM-MELOXICAM (EDS) 95 ENALAPRIL MALEATE 71DOM-METFORMIN 189 ENALAPRIL MALEATE/HYDROCHLOROTHIAZIDE 72DOM-METOPROLOL-L 55 ENBREL (EDS) 223 " 56 ENFUVIRTIDE 12DOM-MIRTAZAPINE 117 ENOXAPARIN 41DOM-NIZATIDINE 167 ENTACAPONE 138DOM-NORTRIPTYLINE 118 ENTECAVIR 18DOM-NYSTATIN 4 ENTOCORT 203DOM-OXYBUTYNIN 212 ENTOCORT (EDS) 165DOM-PAROXETINE 119 ENTROPHEN 92DOMPERIDONE 165 EPINEPHRINE 31DOMPERIDONE MALEATE 165 EPINEPHRINE 31DOM-PINDOLOL 57 EPINEPHRINE HCL 31DOM-PRAVASTATIN 63 EPIPEN 31 " 64 EPIPEN JR. 31DOM-RANITIDINE 169 EPIVAL 108DOM-SALBUTAMOL 32 EPOETIN ALFA 44DOM-SALBUTAMOL RESPIR.SOL 32 EPOPROSTENOL 87DOM-SIMVASTATIN 65 EPREX (EDS) 44 " 66 EPROSARTAN MESYLATE 72DOM-SOTALOL 59 EPROSARTAN MESYLATE/HYDROCHOLORTHIAZIDE 72DOM-SUMATRIPTAN (EDS) 35 EQUATE THIN 234DOM-TERAZOSIN 83 EQUATE ULTRATHIN 234DOM-VALPROIC ACID 112 ERDOL/DRISODAN 217 " 113 ERYC 8DOM-VERAPAMIL SR 86 ERYTHRO-BASE 8DONEPEZIL HCL 28 ERYTHROMYCIN BASE 8DORNASE ALFA 150 ERYTHROMYCIN ESTOLATE 8DORZOLAMIDE HCL 156 ERYTHROMYCIN ETHYLSUCCINATE 8DORZOLAMIDE HCL/TIMOLOL MALEATE 157 ERYTHROMYCIN STEARATE 8DOSTINEX (EDS) 222 ERYTHROMYCIN/BENZOYL PEROXIDE 208DOVOBET 209 ERYTHRO-S 8DOVONEX 208 ESOMEPRAZOLE MAGNESIUM TRIHYDRATE (MAC) 165DOXAZOSIN MESYLATE 71 ESTALIS (EDS) 184DOXEPIN HCL 115 ESTRACE 183DOXYCYCLINE 10 ESTRADERM (EDS) 183DOXYCYCLINE 10 ESTRADIOL 183DOXYCYLINE 10 ESTRADIOL/NORETHINDRONE ACETATE 184DOXYLAMINE SUCCINATE/PYRIDOXINE HCL 164 " 194DRISDOL 217 ESTRADOT (EDS) 183DULOXETINE HYDROCHLORIDE 116 ESTRING 183DUOTRAV 159 ESTROGEL (EDS) 183DURAGESIC MAT (EDS) 98 ETANERCEPT 223DURAGESTIC MAT (EDS) 98 ETHACRYNIC ACID 147DUTASTERIDE 223 ETHINYL ESTRADIOL/DESOGESTREL 180DUVOID 28 ETHINYL ESTRADIOL/DROSPIRENONE 180EDECRIN (EDS) 147 ETHINYL ESTRADIOL/ETHYNODIOL DIACETATE 180EFAVIRENZ 12 ETHINYL ESTRADIOL/ETONORGESTREL 180EFAVIRENZ/EMTRICITABINE/TENOFOVIR ETHINYL ESTRADIOL/L-NORGESTREL 181 DISOPROXIL FUMARATE 13 ETHINYL ESTRADIOL/NORETHINDRONE 181EFFEXOR XR 122 ETHINYL ESTRADIOL/ EFFIENT (EDS) 45 NORETHINDRONE ACETATE 182EFUDEX 209 ETHINYL ESTRADIOL/NORGESTIMATE 182ELAVIL 113 ETHOPROPAZINE 29ELIDEL (EDS) 210 ETHOSUXIMIDE 106ELMIRON (EDS) 228 ETIDROCAL 224ELOCOM 205 ETIDRONATE DISODIUM 224ELTROXIN 195 ETIDRONATE DISODIUM/ EMO-CORT 204 CALCIUM CARBONATE 224

314

Page 337: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

ETODOLAC 93 FLUPHENAZINE DECANOATE 124ETODOLAC (EDS) 93 FLUPHENAZINE HCL 124ETRAVIRINE 13 FLUPHENAZINE OMEGA 124EUGLUCON 188 FLURAZEPAM HCL 135EURAX 200 FLURBIPROFEN 93EURO-FOLIC 216 FLUTICASONE PROPIONATE 154EURO-LAC (EDS) 162 " 177EVISTA (EDS) 184 FLUVASTATIN SODIUM 62EXELON (EDS) 29 FLUVOXAMINE MALEATE 116EXJADE (EDS) 174 FML 154EXTAVIA (EDS) 225 FOLIC ACID 216EZ HEALTH ORACLE 142 FORADIL (EDS) 31 " 234 FORMOTEROL FUMARATE 31EZETIMIBE 61 FORMOTEROL FUMARATE DIHYDRATE/ EZETROL 61 BUDESONIDE 31FAMCICLOVIR 18 FOSAMAX (EDS) 220FAMOTIDINE 165 FOSAMPRENAVIR CALCIUM 15FAMOTIDINE 165 FOSAVANCE 70/5600 (EDS) 220 " 166 FOSFOMYCIN TROMETHAMINE 22FAMVIR 18 FOSINOPRIL 73FEBUXOSTAT 224 FRAGMIN (EDS) 41FELODIPINE 73 FRAMYCETIN SO4 198FENOFIBRATE 62 FRAMYCETIN SO4/GRAMICIDIN/ FENOFIBRATE MICRO 62 DEXAMETHASONE BASE 155FENTANYL 98 FRAXIPARINE (EDS) 41FERRLECIT (EDS) 40 FRAXIPARINE FORTE (EDS) 41FILGRASTIM 44 FREESTYLE 142FINACEA 208 " 234FINASTERIDE 224 FREESTYLE LITE 142FINASTERIDE TABLETS USP 224 FRISIUM 107FINGOLIMOD HYDROCHLORIDE 224 FUCIDIN 198FLAGYL 201 FUCIDIN H 206FLAREX 154 FUCITHALMIC (EDS) 152FLECAINIDE 55 FUROSEMIDE 147FLECAINIDE ACETATE 55 FUROSEMIDE 147FLOCTAFENINE 104 FUSIDIC ACID 152FLOCTAFENINE 104 " 198FLOLAN (EDS) 87 FUSIDIC ACID/HYDROCORTISONE ACETATE 206FLOLAN DILUENT (EDS) 87 FUZEON (EDS) 12FLOLAN SUPP/PER DIEM (EDS) 87 GABAPENTIN 108FLOMAX CR 231 GABAPENTIN 108FLONASE 154 " 109FLORINEF 177 GALANTAMINE HYDROBROMIDE 28FLOVENT DISKUS 177 GARAMYCIN 152FLOVENT HFA 177 GARASONE 155FLUANXOL 124 GATIFLOXACIN 158FLUANXOL DEPOT 123 GD-AMLODIPINE 49FLUCONAZOLE 3 GD-ATORVASTATIN 60FLUCONAZOLE/CLOTRIMAZOLE 3 " 61FLUDROCORTISONE ACETATE 177 GD-AZITHROMYCIN (EDS) 6FLUNARIZINE (EDS) 33 GD-GABAPENTIN 108FLUNARIZINE HCL 33 " 109FLUNISOLIDE 154 GD-LATANOPROST 158FLUOCINOLONE ACETONIDE 204 GD-SERTRALINE 120FLUOCINONIDE 204 GD-VENLAFAXINE XR 122FLUOROMETHOLONE 154 GEMFIBROZIL 62FLUOROMETHOLONE ACETATE 154 GEN-CLOZAPINE (EDS) 123FLUOROURACIL 209 GENTAMICIN 2FLUOXETINE 116 GENTAMICIN SO4 2FLUOXETINE 116 " 152FLUOXETINE CAPSULES BP 116 GENTAMICIN SO4/BETAMETHASONE FLUPENTIXOL DECANOATE 123 SODIUM PHOSPHATE 155FLUPENTIXOL DIHYDROCHLORIDE 124 GILENYA (EDS) 224

315

Page 338: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

GLATIRAMER ACETATE 224 HYDROXYBUTYRATE DEHYDROGENASE 142GLICLAZIDE 187 HYDROXYCHLOROQUINE SO4 19GLICLAZIDE MR 187 HYDROXYZINE 137GLUCAGON 224 HYOSCINE BUTYLBROMIDE 30GLUCAGON 224 HYPURIN NPH 185GLUCOBAY 187 HYPURIN REGULAR 185GLUCOLET FINGERSTIX 234 HYTRIN 83GLUCONORM (EDS) 191 HYZAAR 77GLUCOPHAGE 189 HYZAAR DS 77GLUCOSE OXIDASE/PEROXIDASE REAGENT 143 IBUPROFEN 94GLUCOSE OXIDASE/PEROXIDASE/SODIUM IBUPROFEN 94 NITROFERRICYANIDE/GLYCINE REAGENT 143 IMDUR 88GLYBURIDE 188 IMIPRAMINE 117GLYBURIDE 188 IMIPRAMINE 117GLYCON 189 IMIQUIMOD 209GOLIMUMAB 225 IMITREX (EDS) 35GOSERELIN ACETATE 184 IMITREX DF (EDS) 35GRAVOL 164 IMODIUM 162HALOPERIDOL 124 IMURAN 222HALOPERIDOL 124 INCIVEK (EDS) 231HALOPERIDOL DECANOATE 124 INDAPAMIDE HEMIHYDRATE 148HALOPERIDOL LA 124 INDERAL-LA 59HALOPERIDOL-LA OMEGA 124 INDINAVIR SO4 15HEPARIN 41 INDOMETHACIN 94HEPARIN LEO 41 INFLIXIMAB 225HEPSERA (EDS) 18 INFUFER (EDS) 40HEPTOVIR (EDS) 14 INFUSION SET 236HEXACHLOROPHENE 201 INHIBACE 70HOMATROPINE HYDROBROMIDE 156 INHIBACE PLUS 70HP-PAC (EDS) 166 INNOHEP (EDS) 42HUMALOG (EDS) 186 INSERTION DEVICE 239HUMALOG CART./KWIKPEN (EDS) 186 INSET 11 (EDS) 236HUMATROPE (EDS) 193 " 237 " 194 INSET 30 (EDS) 238HUMATROPE CARTRIDGE (EDS) 193 INSULIN (ISOPHANE) HUMAN BIOSYNTHETIC 185 " 194 INSULIN (ISOPHANE) PORK 185HUMIRA (EDS) 220 INSULIN (REGULAR) ASPART 186HUMIRA PEN (EDS) 220 INSULIN (REGULAR) HUMAN BIOSYNTHETIC 186HUMIRA PF SYRINGE (EDS) 220 INSULIN (REGULAR) LISPRO 186HUMULIN 30/70 186 INSULIN (REGULAR) PORK 185HUMULIN 30/70 CARTRIDGE 186 INSULIN (REGULAR/ISOPHANE) HUMULIN-N 185 HUMAN BIOSYNTHETIC 186HUMULIN-N CARTRIDGE 185 INSULIN DETEMIR 186HUMULIN-R 186 INSULIN GLARGINE 187HUMULIN-R CARTRIDGE 186 INSULIN GLULISINE 187HYCORT 205 INSUPEN 12MM 234HYDERM 204 INSUPEN 6MM 235HYDRALAZINE HCL 73 INSUPEN 8MM 234HYDROCHLOROTHIAZIDE 147 " 235HYDROCHLOROTHIAZIDE 147 INTELENCE (EDS) 13HYDROCORTISONE 178 INTERFERON ALFA-2B 16 " 204 INTERFERON BETA-1A 225HYDROCORTISONE ACETATE 205 INTERFERON BETA-1B 225HYDROCORTISONE SODIUM SUCCINATE 178 INTRON-A (EDS) 16HYDROCORTISONE VALERATE 205 INVEGA SUSTENNA (EDS) 126HYDROCORTISONE/UREA 205 INVIRASE (EDS) 16HYDROMORPH CONTIN 99 IODOCHLORHYDROXYQUIN/ HYDROMORPHONE HCL 98 FLUMETHASONE PIVALATE 155HYDROMORPHONE HCL 99 IOPIDINE 157HYDROMORPHONE HP 10 99 IPRATROPIUM BROMIDE 30HYDROMORPHONE HP 20 99 " 158HYDROMORPHONE HP 50 99 IPRATROPIUM BROMIDE/SALBUTAMOL SO4 31HYDROVAL 205 IRBESARTAN 74

316

Page 339: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

IRBESARTAN 74 KEPPRA 111IRBESARTAN/HCTZ 74 KETO DIASTIX 143 " 75 KETOCONAZOLE 3IRBESARTAN/HYDROCHLOROTHIAZIDE 74 " 199IRON DEXTRAN 40 KETODERM 199IRON SODIUM FERRIC GLUCONATE 40 KETOPROFEN 94IRON SUCROSE 40 KETOPROFEN 94ISDN 88 KETOPROFEN SR 94ISENTRESS (EDS) 15 KETOPROFEN-E 94ISOPROPYL ALCOHOL 234 KETOROLAC TROMETHAMINE 154ISOPROPYL MYRISTATE 200 KETOSTIX 143ISOPTIN SR 86 KETOTIFEN FUMARATE 225ISOPTO ATROPINE 156 KINERET (EDS) 221ISOPTO CARBACHOL 156 KIVEXA (EDS) 13ISOPTO CARPINE 156 KWELLADA-P CREME RINSE 200ISOPTO HOMATROPINE 156 KWELLADA-P LOTION 200ISOSORBIDE DINITRATE 88 LABETALOL HCL 75ISOSORBIDE-5 MONONITRATE 88 LACOSAMIDE 109ISOTRETINOIN 209 LACTULOSE 162ITEST 142 LAMICTAL 110ITRACONAZOLE 3 LAMISIL 4IV SKIN PREPARATION (EDS) 239 " 200JAMP K-20 146 LAMIVUDINE 14JAMP K-8 146 LAMIVUDINE/ZIDOVUDINE 14JAMP-AMLODIPINE 49 LAMOTRIGINE 110JAMP-ATENOLOL 50 LAMOTRIGINE 110 " 51 LANCET 234JAMP-CITALOPRAM 114 LANREOTIDE ACETATE 226JAMP-FINASTERIDE 224 LANSOPRAZOLE (EDS) 166JAMP-FOLIC ACID 216 LANSOPRAZOLE (MAC) 166JAMP-FOSINOPRIL 73 LANSOPRAZOLE/CLARITHROMYCIN/AMOXICILLIN 166JAMP-GABAPENTIN 108 LANTUS 187 " 109 LANTUS SOLOSTAR 187JAMP-INDAPAMIDE 148 LASIX 147JAMP-LACTULOSE (EDS) 162 LATANOPROST 158JAMP-LISINOPRIL 75 LATANOPROST/TIMOLOL MALEATE 158 " 76 LECTOPAM 134JAMP-METOPROLOL-L 55 LEFLUNOMIDE 226 " 56 LEFLUNOMIDE (EDS) 226JAMP-PRAVASTATIN 63 LESCOL 62 " 64 LEUCOVORIN (EDS) 216JAMP-QUETIAPINE 128 LEUCOVORIN CALCIUM (FOLINIC ACID) 216JAMP-RAMIPRIL 80 LEUPROLIDE ACETATE 185 " 81 LEVAQUIN (EDS) 21JAMP-RISPERIDONE 129 LEVEMIR PENFILL 186 " 130 LEVETIRACETAM 110 " 131 LEVETIRACETAM 110JAMP-ROPINIROLE 140 " 111JAMP-SIMVASTATIN 65 LEVOBUNOLOL HCL 158 " 66 LEVOCARB CR 139 " 67 LEVODOPA/BENZERAZIDE 138JAMP-VITAMIN B1 216 LEVODOPA/CARBIDOPA 138JAMP-VITAMIN B6 216 LEVODOPA/CARBIDOPA/ENTACAPONE 139JANUMET (EDS) 192 LEVOFLOXACIN 21JANUVIA (EDS) 192 LEVONORGESTREL 182K-10 146 LEVOTHYROXINE (SODIUM) 195KADIAN 101 LIDEMOL 204KALETRA (EDS) 15 LIDEX 204KAYEXALATE 146 LINESSA 180K-DUR 146 LINEZOLID 11KENALOG 10 179 LIORESAL 36KENALOG 40 179 LIORESAL INTRATHECAL (EDS) 36KEPPRA 110 LIORESAL-DS 36

317

Page 340: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

LIPIDIL EZ 62 MAVIK 84LIPIDIL-MICRO 62 MAXALT (EDS) 34LIPITOR 60 MAXALT RPD (EDS) 34 " 61 MAXIDEX 154LISINOPRIL 75 MAXITROL 155LISINOPRIL/HCTZ (Z) 76 MEBENDAZOLE 2LISINOPRIL/HYDROCHLOROTHIAZIDE 76 MECLIZINE HCL 164LITHIUM CARBONATE 138 MEDROL 178LITHMAX 138 MEDROXYPROGESTERONE ACETATE 194LOCACORTEN-VIOFORM 155 MEFENAMIC 94LODOXAMIDE TROMETHAMINE 158 MEFENAMIC ACID 94LOESTRIN 1.5/30 182 MEGACE OS (EDS) 26LOMOTIL 162 MEGESTROL 26LONITEN (EDS) 78 MELOXICAM 95LOPERAMIDE HCL 162 MELOXICAM (EDS) 95LOPINAVIR/RITONAVIR 15 MEPERIDINE HCL 100LOPRESOR 55 MEPERIDINE HYDROCHLORIDE 100 " 56 MEPRON (EDS) 22LOPRESOR-SR 56 MERCAPTOPURINE 26LOPROX 198 MESASAL 170LORAZEPAM 136 M-ESLON 100LORAZEPAM 136 " 101LOSARTAN POTASSIUM 77 MESTINON 28LOSARTAN POTASSIUM/ METADOL (PALL CARE) 100 HYDROCHLOROTHIAZIDE 77 METFORMIN 189LOSEC (CAP) (EDS) 167 METFORMIN 189LOSEC (EDS) 167 METHADONE HCL 100LOSEC (TAB) (EDS) 167 METHAZOLAMIDE 156LOTENSIN 68 METHAZOLAMIDE 156LOTRIDERM 206 METHENAMINE MANDELATE 22LOVASTATIN 63 METHIMAZOLE 196LOVASTATIN 63 METHOTREXATE 209LOVENOX (EDS) 41 METHOTREXATE 209LOVENOX HP (EDS) 41 METHOTRIMEPRAZINE 137LOXAPINE SUCCINATE 125 METHOXSALEN 210LOZIDE 148 METHSUXIMIDE 106LUCENTIS (EDS) 229 METHYLDOPA 78LUMIGAN RC 157 METHYLDOPA 78LUPRON DEPOT (EDS) 185 METHYLPHENIDATE HCL 133LUVOX 116 METHYLPREDNISOLONE 178 " 117 METHYLPREDNISOLONE 178LYDERM 204 METHYLPREDNISOLONE ACETATE 178LYRICA (EDS) 229 METHYLPREDNISOLONE ACETATE 178M.O.S.-S.R. 101 METOCLOPRAMIDE HCL 166MACROBID 22 METOLAZONE 148MANDELAMINE 22 METOPROLOL 55MANERIX 118 " 56MAPROTILINE 117 METOPROLOL TARTRATE 55MAR-AMLODIPINE 49 " 78MAR-ATENOLOL 50 METROCREAM 201 " 51 METROGEL 201MARAVIROC 226 METROLOTION 201MAR-CIPROFLOXACIN (EDS) 20 METRONIDAZOLE 23MAR-CITALOPRAM 114 " 201MAR-METFORMIN 189 METRONIDAZOLE 23MAR-RISPERIDONE 129 MEVACOR 63 " 130 MEXILETINE HCL 56 " 131 MEZAVANT 170MAR-RIZATRIPTAN (EDS) 34 MIACALCIN (EDS) 192MAR-SIMVASTATIN 65 MICARDIS 82 " 66 MICARDIS PLUS 82 " 67 MICATIN 199MARVELON 180 MICONAZOLE NITRATE 199

318

Page 341: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

MICOZOLE 199 MOS-SULFATE 100MICRO-K EXTENCAPS 146 MOTRIN EXTRA STRENGTH IB 94MICROLET 234 MOTRIN SUPER STRENGTH IB 94MICRONOR 182 MOXIFLOXACIN HCL 21MIDAMOR 148 " 153MIDODRINE HCL 32 MPD THIN 234MIGRANAL 33 MPD ULTRA THIN 234MINESTRIN 1/20 182 MS CONTIN 101MINITRAN 0.2 88 MSIR 100MINITRAN 0.4 88 MUCOMYST 150MINITRAN 0.6 88 MUPIROCIN 198MINOCYCLINE (EDS) 10 MYCOBUTIN (EDS) 229 " 11 MYCOPHENOLATE MOFETIL 227MINOCYCLINE HCL 10 MYCOPHENOLATE MOFETIL (EDS) 227MIN-OVRAL 181 MYCOPHENOLATE SODIUM 227MINOXIDIL 78 MYFORTIC (EDS) 227MINT-AMLODIPINE 49 MYLAN-ACEBUTOLOL 48MINT-ATENOL 50 MYLAN-ACEBUTOLOL (TYPE S) 48 " 51 MYLAN-ACYCLOVIR 17MINT-CIPROFLOXACIN (EDS) 20 " 18MINT-CITALOPRAM 114 MYLAN-ALENDRONATE (EDS) 220MINT-PIOGLITAZONE (EDS) 190 MYLAN-ALPRAZOLAM 134MINT-PRAVASTATIN 63 MYLAN-AMANTADINE 12 " 64 MYLAN-AMIODARONE 48MINT-RISPERDON 129 MYLAN-AMLODIPINE 49 " 131 MYLAN-AMOXICILLIN 8MINT-RISPERIDON 129 MYLAN-ANAGRELIDE 221 " 130 MYLAN-ATENOLOL 50 " 131 " 51MINT-SIMVASTATIN 65 MYLAN-ATORVASTATIN 60 " 66 " 61 " 67 MYLAN-AZATHIOPRINE 222MINT-TOPIRAMATE 112 MYLAN-AZITHROMYCIN (EDS) 6MIRAPEX 139 MYLAN-BACLOFEN 36 " 140 MYLAN-BECLOMETHASONE AQ 153MIRENA 182 MYLAN-BUDESONIDE AQ 153MIRTAZAPINE 117 MYLAN-CANDESARTAN 68MIRTAZAPINE 117 " 69MISOPROSTOL 166 MYLAN-CAPTOPRIL 69MOBICOX (EDS) 95 MYLAN-CARBAMAZEPINE CR 107MOCLOBEMIDE 118 MYLAN-CARVEDILOL (EDS) 51MODAFINIL 133 " 52MODAFINIL (EDS) 133 MYLAN-CILAZAPRIL 70MODECATE CONCENTRATE 124 MYLAN-CIMETIDINE 165MOGADON 105 MYLAN-CIPROFLOXACIN (EDS) 20MOMETASONE FUROATE 205 MYLAN-CITALOPRAM 114MOMETASONE FUROATE MONOHYDRATE 154 MYLAN-CLARITHROMYCIN (EDS) 7MONISTAT 3 COMBINATION 199 MYLAN-CLINDAMYCIN 11MONISTAT 7 COMBINATION 199 MYLAN-CLOBETASOL 203MONISTAT-3 199 MYLAN-CLONAZEPAM 105MONISTAT-7 199 MYLAN-CLOPIDOGREL (EDS) 45MONOJECT ULTRACOMFORT 29G 235 MYLAN-COMBO STERINEBS 31 " 236 MYLAN-CYCLOBENZAPRINE (EDS) 37MONOJECT ULTRACOMFORT 30G 235 MYLAN-DOMPERIDONE 165 " 236 MYLAN-DOXAZOSIN 71MONOPRIL 73 MYLAN-ENALAPRIL 71MONTELUKAST SODIUM 226 " 72MONTELUKAST SODIUM (EDS) 227 MYLAN-ETI-CAL CAREPAC 224MONUROL (EDS) 22 MYLAN-ETIDRONATE 224MORPHINE 100 MYLAN-FAMOTIDINE 165MORPHINE HP50 102 " 166MORPHINE SO4 102 MYLAN-FENOFIBRATE MICRO 62MORPHINE SR 101 MYLAN-FINASTERIDE 224

319

Page 342: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

MYLAN-FLUCONAZOLE (EDS) 3 MYLAN-SALBUTAMOL STERINEB 32MYLAN-FLUOXETINE 116 MYLAN-SELEGILINE (EDS) 140MYLAN-FOSINOPRIL 73 MYLAN-SERTRALINE 120MYLAN-GABAPENTIN 108 MYLAN-SIMVASTATIN 65 " 109 " 66MYLAN-GALANTAMINE ER(EDS) 28 " 67MYLAN-GEMFIBROZIL 62 MYLAN-SOTALOL 59MYLAN-GLYBE 188 MYLAN-SUMATRIPTAN (EDS) 35MYLAN-HYDROXYCHLOROQUINE 19 MYLAN-TAMSULOSIN 231MYLAN-INDAPAMIDE 148 MYLAN-TELMISARTAN 82MYLAN-IPRATROPIUM 30 MYLAN-TELMISARTAN HCTZ 82MYLAN-IRBESARTAN 74 MYLAN-TERBINAFINE 4MYLAN-LAMOTRIGINE 110 MYLAN-TICLOPIDINE (EDS) 45MYLAN-LANSOPRAZOLE (EDS) 166 MYLAN-TIZANIDINE (EDS) 37MYLAN-LEFLUNOMIDE (EDS) 226 MYLAN-TOPIRAMATE 112MYLAN-LEVOFLOXACIN (EDS) 21 MYLAN-VALACYCLOVIR 18MYLAN-LISINOPRIL 75 MYLAN-VALPROIC 113 " 76 MYLAN-VALSARTAN 84MYLAN-LISINOPRIL HCTZ 76 " 85MYLAN-LOSARTAN 77 MYLAN-VALSARTAN-HCTZ 85MYLAN-LOSARTAN HCTZ 77 " 86MYLAN-LOVASTATIN 63 MYLAN-VENLAFAXINE XR 122MYLAN-MELOXICAM (EDS) 95 MYLAN-VERAPAMIL 86MYLAN-METFORMIN 189 MYLAN-VERAPAMIL SR 86MYLAN-METOPROLOL 55 MYLAN-VERAPMIL SR 86MYLAN-METOPROLOL (TYPE L) 55 MYLAN-WARFARIN 42 " 56 " 43MYLAN-MINOCYCLINE (EDS) 10 MYLAN-ZOLMITRIPTAN (EDS) 36 " 11 MYL-RANITIDINE 169MYLAN-MIRTAZAPINE 117 MYOCHRYSINE 172 " 118 MYOZYME (EDS) 221MYLAN-MONTELUKAST (EDS) 226 NABILONE 164 " 227 NABUMETONE 95MYLAN-MYCOPHENOLATE (EDS) 227 NADOLOL 56MYLAN-NABUMETONE (EDS) 95 " 78MYLAN-NIFEDIPINE 57 NADROPARIN CALCIUM 41MYLAN-NIFEDIPINE XL 57 NAFARELIN ACETATE 185MYLAN-NITROL SL SPRAY 88 NALCROM (EDS) 230MYLAN-OLANZAPINE (EDS) 125 NAPROSYN 96 " 126 NAPROSYN-S.R. 96MYLAN-OLANZAPINE ODT (EDS) 126 NAPROXEN 95MYLAN-OLANZAPINE ODT(EDS) 126 NAPROXEN 95MYLAN-OMEPRAZOLE (EDS) 167 " 96MYLAN-OXYBUTYNIN 212 NARATRIPTAN HCL 34MYLAN-PANTOPRAZOLE (EDS) 168 NARDIL 119MYLAN-PAROXETINE 119 NASACORT AQ 154MYLAN-PIOGLITAZONE (EDS) 190 NASONEX 154MYLAN-PRAMIPEXOLE 139 NATALIZUMAB 227 " 140 NATEGLINIDE 189MYLAN-PRAVASTATIN 63 NAVANE 132 " 64 NEEDLE 234MYLAN-PROPAFENONE 58 NELFINAVIR MESYLATE 16MYLAN-QUETIAPINE 128 NEOMYCIN/GRAMICIDIN/NYSTATIN/ MYLAN-RAMIPRIL 80 TRIAMCINOLONE ACETONIDE 206 " 81 NEORAL (EDS) 209MYLAN-RANITIDINE 169 " 223MYLAN-RISEDRONATE (EDS) 230 NEOSPORIN 198MYLAN-RISPERIDONE 129 NEOSTIGMINE BROMIDE 28 " 130 NERISONE 204 " 131 NEULEPTIL 127MYLAN-RIZATRIPTAN ODT (EDS) 34 NEUPOGEN (EDS) 44MYLAN-ROSUVASTATIN 64 NEURONTIN 108 " 65 " 109

320

Page 343: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

NEVIRAPINE 13 NOVO-CLINDAMYCIN 11NEXIUM (EDS) 165 NOVO-CLOBAZAM 107NIACIN 216 NOVO-CLOBETASOL 203NIACIN 216 NOVO-CLONAZEPAM 105NIASPAN FCT 216 NOVO-CLONIDINE 70NIDAGEL 201 NOVO-CLONIDINE (EDS) 70NIFEDIPINE 57 NOVO-CLOXIN 10 " 78 NOVO-CYCLOPRINE (EDS) 37NIFEDIPINE 57 NOVO-DESMOPRESSIN (EDS) 193NIMODIPINE 88 NOVO-DIFENAC 92NIMOTOP (EDS) 88 NOVO-DIFENAC SR 92NITOMAN 231 " 93NITRAZEPAM 105 NOVO-DILTAZEM 52NITRO-DUR 0.2 88 NOVO-DILTAZEM CD 53NITRO-DUR 0.4 88 " 54NITRO-DUR 0.6 88 NOVO-DILTIAZEM HCL 53NITRO-DUR 0.8 88 " 54NITROFURANTOIN 22 NOVO-DIVALPROEX 108NITROFURANTOIN 22 NOVO-DOXAZOSIN 71NITROFURANTOIN MONOHYDRATE 22 NOVO-DOXEPIN 115NITROGLYCERIN 88 NOVO-DOXYLIN 10NITROL 88 NOVO-ENALAPRIL 71NITROLINGUAL PUMPSPRAY 88 " 72NITROPRUSSIDE REAGENT 1 NOVO-ENALAPRIL/HCTZ 72NITROSTAT 88 NOVO-ETIDRONATECAL 224NIX CREME RINSE 200 NOVO-FAMOTIDINE 165NIX DERMAL CREAM 200 " 166NIZATIDINE 167 NOVO-FENOFIBRATE MICRO 62NORETHINDRONE 182 NOVO-FENTANYL (EDS) 98NORFLOXACIN 21 NOVO-FINASTERIDE 224NORITATE 201 NOVOFINE 12MM 234NORLEVO 182 NOVOFINE 6MM 234NORPROLAC (EDS) 229 NOVOFINE 8MM 234NORTRIPTYLINE 118 NOVOFINE ETW 32G 235NORVASC 49 NOVO-FLUCONAZOLE (EDS) 3NORVIR (EDS) 16 NOVO-FLURPROFEN 93NORVIR SEC (EDS) 16 NOVO-FLUVOXAMINE 116NOVA MAX PLUS 142 " 117NOVAMAX 142 NOVO-FURANTOIN 22NOVAMILOR 67 NOVO-GEMFIBROZIL 62NOVAMOXIN 8 NOVO-HYDRAZIDE 147 " 9 NOVO-HYDROXYZIN 137NOVAMOXIN (SUGAR REDUCED) 9 NOVO-INDAPAMIDE 148NOVO-5-ASA 170 NOVO-IPRAMIDE 30NOVO-ACEBUTOLOL 48 NOVO-KETOCONAZOLE (EDS) 3NOVO-ACYCLOVIR 17 NOVO-KETOTIFEN (EDS) 225 " 18 NOVO-LAMOTRIGINE 110NOVO-ALENDRONATE (EDS) 220 NOVO-LANSOPRAZOLE (EDS) 166NOVO-ALFUZOSIN PR 220 NOVO-LEFLUNOMIDE (EDS) 226NOVO-AMPICILLIN 10 NOVO-LEVOCARBIDOPA 138NOVO-AZITHROMYCIN (EDS) 6 NOVO-LEVOFLOXACIN (EDS) 21 " 7 NOVO-LEXIN 6NOVO-BETAHISTINE 87 NOVOLIN GE 30/70 186NOVO-BISOPROLOL 51 NOVOLIN GE 30/70 PENFILL 186NOVO-BROMAZEPAM 134 NOVOLIN GE 40/60 PENFILL 186NOVO-BUSPIRONE 137 NOVOLIN GE 50/50 PENFILL 186NOVO-CAPTORIL 69 NOVOLIN GE NPH 185NOVO-CHLOROQUINE 19 NOVOLIN GE NPH PENFILL 185NOVO-CILAZAPRIL 70 NOVOLIN GE TORONTO 186NOVO-CILAZAPRIL/HCTZ 70 NOVOLIN GE TORONTO PENFIL 186NOVO-CIMETINE 165 NOVO-LISINOPRIL (TYPE P) 75NOVO-CIPROFLOXACIN (EDS) 20 NOVO-LISINOPRIL (TYPE Z) 75NOVO-CLAVAMOXIN (EDS) 9 " 76

321

Page 344: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

NOVO-LISINOPRIL/HCTZ (P) 76 NOVO-SUMATRIPTAN (EDS) 35NOVO-LISINOPRIL/HCTZ (Z) 76 NOVO-SUMATRIPTAN DF (EDS) 35NOVO-LOPERAMIDE 162 NOVO-SUNDAC 96NOVO-LORAZEM 136 NOVO-TAMSULOSIN 231NOVO-LOVASTATIN 63 NOVO-TEMAZEPAM 136NOVO-MAPROTILINE 117 NOVO-TERBINAFINE 4NOVO-MEDRONE 194 NOVO-THEOPHYL SR 213NOVO-MELOXICAM (EDS) 95 NOVO-TIAPROFENIC 96NOVO-METFORMIN 189 NOVO-TICLOPIDINE (EDS) 45NOVO-METHACIN 94 NOVO-TIMOL 59NOVO-METOPROL (UNCOATED) 56 NOVO-TOPIRAMATE 112NOVO-MEXILETINE 56 NOVO-TRIAMZIDE 84NOVO-MINOCYCLINE (EDS) 10 NOVO-TRIMEL 23 " 11 NOVO-TRIMEL DS 23NOVO-MIRTAZAPINE 117 NOVOTWIST TIP NEEDLE 234NOVO-MIRTAZAPINE OD 117 " 235 " 118 NOVO-VALPROIC 113NOVO-MOCLOBEMIDE 118 NOVO-VENLAFAXINE XR 122NOVO-MORPHINE SR 101 NOVO-VERAMIL SR 86NOVO-MYCOPHENOLATE (EDS) 227 NOVO-WARFARIN 42NOVO-NABUMETONE (EDS) 95 " 43NOVO-NADOLOL 56 NU-ACEBUTOLOL 48NOVO-NARATRIPTAN (EDS) 34 NU-ACYCLOVIR 17NOVO-NIZATIDINE 167 " 18NOVO-NORFLOXACIN (EDS) 21 NU-AMILZIDE 67NOVO-NORTRIPTYLINE 118 NU-AMOXI 8NOVO-OLANZAPINE OD (EDS) 126 " 9NOVO-OMEPRAZOLE (EDS) 167 NU-ATENOL 50NOVO-OXYBUTYNIN 212 " 51NOVO-PANTOPRAZOLE (EDS) 168 NU-AZATHIOPRINE 222NOVO-PEN-VK 10 NU-BACLO 36NOVO-PERIDOL 124 NU-BECLOMETHASONE 153NOVO-PINDOL 57 NU-BUSPIRONE 137NOVO-PIOGLITAZONE (EDS) 190 NU-CAPTO 69NOVO-PIROCAM 96 NU-CARBAMAZEPINE 107NOVO-PRAMIPEXOLE 139 NU-CARVEDILOL (EDS) 51 " 140 " 52NOVO-PRANOL 58 NU-CEPHALEX 6NOVO-PRAVASTATIN 63 NU-CIMET 165 " 64 NU-CIPROFLOXACIN (EDS) 20NOVO-PRAZIN 79 NU-CITALOPRAM 114NOVO-PREDNISONE 178 NU-COTRIMOX 23NOVO-PROFEN 94 NU-CYCLOBENZAPRINE (EDS) 37NOVO-QUETIAPINE 128 NU-DICLO 92NOVO-QUININE 19 NU-DILTIAZ 52NOVO-RALOXIFINE (EDS) 184 NU-DILTIAZ-CD 53NOVO-RANIDINE 169 " 54NOVORAPID (EDS) 186 NU-DIVALPROEX 108NOVO-RISEDRONATE (EDS) 230 NU-DOMPERIDONE 165NOVO-RISPERIDONE 129 NU-DOXYCYCLINE 10 " 130 NU-FAMOTIDINE 165 " 131 " 166NOVO-RYTHRO ESTOLATE 8 NU-FLUOXETINE 116NOVO-RYTHRO ETHYLSUCC 8 NU-FLURBIPROFEN 93NOVO-SALBUTAMOL HFA 32 NU-FLUVOXAMINE 116NOVO-SELEGILINE (EDS) 140 " 117NOVO-SEMIDE 147 NU-FUROSEMIDE 147NOVO-SERTRALINE 120 NU-GABAPENTIN 108NOVO-SIMVASTATIN 66 " 109NOVO-SOTALOL 59 NU-GEMFIBROZIL 62NOVO-SPIROTON 148 NU-GLYBURIDE 188NOVO-SPIROZINE 82 NU-HYDRO 147NOVO-SUCRALATE 169 NU-IBUPROFEN 94

322

Page 345: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

NU-INDAPAMIDE 148 OLMESARTAN MEDOXOMIL/HCTZ 78NU-INDO 94 OLMETEC 78NU-KETOCON (EDS) 3 OLMETEC PLUS 78NU-LEVOCARB 138 OLSALAZINE SODIUM 167NU-LOVASTATIN 63 OMEPRAZOLE (EDS) 167NU-MEDROXY 194 OMEPRAZOLE (MAC) 167NU-METFORMIN 189 OMNARIS 153NU-METOCLOPRAMIDE 166 OMNIPOD DEL DEVICE (EDS) 236NU-METOP 55 OMNITROPE (EDS) 193 " 56 " 194NU-MOCLOBEMIDE 118 ON-CALL PLUS 142NU-NAPROX 95 ONE TOUCH DELICA 234 " 96 ONE TOUCH ULTRA 142NU-NIZATIDINE 167 ONE TOUCH ULTRA SOFT 234NU-NORTRIPTYLINE 118 ONE-ALPHA (EDS) 217NU-OXYBUTYN 212 ONETOUCH VERIO 142NU-PAROXETINE 119 ONGLYZA (EDS) 191NU-PEN-VK 10 OPTIMYXIN PLUS 152NU-PINDOL 57 ORACORT DENTAL PASTE 205NU-PIROX 96 ORAP 127NU-PRAVASTATIN 63 ORCIPRENALINE SO4 32 " 64 ORENCIA (EDS) 220NU-PROPAFENONE 58 ORTHO 0.5/35 181NU-PROPRANOLOL 58 ORTHO 1/35 181NU-RANIT 169 ORTHO 7/7/7 181NU-SELEGILINE (EDS) 140 ORTHO-CEPT 180NU-SERTRALINE 120 OXAZEPAM 136NU-SIMVASTATIN 65 OXCARBAZEPINE 111 " 66 OXEZE TURBUHALER (EDS) 31 " 67 OXSORALEN (EDS) 210NU-SOTALOL 59 OXSORALEN ULTRA (EDS) 210NU-SUCRALFATE 169 OXTRIPHYLLINE 213NU-SULINDAC 96 OXYBUTYNIN 212NU-TERAZOSIN 83 OXYBUTYNIN CHLORIDE 212NU-TERBINAFINE 4 OXYCODONE HCL 103NU-TIAPROFENIC 96 OXY-IR 103NU-TICLOPIDINE (EDS) 45 OXYNEO (EDS) 103NU-TRAZODONE 121 PALIPERIDONE PALMITATE 126NU-TRIAZIDE 84 PAMIDRONATE DISODIUM 228NUTROPIN (EDS) 194 PAMIDRONATE DISODIUM(EDS) 228NUTROPIN AQ (EDS) 194 PANCREASE MT 10 163NUTROPIN AQ PEN (EDS) 194 PANCREASE MT 16 163NU-VALPROIC 113 PANCREASE MT 4 163NUVARING 180 PANCRELIPASE (LIPASE/AMYLASE/PROTEASE) 163NU-VERAP 86 PANECTYL 232NU-VERAP SR 86 PANOXYL-10 207NYADERM 200 PANOXYL-20 207NYSTATIN 4 PANTOLOC (EDS) 168 " 200 PANTOPRAZOLE (EDS) 168OCTOSTIM (EDS) 193 PANTOPRAZOLE MAGNESIUM (MAC) 167OCTREOTIDE 228 PANTOPRAZOLE SODIUM (MAC) 168OCTREOTIDE ACETATE (EDS) 228 PARADIGM MIO (EDS) 237OCUFLOX (EDS) 153 PARADIGM MIO/BLUE (EDS) 236ODAN K-20 146 PARADIGM MIO/PINK (EDS) 236ODAN K-8 146 PARADIGM POLYFIN (EDS) 239OESCLIM (EDS) 183 PARADIGM QUICK-SERTER (EDS) 239OFLOXACIN 153 PARADIGM QUICK-SET (EDS) 236OLANZAPINE 125 " 237OLANZAPINE (EDS) 125 PARADIGM RESERVOIR (EDS) 236 " 126 PARADIGM SIL. FULL (EDS) 238OLANZAPINE ODT (EDS) 126 " 239OLESTYR 61 PARADIGM SOF-SET MICRO (EDS) 236OLMESARTAN MEDOXOMIL 78 " 237

323

Page 346: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME PagePARADIGM SOF-SET QR (EDS) 237 PMS-ANAGRELIDE 221PARADIGM SURE-T (EDS) 239 PMS-ASA EC 92PARIET (EDS) 168 PMS-ATENOLOL 50PARNATE 120 " 51PAROXETINE 119 PMS-ATORVASTATIN 60PAROXETINE HCL 119 " 61PARSITAN 29 PMS-AZITHROMYCIN (EDS) 6PAT-GALANTAMINE ER (EDS) 28 " 7PAXIL 119 PMS-BACLOFEN 36PEDIAPRED 178 PMS-BENZTROPINE 29PEGASYS (EDS) 17 PMS-BISOPROLOL 51PEGASYS RBV (EDS) 17 PMS-BRIMONIDINE 157PEGETRON (EDS) 17 PMS-BUPROPION SR 113PEGETRON REDIPEN (EDS) 17 PMS-BUSPIRONE 137PEGINTERFERON ALFA-2A 17 PMS-CARBAMAZEPINE CHEWS 107PEGINTERFERON ALFA-2A/RIBAVIRIN 17 PMS-CARBAMAZEPINE CHEWTAB 107PEGINTERFERON ALFA-2B/RIBAVIRIN 17 PMS-CARBAMAZEPINE CR 107PENICILLAMINE 174 PMS-CARVEDILOL (EDS) 51PENICILLIN V (POTASSIUM) 10 " 52PENTASA 170 PMS-CHLORAL HYDRATE SYRUP 137PENTAZOCINE 104 PMS-CILAZAPRIL 70PENTOSAN POLYSULFATE SO4 228 PMS-CIPROFLOXACIN (EDS) 20PENTOXIFYLLINE 45 " 153PEPCID 165 PMS-CITALOPRAM 114 " 166 PMS-CLARITHROMCYIN (EDS) 7PERICYAZINE 127 PMS-CLARITHROMYCIN (EDS) 7PERINDOPRIL ERBUMINE 78 PMS-CLOBAZAM 107PERINDOPRIL ERBUMINE/INDAPAMIDE 79 PMS-CLOBETASOL 203PERMETHRIN 200 PMS-CLONAZEPAM 105PERPHENAZINE 127 PMS-CLONAZEPAM-R 105PERPHENAZINE 127 PMS-CLOPIDOGREL (EDS) 45PHENELZINE SO4 119 PMS-CYCLOBENZAPRINE (EDS) 37PHENOBARB 104 PMS-DESMOPRESSIN (EDS) 193PHENOBARB ELIXIR 104 PMS-DESONIDE 203PHENOBARBITAL 104 PMS-DEXAMETHASONE 177 " 134 PMS-DIAZEPAM 135PHENYTOIN 106 PMS-DICLOFENAC 92PHISOHEX 201 " 93PHOSLO (EDS) 146 PMS-DICLOFENAC-SR 92PILOCARPINE HCL 156 " 93PILOPINE-HS 156 PMS-DILTIAZEM CD 53PIMECROLIMUS 210 " 54PIMOZIDE 127 PMS-DOMPERIDONE 165PINDOLOL 57 PMS-DOXAZOSIN 71 " 79 PMS-ENALAPRIL 71PINDOLOL/HYDROCHLOROTHIAZIDE 79 " 72PIOGLITAZONE (EDS) 190 PMS-FAMCICLOVIR 18PIOGLITAZONE HCL 190 PMS-FENOFIBRATE MICRO 62PIPORTIL L4 127 PMS-FENTANYL (EDS) 98PIPOTIAZINE PALMITATE 127 PMS-FENTANYL MTX (EDS) 98PIROXICAM 96 PMS-FINASTERIDE 224PIZOTYLINE HYDROGEN MALATE 34 PMS-FLUCONAZOLE 3PLAN B 182 PMS-FLUCONAZOLE (EDS) 3PLAQUENIL 19 PMS-FLUOROMETHOLONE 154PLAVIX (EDS) 45 PMS-FLUOXETINE 116PLENDIL 73 PMS-FLUPHENAZINE 124PMS-ALENDRONATE FC (EDS) 220 PMS-FLUVOXAMINE 116PMS-AMANTADINE 12 " 117PMS-AMIODARONE 48 PMS-FUROSEMIDE 147PMS-AMLODIPINE 49 PMS-GABAPENTIN 108PMS-AMOXICILLIN 8 " 109 " 9 PMS-GEMFIBROZIL 62

PMS-GLYBURIDE 188

324

Page 347: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

PMS-HYDROCHLOROTHIAZIDE 147 PMS-PREDNISOLONE 178PMS-HYDROMORPHONE 98 PMS-PROCYCLIDINE 30 " 99 PMS-PROPAFENONE 58PMS-HYDROXYZINE 137 PMS-QUETIAPINE 128PMS-INDAPAMIDE 148 PMS-RABEPRAZOLE EC (EDS) 168PMS-IPRATROPIUM 30 PMS-RAMIPRIL 80 " 158 " 81PMS-IRBESARTAN 74 PMS-RAMIPRIL/HCTZ 81PMS-IRBESARTAN HCTZ 74 PMS-RANITIDINE 169 " 75 PMS-REPAGLINIDE (EDS) 191PMS-ISMN 88 PMS-RISEDRONATE (EDS) 230PMS-KETOPROFEN 94 PMS-RISPERIDONE 129PMS-LACTULOSE (EDS) 162 " 130PMS-LAMOTRIGINE 110 " 131PMS-LEFLUNOMIDE (EDS) 226 PMS-RIVASTIGMINE (EDS) 29PMS-LEVETIRACETAM 110 PMS-ROPINIROLE 140 " 111 PMS-ROSUVASTATIN 64PMS-LEVOBUNOLOL 158 " 65PMS-LEVOFLOXACIN (EDS) 21 PMS-SALBUTAMOL 32PMS-LISINOPRIL 75 PMS-SALBUTAMOL RESP. SOL. 32 " 76 PMS-SERTRALINE 120PMS-LITHIUM CARBONATE 138 PMS-SIMVASTATIN 65PMS-LOPERAMIDE 162 " 66PMS-LOPERAMIDE HCL 162 " 67PMS-LORAZEPAM 136 PMS-SOD POLY SULF (120ML) 146PMS-LOSARTAN 77 PMS-SOD POLYSTYRENE SULF 146PMS-LOVASTATIN 63 PMS-SODIUM CROMOGLYCATE 230PMS-MELOXICAM (EDS) 95 PMS-SOTALOL 59PMS-METFORMIN 189 PMS-SULFASALAZINE 170PMS-METHYLPHENIDATE 133 PMS-SUMATRIPTAN (EDS) 35PMS-METOCLOPRAMIDE 166 PMS-TERAZOSIN 83PMS-METOPROLOL-L 55 PMS-TIMOLOL 159 " 56 PMS-TOBRAMYCIN (EDS) 152PMS-MINOCYCLINE (EDS) 10 PMS-TOPIRAMATE 112 " 11 PMS-TRAZODONE 121PMS-MIRTAZAPINE 117 PMS-URSODIOL C (EDS) 162PMS-MONTELUKAST (EDS) 226 PMS-VALACYCLOVIR 18 " 227 PMS-VALPROIC 113PMS-NABILONE (EDS) 164 PMS-VALPROIC ACID 112PMS-NAPROXEN 96 PMS-VALPROIC ACID E.C. 113PMS-NIZATIDINE 167 PMS-VALSARTAN 84PMS-NORFLOXACIN (EDS) 21 " 85PMS-NORTRIPTYLINE 118 PMS-VANCOMYCIN (EDS) 12PMS-NYSTATIN 4 PMS-VENLAFAXINE XR 122PMS-OFLOXACIN (EDS) 153 PMS-VERAPAMIL SR 86PMS-OLANZAPINE (EDS) 125 PMS-ZOLMITRIPTAN (EDS) 36 " 126 PMS-ZOLMITRIPTAN ODT (EDS) 36PMS-OLANZAPINE ODT (EDS) 126 PODOFILOX 208PMS-OMEPRAZOLE DR (EDS) 167 POLYMYXIN B SO4/BACITRACIN (ZINC)/ PMS-OXTRIPHYLLINE 213 NEOMYCIN SO4/HYDROCORTISONE 155PMS-OXYBUTYNIN 212 " 206PMS-OXYCODONE 103 POLYMYXIN B SO4/NEOMYCIN SO4/ PMS-PANTOPRAZOLE (EDS) 168 BACITRACIN (ZINC) 198PMS-PAROXETINE 119 POLYMYXIN B SO4/NEOMYCIN SO4/ PMS-PINDOLOL 57 DEXAMETHASONE 155PMS-PIOGLITAZONE (EDS) 190 POLYMYXIN B SO4/NEOMYCIN SO4/GRAMICIDIN 152PMS-PIROXICAM 96 POLYMYXIN B SO4/NEOMYCIN SO4/ PMS-POLYTRIMETHOPRIM 152 HYDROCORTISONE 155PMS-POTASSIUM CHLORIDE 146 POLYMYXIN B SO4/TRIMETHOPRIM SO4 152PMS-PRAMIPEXOLE 139 POLYTRIM 152 " 140 PORTIA 21 181PMS-PRAVASTATIN 63 PORTIA 28 181 " 64 POTASSIUM CHLORIDE 146

325

Page 348: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

PRADAX (EDS) 40 PYRIMETHAMINE 19PRAMIPEXOLE 139 QUETIAPINE 128 " 140 QUETIAPINE 128PRAMIPEXOLE DIHYDROCHLORIDE 139 QUINAGOLIDE HCL 229PRASUGREL 45 QUINAPRIL HCL 79PRAVACHOL 63 QUINAPRIL HCL/HYDROCHLOROTHIAZIDE 80 " 64 QUININE SO4 19PRAVASTATIN 63 QUININE-ODAN 19PRAVASTATIN 63 QVAR 176 " 64 R&C SHAMPOO/CONDITIONER 200PRAZIQUANTEL 2 RABEPRAZOLE EC (EDS) 168PRAZOSIN 79 RABEPRAZOLE SODIUM (MAC) 168PRECISION THIN 234 RALOXIFENE HCL 184PRECISION XTRA 142 RALTEGRAVIR 15PRECISION XTRA KETONE 142 RAMIPRIL 80PRED FORTE 154 RAMIPRIL 80PRED MILD 154 " 81PREDNISOLONE ACETATE 154 RAMIPRIL/HYDROCHLOROTHIAZIDE 81PREDNISOLONE SODIUM PHOSPHATE 178 RAN-AMLODIPINE 49PREDNISONE 178 RAN-ATENOLOL 50PREGABALIN 229 " 51PREMARIN 183 RAN-ATORVASTATIN 60PREVACID (EDS) 166 " 61PREVACID FASTAB (EDS) 166 RAN-CARVEDILOL (EDS) 51PREZISTA (EDS) 15 " 52PRIMIDONE 104 RAN-CEFPROZIL (EDS) 5PRIMIDONE 104 RAN-CIPROFLOX (EDS) 20PRINIVIL 75 RAN-CITALO 114 " 76 RAN-CLARITHROMYCIN (EDS) 7PRINZIDE 76 RAN-CLOPIDOGREL (EDS) 45PROBENECID 148 RAN-DOMPERIDONE 165PROCAINAMIDE HCL 58 RAN-ENALAPRIL 71PROCAN-SR 58 " 72PROCHLORPERAZINE 127 RAN-FENTANYL MATRIX (EDS) 98PROCHLORPERAZINE MESYLATE 127 RAN-FINASTERIDE 224PROCYCLIDINE HCL 30 RAN-FOSINOPRIL 73PROGESTERONE (MICRONIZED) 194 RAN-GABAPENTIN 108PROGRAF (EDS) 231 " 109PROLIA (EDS) 223 RANIBIZUMAB 229PROLOPA 138 RAN-IRBESARTAN HCTZ 74PROMETRIUM (EDS) 194 " 75PROPADERM 201 RANITIDINE 169PROPAFENONE 58 RANITIDINE 169PROPAFENONE HCL 58 RAN-LISINOPRIL 75PROPRANOLOL 34 " 76 " 58 RAN-METFORMIN 189 " 79 RAN-NABILONE (EDS) 164PROPYLTHIOURACIL 196 RAN-OMEPRAZOLE (EDS) 167PROPYL-THYRACIL 196 RAN-PANTOPRAZOLE (EDS) 168PROSCAR 224 RAN-PIOGLITAZONE (EDS) 190PROSTIGMIN 28 RAN-PRAVASTATIN 63PROTOPIC (EDS) 210 " 64PROVERA 194 RAN-RABEPRAZOLE (EDS) 168PROZAC 116 RAN-RAMIPRIL 80PULMICORT NEBUAMP 176 " 81PULMICORT TURBUHALER 176 RAN-RANITIDINE 169PULMOZYME (EDS) 150 RAN-RISPERIDONE 129PURINETHOL (EDS) 26 " 130PYRANTEL PAMOATE 2 " 131PYRETHINS/PIPERONYL BUTOXIDE/ RAN-ROPINIROLE 140 PETROLEUM DISTILLATE 200 RAN-ROSUVASTATIN 64PYRIDOSTIGMINE BROMIDE 28 " 65PYRIDOXINE HCL 216 RAN-SERTRALINE 120

326

Page 349: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

RAN-SIMVASTATIN 65 RATIO-LISINOPRIL P 76 " 66 RATIO-LISINOPRIL Z 75 " 67 " 76RAN-VALSARTAN 84 RATIO-LOVASTATIN 63 " 85 RATIO-METFORMIN 189RAN-VENLAFAXINE XR 122 RATIO-METHOTREXATE 209RAPAMUNE (EDS) 230 RATIO-MOMETASONE 205RASAGILINE MESYLATE 229 RATIO-MORPHINE 102RATIO-ACLAVULANATE (EDS) 9 RATIO-NYSTATIN 4RATIO-ACYCLOVIR 17 " 200 " 18 RATIO-OMEPRAZOLE (EDS) 167RATIO-ALENDRONATE (EDS) 220 RATIO-PAROXETINE 119RATIO-AMCINONIDE 201 RATIO-PIOGLITAZONE (EDS) 190RATIO-AMIODARONE 48 RATIO-PREDNISOLONE 154RATIO-AMLODIPINE 49 RATIO-RAMIPRIL 80RATIO-ATENOLOL 50 " 81 " 51 RATIO-RANITIDINE 169RATIO-ATORVASTATIN 60 RATIO-RISEDRONATE (EDS) 230 " 61 RATIO-RIVASTIGMINE (EDS) 29RATIO-AZITHROMYCIN (EDS) 6 RATIO-SALBUTAMOL 32RATIO-BACLOFEN 36 RATIO-SALBUTAMOL P.F. 32RATIO-BRIMONIDINE 157 RATIO-SOTALOL 59RATIO-BUPROPION SR 113 RATIO-TAMSULOSIN 231RATIO-CARVEDILOL (EDS) 51 RATIO-TERAZOSIN 83 " 52 RATIO-TOPILENE 202RATIO-CEFUROXIME (EDS) 5 RATIO-TOPISALIC 202RATIO-CIPROFLOXACIN (EDS) 20 RATIO-TOPISONE 202RATIO-CITALOPRAM 114 RATIO-TRIACOMB 206RATIO-CLARITHROMYCIN (EDS) 7 RATIO-VALPROIC 112RATIO-CLOBETASOL 203 RATIO-VENLAFAXINE XR 122RATIO-CLONAZEPAM 105 RBX-RISPERIDONE 129RATIO-CODEINE 97 " 130RATIO-DEXAMETHASONE 177 " 131RATIO-DILTIAZEM CD 53 REBIF (EDS) 225 " 54 REBIF INITIATION PAC (EDS) 225RATIO-DOMPERIDONE 165 REMERON 117RATIO-ECTOSONE 202 REMERON RD 117 " 203 " 118RATIO-ECTOSONE MILD 203 REMICADE (EDS) 225RATIO-EMTEC 97 REMINYL ER (EDS) 28RATIO-FENOFIBRATE MC 62 REMODULIN (EDS) 89RATIO-FENTANYL (EDS) 98 REMODULIN SUPP/DIEM (EDS) 89RATIO-FINASTERIDE 224 RENAGEL (EDS) 230RATIO-FLUOXETINE 116 RENEDIL 73RATIO-FLUTICASONE 154 REPAGLINIDE 191RATIO-FLUVOXAMINE 116 REQUIP 140 " 117 RESCRIPTOR (EDS) 12RATIO-GABAPENTIN 108 RESONIUM CALCIUM 146 " 109 RESTORIL 136RATIO-GLYBURIDE 188 RESULTZ 200RATIO-IPRA SAL UDV 31 RETIN A 207RATIO-IPRATROPIUM UDV 30 RETIN A (EDS) 207RATIO-IRBESARTAN 74 RETROVIR (EDS) 14RATIO-IRBESARTAN HCTZ 74 REVATIO (EDS) 89 " 75 REYATAZ (EDS) 15RATIO-KETOROLAC (EDS) 154 RHINARIS-CS 158RATIO-LACTULOSE (EDS) 162 RHINOCORT AQUA 153RATIO-LAMOTRIGINE 110 RHINOCORT TURBUHALER 153RATIO-LENOLTEC NO.2 97 RHO-NITRO PUMPSPRAY 88RATIO-LENOLTEC NO.3 97 RIDAURA 172RATIO-LENOLTEC NO.4 97 RIFABUTIN 229RATIO-LEVOBUNOLOL 158 RISEDRONATE (EDS) 230RATIO-LISINOPRIL P 75 RISEDRONATE SODIUM 230

327

Page 350: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

RISPERDAL 129 SANDOZ CITALOPRAM 114 " 130 SANDOZ CLARITHROMYCIN (EDS) 7 " 131 SANDOZ CLONAZEPAM 105RISPERDAL CONSTA (EDS) 131 SANDOZ CLOPIDOGREL (EDS) 45RISPERDAL M-TAB 129 SANDOZ CORTIMYXIN 155 " 130 SANDOZ DEXAMETHASONE 154 " 131 SANDOZ DICLOFENAC 92RISPERDONE 129 " 93RISPERIDONE 129 SANDOZ DICLOFENAC SR 92RISPERIDONE 129 " 93 " 130 SANDOZ DILTIAZEM CD 53 " 131 " 54RITALIN 133 SANDOZ DILTIAZEM T 53RITALIN SR 133 " 54RITONAVIR 16 SANDOZ DORZOLAMIDE 156RITUXAN (EDS) 230 SANDOZ DORZOLAMIDE-TIMOLO 157RITUXIMAB 230 SANDOZ ENALAPRIL 71RIVAROXABAN 42 " 72RIVASTIGMINE 29 SANDOZ ENTACAPONE 138RIVOTRIL 105 SANDOZ ESTRADIOL DERM (EDS) 183RIZATRIPTAN BENZOATE 34 SANDOZ FAMCICLOVIR 18ROCALTROL (EDS) 217 SANDOZ FELODIPINE 73ROPINIROLE 140 SANDOZ FENTANYL PATCH (EDS) 98ROPINIROLE HCL 140 SANDOZ FINASTERIDE 224ROSASOL 201 SANDOZ FLUOXETINE 116ROSIGLITAZONE MALEATE 191 SANDOZ FLUVOXAMINE 116ROSIGLITAZONE MALEATE/METFORMIN HCL 191 " 117ROSUVASTATIN CALCIUM 64 SANDOZ GENTAMICIN 152RYTHMODAN 55 SANDOZ GLYBURIDE 188RYTHMOL 58 SANDOZ INDOMETHACIN 94SABRIL 113 SANDOZ IRBESARTAN 74SAIZEN (EDS) 193 SANDOZ IRBESARTAN HCT 74 " 194 " 75SALAZOPYRIN 170 SANDOZ LATANOPROST 158SALBUTAMOL SO4 32 SANDOZ LEFLUNOMIDE (EDS) 226SALMETEROL XINAFOATE 33 SANDOZ LEVOBUNOLOL 158SALMETEROL XINAFOATE/ SANDOZ LEVOFLOXACIN (EDS) 21 FLUTICASONE PROPIONATE 33 SANDOZ LISINOPRIL 75SALOFALK 170 " 76SALOFALK RETENTION ENEMA 170 SANDOZ LISINOPRIL HCT 76SANDOMIGRAN 34 SANDOZ LOPERAMIDE 162SANDOMIGRAN DS 34 SANDOZ LOSARTAN 77SANDOSTATIN (EDS) 228 SANDOZ LOSARTAN HCT 77SANDOSTATIN LAR (EDS) 228 SANDOZ LOSARTAN HCT DS 77SANDOZ ALENDRONATE (EDS) 220 SANDOZ LOVASTATIN 63SANDOZ ALFUZOSIN 220 SANDOZ METFORMIN FC 189SANDOZ AMIODARONE 48 SANDOZ METHYLPHENIDATE SR 133SANDOZ AMLODIPINE 49 SANDOZ METOPROLOL L 55SANDOZ ANAGRELIDE 221 " 56SANDOZ ATENOLOL 50 SANDOZ METOPROLOL SR 56 " 51 SANDOZ MINOCYCLINE (EDS) 10SANDOZ ATORVASTATIN 60 " 11 " 61 SANDOZ MIRTAZAPINE 117SANDOZ AZITHROMYCIN (EDS) 6 SANDOZ MONTELUKAST (EDS) 226 " 7 " 227SANDOZ BISOPROLOL 51 SANDOZ MORPHINE SR 101SANDOZ BRIMONIDINE 157 SANDOZ MYCOPHENOLATE (EDS) 227SANDOZ BUPROPION SR 113 SANDOZ NARATRIPTAN (EDS) 34SANDOZ CALCITONIN NS (EDS) 192 SANDOZ NITRAZEPAM 105SANDOZ CARBAM. CR 107 SANDOZ OLANZAPINE (EDS) 125SANDOZ CARBAMAZEPINE CHEW 107 " 126SANDOZ CEFPROZIL (EDS) 5 SANDOZ OLANZAPINE ODT (EDS) 126SANDOZ CIPROFLOXACIN (EDS) 20 SANDOZ OMEPRAZOLE (EDS) 167

328

Page 351: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

SANDOZ OPTICORT 155 SEPTA-CIPROFLOXACIN (EDS) 20SANDOZ PANTOPRAZOLE (EDS) 168 SEPTA-CITALOPRAM 114SANDOZ PAROXETINE 119 SEPTA-METFORMIN 189SANDOZ PENTASONE 155 SERC 87SANDOZ PINDOLOL 57 SEREVENT (EDS) 33SANDOZ PIOGLITAZONE (EDS) 190 SEREVENT DISKUS (EDS) 33SANDOZ PRAMIPEXOLE 139 SEROQUEL 128 " 140 SEROQUEL XR 128SANDOZ PRAVASTATIN 63 " 129 " 64 SERTRALINE 120SANDOZ PREDNISOLONE 154 SERTRALINE HYDROCHLORIDE 120SANDOZ PROCHLORPERAZINE 127 SEVELAMER HCL 230SANDOZ QUETIAPINE 128 SIG-ENALAPRIL 71SANDOZ RABEPRAZOLE (EDS) 168 " 72SANDOZ RAMIPRIL 80 SILDENAFIL CITRATE 89 " 81 SILHOUETTE (EDS) 238SANDOZ RANITIDINE 169 " 239SANDOZ REPAGLINIDE (EDS) 191 SIL-SERTER (EDS) 239SANDOZ RISEDRONATE (EDS) 230 SIMPONI (EDS) 225SANDOZ RISPERIDONE 129 SIMVASTATIN 65 " 130 SIMVASTATIN 65 " 131 " 66SANDOZ RIVASTIGMINE (EDS) 29 " 67SANDOZ RIVISTIGMINE (EDS) 29 SIMVASTATIN-ODAN 65SANDOZ RIZATRIPTAN ODT (EDS) 34 " 66SANDOZ ROSUVASTATIN 64 " 67 " 65 SINEMET 138SANDOZ SALBUTAMOL RES.SOL 32 SINEMET CR 139SANDOZ SERTRALINE 120 SINEQUAN 115SANDOZ SIMVASTATIN 66 SINGULAIR (EDS) 226 " 67 " 227SANDOZ SUMATRIPTAN (EDS) 35 SINTROM 40SANDOZ TAMSULOSIN 231 SIROLIMUS 230SANDOZ TAMSULOSIN CR 231 SITAGLIPTIN PHOSPHATE 192SANDOZ TELMISARTAN 82 SITAGLIPTIN PHOSPHATE/METFORMIN HCL 192SANDOZ TERBINAFINE 4 SKIN PREPARATION 239SANDOZ TIMOLOL 159 SLOW-K 146SANDOZ TOBRAMYCIN (EDS) 152 SODIUM AUROTHIOMALATE 172SANDOZ TOPIRAMATE 112 SODIUM AUROTHIOMALATE 172SANDOZ TRIFLURIDINE 152 SODIUM CROMOGLYCATE 158SANDOZ VALPROIC 113 " 230SANDOZ VALSARTAN 84 SODIUM FUSIDATE 198 " 85 SODIUM NITROPRUSSIDE REAGENT 143SANDOZ VALSARTAN HCT 85 SODIUM POLYSTYRENE SULFONATE 146 " 86 SODIUM SULAMYD 152SANDOZ VENLAFAXINE XR 122 SOFRACORT 155SANDOZ ZOLMITRIPTAN (EDS) 36 SOFRA-TULLE 198SANDOZ-CANDESARTAN 68 SOF-SERTER (EDS) 239 " 69 SOFTCLIX 234SANDOZ-METOPROLOL(TYPE L) 55 SOFTCLIX PRO 234 " 56 SOLIFENACIN SUCCINATE 212SAQUINAVIR 16 SOLU-CORTEF 178SARNA HC 205 SOMATROPIN 193SAXAGLIPTIN 191 SOMATULINE AUTOGEL (EDS) 226SCOPOLAMINE 164 SORIATANE (EDS) 208SDZ ZOLMITRIPTAN ODT (EDS) 36 SOTALOL HCL 59SECTRAL 48 SPECTRO ECZEMA CARE 203SELECT 1/35 181 SPIRIVA (EDS) 31SELEGILINE HCL 140 SPIRONOLACTONE 148SEN-SERTER (EDS) 239 SPIRONOLACTONE/HYDROCHLOROTHIAZIDE 82SEPTA-AMLODIPINE 49 SPORANOX (EDS) 3SEPTA-ATENOLOL 50 STALEVO 139 " 51 STARLIX (EDS) 189

329

Page 352: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

STATEX 100 TEGRETOL CHEWTABS 107 " 102 TEGRETOL CR 107STAVUDINE 14 TELAPREVIR 231STELARA (EDS) 232 TELMISARTAN 82STIEVA-A 207 TELMISARTAN/AMLODIPINE 82STIEVA-A FORTE (EDS) 207 TELMISARTAN/HYDROCHLOROTHIAZIDE 82STRATTERA (EDS) 221 TELZIR (EDS) 15SUBOXONE (EDS) 104 TEMAZEPAM 136SUCRALFATE 169 TENOFOVIR DISOPROXIL FUMARATE 14SULCRATE 169 TENORETIC 68SULCRATE SUSPENSION PLUS 169 TENORMIN 50SULFACETAMIDE (SODIUM) 152 " 51SULFACETAMIDE (SODIUM)/COLLOIDAL SULPHUR 201 TERAZOL-3 DUAL-PAK 200SULFACETAMIDE SODIUM/ TERAZOL-7 200 PREDNISOLONE ACETATE 155 TERAZOSIN 83SULFACET-R 201 TERAZOSIN HCL 83SULFAMETHOXAZOLE/TRIMETHOPRIM TERBINAFINE 4 (CO-TRIMOXAZOLE) 23 TERBINAFINE HCL 4SULFASALAZINE (SALICYLAZOSULFAPYRIDINE) 170 " 200SULFINPYRAZONE 44 TERBUTALINE SO4 33 " 148 TERCONAZOLE 200SULINDAC 96 TESTOSTERONE CYPIONATE 179SUMATRIPTAN 35 TESTOSTERONE CYPIONATE 179SUMATRIPTAN (EDS) 35 TESTOSTERONE ENANTHATE 179SUPER-FINE MICRO 5MM 235 TESTOSTERONE UNDECANOATE 179SUPER-FINE STANDARD/12.7 234 TETRABENAZINE 231SUPER-FINE XTRA 8MM 235 TETRACYCLINE 11SUPEUDOL 103 TETRACYCLINE 11SUPRAX (EDS) 4 TEVA-ALENDRONATE (EDS) 220SUPREFACT (EDS) 184 TEVA-ALPRAZOL 134SURE T (EDS) 236 TEVA-AMIODARONE 48 " 237 TEVA-AMLODIPINE 49SUSTIVA (EDS) 12 TEVA-ATENOL 50SYMBICORT TURBUHALER (EDS) 31 " 51SYNACTHEN DEPOT 193 TEVA-ATENOL/CHLORTHAL 68SYNAREL (EDS) 185 TEVA-ATORVASTATIN 60SYNPHASIC 181 " 61SYNTHROID 195 TEVA-AZATHIOPRINE 222SYRINGE 235 TEVA-CANDESARTAN 68TACROLIMUS 210 " 69 " 231 TEVA-CARBAMAZEPINE 107TADALAFIL 89 TEVA-CHLORPROMAZINE 123TALWIN 104 TEVA-CITALOPRAM 114TAMBOCOR 55 TEVA-CLINDAMYCIN 11TAMSULOSIN HCL 231 TEVA-CLOPIDOGREL (EDS) 45TAPAZOLE 196 TEVA-DOMPERIDONE 165TARO-CARBAMAZEPINE 107 TEVA-DORZOTIMOL 157TARO-CARBAMAZEPINE CHEWS 107 TEVA-ENTACAPONE 138TARO-CLINDAMYCIN 198 TEVA-FLUOXETINE 116TARO-CLOBETASOL CREAM 203 TEVA-FOSINOPRIL 73TARO-CLOBETASOL OINTMENT 203 TEVA-GABAPENTIN 108TARO-CLOBETASOL SOLUTION 203 " 109TARO-MOMETASONE OINTMENT 205 TEVA-GALANTAMINE ER (EDS) 28TARO-MUPIROCIN 198 TEVA-GLYBURIDE 188TARO-PHENYTOIN 106 TEVA-HYDROCHLOROTHIAZIDE 147TARO-SONE 202 TEVA-HYDROMORPHONE 98TARO-TERCONAZOLE 200 " 99TARO-WARFARIN 42 TEVA-IRBESARTAN 74 " 43 TEVA-IRBESARTAN/HCTZ 74TAZAROTENE 210 " 75TAZORAC 210 TEVA-LACTULOSE (EDS) 162TECTA (EDS) 167 TEVA-LISINOPRIL (TYPE P) 76TEGRETOL 107 TEVA-LISINOPRIL/HCTZ (Z) 76

330

Page 353: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

TEVA-LOSARTAN 77 TOBI (EDS) 2TEVA-LOSARTAN/HCTZ 77 TOBI PODHALER (EDS) 2TEVA-MELOXICAM (EDS) 95 TOBRADEX (EDS) 155TEVA-METOPROLOL 55 TOBRAMYCIN 2 " 56 " 152TEVA-MONTELUKAST (EDS) 226 TOBRAMYCIN/DEXAMETHASONE 155 " 227 TOBREX (EDS) 152TEVA-NABILONE (EDS) 164 TOCILIZUMAB 232TEVA-NAPROXEN 95 TOLBUTAMIDE 192 " 96 TOLBUTAMIDE 192TEVA-NEVIRAPINE (EDS) 13 TOLOXIN 52TEVA-OLANZAPINE (EDS) 125 TOLTERODINE L-TARTRATE 212 " 126 TOPAMAX 112TEVA-PAROXETINE 119 TOPICORT 204TEVA-RABEPRAZOLE EC (EDS) 168 TOPICORT MILD 204TEVA-RAMIPRIL 80 TOPIRAMATE 112 " 81 TOPIRAMATE 112TEVA-ROSUVASTATIN 64 TRACLEER (EDS) 87 " 65 TRANDATE 75TEVA-SERTRALINE 120 TRANDOLAPRIL 84TEVA-SIMVASTATIN 65 TRANSDERM-NITRO 0.2 88 " 67 TRANSDERM-NITRO 0.4 88TEVA-TAMSULOSIN CR 231 TRANSDERM-NITRO 0.6 88TEVA-TELMISARTAN 82 TRANSDERM-V 164TEVA-TELMISARTAN HCTZ 82 TRANYLCYPROMINE SO4 120TEVA-TERAZOSIN 83 TRAVATAN Z 159TEVA-TRAZODONE 121 TRAVOPROST 159TEVA-VALSARTAN 84 TRAVOPROST/TIMOLOL MALEATE 159 " 85 TRAZODONE 121TEVA-VALSARTAN/HCTZ 85 TRAZODONE 121 " 86 TRAZOREL 121TEVA-VENLAFAXINE XR 122 TRENTAL 45TEVA-ZOLMITRIPTAN (EDS) 36 TREPROSTINIL 89TEVA-ZOLMITRIPTAN OD (EDS) 36 TRETINOIN 207TEVETEN 72 TRIADERM 205TEVETEN PLUS 72 TRIAMCINOLONE 179THEOLAIR LIQUID 213 " 154THEOPHYLLINE (ANHYDROUS) 213 " 179THIAMIJECT 216 " 205THIAMINE HCL 216 TRIAMCINOLONE ACETONIDE 179THINSET 90 (EDS) 236 TRIAMCINOLONE HEXACETONIDE 179 " 237 TRIAMTERENE/HYDROCHLOROTHIAZIDE 84THIOTHIXENE 132 TRIAZOLAM 136THYROID 195 TRI-CYCLEN 182THYROID 195 TRI-CYCLEN LO 182TIAPROFENIC ACID 96 TRIFLUOPERAZINE 132TIAZAC 53 TRIFLUOPERAZINE 132 " 54 TRIFLURIDINE 152TIAZAC XC 53 TRIHEXYPHENIDYL 30 " 54 TRIHEXYPHENIDYL HCL 30TICAGRELOR 45 TRILEPTAL (EDS) 111TICLOPIDINE (EDS) 45 TRIMEPRAZINE TARTRATE 232TICLOPIDINE HCL 45 TRIMETHOPRIM 22TIMOLOL MALEATE 59 TRIMETHOPRIM 22 " 83 TRIMIPRAMINE 121 " 159 TRIMIPRAMINE 121TIMOLOL MALEATE-EX 159 TRINIPATCH 0.2 88TIMOPTIC 159 TRINIPATCH 0.4 88TIMOPTIC-XE 159 TRINIPATCH 0.6 88TINZAPARIN SODIUM 42 TRIQUILAR 181TIOTROPIUM BROMIDE MONOHYDRATE 31 TRIZIVIR (EDS) 13TIPRANAVIR 16 TROSEC (EDS) 212TIZANIDINE HCL 37 TROSPIUM CHLORIDE 212

331

Page 354: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page PRODUCT NAME Page

TRUETEST 142 VENOFER (EDS) 40TRUETRACK SMART SYSTEM 142 VENTOLIN HFA 32TRUSOPT 156 VENTOLIN NEBULES P.F. 32TRUVADA (EDS) 14 VENTOLIN RESPIRATOR SOL. 32TWINJECT 31 VERAPAMIL HCL 59TWYNSTA 82 " 86TYLENOL WITH CODEINE ELX 97 VERMOX 2TYLENOL WITH CODEINE NO.2 97 VESICARE (EDS) 212TYLENOL WITH CODEINE NO.3 97 VFEND (EDS) 4TYLENOL WITH CODEINE NO.4 97 VIADERM-KC 206TYSABRI (EDS) 227 VIBRAMYCIN 10ULORIC (EDS) 224 VICTRELIS (EDS) 222ULTICARE 28G 1/2 235 VICTRELIS TRIPLE (EDS) 222ULTICARE 28G/1/2 236 VIDEX EC (EDS) 13ULTICARE 29G 235 VIGABATRIN 113 " 236 VIGAMOX (EDS) 153ULTICARE 29G 1/2 235 VIMPAT (EDS) 109 " 236 VIOKASE 163ULTICARE 30G 235 VIRACEPT (EDS) 16 " 236 VIRAMUNE (EDS) 13ULTICARE 30G 1/2 235 VIREAD (EDS) 14 " 236 VIROPTIC 152ULTICARE 30G 5/16 235 VISKAZIDE 79 " 236 VISKEN 57ULTICARE 30G/1/2 236 VITAMIN A ACID 207ULTICARE 31G 5/16 235 VITAMIN B1 216 " 236 VITAMIN B12 216ULTICARE PEN 29G 12MM 234 VITAMIN B6 216ULTICARE PEN 31G 6MM 235 VOLIBRIS (EDS) 87ULTICARE PEN 31G 8MM 235 VOLTAREN 92ULTRASE MS4 163 " 93ULTRASE MT12 163 VOLTAREN OPHTHA (EDS) 157ULTRASE MT20 163 VOLTAREN-SR 92UNIFINE 12MM 234 " 93UNIFINE 6MM 235 VORICONAZOLE 4UNIFINE 8MM 235 WARFARIN 42UNIPHYL 213 WARFARIN 42UREMOL-HC 205 " 43UROMAX (EDS) 212 WARTEC 208URSO (EDS) 162 WEBCOL ALCOHOL PREP 234URSO DS (EDS) 162 WELLBUTRIN SR 113URSODIOL 162 WELLBUTRIN XL 113USTEKINUMAB 232 WINPRED 178VAGIFEM 10 183 XALACOM 158VALACYCLOVIR 18 XALATAN 158VALCYTE (EDS) 19 XAMIOL 209VALGANCICLOVIR HCL 19 XANAX 134VALISONE 203 XARELTO (EDS) 42VALIUM 135 XATRAL 220VALPROATE SODIUM 112 XEOMIN (EDS) 223VALPROIC ACID 113 XYLAC 125VALSARTAN 84 YASMIN 21 180VALSARTAN/HYDROCHLOROTHIAZIDE 85 YASMIN 28 180VALTREX 18 YAZ (28) 180VAL-VANCO (EDS) 12 ZADITEN (EDS) 225VANCOCIN (EDS) 11 ZAFIRLUKAST 232VANCOMYCIN HCL 11 ZANAFLEX (EDS) 37VARENICLINE TARTRATE 37 ZANTAC 169VASERETIC 72 ZARONTIN 106VASOTEC 71 ZAROXOLYN 148 " 72 ZELDOX 132VENLAFAXINE HCL 122 ZERIT (EDS) 14VENLAFAXINE XR 122 ZESTORETIC 76

332

Page 355: Formulary - Saskatchewanformulary.drugplan.health.gov.sk.ca/Publns/Formularyv62.pdf · The Saskatchewan Formulary is a listing of the therapeutically effective drugs of proven ...

PRODUCT NAME Page

ZESTRIL 75 " 76ZIAGEN (EDS) 13ZIDOVUDINE 14ZIPRASIDONE 132ZITHROMAX (EDS) 6 " 7ZOCOR 65 " 66 " 67ZOLADEX (EDS) 184ZOLEDRONIC ACID 232ZOLMITRIPTAN 36ZOLOFT 120ZOMIG (EDS) 36ZOMIG RAPIMELT (EDS) 36ZOVIRAX 17ZOVIRAX WELLSTAT PAC 17ZUCLOPENTHIXOL ACETATE 132ZUCLOPENTHIXOL DECANOATE 132ZUCLOPENTHIXOL DIHYDROCHLORIDE 132ZYBAN 113ZYLOPRIM 221ZYM-AMLODIPINE 49ZYMAR (EDS) 158ZYPREXA (EDS) 125 " 126ZYPREXA ZYDIS (EDS) 126ZYVOXAM (EDS) 11

333


Recommended